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SUMMARY
The effects of pharm acological and pathological m anipulation  of 
hippocam pal cholinergic and glutam atergic neurotransm itter receptor 
systems were examined using quantitative in vivo [14C ]-deoxyglucose 
autoradiography and in vitro ligand binding autoradiography. In three 
series of rats, local cerebral glucose utilisation was assessed in 76 
anatomically defined hippocampal, limbic and other structures following 
adm inistration of three novel cholinergic or glutam atergic agents in 
order to assess the physiological changes in cerebral m etabolism  in 
response to pharmacological challenge. Secondly, to assess the plastic 
responses of hippocam pal cholinergic and glutam atergic transm itter 
systems in the hippocam pus to cholinergic denervation, ligand binding 
to N-methyl-D-aspartate (NMDA), AMPA-sensitive quisqualate, kainate 
and m uscarinic receptors was perform ed in rats which had received 
surgery to lesion the medial septum  three weeks previously. The status 
of cholinergic system s was fu rther investigated using biochemical 
techniques to estim ate  m uscarin ic-stim ulated  second m essenger 
turnover following septal lesions. Local cerebral glucose utilisation was 
m easured in rats using the deoxyglucose technique three weeks after 
medial septal lesion as an index of function. Finally, the effects of acute 
experim ental subdural haem atom a, a novel ischaemic technique, on 
functional activity in the hippocam pus and associated limbic regions 
were assessed using deoxyglucose autoradiography. The ability of a novel 
glutam ate antagonist to prevent functional disturbances produced by 
subdural haematoma were also assessed, with a view to potential clinical 
treatm ent of ischaemia.
These studies dem onstrate  that m anipulation of cholinergic and 
glutam atergic transm itter systems in the CNS may result in w idespread 
functional alterations in the brain, and suggest that cholinergic and 
glutam atergic systems m ay interact in the plastic modifications which
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accompany cholinergic denervation in the limbic system.
1. Pharmacological Effects of Cholinergic and Glutamatergic Agents on 
Cerebral Glucose Use
The effects on functional activity in the hippocam pus and other 
regions of the CNS of a glutamate antagonist, a muscarinic agonist and a 
cholinesterase inhibitor w ith potential g lutam atergic  activity  were 
examined using deoxyglucose autoradiography.
The novel com petitive NMDA antagonist D-CPP-ene (0.3, 3 or 
30mgkg_1) induced widespread, heterogeneous patterns of altered glucose 
utilisation in the brain. These alterations were not directly related to 
glutam ate receptor density: in the hippocam pus, D-CPP-ene treatm ent 
(3mgkg_1) significantly depressed glucose utilisation in the subiculum  
and CA4 pyram idal layer (22% and 31% relative to saline-treated 
controls), while other regions of the hippocam pus such as the glutamate 
receptor-dense CA1 were not significantly affected. In cortical and 
subcortical regions involved with sensory processing, D-CPP-ene evoked 
marked depression of glucose utilisation. The most m arked reduction in 
glucose use occurred in auditory cortex (Layer IV), which exhibited a 49% 
decrease relative to controls. In contrast, D-CPP-ene (30mgkg_1) elicited 
m arked increases in glucose use in olfactory regions: in the lateral 
olfactory tract, glucose use increased by 79% relative to control values 
following D-CPP-ene treatment.
The novel potent muscarinic agonist L-679-512 (3, 10 or 30 jigkg '1) 
produced few significant alterations in glucose utilisation in 76 brain 
regions. In the hippocam pus, L-679-512 resulted in decreased glucose 
utilisation in the CA1 and CA2 stratum  lacunosum moleculare (11% and 
14% reduction relative to controls, respectively), and the CA2 stratum  
o riens/py ram idale  (15%). In limbic regions, glucose utilisation was
1 7
consistently reduced in the j  mamillary body follow ing L-679-512 
adm inistration. L-679-512 OOjigkg'1) induced decreased glucose use in 
olfactory regions: glucose utilisation in the entorhinal cortex was reduced 
by 25% relative to controls.
The cholinesterase inhibitor THA (2.5mgkg_1) evoked little functional 
response in hippocam pal or limbic regions. Glucose utilisation was 
increased significantly  in the subiculum  (17%) and an teroven tra l 
thalam ic nucleus (25%), and was decreased significantly in the dorsal 
raphe (15%), but rem ained unaltered in other limbic regions. Instead, 
THA elicited large, highly significant increases in glucose use in visual 
struc tu res such as the superior colliculus (40%) and dorso lateral 
geniculate body (28%), thus providing evidence for a cholinergic, rather 
than glutamatergic, mode of action.
Effect of Cholinergic Denervation on the Integrity of Muscarinic and 
Glutamatergic Transmission in the Hippocampus
Medial septal lesions were produced in rats using stereotaxic injection 
of ibotenic acid (6|ig). Lesions resulted  in a decrease in choline 
acetyltransferase activity of 25% compared to sham -operated controls. 
Three weeks after lesions of the medial septum , quantitative in vitro 
ligand binding  autoradiography was used to estim ate densities of 
cholinergic and , glutam atergic receptors in hippocam pal and limbic 
regions. [3H]-QNB, [3H]-AMPA, [3H]-kainate and NM DA-displaceable 
[3H ]-g lu tam ate  w ere used to assess m uscarinic, A M PA -sensitive 
quisqualate, kainate and NMDA receptors in hippocam pal and limbic 
regions. Cerebral glucose use was m easured using [14C ]-deoxyglucose 
autoradiography. There were no alterations in [3H]-kainate and NMDA- 
displaceable [3H]-glutamate binding in hippocam pal and limbic regions; 
however, [3H]-QNB binding was significantly reduced in the subiculum
(14%) and in the medial and lateral septum  (32% and 13% respectively). 
[3H]-AMPA binding was also found to be reduced following septal lesions: 
binding was significantly reduced throughout the pyram idal region, with 
the most significant decrease in CA2 (18%). [3H]-AMPA binding was also 
reduced in the CA1 stratum  radiatum  and CA2 stratum  lacunosum  
moleculare, and in the entorhinal cortex. In the septal region, a 49% 
reduction in [3H]-AMPA binding was observed in the m edial septal 
nucleus. In comparison, glucose use was not altered three weeks post­
lesion compared to sham -operated control values. These results provide 
evidence that glutam atergic receptors are m odified in response to 
cholinergic denervation of the hippocampus.
To assess further the integrity of the cholinergic system following 
medial septal lesions, carbachol-stimulated accumulation of [3H]-inositol 
phosphate accum ulation was m easured in hippocam pal slices three 
weeks follow ing septal lesion or sham operation. N o significant 
difference was measured between sham and lesioned groups, suggesting 
that muscarinic coupling to phosphoinositide metabolism is unaltered in 
the absence of the major cholinergic input to the hippocampus.
Effects of Acute Subdural Haematoma on Cerebral Glucose Use in the Rat
Cerebral glucose use in hippocampal, limbic and other structures was 
investigated in 4 novel model of ischaemia in the rat. Acute subdural 
haematoma was produced by injection of 0.4ml autologous blood below 
the dura, over the left parietal cortex, two hours p rior to [14C ]- 
deoxyglucose autoradiography. In rats which received haem atom a, 
m arked increases in glucose utilisation w ere m easured  bilaterally 
throughout the glutamate receptor-dense hippocampus. In the ipsilateral 
CA1 stratum  radiatum , glucose use was increased by 142% compared to 
sham -operated controls, while in the dentate molecular layer, glucose use
was increased by 112%. The ischaemic cortex was alm ost devoid of 
deoxyglucose up take, w hile in the bo rdering  "penum bral" zone, 
deoxyglucose uptake was observed to be higher than in the surrounding 
non-ischaemic cortex. Acute subdural haem atom a also reduced glucose 
utilisation in auditory and visual regions: glucose use was decreased by 
48% following subdural haematoma.
In a third group of rats, pretreatm ent w ith the competitive NMDA 
a n ta g o n is t D -C PP-ene fifteen  m in u te s  be fo re  d eo x y g lu co se  
autoradiography reduced the functional disturbances associated with 
acute subdural haematoma. In the hippocam pal CA1 and CA3 regions, 
D-CPP-ene pretreatm ent resulted in rates of glucose use significantly 
lower than those in the non-pretreated group. In addition, D-CPP-ene 
abolished the rim of increased deoxyglucose uptake surrounding  the 
infarct, and reduced the functional deficit produced by the haematoma in 
aud ito ry  and visual regions. These resu lts p rov ide  an in vivo 
perspective of the functional disturbances which accompany ischaemia, 
and support the glutam atergic hypothesis of ischaemia; further, these 
results suggest that glutam atergic antagonists may be of benefit in the 
clinical treatment of ischaemia.
The results presented in this thesis highlight the advantages of in 
vivo  m apping of cerebral events, particu larly  in situations w here 
dynam ic alterations in function are likely to occur, such as acute 
pharmacological, or pathological challenge. Furtherm ore, the use of 
receptor au to rad iog raphy  prov ides insights in to  the processes of 
m od ifica tion  fo llow ing  d en erv a tio n , and  su g g est th a t in the 
hippocam pus, both cholinergic and glutam atergic systems are involved 
in synaptic modifications which accompany cholinergic denervation.
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PREFACE AND DECLARATION
This thesis p resen ts resu lts  from s tu d ies  of deoxyg lucose  
autoradiography and ligand binding autoradiography in the rat brain. 
Quantitative [14C]-deoxyglucose autoradiography was used to measure the 
local cerebral glucose utilisation as an index of cerebral function in the 
conscious rat. Ligand binding techniques were used to measure receptor 
binding densities in vitro.
Investigations have been conducted in three broadly defined areas:
(1) The effects of in travenous adm inistration  of cholinergic and 
glutamatergic agents on cerebral function in the rat.
(2) The effects of cholinergic denervation on glutam atergic and 
muscarinic transmitter systems and on cerebral glucose use in the 
hippocam pus.
(3) The effects of a novel model of ischaemia on cerebral glucose 
utilisation in the hippocam pus, and the ability of a glutam ate 
antagonist w ith anti-ischaemic efficacy to ameliorate ischaemia- 
induced functional disturbances.
Results of the$e studies are discussed separately. In the final overview 
I have attem pted to discuss critically the techniques, in terms of their 
advantages and limitations, in relation to their employment in studies of 
the hippocampus.
This thesis com prises my ow n original work and has not been 
presented previously as a thesis in any form.
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CHAPTER I 
INTRODUCTION
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THE HIPPOCAMPUS: A BRIEF HISTORICAL OVERVIEW.
The h ippocam pus form s p art of the tem poral cortical m antle, 
im m ediately caudal to the am ygdala and is so-nam ed because of its 
resemblance when dissected to a seahorse lying along the inferior horn of 
the lateral ventricle. In the nineteenth century, the use of the Golgi 
technique to stain neurones revealed that in comparison to other cortical 
areas, the hippocam pus is comprised of a striking, highly distinct laminar 
organisation; this provided the im petus for expanded neuroanatom ical 
research, and consequently the h ippocam pus has becom e the m ost 
topographically defined cortical region in terms of its intrinsic neuronal 
circuitry and its efferent and afferent connections. In contrast, however, 
the precise role of the h ippocam pus in cerebral function rem ains 
enigmatic.
The hypothesis that the hippocam pus plays a critical role in learning 
and memory has become accepted in recent years due to a vast body of 
experim ental evidence that lesions of the hippocam pus or its afferents 
result in deficits in a variety of learning and m em ory tasks (O'Keefe & 
N adel, 1978; Squire & Zola-Morgan, 1983). In hum ans, destruction of 
hippocam pal neurones is associated with cognitive deficits in diseases 
such as Alzheimer's Disease (Hyman et al., 1984), and certain types of 
amnesia (Zola-Morgan et al., 1986). Further, long-term  potentiation (or 
LTP), an increase in synaptic efficacy in response to bursts of high 
frequency neurorial firing (Collingridge, 1985), has been dem onstrated to 
occur in m ost hippocam pal regions, and has been proposed  as the 
synaptic com ponent of learning: blockade of long-term  potentiation by 
pharm acological m eans in rats is associated w ith im paired cognitive 
ability in behavioural learning tasks (Morris et al., 1986).
Two factors are param ount in the sustained interest in hippocam pal 
function: firstly , the rela tive  sim plicity  of neuronal circu itry  has 
facilitated the study and analysis of long-term  potentiation, and its
m o d u la tio n  by pharm acolog ical m an ip u la tio n s or physio log ical 
stim ulation of afferent structures. The hippocam pus therefore provides 
a m odel upon which to challenge hypotheses of synaptic efficacy and 
plasticity in the analysis of learning and memory. Secondly, a num ber of 
disease states which affect memory and mnemonic processes in hum ans 
have been dem onstrated  to result in alterations in receptors, second 
m essengers and  cellu lar com ponents w ith in  the h ippocam pus. 
Therefore, a focus of recent research has been to quantify alterations in 
hippocam pal transduction m echanisms underlying the disease process 
w ith  the aim  of treating  or even p reven ting  the d isru p tio n  of 
hippocampal function. These two separate approaches have resulted in a 
num ber of hypotheses which address the m echanism s underly ing  
hippocam pal transmission; yet neither have been able to elucidate the 
precise physiological actions of transm itters and  receptors in the 
hippocam pus, and the degree of involvement of individual transm itter 
systems in neurodegenerative diseases remains obscure.
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2. ANATOMICAL ORGANISATION OF THE HIPPOCAMPUS
The anatomical organisation of the hippocampus is detailed in Figure 
1. The hippocampal formation may be divided into four major areas (for 
review, see Swanson et al., 1987): the entorhinal area, the subicular 
complex, the dentate gyrus, and Ammon's horn (Cornu Ammonis or 
CA).
A variety of staining techniques reveal the existence of four laminae 
of Am m on's horn: from the superficial to deep layers, these are the 
stratum  lacunosum  m oleculare (or m olecular layer), the cell-sparse 
stratum  radiatum , the stratum  pyram idale (or pyram idal cell layer), and 
the stratum  oriens which lies adjacent to the hippocampal white m atter 
or alveus. On morphological grounds, Ammon's horn has been sub­
divided into distinct CA sectors (Lorente de No, 1934), a term inology 
which has w ide acceptance, and which is used in the present study. 
Fields CA1 and CA3 are anatomically distinct: CA3 contains an additional 
lamina, the stratum  lucidum, which represents the terminal region for 
den ta te  mossy fibres. CA1 and CA3 have d ifferent pa tterns of 
innervation, and are separated by a narrow  transitional zone, CA2; the 
functional significance of CA2 is not clear.
The dentate gyrus consists of three laminae: the molecular layer, an 
underly ing  granular cell layer, and an in fragranular layer, w hich 
corresponds to the CA4 or hilus region, and borders the CA4 stratum  
pyram idale. The dentate gyrus is also sub-divided into a superior and 
inferior blade, and on functional grounds the outer and inner portions of 
the molecular layer can be considered distinctly.
The subicular complex consists of the subiculum, parasubiculum  and 
presubiculum . Com pared to other hippocampal regions, these are less 
well-defined in terms of their laminar organisation, and their function 
within hippocampal neuronal has attracted less attention, although they 
receive extensive projections from sensory cortical regions, as well as a
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LEGEND TO FIGURE 1 
ANATOMY OF THE HIPPOCAMPAL FORMATION
Diagrammatic representation of coronal sections at the level of the ventral 
(A) and dorsal (B) hippocampus.
A bbreviations: or: stratum  oriens; pyr: stratum pyramidale; rad: stratum  
radiatum ; lac.mol: lacunosum  moleculare; DG: dentate  gyrus; mol: 
m olecular layer; infra: infragranular region; S: subiculum ; ENT: 
entorhinal cortex; MG: medial geniculate body; SC: superior colliculus; 
Au C: auditory cortex; THAL: thalamus; Par C: parietal cortex.
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FIGURE 1: ANATOMY OF THE HIPPOCAMPAL FORMATION
d irec t in p u t from  the en to rh inal and septal areas. W hile the 
presubiculum  and parasubiculum  have a similar architecture to that of 
the entorhinal cortex immediately adjacent, the subiculum  represents a 
m arked change in lam ination, and is composed of a deep pyram idal 
layer, an intermediate cell-sparse layer which is continuous with the CA 
stratum  radiatum , and a superficial molecular layer, continuous with 
that of the presubiculum  and CA1 on either side. However, in contrast 
to the highly stratified patterns of receptor distribution and local cerebral 
glucose u tilisation which are dem onstrated  in o ther h ippocam pal 
regions, the subicular complex has relatively hom ogeneous rates of 
glucose use and receptor binding densities, and is therefore considered 
homogeneous in the present study.
Finally, the entorhinal cortex can be divided imm ediately into lateral 
and m edial portions on the grounds of anatom ical struc tu re  and  
innervation: each portion contains six structurally distinct layers, while 
clusters of stellate cells in layer II of the lateral portion are absent in the 
m edial portion of the entorhinal cortex, and the lateral and m edial 
entorhinal cortices are functionally distinct in terms of their efferent 
hippocam pal projections.
2.1. THE TRISYNAPTIC PATHWAY
The perforant pathw ay, perhaps the best characterised hippocam pal 
pathw ay (Ramon y Cajal, 1911), originates in the entorhinal cortex, and 
projects to the molecular layer of the dentate gyrus to form the first 
synapse in the trisynaptic pathw ay (Figure 2). Lesions confined to the 
lateral entorhinal area result in degeneration of nerve term inals in the 
outer third of the dentate molecular layer, while lesions of the medial 
entorhinal area cause neurodegeneration in the m iddle portion of the 
m olecular layer (Hjorth-Simonsen, 1972; H jorth-Sim onsen & Jeune,
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1972), providing evidence for distinct lateral and medial components of 
the perforant path. This has been confirm ed electrophysiologically 
(McNaughton, 1980). The perforant path fibres synapse with dendrites of 
granule cells in the dentate gyrus, and are thought to use glutam ate as a 
neurotransm itter (Storm-Mathisen, 1977; Storm-Mathisen et al., 1983).
The dentate granule cells in turn give rise to apical m ossy fibre 
jprojections, characterised by large boutons which synapse in the stratum  
lu c id u m  on the  sp in e s  of p ro x im a l d e n d r i te s  of the  
CA3 pyram idal cells (Blackstad & Kjaerheim, 1961), to form the second 
connection in the trisynaptic pathway. These synapses are putatively 
glutam atergic (Fonnum et al., 1979; Storm-M athisen & Iversen, 1979), 
and possibly act through kainate receptors, as evidenced by the high 
density of kainate receptor binding in the stratum  lucidum  (Cotman et 
al., 1987).
The CA3 pyramidal cells thence send out divergent Schaffer collateral 
fibres and commissural fibres which course through the strata radiatum  
and oriens, and synapse with the CA1 pyram idal dendrites in the same 
layers, to form the third synapse in the trisynaptic pathway. A bundant 
evidence suggests that these synapses are glutamatergic (for example, see 
Nadler et al., 1976; Fonnum & Walaas, 1978; Storm-Mathisen & Iversen, 
1979; Collingridge et al., 1983), and there is a large projection from CA3 to 
the contralateral CA1, via the fimbria fornix (Gottlieb & Cowan, 1973).
In addition to the perforant path, the entorhinal cortex gives rise to, 
fibres which synapse directly in the stratum  lacunosum moleculare with 
distal dendrites of the CA pyram idal cells. Thus the entorhinal cortex is 
afforded the potential for considerable control over hippocampal firing.
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2.2. THE SEPTOHIPPOCAMPAL PATHWAY
The hippocam pus receives its major extrinsic cholinergic input from 
the septal area, situated in the forebrain; in comparison to the entorhinal 
g lutam atergic input, the cholinergic input is relatively diffuse, and 
appears to innervate all hippocam pal fields (Lewis et al., 1967). The 
septal area may be sub-divided: the medial septum and the diagonal band 
nucleus form a continuum, although evidence suggests that these can be 
c o n sid e red  se p a ra te  d ue  to d ifferences in in n e rv a tio n  and  
neurochem istry (Amaral & Kurz, 1985; Saper, 1984; Swanson & Cowan, 
1979). Both structures contain large cholinergic cell bodies, which are 
distinct from the smaller cells of the adjacent lateral septum. In addition 
to a cholinergic projection, a large proportion of cells in the m edial 
septum  are GABAergic (Kohler et al., 1984).
Although it has been demonstrated that the medial septal cholinergic 
input to the hippocam pus innervates all regions of the hippocam pal 
form ation (Mellgren & Srebro, 1973; Nyakas et al, 1987; Swanson & 
Cowan, 1979), projections to the dentate gyrus are particularly dense, and 
synapse mainly within the dentate hilar region. In the CA region, fibres 
from the medial septum  project to the strata oriens and radiatum  of CA3, 
and less densely to the stratum  oriens of CA1. In comparison, a diffuse 
septal input to the subicular complex exists. Additionally, the septum  
projects to the entorhinal cortex, specifically to layers II, IV and VI.
The vast m ajority of septal fibres reach the hippocam pus via the 
fimbria fornix; however, two additional routes appear to exist. Firstly a 
projection from the diagonal band runs over the genu of the corpus 
callosum, and innervates the anterior cingulate and retrosplenial areas, 
ending in tem poral regions of the subicular complex. The second 
projection, which accounts for approxim ately 10% of the cholinergic 
input into the hippocam pus, runs ventrally through the amygdala and 
term inates w ithin the tem poral hippocam pus (Milner & Amaral, 1984;
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Gage et al., 1984).
The topography of projections from the septal region is a m atter of 
som e debate, although there is acceptance that m edial septal cells 
innervate septal (or dorsal) regions of the hippocam pus preferentially 
(Meibach & Siegel, 1977).
There is extensive evidence to support acetylcholine as the major 
transm itter in the septohippocampal pathway. Acetylcholinesterase and 
choline acety ltransferase  (ChAT) are m arked ly  reduced  in the 
hippocam pus following lesions of the septal area or fimbria fornix (Lewis 
et al., 1967; Mellgren & Srebro, 1973; Storm-Mathisen, 1970). However, 
the invo lvem ent of o ther tran sm itte r substances w ith in  sep tal 
hippocam pal afferents merits consideration: it has been reported that as 
m uch as 50% of medial septal neurones do not stain positively w ith 
an tise ra  to ChAT (M esulam  et al., 1983). At least 30% of 
septohippocam pal neurones stain positively w ith antisera to glutam ic 
acid decarboxylase (GAD), and therefore a sizeable com ponent of the 
septal hippocampal input can be presum ed to be GABAergic (Kohler et 
al., 1984). While the role of septal cholinergic transm ission has been 
examined in detail, the function of GABAergic septohippocam pal fibres 
in hippocam pal neuronal firing have received little attention to date, 
and therefore remains obscure.
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3. GLUTAMATE AND THE HIPPOCAMPUS
3.1. GLUTAMATE AS A NEUROTRANSMITTER
Since Curtis and colleagues (1959) dem onstrated that application of 
glutam ate resulted in depolarisation of single neurones in the brain, and 
despite considerable scepticism, extensive evidence has accumulated that 
glutam ate is an excitatory neurotransm itter in the m am m alian central 
nervous system  (CNS). G lutam ate-like im m unoreactivity  has been 
located to synaptic vesicles (Ottersen & Storm-Mathisen, 1984), and the 
distribution of these corresponds with that of a high affinity uptake site 
localised im m unohistochem ically  (Fonnum , 1984), suggesting  that 
glutam ate is stored presynaptically within specific neuronal populations. 
Ligand-binding studies have established that glutamatergic receptors are 
organised into specific, anatomically defined pathw ays (Cotman et al.,
1987), and the existence of specific agonists and antagonists for glutamate 
receptors substantiates further the belief that g lu tam ate acts as a 
neurotransm itter in the CNS. Recently, the use of the [14C]-deoxyglucose 
au torad iographic  technique has dem onstrated that pharm acological 
b lockade of g lu tam ate  receptors can resu lt in cerebral m etabolic 
a ltera tions w hich are lim ited to d iscrete  neu ronal popu la tions 
(Kurumaji et al., 1989); these studies provide evidence for the action in 
vivo of glutam ate in the m odulation of neuronal activity.
3.1.1. Sub-types of Glutamate Receptor
At least three distinct sub-types of glutamatergic receptor have been 
described (Watkins & Evans, 1981), based on their relative affinities for 
the glutam atergic agonists N-m ethyl-D-aspartate (NMDA), kainate and 
quisqualate. A fourth receptor sub-type, defined by binding of the 
an tagon is t L -2 -am inophosphonobu ty ra te  (L-AP4), has also been
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described; however, the precise physiological significance of this receptor 
is unclear.
NMDA Receptors
The availability of high affinity agonists and antagonists, and the use 
of radioligand assays have enabled the NMDA receptor to become the 
most clearly defined glutamatergic receptor (Figure 3). NMDA receptors 
were defined initially by their high affinity for the agonists NMDA, 
NMLA, aspartate and ibotenate. Competitive NMDA antagonists with 
high affinity and relatively high specificity for the NMDA binding site, 
such as APV and CPP, have been employed in radioligand assays to 
characterise further the NMDA site; these com pounds have been 
superseded by the recent development of a num ber of derivatives, such 
as CGS 19755 and D-CPP-ene, which have much higher affinity for the 
NMDA site.
In addition, a num ber of compounds, including MK-801 (dizocilpine) 
and the dissociative anaesthetics, phencyclidine and ketamine, have been 
classified as non-com petitive antagonists, and are show n to act at a 
functionally distinct site (Kemp et al., 1987). Antagonism  of NMDA- 
receptor-m ediated neuronal firing by these com pounds is agonist- and 
voltage-dependent (Kemp et al., 1987), and it is suggested that these 
com pounds bind w ithin an ion channel associated w ith the NMDA 
receptor. Divalent ions, particularly Mg2+, impose a voltage-dependent 
blockade on th.e ion channel, a phenom enon w hich is thought to 
underlie the voltage-dependency of NM DA-mediated firing: addition of 
physio log ica l concen tra tions of M g2+ to h ippocam pal cells in 
m agnesium -free solutions p reven t NM DA-evoked neuronal firing, 
unless the cell membrane is depolarised sufficiently to remove the Mg2+ 
blockade of the ion channel (Ascher & Nowack, 1987). In contrast, 
NM DA-m ediated neuronal firing is enhanced by glycine; therefore the 
NM DA receptor represents a complex, m ultifarious com ponent of
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excitatory amino acidergic transmission in the hippocampus.
Quisqualate Receptors
These are activated selectively by quisqualate and L-glutamate. The 
high affinity agonist oc-amino-3-hydroxy-5-methyl-4-isoxazole propionic 
acid (AMPA) activates a sub-set of quisqualate receptors, the AMPA 
receptor or AMPA-sensitive quisqualate receptor, associated with an ion 
channel. No specific antagonists exist for AMPA-sensitive quisqualate 
receptor. However, three com pounds exist w ith potent antagonistic 
properties at non-NM DA receptors: 6,7-dinitro-quinoxaline-2,3-dione 
(DNQX), 6-cyano-7-nitro-quinoxaline-2,3-dione (CNQX), and 2,3-dihydro- 
6-nitro-7-sulpham ylbenzo(f)quinoxaline (NBQX) have a high specific 
activity for AMPA-sensitive quisqualate receptors (Honore et al., 1988; 
Sheardown et al., 1990).
Recently, a quisqualate receptor associated w ith activation of a G- 
protein and phosphoinositide hydrolysis has been described and nam ed 
the metabotropic or Qp receptor (Sugiyama et al., 1987). This quisqualate 
receptor is activated by ibotenate and ACPD, and is inhibited by AP4. 
This receptor has been deem ed distinct from the AM PA-sensitive 
quisqualate receptor on the grounds that AMPA does not stim ulate 
phospho inositide  hydrolysis (Schoepp & Johnson, 1988), and the 
an tagonists GDEE and CNQX do not inhibit quisqualate-induced  
phosphoinositide turnover (Nicoletti et al., 1986). The precise function 
of the Qp receptpr is not fully understood, but it appears to be involved 
in synaptic plasticity associated with long-term potentiation (Collingridge 
& Singer, 1990).
Kainate Receptors
Kainate-induced neuronal impulses are unaffected by antagonists of 
the NMDA site, and show little sensitivity to the quisqualate-sensitive 
antagonist GDEE, suggesting that kainate receptors represent a distinct
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class of glutam ate receptor (McLennan & Lodge, 1979). Kainate and 
dom oate are highly potent agonists at kainate receptors, w hile AMPA 
and glutamate are moderately affected (Davies et al., 1982).
3.1.2. Ligand-Binding to Glutamate Receptors
The "mixed agonist" property of glutamate requires the use of ligands 
selective for g lutam atergic  receptor sub-types. On the basis of 
electrophysiological data, the prototypic agonists NMDA, quisqualate and 
kainate  w ould  be considered the m ost app ropria te  candidates for 
radioligands. However, [3H]-NMDA binds w ith low affinity and low 
specificity to the NMDA receptor, and has not been em ployed routinely 
as a ligand (Foster & Fagg, 1987 ). The NMDA antagonists [3H]-APV and 
[3H]-CPP have been used with some success as m arkers for the NMDA 
receptor (Foster & Fagg, 1987 ; Olverman et al., 1986); however, the high 
degree of non-specific binding and rapid  dissociation tim e of these 
compounds has limited their use. [3H]-L-glutamate has been show n to 
exhibit a high degree of specific binding to NMDA receptors under 
appropriate  binding conditions, and w ith the use of NM DA as the 
displacer, has been em ployed successfully to label NM DA receptors 
(Monaghan & Cotman, 1985).
AMPA rather than quisqualate has been used to label quisqualate 
receptors, due to concern about the possibility of quisqualate binding to 
kainate receptors (Honore et al., 1982). The affinity of [3H]-AMPA for its 
binding site is increased by chaotropic ions (e.g. SCN"), an observation 
which has facilitated the au toradiographic investigation of AMPA- 
sensitive quisqualate receptors (Honore & Nielsen, 1985). More recently, 
the "metabotropic" (or Qp) quisqualate receptor has been proposed to 
exist (Sugiyama et al., 1987). To date, however, there is no convincing 
method for autoradiographic analysis of this receptor sub-type.
[3H]-Kainate has been reported to bind to both high and low affinity 
sites (Foster & Fagg, 1984); [3H]-kainate binding to the high affinity site
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has similar distribution to the kainate-sensitive [3H]-L-glutamate binding 
site. It has been suggested that the low affinity site represents the AMPA- 
sensitive quisqualate site (Honore & Nielsen, 1985). Kainate and AMPA- 
sensitive quisqualate receptors therefore show considerable overlap in 
their pharmacological profile, an observation which has fuelled the belief 
by some groups that these sub-types represent the same receptor (Jahr & 
Stevens, 1987; Cull-Candy & Usowicz, 1987).
3.1.3. Anatomical Distribution of Glutamatergic Receptors
Electrophysiological studies indicate that NMDA receptors are 
activated in conjunction with quisqualate a n d /o r  kainate receptors 
(Collingridge and Bliss, 1987). Thus, it is of interest to compare the 
anatomical distribution of these receptor sub-types.
NMDA, AMPA-sensitive quisqualate and kainate receptors are found 
in highest levels in the hippocampus (Cotman et al., 1987; Monaghan et 
al., 1983; Monaghan & Cotman, 1985). AMPA and NMDA receptors are 
generally co-localised in the hippocam pus. NM DA-sensitive [3H]-L- 
glutamate binds in highest concentations within CA1 strata radiatum  and 
oriens; [3H]-AMPA binding is also concentrated in the strata oriens and 
radiatum , but has been reported to bind in higher am ounts in the CA1 
stratum pyram idale (Cotman et al, 1987). In contrast, [3H]-kainate binding 
shows a remarkably different pattern of distribution in the hippocampus; 
kainate receptors are confined prim arily to the term inal zone of the 
dentate  mossy fibres in the CA3 stratum  lucidum , a region which 
displays low concentrations of AMPA and NMDA sites. In the dentate 
gyrus, AMPA and NMDA receptors are found in highest quantities in the 
dentate m olecular layer; however, NMDA receptors are concentrated 
towards the inner portion of the molecular layer. Kainate receptors are 
also concentrated w ithin the extrem e inner portion of the dentate 
molecular layer. Therefore, each receptor sub-type is organised distinctly
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within the hippocampus.
3.2. GLUTAMATE AND LONG-TERM POTENTIATION (LTP)
In the hippocam pus, brief, high-frequency stim ulation of the major 
glutam atergic afferents leads to a long-lasting enhancem ent in the 
synaptic response: this phenomenon is known as long-term potentiation 
(LTP). The long-lasting nature of LTP, and the involvem ent of the 
hippocam pus in memory processes has lead to considerable speculation 
that LTP represents a physiological substrate for learning and memory, 
and consequently, the physiological processes which contribute to the 
induction  of LTP in the hippocam pus, and their m anipulation by 
pharmacological means, have been studied in detail.
3.2.1. Induction of LTP
U nder conditions of low -frequency firing in the h ippocam pus, 
neu ronal im pulses are depressed  by b road  spectrum  g lu tam ate  
antagonists and by non-NMDA antagonists, suggesting that under these 
conditions, activation of glutam atergic receptors other than the NMDA 
sub-type is required for neuronal transm ission. Indeed, extensive 
evidence suggests that NMDA receptors are inhibited under conditions 
of low-frequency firing by a voltage-dependent Mg2+ blockade (Nowak et 
al., 1984). It has been hypothesised that tetanic stim ulation  of 
glutam atergic afferents depolarises the cell m em brane for sufficiently 
long to tem porarily rem ove the Mg2+ blockade of NM DA channels, 
allowing activation of NMDA receptors and induction of LTP. Thus a 
single volley of neuronal im pulses does not lead to NMDA receptor 
activation and LTP induction , since the cell m em brane becom es 
hyperpolarised rapidly following the impulse, and the M g2+ blockade is
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replaced.
That NMDA receptor activation is required for the induction of LTP is 
well established. The competitive NMDA receptor antagonist amino- 
phosphonovalerate (APV, AP5) has been dem onstrated to prevent the 
induction of LTP in most regions of the hippocam pus (Bliss & Lomo, 
1973; Collingridge et al., 1983; Mody & Heinem ann 1987; Morris et al.,
11986), and application of NMDA leads to an LTP-like enhancem ent of 
neuronal firing, which is sensitive to APV (Collingridge et al., 1983).
Although NMDA receptor activation is required for LTP induction, it 
appears that other mechanisms are involved in its maintenance. LTP 
canno t be d im in ished  post-induction  by app lica tion  of NMDA 
antagonists (Collingridge et al., 1983). However, LTP is diminished by the 
AMPA-sensitive quisqualate receptor antagonist, CNQX, s u g g e s t i n g  that 
quisqualate receptors mediate to an extent the maintenance of LTP in the 
hippocampus (Davies et al., 1989).
NMDA receptors are not responsible for the induction of LTP in all 
hippocam pal regions: APV does not prevent LTP induction in the CA3 
region follow ing stim ulation  of the m ossy fibre inputs, a result 
consistent with the observation that the terminal zone of the mossy fibre 
inputs to CA3 contains very few NMDA receptors. It is likely that 
kainate receptors, which in contrast are present in this area in extremely 
high quantities, are involved in the induction of LTP in the mossy fibre 
pathway; however, this mechanism is not fully understood.
3.2.2. M echanisms of M aintenance of LTP
' Although the mechanisms which contribute to the induction of LTP 
are generally well understood, the processes which provide maintenance 
of LTP are less clearly defined. Since the discovery of LTP, the locus of 
change responsible for its m aintenance has been in question, and 
remains a matter of controversy. Bliss and colleagues have demonstrated
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that LTP is associated with an increased release of glutam ate (Bliss et al., 
1986), an effect which is prevented by APV (Errington et al, 1987), and the 
authors have suggested therefore that LTP is m aintained by presynaptic 
mechanisms. In contrast, evidence for a postsynaptic mechanism  has 
arisen from observations of slice preparations in electrophysiological 
conditions w hich allow activation of both  NM DA receptors and 
quisqualate receptors, such as low Mg2+ concentrations (Muller & Lynch, 
1988). When hippocampal neurones were subjected to conditions which 
induce LTP formation, quisqualate receptor-mediated ionic currents were 
po ten tia ted  to a considerably larger degree than N M D A -m ediated 
currents, suggesting that a quisqualate receptor-linked event is involved 
in the m aintenance of LTP. Had LTP resulted in simply an increased 
transm itter release, then responses to NMDA and quisqualate receptor 
activation might have been expected to be potentiated in parallel; thus it 
was suggested that quisqualate-sensitive responses in the postsynaptic 
neurone are modified selectively in response to LTP. Further evidence 
for a postsynaptic  location for LTP m aintenance is derived  from 
iontophoretic experim ents which dem onstrated that LTP is associated 
w ith  an increase in sensitiv ity  of CA1 neurones to AMPA and 
quisqualate (Davies et al., 1989). The increased sensitivity was prevented 
if APV was present during tetanic stimulation of neurones, and thus is 
apparen tly  dependen t on induction of LTP th rough  stim ulation of 
NMDA receptors. Further, the increase in sensitivity developed slowly 
after induction Qf LTP, and reached maximum approxim ately one hour 
after induction of LTP. These observations have lead to the suggestion, 
therefore, that LTP may be m ain tained  in itially  by presynap tic  
mechanisms, such as increased transmitter release, and at later times by 
m odulation of postsynaptic events.
In addition, a num ber of second messenger-related events are thought 
to be involved in the m aintenance of LTP. There is considerable 
evidence that Ca2+ enters the postsynaptic cell through NMDA channels,
37
and may be involved in postsynaptic events. LTP can be prevented by the 
injection of calcium chelators (Lynch et al., 1988), while increasing the 
Ca2+ concentration induces an LTP-like increase in synaptic transmission 
(M alenka et al., 1988). The effect is specific to NMDA receptors: 
prom pting Ca2+ entry through voltage-gated ion channels by depolarising 
the cell does not induce LTP, and thus calcium entry specifically through 
NMDA channels would seem to be a requirement for LTP. Substantial 
experim en ta l ev idence  exists to su p p o rt a ro le  for p ro te in  
phosphorylation in LTP. Phosphorylation of protein FI (or GAP43; B50), 
a substrate for protein kinase C, has been dem onstrated in the dentate 
gyrus following LTP induction (Linden et al., 1988); this mechanism is 
prevented by APV. However, the precise function of protein kinase C in 
LTP is unclear. Incubation of hippocam pal slices with phorbol ester, 
which activates protein kinase C, results in a synaptic facilitation which is 
similar to LTP (Muller et al., 1988b); however, the effect is dependent on 
the presence of phorbol ester, and is reversed when the slices are 
returned to control medium. Further, the protein kinase C inhibitor H-7 
did not block the form ation of LTP in response to high-frequency 
stimulation, suggesting that protein kinase C activation is not critical in 
the induction of LTP. Other authors have reported that incubation of 
hippocampal slices in the presence of protein kinase C inhibitors results 
in the formation of LTP which is short-lasting (Malinow et al., 1988), and 
hypothesised that protein kinase C activation may be required for the 
long-term maintenance, rather than the induction, of LTP. The protein 
kinase C inhibitor K-252-b has been demonstrated to block the prolonged 
m aintenance of LTP and the increase in sensitivity to AMPA of CA1 
neurones (Collingridge et al., 1989); these observations support the role 
for a slowly-developing postsynaptic mechanism of LTP maintenance. 
H ow ever, the actions of K-252-b on o ther kinases, in particu lar 
C a2+ /ca lm odu lin -dependen t kinase, have not been quantified, and 
therefore the particu lar kinase involved in this response cannot be
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identified with certainty.
The quisqualate metabotropic receptor has been suggested to play a 
role in synaptic plasticity, and has therefore received attention as a 
possible m ediator of LTP in the hippocam pus. A ctivation of the 
m etabotropic receptor results in stim ulation of phospholipase C and 
consequent p roduction  of the second m essengers diacylglycerol and 
inositol tris-phosphate (IP3), and therefore may be responsible for the 
observed phosphorylation of protein FI following LTP. Nicoletti and 
colleagues (1988) provided further evidence for the involvem ent of the 
phospho inositide  system  in the dem onstration that stim ulation  of 
phosphoinositide  hydrolysis by glutam ate and ibotenate in the rat 
h ippocam pus is potentiated following spatial learning. This w ould 
support a function for a glutam ate receptor linked to phosphoinositide 
m etabo lism  in the a lte ra tions w hich accom pany  LTP in the 
hippocam pus.
If a presynaptic mechanism such as increased transm itter release is 
responsible for m aintaining LTP imm ediately following its induction, 
then it is of interest to consider how this mechanism may be initiated. It 
is possible that increased transmitter release is the result of the actions of 
glutam ate at presynaptic autoreceptors; indeed, some evidence exists to 
suggest that glutam atergic receptors situated on the presynaptic nerve 
term inal do m ediate increased release of glutam ate from the nerve 
ending (Nadler et al., 1990).
Bliss and colleagues have proposed that arachidonic acid metabolites 
may act as second messengers in LTP; these are able to diffuse across the 
cell m em brane, and  hence m ay be em ployed as trans-synap tic  
messengers, produced postsynaptically when LTP is induced, and acting 
p resynap tica lly  to increase transm itter release. A ccordingly, the 
lipoxygenase inh ib ito r nord ihydroguaiare tic  acid (NDGA), w hich 
prevents arachidonic acid metabolism , blocked LTP induction in the 
dentate gyrus, and prevented the maintenance of LTP in CA1 (Williams
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& Bliss, 1988). In addition, NDGA has been show n to reduce pre- 
established LTP (Williams & Bliss, 1989), suggesting a direct role for 
arachidonic acid and its metabolites in the maintenance of LTP.
Finally, Lynch & Baudry (1984) have proposed that Ca2+ flux during 
LTP activates calpain, a protease which degrades a structural, spectrin-like 
protein called fodrin. The authors suggested that proteolysis induces a 
conform ational alteration of the postsynaptic m em brane, resulting in 
liberation of previously occluded glutamatergic receptors, allowing them 
to participate in the postsynaptic element of LTP. The use of such a 
system may explain the increased sensitivity of CA1 neurones to AMPA 
following induction of LTP.
The availability of pharm acological agents specific for glutam ate 
receptor sub-types, and the relative neuroanatom ical sim plicity of 
hippocam pal excitatory am ino acidergic pathw ays, have facilitated 
experim ental analysis of glutam atergic m echanism s in hippocam pal 
transmission. The discovery of LTP and its implications as a substrate for 
learning and memory have enhanced interest in the processes directly 
responsible for its induction and m odulation. Indeed, despite  its 
relatively recent discovery, much more is known about the hippocampal 
glutamatergic system than many other transmitter systems dem onstrated 
to m odulate hippocampal transmission.
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4. ACETYLCHOLINE AND THE HIPPOCAMPUS
4.1. ACETYLCHOLINE AS A NEUROTRANSMITTER
Ironically, although acetylcholine occupies a historically senior 
position among neurotransm itter candidates, much more information is 
available on the anatom ical organisation of other, non-cholinergic 
neurones identified more recently. A major factor for this has been the 
lack of unequivocal m ethodology for identify ing CNS cholinergic 
neurones: the precursors to acetylcholine (choline and acetate) are 
entrenched in m any other biological pathways, and thus cannot be used 
to discriminate specific cholinergic sites from non-specific metabolic sites. 
However, in recent years, histochemical and im m unoassay techniques 
have been used to m ap successfully the enzym es which catalyse the 
form ation and subsequent breakdow n of acetylcholine: these are, 
respectively, choline acetyl transferase and acetylcholinesterase, and their 
use has enabled cholinergic neurones to be identified throughout the 
CNS (for review see Cuello & Sofroniew, 1984).
The recent developm ent of rad io labelled  ligands specific for 
cholinergic receptors has facilitated more specifically the distribution of 
cholinergic receptors to be studied, and these techniques have lead within 
a relatively  recent tim e-fram e to detailed  anatom ical analysis of 
cholinergic systems; however, the precise function of acetylcholine 
within many are^s of the CNS remains obscure.
4.1.1. Sub-types of Acetylcholine Receptor
On the basis of their affinities for muscarine and nicotine, cholinergic 
receptors may be sub-divided into muscarinic and nicotinic receptors. 
These two classes of receptors have markedly different distributions and 
functions w ith in  the CNS. H ow ever, in view of the belief that
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transm ission  in the sep toh ippocam pal pa thw ay  is m ediated  by 
m uscarinic receptors (Cole & Nicoll, 1984b), this thesis will focus on 
muscarinic mechanisms of transmission only.
M uscarinic receptors have been sub-div ided  follow ing rigorous 
pharm acological, electrophysiological and m ore recently m olecular 
biological investigations. Around 1970, observations were m ade that 
muscarinic drugs affected selectively the physiological responses of some 
peripheral organ system s. For exam ple, the m uscarinic antagonist 
pirenzepine produced very few of the side effects attributed to muscarinic 
blockade by atropine (Ishimori & Yamagata, 1982), and Ham m er and 
colleagues (1980) dem onstrated that m uscarinic receptors may be sub­
divided depending on their affinity for pirenzepine. Further evidence 
for receptor heterogeneity has arisen from ligand-binding experiments. 
While the classical antagonists such as atropine, N-m ethylscopolam ine 
and quinuclid inylbenzilate  fail to differentiate betw een m uscarinic 
receptor subpopulations, [3H]-pirenzepine binding occurs with different 
affinities in different tissue populations: for exam ple, the affinity for 
pirenzepine in sym pathetic ganglion cells has been m easured to be 23- 
fold higher than in isolated rat ileum (Brown et al., 1980). Goyal and 
Rattan (1978) proposed the existence of two receptor sub-types: those 
which m ediated inhibition in ganglionic receptors were designated Ml 
receptors, w hile those receptors w hich m ediated  sm ooth m uscle 
contraction were nam ed M2; while the precise inhibitory or excitatory 
role of each receptor sub-type is unclear, this nom enclature is widely 
accepted. Thus, M l receptors display a high affinity, and M2 receptors 
display a low affinity, for the muscarinic antagonist pirenzepine. Using 
ligand-binding techniques, Mash and colleagues (1985) observed that M2 
receptors are selectively reduced following denervation, and concluded 
that M l receptors were located postsynaptically, while M2 receptors were 
found presynaptically, perhaps acting as autoreceptors in the control of 
acetylcholine release. However, other authors have not replicated these
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results (see Results and Commentary, Section 2.5.2., this study).
Until recently, the molecular basis for the diversity of m uscarinic 
receptors has been the subject of debate. Some reports have claimed that 
M l and M2 binding sites are interconvertible, since muscarinic receptors 
lose their pirenzepine selectivity upon solubilization, indicating that 
m em brane-related factors such as coupling to an effector system may 
determine the binding characteristics of muscarinic receptors (Baumgold 
et al., 1987). Further, it has been suggested that specific antagonists induce 
receptor isomerisation, resulting in an enhanced affinity for the binding 
site for those antagonists (Luthin & Wolfe, 1984). Recently, the existence 
of two separate populations of Ml receptors with high or low affinity for 
carbachol has been observed (Flynn et al., 1991; Freedm an et al., 1988; 
Potter & Ferrendelli, 1989), and it has been suggested that these represent 
states of coupling to the regulatory G proteins. One report has correlated 
inhibition of phosphoinositide turnover in the striatum  by selective 
muscarinic agonists with receptor occupancy (Monsma et al., 1988); the 
authors noted that inhibition of carbachol-stim ulated phosphoinositide 
turnover by the selective Ml antagonist pirenzepine conformed to a two- 
site model, thus from these results it would appear that high and low 
affinity Ml receptors are coupled to the same second messenger system.
With the advent of cloning techniques, it has become apparent that 
muscarinic receptors may be sub-divided in terms of their m olecular 
structure. In a recent review, five structurally  distinct m uscarinic 
receptors have been identified (Bonner, 1989), but it is unclear w hether 
these are functionally heterogeneous, since there exists at present no 
pharmacological means for their discrimination.
4.1.2. M uscarinic Receptors and Second Messenger Activity
Other attem pts to classify muscarinic receptors according to their 
effector systems have dem onstrated a complex relationship betw een
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receptors and transduction mechanisms. It has been suggested that the 
M l receptor is coupled to phosphoinositide hydrolysis (Fisher & Bartus, 
1985) through the activation of a phospholipase-specific G-protein, Gp, 
while the M2 receptor activates a G-protein, Gj, which leads to inhibition 
of adenylate cyclase activity (Onali et al., 1983). However, other reports 
have suggested that in the rat brain Ml and M2 receptors may be coupled 
to phosphoinositide turnover (Ashkenazi et al., 1987; Brown et al., 1985; 
Fisher & Bartus, 1985; Lazareno et al., 1985). The possibility of "cross-talk" 
betw een adenylate  cyclase and phosphoinositide second m essenger 
system s (Otte et al., 1989), and also the lack of agonists with high 
specificity for M l and M2 receptors, are factors which have as yet 
prevented the elucidation of the precise function of M l and M2 receptors 
in CNS cholinergic transmission. The evidence for muscarinic coupling 
to phospho inositide  m etabolism  and adenylate cyclase activity is 
reviewed below.
Phosphoinositide Metabolism
There is convincing evidence that muscarinic receptors are coupled to 
the phosphoinositide cycle: muscarinic agonists have been dem onstrated 
to induce phosphoinositide hydrolysis in the brain (see Berridge et al., 
1983; Fisher & Agranoff, 1987 for reviews). An apparent relationship 
exists betw een the potency  of a m uscarinic  agonist to induce 
phosphoinositide hydrolysis and the density of muscarinic binding sites 
in different brain regions. Accordingly, phosphoinositide turnover is 
pronounced in the hippocam pus, cortex and striatum , which contain 
large num bers of m uscarinic receptors, w hile the brainstem  and 
cerebellum yield less inositol phosphate metabolism. However, studies 
which employ selective agonists and antagonists reveal a more complex 
receptor-effector relationship. Inositol phosphate m etabolism  in the 
cortex and hippocam pus is inhibited readily by low concentrations of 
pirenzepine, suggesting the involvem ent of an M l receptor (Fisher &
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Bartus, 1985; Fisher & Snider, 1987; Gil & Wolfe, 1985; Lazareno et al., 
1985). In contrast, in the striatum and brainstem pirenzepine displays a 
m oderate potency in blocking phosphoinositide metabolism , indicating 
that M2 receptors are involved (Fisher & Bartus, 1985; Fisher & Snider, 
1987; Lazareno et al., 1985).
If the majority of muscarinic receptors coupled to phosphoinositide 
metabolism in the hippocampus and cortex are of the M l sub-type, then 
it w ould be expected that M l-selective agonists should  stim ulate  
m axim ally phosphoinositide  turnover in these areas. It has been 
suggested how ever that the intrinsic agonist activity as well as the 
occurrence of receptor reserve, i.e., the efficacy of receptor-effector 
coupling as well as receptor density determine the final cellular response 
to muscarinic stimulation. Fisher and colleagues (Fisher & Bartus, 1985; 
Fisher & Snider, 1987) reported a different regional efficacy of coupling 
betw een m uscarinic receptors and phosphoinositide hydrolysis, and 
postulated that spare receptors may underlie the differences in efficiency 
of coupling. Thus in the striatum an efficient coupling is achieved by the 
presence of spare receptors, while in the hippocam pus and cortex, the 
apparen t paucity  of receptor reserve w ould indicate a less efficient 
coupling. As a consequence, full agonists produce phosphoinositide 
hydrolysis in the hippocam pus and cortex, while partial agonists are 
alm ost entirely  ineffective (Brown et al., 1984; Fisher et al., 1983). 
Paradoxically, carbachol, a full agonist with apparent M2-selectivity, is 
highly active in the hippocam pus and cortex, and is used routinely to 
promote phosphoinositide hydrolysis (Gonzales & Crews, 1984; Janowsky 
et al., 1984); the most obvious explanation is that carbachol displays some 
affinity for M l receptors; however, carbachol has been used in ligand- 
binding experim ents to differentiate betw een M l and M2 receptors, 
although it has been suggested that under certain conditions, carbachol 
may bind to both M l and M2 receptors (see M ash & Potter, 1986 for 
discussion). Instead, M2 receptors in the hippocam pus m ay indeed be
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linked to phosphoinositide hydrolysis in the hippocam pus and cortex, 
and may be responsible for the efficacy of carbachol in the induction of 
phosphoinositide  metabolism . The developm ent of full m uscarinic 
agonists with specific Ml-selectivity would perhaps clarify the role of M l 
receptors in phosphoinositide hydrolysis. At present, therefore, the 
relative contributions of M l and M2 muscarinic receptor sub-types to 
phosphoinositide metabolism in the brain are not fully understood.
Adenylate Cyclase Activity
M uscarinic agonists have been observed to inhibit adenylate cyclase- 
m ediated form ation of cyclic AMP (cAMP). Thus, neuronal adenylate 
cyclase is thought to be coupled to muscarinic receptor occupation via an 
inhibitory G -protein (Onali et al., 1983), and cAMP levels have been 
observed to dim inish in the presence of m uscarinic agonists such as 
oxotrem orine. Gil and Wolfe (1985) dem onstrated that the inhibitory 
effects of m uscarinic receptor activation on striatal adenylate cyclase 
activity were not sensitive to pirenzepine, supporting the involvem ent 
of M2 rather than Ml receptors in this response. Further, muscarinic 
receptor-m ediated inhibition of adenylate cyclase is apparently achieved 
through activation of a pertussis toxin-sensitive G-protein; therefore 
cAMP inhibition by muscarinic agonists is reduced by treatm ent w ith 
pertussis toxin, while phosphoinositide hydrolysis is unaffected (Kelly et 
al., 1985a). Therefore, M2 receptors appear to be coupled independently to 
both adenylate cyclase and phosphoinositide second messenger systems.
4.1.3. Ligand-Binding to Muscarinic Receptors
The d istribu tion  of m uscarinic receptors in the brain  has been 
dem onstrated convincingly with the use of ligand-binding techniques. 
Two ligands have been em ployed extensively: the tertiary com pound 
[3H ]-quinuclidinyl benzilate ([3H]-QNB; Wamsley et al., 1984), and the
46
quaternary com pound [3H]-N-methylscopolamine ([3H]-NMS; W amsley 
et al., 1980). These ligands do not show selectivity for M l or M2 sub-types 
of muscarinic receptors. Several groups, however, have noted that [3H]- 
NMS labels far fewer muscarinic receptor sites than does [3H]-QNB in 
intact cells or brain  homogenates, and it has been suggested that the 
lipophilicity  of [3H]-QNB allows it to label internalised m uscarinic 
receptors which, because of their position in the cell m em brane, are 
inaccessible to the positively charged [3H]-NMS (Lee et al., 1986). 
However, NMS has been dem onstrated to inhibit fully phosphoinositide 
hydrolysis, suggesting that the sub-set of muscarinic receptors detected by 
[3H]-QNB probably do not contribute to the physiological response 
(Brown & Goldstein, 1986). Therefore [3H]-QNB has been suggested to 
m easure the total num ber of receptors within the cell, while [3H]-NM S 
measures only those receptors whose occupation contributes to a cellular 
response.
C onfirm ation  of d ifferent m uscarinic sub-types, and  deta iled  
description of their anatomical distribution, has been ham pered by the 
lack of radiolabelled ligands specific for sub-types of muscarinic receptors. 
[3H]-Pirenzepine has been used with some success in assays to locate Ml 
muscarinic receptors (Tonnaer et al., 1988; Wamsley et al, 1984), while the 
partial agonist [3H]-Oxotremorine-M has been used to label M2 receptors 
specifically (Mash et al., 1985; Spencer et al., 1986). An alternative 
approach has been used by Mash and colleagues in subsequent studies 
(Mash & Potter, 1986): muscarinic receptors were labelled with [3H]-QNB 
in the presence of non-labelled pirenzepine or carbachol, in o rder to 
displace binding to M l or M2 receptors respectively.
Recently, Regenold and colleagues (1989) used [3H]-AF-DX 116, a novel 
m uscarinic antagonist highly selective for M2 receptors in quantitative 
autoradiographic studies of the rat brain. The authors show ed that 
differences occurred between the regional distributions of [3H]-AF-DX 116 
binding and those of [3H]-oxotrem orine-m ethiodide ([3H]-OXO-M), a full
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M2-selective muscarinic agonist (Spencer et al., 1986), and suggested that 
these discrepancies may be due to the existence of sub-types of M2 
receptors. However, until more specific pharmacological agents become 
available, the further sub-division of muscarinic receptor sub-types by 
ligand-binding techniques is not possible, and their functional relevance 
will remain uncertain.
4.1.4. Anatomical Distribution of Muscarinic Receptors
Ligand-binding studies which employ agonists or antagonists specific 
for M l or M2 sub-types of muscarinic receptors have dem onstrated that 
these two sub-types differ m arkedly in their anatomical d istribution 
(Mash & Potter, 1986; Regenold et al., 1989; Tonnaer et al., 1988).
M ash & Potter used [3H]-QNB in the presence of the M l-selective 
antagonist pirenzepine, or the M2-selective agonist carbachol, in order to 
m easure M2 or M l receptor densities respectively. The authors reported 
th a t M2 recep to rs  are  d is tr ib u te d  in a s im ila r m an n er to 
acetylcholinesterase, and suggested therefore that M2 bind ing  sites 
represen t presynaptic  autoreceptors, while M l receptors are found 
postsynaptically. Consequently, in the hippocam pus, M2 receptors are 
prevalent as a sharp band in the stratum  oriens throughout CA1-CA4, in 
agreem ent w ith the distribution of acetylcholinesterase (Mosko et al.,
1973). In the dentate gyrus, M2 receptors were concentrated in the 
in frag ranu la r l^yer. [3H]-QNB binding  to M l receptors in the 
hippocam pus was m arked in the CA1 stratum  radiatum  and in the 
dentate molecular and granule cell layers. M l binding was observed to be 
very low in the subiculum.
A m ore quantitative approach which involved histological definition 
of ligand-binding in distinct hippocampal regions was used by Tonnaer 
and colleagues (Tonnaer et al., 1988). The authors employed [3H]-QNB to 
m easure total muscarinic receptor concentrations, and [3H ]-pirenzepine
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to m easure M l receptors; M2 receptor concentrations were inferred by 
the [3H ]-Q N B /[3H]-pirenzepine ratio. In contrast to the previous report, 
Tonnaer and colleagues observed that M l receptors were dense in the 
subiculum  and in the stratum  oriens/pyram idale of CA1. Less binding 
was evident in the stratum  radiatum . While these discrepancies may be 
due partly to the more histologically specific approach of the authors, the 
m ore likely reason for the m arked difference in reported M l receptor 
levels in the subiculum  may be differences in the ligand-binding 
protocols. It is possible that the low subicular density of M l receptors 
noted by Mash and Potter (1986) represents an action of the M2 displacer 
carbachol on M l receptors. It has been suggested that some binding 
conditions uncouple receptor sub-types such that "high and low" affinity 
sites for carbachol b inding  correspond to M2 and M l receptors 
respectively, (see Mash & Potter, 1986 for discussion), so that carbachol 
under certain conditions may not be selective for M2 receptors. Further, 
Regenold et al. (1989) have shown that [3H]-AF-DX 116, the highly 
selective M2 antagonist, binds in large quantities in the subiculum: it is 
possible that these discrepancies are due to the existence of a sub-type of 
muscarinic receptors, for which [3H]-AF-DX 116 has high affinity, in the 
subiculum.
4.2. ACETYLCHOLINE AND THE SEPTOHIPPOCAMPAL PATHWAY
The involvem ent of cholinergic neurones in septohippocam pal 
transmission is well-documented (see Nicoll, 1985 for review), and stems 
from the observation that w hereas m uch of the cerebral cortex is 
innervated diffusely by cholinergic afferents, the hippocam pus receives a 
dense cholinergic projection from the medial septum. The hippocampus 
is well-defined in terms of its other major, glutam ate afferent (Swanson 
et al., 1987), and therefore provides a rare opportunity to study in detail
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the m odulatory actions of acetylcholine on glutamatergic transmission.
Pharm acological studies have dem onstrated  that application  of 
acetylcholine or m uscarinic agonists to the hippocam pus results in 
increased firing of hippocampal pyram idal cells (Cole & Nicoll, 1984a). 
Further, electrical stimulation of the medial septum  results in facilitation 
of glutam atergic-m ediated pyram idal cell firing within the hippocam pal 
CA1-2 regions; the facilitation is com parable to that p roduced  by 
iontophoretic application of acetylcholine (Krnjevic & Ropert, 1982), 
providing evidence for the involvem ent of the medial septum  in the 
cholinergic m odulation  of hippocam pal transm ission. Conversely, 
removal of the medial septum  in rats resulted in im paired function in 
cognitive tasks thought to involve hippocam pal activity (H agan & 
Morris, 1988).
E lectrophysio logical analysis of cholinergic sep toh ippocam pal 
transmission has revealed that acetylcholine acts primarily to abolish two 
K+ currents, an afterhyperpolarisation current (IAnp) and the M-current. 
The M -current is a voltage- and tim e-dependent K+ current which has 
some activity when the cell is at rest, and which acts to repolarise the cell: 
Cole and Nicoll, (1984a) postulated that the value of the m em brane 
potential in hippocam pal neurones may reflect a balance betw een the 
actions of the M-current and the continuous leakage of K+ ions across the 
m em brane according to their concentration gradient. Thus the M- 
current under resting circumstances helps to maintain the polarity of the 
neurone. Wheyt the cell m em brane is depolarised by firing of its 
glutam atergic afferents, the M -current becomes fully activated, thus 
acting to repolarise the cell membrane.
The afterhyperpolarising current, the IAHp is a Ca2+ -activated K+ 
curren t which becom es active during  cell firing, and resu lts in 
hyperpolarisation  of the m em brane follow ing the action po ten tial 
discharge, thus inhibiting further cell mem brane depolarisation. Both 
currents are inhibited by muscarinic agonists and acetylcholine, resulting
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in an increased cell excitability: abolition of the M -current facilitates 
d ep o la risa tio n  of the cell m em brane, w hile  rem oval of the  
afterhyperpolarisation current reduces the delay between action potential 
discharge.
D espite the apparen tly  w ell-understood m echanism s by w hich 
acetylcholine exerts it actions on hippocam pal neurones, the degree of 
involvem ent of individual muscarinic receptor sub-types in the cellular 
response to cholinergic stimulation is less clear. In a recent report, Dutar 
and  Nicoll (1988) exam ined the electrophysiological responses to 
pharm aco log ica l m an ipu la tions of m uscarin ic  recep to rs in the 
hippocam pus. The authors were able to dem onstrate  that the M2 
receptor antagonist gallamine prevented the muscarinic blockade of the 
M-current, suggesting a role for M2 receptors; in contrast, the IAhp was 
unaffected by gallamine, and was therefore presum ed to be linked to an 
M l recep to r-m ed ia ted  m echanism . H ow ever, the M l-se lec tive  
antagonist pirenzepine did not display a discrim inatory  effect, and 
blocked both the M-current and the IAj_ip in a dose-dependent fashion, 
suggesting that M l receptors may be involved in both components.
The M -current has been dem onstrated to be insensitive to the actions 
of phorbol esters (Baraban et al., 1985) and muscarinic drugs which act as 
partial agonists such as arecoline and oxotrem orine (Dutar & Nicoll, 
1988). However, full agonists such as carbachol and oxotremorine-M are 
able to inh ib it the M -current; fu rther, increasing  in trace llu lar 
concentrations of; inositol tris-phosphate markedly reduced the size of the 
M-current, suggesting that inositol tris-phosphate, but not protein kinase 
C activation, is involved in the muscarinic receptor-m ediated abolition 
of the M-current. However, inositol tris-phosphate may exert some of its 
actions non-specifically, through release of calcium from intracellular 
stores, resu ltin g  in w idesp read  cellu lar m odifica tions such as 
phosphorylation of ion channels. In contrast, phorbol esters have potent 
ability to abolish the IAHp (Baraban et al., 1985), prom oting a role for
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protein kinase C. This observation at least is in accordance with the view 
that M l receptors m ediate blockade of the IAHp in the hippocam pus, 
through stim ulation of the phosphoinositide system.
Finally, it has been demonstrated that both the IAHP and the M-current 
are insensitive to treatm ent with pertussis toxin (Dutar & Nicoll, 1988) 
suggesting that pertussis toxin-sensitive G-proteins, such as Gj or G0, and 
hence m uscarinic-m ediated inhibition of adenylate cyclase, are not 
involved in these mechanisms.
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5. NEUROPATHOLOGY OF THE HIPPOCAMPUS
The hippocam pus is vulnerable to a number of neurodegenerative 
diseases, which appear to result in particular patterns of pathology within 
specific neurotransmitter systems. Alzheimer's Disease is associated with 
p ro found  neurodegeneration  in the hippocam pus, neocortex, and 
destruction of large numbers of neurones in the cholinergic basal 
forebrain nuclei; the cognitive impairments of the disease have been 
attributed  to the loss of cholinergic innervation of the cortex and 
hippocampus (Perry et al., 1978); however, recent evidence implies a role 
for g lu ta m a te  in the observed  n eu ro d eg en e ra tiv e  a lte ra tions  
(Greenamyre et al., 1987).
Cerebral ischaemia has also been shown to be associated with specific 
neurodegeneration in the hippocampus and neocortex (Kirino, 1982; 
Volpe & Hirst, 1983); there is a correlation between the areas vulnerable 
to ischaemic damage and the densities of glutamate receptors within the 
brain, and the extremely high levels of glutamate found in the brain 
during ischaemia have been implicated in the ischaemic damage.
The evidence for cholinergic and glutamatergic mechanisms in the 
pathophysiology of Alzheimer's Disease, and the role of glutamate in the 
neurodegeneration which accompanies cerebral ischaemia is reviewed 
below.
5.1. ALZHEIMER'S DISEASE
By far the m ost common dementia in the developed w orld  is 
Alzheimer's Disease, a progressive disorder characterised by severe 
memory loss and general cognitive decline (Huppert & Tym, 1986). In 
Britain, it has been estimated that 5% of the population over the age of 
65, and almost 25% of those over 80 have Alzheimer's Disease (Deary &
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Whalley, 1988); however, despite concentrated research efforts, the 
aetiology of Alzheimer's Disease remains obscure.
Alzheimer's Disease may be separated from other types of dementia by 
neuropathological diagnosis post-mortem. There is atrophy of the brain, 
particularly of the temporal and frontal lobes, manifested by shrinkage of 
the gyri and widening of the sulci. Microscopical examination reveals a 
diffuse loss of neurones in the cortex and hippocampus, and a profound 
loss of cells in the cholinergic basal forebrain nuclei. The most striking 
feature, however, and that upon which positive diagnosis of Alzheimer's 
Disease is based (Khachaturian, 1985) is the presence of large numbers of 
senile plaques and neurofibrillary tangles.
The general histological features of plaques are usually described in 
terms of a central spherical amyloid "core" surrounded by degenerating 
neurites (presynaptic nerve terminals) and glial cells (Brun 1983). 
Wisniewski and Terry (1973) have, however, sub-divided plaques into 
three categories depending on their stage of development: first, a
primitive plaque, consisting of a small number of neurites and a small 
am ount of amyloid, found typically in young Alzheimer patients; 
second, a mature plaque consisting of a dense core of amyloid and 
numerous neurites, found in greater quantities in older patients; and 
third, a "burnt-out" plaque which consists almost entirely of amyloid. 
Plaque amyloid is composed predom inantly  of (3-amyloid, a low 
molecular weight protein which is also found in cerebrovascular amyloid 
(Selkoe, 1987). Analysis of the plaque core has suggested the presence of a 
form of aluminosilicate, lending support to the hypothesis that mineral 
deposition may be a stimulus for plaque formation (Bertholf, 1987). 
Plaque neurites appear to derive from a variety of neurone types, 
including cholinergic, noradrenergic, somatostatinergic (Walker et al.,
1988), and possibly glutamatergic (Perry, 1986) neurones.
Plaques are found in high quantities in the hippocampus, frontal and 
temporal cortex, and amygdala, but are sparse in other cortical areas
54
(Mann 1988), suggesting that some selective process for plaque formation 
exists.
Neurofibrillary tangles are also present in large num bers in the 
hippocampus and cortex, but are also found in subcortical structures such 
as the cholinergic forebrain nuclei, the raphe nuclei and the locus 
coeruleus (Mann et al., 1985; Perry, 1986; Wilcock & Esiri, 1982). Tangles 
appear to be an accumulation of filamentous material within the 
neuronal perikarya (Brun, 1983), and electroscopy has revealed their 
structure to be a pair of tightly adhered, helically wound filaments, 
referred to as paired helical filaments (Kidd, 1963). It is unclear whether 
these represent a modification of normal cytoskeletal elements, or the 
synthesis of an abnormal protein. However, considerable cross-reactivity 
has been dem onstra ted  immunologically between tangles and the 
microtubule-associated proteins, MAP2 and tau.
The formation of tangles within the neuronal perikarya has been 
postulated to underlie the cell loss in Alzheimer's Disease (Saper et al., 
1985), and it is possible that accumulation of tangles results in progressive 
disruption of essential intracellular functions such as protein synthesis, 
and oxidative metabolism (Sumpter et al., 1986), leading ultimately to 
neuronal death.
Although diagnosis of Alzheimer's Disease is based on the presence of 
neuronal plaques and tangles, their functional significance remains 
obscure. Numbers of plaques have been correlated positively by some 
researchers with the degree of cognitive decline in Alzheimer patients 
(Blessed et al., 1968; Wilcock & Esiri, 1982), while other researchers found 
no relationship between dementia and tangle or plaque counts (Neary et 
al., 1986)
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5.1.1. Cholinergic Dysfunction in Alzheimer's Disease and the Cholinergic 
Hypothesis of Learning and Memory
Of the many neurotransmitter systems which have been observed to 
suffer a degree of disruption in the course of Alzheimer's Disease, the 
most consistent neurochemical alterations are related to the cholinergic 
system. With few exceptions, reductions in choline acetyltransferase 
(ChAT) activity have been demonstrated in the cerebral cortex and 
hippocampus of Alzheimer patients (Davies & Terry, 1981; Mountjoy et 
al., 1984; Perry et al., 1977; White et al., 1977). Reduction in ChAT activity 
is most likely to stem from the vast degeneration of cholinergic neurones 
in the basal forebrain nuclei (McGeer et al., 1984; Saper et al., 1985; 
Whitehouse et al., 1982), which provide the cortex and hippocampus 
with their major cholinergic innervation. The degree of reduction in 
ChAT activity has been correlated with plaque counts and the degree of 
cognitive impairment in Alzheimer patients (Perry et al., 1978), and this 
has lead to the formation of the "cholinergic hypothesis" of memory, 
which postulates that the cognitive impairments of Alzheimer's Disease 
are linked directly to the degree of d isturbance  in cholinergic 
transmission. The cholinergic hypothesis has been reviewed critically by 
Bartus and colleagues (1982), who put forward three criteria which 
should be satisfied if such a hypothesis were to receive credence. The first 
criterion, which requires that Alzheimer's Disease is associated with 
specific alterations in cholinergic markers, is satisfied by the consistent 
observation of depleted ChAT in Alzheimer brains. In addition, deficits 
in high affinity choline uptake (Rylett et al., 1983) have been observed in 
Alzheimer hippocampus and cortex, while reduced concentrations of 
acetylcholine have been measured in the cortex of Alzheimer patients 
(Richter et al., 1980).
The second criterion requires that if cognitive deficits are due to 
dysfunction of cholinergic neurones, then these deficits should be able to 
be reproduced in animals, through pharm acological blockade of
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cholinergic  m echanism s or th rough  destruction  of cortical or 
hippocampal cholinergic afferent pathways. This criterion is satisfied to a 
large extent: administration of the muscarinic antagonist scopolamine to 
rodents and primates results in generally impaired performance of 
cognitive tasks such as discriminatory and acquisition learning (see 
Collerton et al., 1986 for review). Secondly, lesions of cholinergic basal 
forebrain nuclei such as the medial septum or nucleus basalis, or the 
transection of forebrain cholinergic projections to the cortex and 
hippocam pus, have yielded some success in producing  cognitive 
impairments in a number of behavioural tasks (Collerton, 1986).
The third criterion to be satisfied in the cholinergic hypothesis is that 
enhancement of cholinergic function should reverse the cognitive deficit 
in Alzheimer patients and the behavioural deficits produced by 
cholinergic denervation in animals. However, pharmacological attempts 
to improve cognitive ability in Alzheimer patients have produced at best 
equivocal results (Bartus et al., 1982), while little or no improvement has 
been dem onstrated in lesion-induced behavioural deficits following 
administration of cholinomimetic agents (Collerton, 1986). The failure to 
satisfy this final criterion, therefore, suggests that the dementia associated 
with Alzheimer's Disease cannot be explained solely by cholinergic 
mechanisms.
While deficits in presynaptic cholinergic markers are detected 
consistently in Alzheimer brain, ligand binding studies of muscarinic 
receptor density have demonstrated less consensus. Muscarinic receptors 
labelled with non-specific muscarinic antagonists have been found to be 
unaltered (Davies & Verth, 1978; Greenamyre et al., 1987) or moderately 
reduced (Rinne et al., 1984) in Alzheimer brains. Binding to Ml receptors 
has been detected to be normal, while M2 receptors are found to be 
decreased (Mash et al., 1985; Perry et al., 1986) in Alzheimer's Disease 
post-mortem. In a similar manner, nicotinic receptors have been 
demonstrated to be both decreased (Whitehouse et al., 1986) or unaltered
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(Shimohama et al., 1986b). Consistent loss of presynaptic CAT activity, 
therefore, is not associated with any consistent cholinergic receptor 
alteration.
An increasing num ber of neurotransm itter systems have been 
demonstrated to be disrupted in the neuropathological degeneration of 
A lzhe im er 's  Disease. For exam ple, biochem ical m arkers  for 
dopaminergic, noradrenergic, serotonergic, peptidergic, GABAergic and 
glutam atergic  transmission have been shown to be altered in the 
hippocampus and cortex of Alzheimer brains (Hardy et al., 1987; Lowe et 
al., 1988; Quirion et al., 1986; Rossor & Iversen, 1986). Further, cortical 
deficits in adrenergic receptors (Shimohama et al., 1986a, 1987), 5HT-J and 
5HT2 receptors (Cross et al., 1984, 1988), somatostatin and corticotrophin- 
releasing factor receptors (Beal et al., 1985; DeSouza et al., 1986), GABAa 
and GABAb receptors, benzodiazepine receptors (Shimohama et al., 1988) 
and glutamate receptors (Greenamyre & Young, 1989) have been reported 
in Alzheimer brains. Statistical correlations have been made between 
many neurotransm itter receptor abnormalities and neuropathological 
changes of Alzheimer's Disease (Mountjoy et al., 1984; Mountjoy 1986). 
The contributions of these alterations to the clinical manifestations and 
neuropathological progression of the disease, however, are unknown.
5.1.2. Glutamate and Alzheimer's Disease
The role of glutamate in long-term potentiation and the ability of 
glutamate antagonists to disrupt memory in behaving animals (Morris et 
al., 1986; Morris, 1989) has no doubt enhanced the interest in glutamate as 
a contributory factor in Alzheimer's Disease. While the significance of 
the widespread pattern of neuronal degeneration is unclear, studies of 
the neuroanatomical distribution of Alzheimer pathology indicate that 
these alterations affect specific hippocampal and cortical regions which 
are interconnected by well-defined groups of neuronal projections, and
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that the disease may progress along connecting fibres to sub-cortical 
regions (Pearson et al., 1985). Thus, the glutamatergic pyramidal cells of 
the hippocampus and interconnected olfactory and "association" areas of 
cortex exhibit severe neuropathology, while somatosensory areas are 
affected minimally. The role for glutamate as the major excitatory 
neurotransm itter in the hippocampus and cortex, and the neurotoxic 
properties of glutamate, have been the basis for the hypothesis that the 
glutamatergic system is involved in the pathophysiology of Alzheimer's 
Disease; further, these observations fuel the postulation that the primary 
lesion in Alzheimer's Disease occurs in the cortex, with the subsequent 
occurrence of sub-cortical lesions. It has been demonstrated that a close 
correspondence exists between the ability of glutamate and its analogues 
to depolarise neurones and their neurotoxic potency (Olney et ai., 1971): 
thus, Olney suggested the term "excitotoxin" to emphasise that the 
neurotoxic effect of these compounds was mediated through a prolonged 
depolarising action at post-synaptic receptor sites. Therefore if glutamate 
were to mediate in neuronal death in Alzheimer's Disease, it would be 
expected that the neuropathological alterations would occur in a pattern 
similar to the disruption of the terminal fields of glutamatergic pathways. 
Consistent with this hypothesis, neurofibrillary tangles have been found 
to be most dense in the terminal zones for presumably glutamatergic 
"association" fibres (Pearson et al., 1985).
The suggestion that the primary lesion of Alzheimer's Disease is 
glutamatergic, and that the neuropathological degeneration is propagated 
along associational pathways is strengthened further by the observation 
that application of glutamate to human neurones in culture induces the 
formation of paired helical filaments similar to those which constitute 
neurofibrillary tangles in Alzheimer's Disease (De Boni & Crapper- 
McLachlan, 1985). Retrograde cellular degeneration has been found in 
the nucleus basalis of M eynert in the hum an  brain  following 
hemidecortication, and in the monkey following large lesions of the
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neocortex (Pearson et al., 1983); in addition, Sofroniew and Pearson 
(1985) have demonstrated that application of NMDA or kainate to the 
cortical surface in rats results in retrograde degeneration of cholinergic 
neurones in the nucleus basalis; the degeneration was similar to that 
produced by mechanical destruction of the cholinergic terminals, and 
indicates that excitotoxic damage in the cortex, presumably mediated 
through post-synaptic excitation, can produce pathological changes in 
subcortical regions similar to those which occur in Alzheimer's Disease.
However, Sanfeliu and colleagues (1990) have dem onstrated that 
exposure of NMDA to septal cells in culture did not result in typically 
prolonged cell activity, and suggested that glutamate-mediated toxicity is 
not likely to be the cause of cell death in septal cholinergic neurones at 
least in Alzheimer's Disease.
An inevitable consequence of excitotoxic cell death is the loss of 
glutamate receptors and terminals as cells are lost. However, evidence 
for glutamatergic receptor alterations indicated by ligand binding studies 
of Alzheimer's Disease post-mortem is less clear cut. NMDA receptors 
have been reported by some groups to be reduced in the cortex and 
hippocampus in Alzheimer brains (Greenamyre, 1986; Greenamyre et al., 
1987; Represa et al., 1988); however, others have reported that NMDA 
receptors are unaltered in the cortex or hippocampus (Cowburn et al., 
1988a,b; Geddes et al., 1986). Similar controversy reigns over studies of 
[3H]-TCP binding to the NMDA ion channel: a loss of [3H]-TCP binding in 
the hippocampus has been reported (Maragos et al., 1987; Monaghan et 
al., 1987), although [3H]-TCP binding in homogenate preparations has 
been demonstrated to be unaltered in the hippocampus, but decreased in 
the frontal cortex, of Alzheimer brains (Simpson et al., 1988).
The status of other glutamatergic receptor sub-types in Alzheimer's 
Disease ! has . been equally difficult to establish. Greenamyre and 
colleagues (1987) have reported a reduction in [3H]-glutamate binding to 
quisqualate receptors in the CA1 and dentate gyrus, while Dewar et al.
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(1991) reported deficits in [3H]-AMPA binding to quisqualate receptors in 
the CA1 and subiculum of Alzheimer brains. Finally, an expansion of 
the kainate receptor field has been reported to occur in the dentate gyrus 
(Geddes et al., 1985); however, this result has not been reproduced by 
other researchers, and Represa et al. (1988) reported a loss of [3H]- 
kainate receptors from Alzheimer hippocampus, with no alteration in 
the kainate receptor distribution field.
5.1.3. Second M essenger Systems and Alzheimer's Disease
It has become evident that neuronal transmission is dependent not 
only on the integrity of the neurotransmitter receptor, but also on the 
integrity of the second messenger signalling systems within the cell. 
Consequently, a number of diseases have been identified in which second 
messenger dysfunction may contribute to their aetiology. However, 
despite the massive disruption of neuronal transmitter systems known 
to occur, little attempt has been made to characterise the functional state 
of second messengers in Alzheimer's Disease.
There is evidence to suggest that dysfunction of second messenger 
systems may underlie the clinical manifestations of affective disorders. 
Decreased activity in the adenylate cyclase system, and the relative 
dominance of the phosphoinositide system has been proposed to occur 
during depression, while during mania the converse has been suggested 
(Wachtel, 1988, J989). Thus the therapeutic efficacy of lithium in the 
treatment of depression may be explained by its ability to inhibit the 
hydrolysis of inositol phosphate, therefore preventing the re-synthesis of 
phosphatidyl inositol 4,5 bisphosphate (see Methods section 3) and 
further activity of the phosphoinositide system. Alternatively, lithium at 
therapeutic concentrations has been shown to inhibit adenylate cyclase 
(Newman et al., 1983); therefore in the treatment of mania, lithium may 
act to inhibit the overactive adenylate cyclase system.
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Second messenger abnormalities have been proposed to occur in 
epilepsy, a condition characterised by spontaneous, recurrent epileptic 
seizures in the absence of a known precipitatory cause or illness. 
Electroconvulsive shock therapy and administration of a number of 
convulsants have been observed to increase markedly the concentrations 
of cAMP in the brain; in contrast, cAMP levels may be reduced by 
anticonvulsants (Wasterlain & Dwyer, 1983). During seizures, activity of 
the phosphoinositide system is enhanced, possibly through activation of 
protein kinase C (Wasterlain, 1989), and an increase in protein kinase C 
activity has been proposed to be associated with neuronal death and 
apparent around epileptic foci in human brains.
Recently, post-m ortem  studies of A lzheim er's  Disease have 
demonstrated that despite widespread neuronal cell loss, [3H ]-phorbol 
ester binding to protein kinase C is preserved in the hippocampus and 
cortex of Alzheimer patients (Horsburgh et al., 1991a). In contrast, using 
immunohistological staining, alterations in distinct isozymes of protein 
kinase C have been found in Alzheimer brain: in particular, intensely 
increased staining occurred in the hippocampal CA3-4 region compared 
with controls (Masliah et al., 1990).
In an effort to investigate the plasticity of second messenger systems, 
w ith reference to a lterations in second m essenger function in 
Alzheimer’s Disease, some attem pt has been m ade to measure the 
response of second messenger systems to experimental denervation in 
animals. Increases in cholinergic-mediated phosphoinositide hydrolysis 
have been demonstrated following disruption of the septohippocampal 
fibres (Connor & Harrell., 1989; Court et al., 1990; Smith et al., 1989). 
While some researchers report alterations in cholinergic-m ediated 
phosphoinositide in the cortex following lesions of the nucleus basalis, 
(Reed & de Belleroche, 1988), these results have not been replicated by 
others (Raulli et al., 1989; Scarth et al., 1989). More subtle alterations in 
second messenger distribution have been measured using ligand binding
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techniques. In contrast to the lack of alterations observed in Alzheimer 
hippocampus, following medial septal lesions in rats, [3H ]-forsko lin  
binding to adenylate cyclase was demonstrated to increase in the dentate 
gyrus-CA3 region of the hippocampus, whereas [3H]-phorbol ester 
binding to protein kinase C increased in the entorhinal cortex (Horsburgh 
et al., 1991b). These results would suggest that following denervation at 
least, second messenger systems are capable of plastic alterations. The 
success of pharmacological approaches to the treatment of cognitive 
deficits in Alzheimer's Disease is dependen t on the integrity  of 
intracellular transduction systems, and thus expanded research into the 
functional state of second messenger systems in Alzheimer's Disease and 
animal models of denervation is merited.
5.1.4. Animal Models of Alzheimer's Disease: Cholinergic Denervation
The diversitv of neuropathological and neurochemical abnormalities 
in Alzheimer's Disease has posed a complex problem in the aim to 
provide animal models which mimic adequately the disease state. No 
animal model has been developed which replicates all the elements of 
Alzheimer's Disease; however, a number of experimental models have 
been useful in challenging hypotheses based on individual components 
of the disease.
The most consistent neurochemical a ltera tions in Alzheimer's 
Disease are the. depletions in presynaptic cholinergic markers in the 
cortex and hippocampus, and loss of cholinergic cell bodies from the basal 
forebrain. This has lead to the development of a number of animal 
models in which the cortical or hippocampal cholinergic afferents are 
denervated, either through transection of afferent fibre pathways, or 
through specific lesions of cholinergic cells within the nucleus basalis or 
medial septal area. These lesions result in depletion of choline 
acetyltransferase activity in the cortex or hippocampus, and the impaired
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performance in specific tasks; the degree of cognitive impairment has 
been correlated positively with the depletion of choline acetyltransferase 
in the denervated area (Everitt et al., 1987).
A number of approaches have been used to denervate the cortex and 
hippocampus. Knife-cut lesions of cholinergic afferent fibres, and 
electrolytic and excitotoxin-induced lesions of the nucleus basalis or 
septal area have been commonly used (Fisher & Hanin, 1986; Smith, 
1988). Such models have been used with variable success in order to 
dem onstra te  the plastic response of the cholinergic system to 
denervation, in the hope that alterations in receptor density may help to 
clarify the som ew hat obscure status of cholinergic receptors in 
Alzheimer's Disease. However, studies of cholinergic receptor binding 
following experimental denervation have to date demonstrated equally 
diverse alterations in hippocam pal muscarinic receptor density. 
Cholinergic denervation has been shown by some groups to result in an 
increase in muscarinic receptor density (Dawson & Wamsley, 1990; Joyce 
et al., 1989; McKinney & Coyle, 1982; Westlind et al., 1981); however, 
other studies have not provided evidence for muscarinic receptor 
regulation (Court et al., 1990; Kamiya et al., 1981; Overstreet et al., 1980; 
Smith et al., 1989; Yamamura & Snyder, 1974), and some have 
demonstrated decreased muscarinic receptor density (Mash et al., 1985; 
Watson et al., 1985) following cholinergic denervation.
The demonstrated role for muscarinic mechanisms in modulating 
glutamatergic firjng in the hippocampus lead Monaghan and colleagues 
(1982) to examine the effects of entorhinal cortex ablation on muscarinic 
receptor density in the hippocampus: the authors reported decreased 
muscarinic receptor binding in the hippocampus, and suggested that 
hippocampal muscarinic receptors were regulated by the entorhinal 
cortex, rather than the septum. Further, it has been demonstrated that 
removal of the septum in neonatal rats does not affect the development 
of muscarinic receptor populations in the hippocampus (Ben-Barak &
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Dudai, 1980), despite  the lack of development of the presynaptic 
cholinergic marker, acetylcholinesterase. The entorhinal cortex is known 
to suffer severe neuronal degeneration in Alzheimer's Disease, and 
therefore if the maintenance of hippocampal cholinergic receptors 
depends on the integrity of the entorhinal cortex, then the role of the 
septohippocam pal pathway in the neurodegenerative alterations in 
Alzheimer's Disease must be re-examined. Despite the importance of 
these findings, there has been little emphasis on the possible effects of 
cholinergic denervation on glutamatergic systems in the hippocampus. 
The use of animal models of cholinergic denervation may clarify 
whether glutamatergic mechanisms are implicated in the cholinergic 
deficits of Alzheimer's Disease; furthermore, their use provides a rare 
opportunity to manipulate neurotransmitter systems in the attempt to 
elucidate the relationship between cholinergic and glutamatergic systems 
in the normal functions of the brain.
65
5.2. CEREBRAL ISCHAEMIA
In order to fuel cerebral metabolism, the brain receives a continuous 
supply of oxygen and glucose from its arterial blood supply. If the blood 
flow to the brain is interrupted for more than a few minutes, then 
cerebral tissue is irreversibly damaged. Ischaemic attacks commonly 
occur either localised to individual vascular territories in the form of 
stroke, or globally as a cardiac arrest, and are j  a major cause of death in 
the western hemisphere (Grotta et al., 1987).
Despite the prevalence, and consequently socioeconomic impact, of 
ischaemia-induced neuronal damage, and in the wake of intense 
research, little is known about the cellular pathogenesis of ischaemic cell 
death, and there exists to date no effective therapy for ischaemic damage.
It has been observed that while the brain in comparison with other 
organs is particularly susceptible to ischaemic damage, a distinct pattern 
of vulnerability  exists within the brain itself: the h ippocam pus, 
particularly the neurones in CA1, and areas of the neocortex are 
inordinately vulnerable to ischaemic damage (Cummings et al., 1984; 
,Kirino, 1982; Pulsinelli et al., 1982a; Volpe & Hirst, 1983) and are 
characteristically destroyed after even brief periods of ischaemia which 
spare most other brain regions. The observation that these areas contain 
large quantities of glutamate receptors (Monaghan et al., 1983) has lead to 
the "excitotoxic hypothesis" of ischaemic damage: that during ischaemic 
attack, glutamate is released and accumulates within the brain in toxic 
amounts.
5.2.1. Glutamate Neurotoxicity and Ischaemia
A link between glutamate and cerebral ischaemia was anticipated by 
Van Harreveld (1959), who demonstrated that spreading depression in 
the rabbit could be produced by application of glutamate to the cortical
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surface, and suggested that the phenomenon of spreading depression was 
in some way connected to neuronal hypoxia. Since then, a wealth of 
evidence has accumulated to support this speculation. Early research in 
the field of glutam ate transmission in the CNS revealed that exposure of 
the retina to glutam ate resulted in the destruction of the inner neuronal 
cell layer of the retina (Lucas & N ew house, 1957). Further, Olney 
dem onstra ted  that rats fed w ith  large quantities of m onosodium  
glutam ate sustained neuronal lesions in brain regions which lacked a 
blood-brain barrier (Olney, 1969).
Two other factors have been pivotal in the establishm ent of the 
excitotoxic hypothesis of cerebral ischaemia. Firstly, the use of in vivo 
dialysis techniques has dem onstrated raised extracellular concentrations 
of glutam ate following both focal (Bullock et al., 1991a; Graham  et al.,
1990) and global (Benveniste et al., 1984) ischaemia. Secondly, there is 
extensive evidence that glutam ate antagonists, particularly those which 
act at the  NM DA receptor or its associated ion channel, afford 
neuroprotection in the ischaemic brain (Bullock et al., 1990; Frandsen et 
al., 1989; Gill et al., 1987; Ozyurt et al., 1988; Park et al., 1988a,b; Simon et 
al., 1984), and NMDA-treated neuronal tissue (Foster et al., 1987; Goldberg 
et al., 1988; Olney et al., 1987). The enorm ous therapeutic potential of 
glutam ate antagonists in the clinical prevention of ischaemic damage has 
lead to intensive research into the mechanisms underlying neurotoxicity 
in cerebral ischaemia.
5.2.2. Mechanisms of Excitotoxicity
Excitotoxicity exhibits a characteristic, acute cytopathology, which is 
post-synaptic, sparing axons and presynaptic terminals. Dendrites are 
found to have focal swelling, while in the initial stages of excitotoxic 
damage, the m itochondria of the perikarya become swollen, and the 
endoplasm ic reticu lum  becom es dilated  in appearance. Secondary
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alterations include condensation of nuclear chromatin, and cytoplasmic 
condensation with multiple vacuolations; these alterations are identical 
to those observed in the hippocampus and cortex following transient 
forebrain ischaemia (Arsenio-Nunez et al., 1 9 7 3 ;  | B r o w n  & Brierley, 1972; 
Simon et al., 1 9 8 4 ) .
The primary effects of activating glutamate receptors are) to open ion 
channels (MacDermott & Dale, 1 9 8 7 ) ,  resulting in a cascade of cellular 
events, including elevated intracellular calcium and second messenger 
activation. Stimulation of kainate and AMPA receptors results in entry 
of sodium  and potassium  ions through ion channels in the cell 
m em brane, while stimulation of NMDA receptors results in the 
additional entry of calcium. Depolarisation of the cell membrane will 
result in activation of voltage-dependent calcium channels on the cell 
membrane, resulting in further elevation in the intracellular calcium 
concentration; an increase in calcium will activate chloride and 
potassium conductances, with the resultant flow of water from the cell 
according to an osmotic gradient. As a response to the ionic 
redistribution across the cell membrane, activation of ATPases in the cell 
membrane occurs in order to restore the ionic gradients, with the result 
of increased dem and for ATP and therefore enhanced mitochondrial 
oxidative metabolism.
While these cellular events are normally short-lived -  neuronal and 
glial re-uptake mechanisms result in the rapid removal of glutamate 
from the synapse -  under excitotoxic conditions in which glutamate 
receptors are stimulated for prolonged periods, the ionic changes within 
the cell are greatly augmented, resulting in widespread disruption of 
cellular events. Prolonged stimulation of glutamate receptors while the 
blood supply to the brain remains compromised, leads to rapid depletion 
of existing cellular ATP supplies, thus preventing restoration of the 
cellular ionic balance. Raised calcium is unable to be removed either by 
ATP-dependent plasma membrane transport or mitochondrial buffering,
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with the result of massive disruption of intracellular mechanisms, and 
the eventual death of the cell.
5.2.3. Cytotoxicity and Calcium
Raised intracellular calcium appears to play an important role in the 
excitotoxic and ischaemic cell death (Choi et al., 1987). Calcium has been 
show n to result in the activation of protein kinases, proteases and 
phospholipases. The production of second messengers such as inositol 
phosphates may act to release calcium from intracellular stores, thus 
cytosolic calcium concentrations are increased further. The activation of 
protein kinases may influence the activity of many enzymes and proteins 
including ion channels and receptors: for example phosphorylation of 
GABAa receptors decreases the cellular response to GABA, while 
phosphorylation of NMDA receptors enhances the post-synaptic response 
(Mody et al., 1988). There is evidence that protein kinase C is involved in 
excitotoxic cell death: increased [3H]-phorbol ester binding to protein 
kinase C has been reported in the hippocam pus of rats following 
ischaemia (Onodera et al., 1989), and gangliosides which inhibit 
glutamate- and kainate-induced translocation of protein kinase C to the 
cell membrane are neuroprotective (Vaccarino et al., 1987). Further, 
ischaemic damage in the CA1 region of the gerbil hippocampus can be 
prevented by pre-treatment with a protein kinase C antagonist (Hara et 
al., 1990).
Increasing the cytosolic calcium concentration resu lts  in the 
stimulation of calcium-dependent proteases, or calpains, which are able 
to effect changes in cytoskeletal elements and integral m em brane 
proteins. Calpain I has been shown to be activated in hippocampal 
neurones by excitotoxic doses of kainate or NMDA (Siman et al., 1989). 
Calpain I-mediated spectrin breakdown is evident in the CA3 region 
following intraventricular injections of kainate, while in CA1, the rapid
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proteolysis of spectrin in response to ischaemia appears to be dependent 
on NMD A receptor activation (Seubert et al., 1989); these observations are 
in accordance with the high densities of NMD A receptors in CA1, and the 
high levels of kainate receptors in CA3 (Cotman et al., 1987). Disruption 
of the cytoskeleton and consequently im paired transport of proteins to 
nerve term inals (Persson et al., 1989) may underlie in part the "delayed 
neuronal death" which has been observed to accom pany ischaemia 
(Kirino, 1982).
Increased intracellular calcium will also result in a m arked elevation 
in the concentration of the second m essenger arachidonic acid, and 
in itiation  of the arachidonic acid cascade, th rough  stim ulation of 
p h o sp h o lip a se  A 2. Further m etabolism  of arachidonic acid by 
cyclooxygenases and lipoxygenases m ay lead to the production of free 
radical groups, and results in lipid peroxidation (Werns et al., 1990). The 
role of free radicals in ischaemic dam age is streng thened  by the 
observation that free radical scavenging agents exhibit neuroprotection 
from excitotoxicity in cell culture (Dykens et al., 1987), and in global and 
focal ischaemia (Panetta et al., 1989). Free radicals are also possibly 
form ed as a consequence of calcium-induced activation of a protease 
which converts xanthine dehydrogenase to xanthine oxidase. Xanthine 
is produced by the breakdown of AMP in the cell, to yield ultimately uric 
acid. Xanthine oxidase utilises molecular oxygen to generate superoxide 
radicals, which are directly cytotoxic, but m ay also be converted into 
hydroxyl radicals in the presence of transition metals. This mechanism is 
thought to occur when kainate is applied to cultured cerebellar neurones 
(Dykens et al., 1987) and poses another problem  in the treatm ent of 
ischaemia: during  reperfusion following an ischaemic insult, xanthine 
and oxygen levels are high, and therefore may contribute to reperfusion 
injury within previously ischaemic tissue.
Finally, increased calcium concentrations are able to influence the 
activity of genom e-linked enzym es such as endonucleases. In the
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norm al cell, a num ber of morphological changes j presage the natural 
death  of the cell, such as plasm a and nuclear m em brane blebbing, 
compacting of organelles, and chromatin condensation (See Orrenius et 
al., 1989). The m ost characteristic m arker for cell death  is calcium- 
dependent activation of endonucleases, which results in the cleavage of 
chromatin into fragments (Orrenius et al., 1989). Thus, m arked elevation 
of calcium may induce prem aturely those processes which result in cell 
death.
In the light of such findings, it appears, therefore, that to prevent 
ischaemic dam age w ould require prom pt pharmacological intervention, 
either at the level of the receptor or ion channel, in order to prevent toxic 
influx of calcium, or at an intracellular level, to prevent the actions of 
augm ented cytosolic calcium on a range of cellular systems. With these 
aims, a num ber of pharmacological approaches have been advocated. It 
is clear, however, that to prevent the initial increase in calcium influx, 
and thus avoid the subsequent, m arked cellular d isruption, the most 
successful m ethod of preventing ischaemic damage w ould be expected to 
be through antagonism of glutamate receptors.
5.2.4. Neurochemical Alterations in Response to Cerebral Ischaemia
A limited num ber of reports deal w ith the possibility that alterations 
in receptor density occur following cerebral ischaemia. W ester berg and 
colleagues (198.7, 1989) exam ined the tim e-course of alterations in 
excitatory amino acid binding sites following transient global cerebral 
ischaemia, and reported a transient decrease in [3H]-AMPA binding in the 
dentate  gyrus and CA1 of the hippocam pus im m ediately after the 
ischaemic insult, and a more prolonged, severe decrease which became 
apparent two days after ischaemia and developed over two to four weeks. 
[3H]-Glutamate binding to NMD A receptors was not found to be altered 
acutely after the ischaemic insult, but decreased m oderately in the CA1
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stratum radiatum between four days and four weeks after the ischaemic 
insult. Additionally, [3H]-kainate binding was decreased in the CA4 
region one and four weeks after the ischaemic insult. The authors 
suggested that AMPA receptors become desensitised acutely following 
ischaemia, while subsequent long -term reduction in [3H]-AMPA binding 
may reflect cell loss in regions of the hippocam pus dam aged by 
ischaemia. The relative preservation of the NMDA receptor binding 
sited has been replicated in a model of focal ischaemia in the rat (Dewar 
et al., 1989), and transient global ischaemia in the gerbil (Bowery et al.,
1988), with the suggestion that although damaged neurones fail to take 
up histological stains, binding sites for the NMDA receptor are preserved.
5.2.5. Animal Models of Cerebral Ischaemia
The number of animal models of ischaemia is perhaps reflective of 
the diversity of manifestations, causes, and anatomical sites of human 
ischaemic stroke. The situation is further complicated by the lack of 
opportunity to study in detail the pathophysiological sequelae of the 
condition in humans: events occurring during the first minutes of an 
ischaemic insult may only be studied in laboratory animals. This 
necessitates careful modelling of the condition to provide a variety of 
circumstances which mimic as closely as possible one or more of the 
features of stroke (for review see Ginsberg and Busto, 1989).
Laboratory rodents, particularly rats and gerbils, are readily available at 
low cost, and are highly suitable for investigations into cerebral 
ischaemia: there is a close resemblance between the cerebrovascular 
anatomy and physiology of rodents and that of higher species, and the 
small brain size of rodents and studies of tracer analysis, which in larger 
species would be limited by cost. Nevertheless, several studies have 
employed higher, gyrencephalic species such as cats or primates, in order 
to produce ischaemia in animal models which resemble closely the
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hum an brain.
Global Cerebral Ischaemia
While these may be criticised due to their lack of specificity, models of 
global cerebral ischaemia have provided an opportunity to study the 
effects of transient ischaemia and subsequent reperfusion. The 
advantages of global models such as two- or four-vessel occlusion are 
their manipulation and theoretically their reproducibility. Blood flow to 
the brain is interrupted by ligating the common carotid arteries, with or 
w ithout cauterization of the vertebral arteries, to produce reversible 
forebrain ischaemia. While these techniques have been used to assess 
behavioural and neurochemical alterations at time-points other than 
acutely after the ischaemic insult, the mortality rate and the vast 
differences in the reproducibility of ischaemia between strains of rats has 
limited the use of four-vessel occlusion (Blomqvist et al., 1984), while the 
anaesthesia required to perform two-vessel occlusion raises questions on 
its suitability in drug studies aimed at neuroprotection.
Focal Cerebral Ischaemia
Models of focal cerebral ischaemia are now generally preferred to 
those of global ischaemia: focal lesions are discrete and reproducible, and 
allow observations of pathophysiological events in sites remote from the 
ischaemic insult. Moreover, focal ischaemic models appear to reflect 
more closely the,sequence of events which occur in human stroke.
Possibly the most commonly employed model of focal cerebral 
ischaemia is occlusion of the middle cerebral artery (MCA) in the rat; this 
has gained increasing respect in recent years due to its similarity with 
human stroke. In simple terms the MCA is occluded unilaterally (see 
Tamura et al., 1981, for example), resulting in the interruption of the 
major blood supply to the ipsilateral caudate nucleus, olfactory and 
frontal cortices. The relative reproducibility of this model has propelled
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its use in studies which assess the neuroprotective effect of drugs (for 
example, see Park et al., 1988). However, study of its events following 
ischaemia is limited to the dynamic alterations which surround the area 
of infarction. In order to estimate the direct effects of ischaemia on other 
brain regions, other models of focal cerebral ischaemia are required.
The most common mass CNS lesion to occur in the clinic is acute 
subdura l haem atom a, and it provides a major clinical challenge: 
although 80% of patients with acute subdural haematoma are conscious 
at some time after the injury, 60% die or remain severely disabled 
(Jamieson and Yelland, 1972, Stone et al., 1983). Thus it appears that 
some mechanism secondary to the initial insult is involved in the onset 
of much of the ischaemic damage. Again, a major problem in elucidating 
these putative mechanisms has been the inability to study the events 
which occur in the patient’s brain during the initial insult. Despite the 
enormous cost of management of patients, however, and the potential 
benefits which an animal model may provide in order to test therapeutic 
regimes, there has to date been no altogether suitable model of acute 
subdural haematoma.
To this end, there has been developed in this laboratory a new rat 
model of acute subdural haematoma, designed to imitate as closely as 
possible those events which occur following subdural haematoma in 
humans (Miller et al, 1990). Briefly, the model involves injection of 
0.4ml autologous venous blood into the subdural space. This results in 
an immediate ri$e in intracranial pressure, which is maintained above 
normal values for at least three hours. Histological examination of 
cerebral tissue at four and 24 hours reveals an extensive infarcted area 
directly below the haem atom a, easily d is tinguishab le  from the 
underlying normal tissue. At a survival time of 72 hours, there is 
evidence of hippocampal damage, especially in the CA1 sector (Bullock, 
personal communication). These findings are consistent with the 
neuropathological alterations following ischaemic infarct in humans,
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and hence this method provides a model of ischaemia in which other 
secondary mechanisms leading to ischaemic damage in vulnerable 
regions such as the hippocampus may be investigated.
5.2.6. N europrotection and Ischaemia: NMDA Antagonists
While it is clear that there exist a number of possible sites of action at 
which pharmacological prevention of ischaemic neuronal death may be 
successful, the most effective neuroprotection has been observed 
following treatment with glutamate antagonists specific for sub-types of 
g lutam ate  receptor. The developm ent of highly specific NMDA 
antagonists with high potency has propelled research into the ability of 
this class of drug to prevent ischaemic neuronal damage. Table 1 
presents selected studies in which NMDA antagonists have been shown 
to be neuroprotective in focal cerebral ischaemia. Competitive and non­
competitive NMDA antagonists differ in their site of action: competitive 
NMDA antagonists bind to the recognition site for glutamate and 
therefore exert their action by direct competition with the endogenous 
agonist; non-competitive NMDA antagonists on the other hand bind to 
a site within the associated ion channel, and therefore depend on the 
presence of the endogenous agonist to open the channel. In treatment of 
ischaemic damage, this represents an important difference in drug action, 
for while the action of non-competitive antagonists will be potentiated by 
the raised extracellular concentration of glutam ate, competitive 
antagonists will be displaced by the increased concentration of glutamate, 
and thus may not be effective in antagonising glutamatergic responses.
The hydrophilic nature of competitive antagonists may limit their 
efficacy as anti-ischaemic drugs further. Non-competitive antagonists 
such as MK-801 are highly lipophilic, and therefore cross the blood brain 
barrier freely; thus they are able rapidly to achieve therapeutic 
concentrations within the cerebral tissue. Competitive antagonists,
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however, have relatively low lipophilicity, and therefore enter the brain 
slowly, where they attain only a fraction of the total plasma concentration 
(McCulloch & Iversen, 1991). The slow brain entry  of com petitive 
antagonists, and the likelihood that the raised extracellular glutam ate 
concentration will overcome the competitive antagonist blockade, may 
explain  the failure of these drugs to p rovide neuropro tection  in 
ischaemia; for example, although MK-810 adm inistration after induction 
of the ischaemic insult has been shown to reduce ischaemic damage (Park 
et al., 1988), D-CPP-ene administration following occlusion of the MCA in 
cats d id  not produce significant reduction in infarct size (Chen et al.,
1991).
A lim iting factor in the use of non-com petitive NMDA antagonists 
such as MK-801 and phencyclidine, how ever, is that they induce 
pathom orphological alterations in certain cortical regions (Olney et al.,
1989): single peripheral injections of these drugs at neuroprotective doses 
were found to cause cytoplasmic vacuolation and pyram idal cell swelling. 
Further, the [14C]-deoxyglucose autoradiographic technique has been used 
to dem onstrate m arked functional disturbances in these areas (Kurumaji 
et al., 1989). It is thought that these side effects might be controlled by the 
use of anaesthetics such as halothane, w hich abolish the m arked 
increases in cortical glucose use produced by MK-801 (Kurumaji & 
McCulloch, 1989). However, the possible potentiation of these side effects 
as a consequence of the raised extracellular levels of glutam ate in the 
ischaemic tissue, combined with the use-dependency of the drug, is an 
im portan t consideration  in the choice of g lutam ate antagonist for 
treatm ent of ischaemic dam age in hum ans (see McCulloch & Iversen, 
1991 for discussion). In this respect, competitive antagonists, due to their 
apparent lack of side effects, may be more beneficial in ischaemic injury, 
and have therefore received increasing attention as potential therapeutic 
agents.
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6. AUTORADIOGRAPHIC IM AGING OF THE CENTRAL NERVOUS 
SYSTEM
The manufacture of the radio-labelled analogues specific for receptors 
or uptake  by other cellular components, and the developm ent of 
quantitative densitometric techniques has in recent years permitted high- 
resolution mapping of receptors and cellular pathways within the CNS. 
This study  employs two autoradiographic  techniques: the [14C]- 
deoxyglucose autoradiographic technique for estimation of local cerebral 
glucose utilisation, and radio-ligand receptor au torad iography  for 
estimation of specific receptor densities within the CNS. These are 
considered separately below.
6.1. DEOXYGLUCOSE AUTORADIOGRAPHY
The energy which fuels cerebral metabolism is provided, under 
normal physiological conditions, almost exclusively by the oxidative 
catabolism of glucose. Consequently, the functional activity within a 
region of cerebral tissue is directly p roportional to the energy 
consumption within that region.
Estimation of glucose utilisation and hence functional activity within 
distinct brain regions has been made possible with the [14C]-deoxyglucose 
autoradiographic technique (Sokoloff et al., 1977). Deoxyglucose, a 
structural analogue of glucose is transported across the blood-brain 
barrier, and enters the glycolytic pathway. It competes with glucose for 
hexokinase, and is phosphorylated to deoxyglucose-6-phosphate, at a 
defined rate relative to that of phosphorylation of glucose. While 
however glucose-6-phosphate undergoes metabolism by hexokinase, 
deoxyglucose-6-phosphate is not a substrate for further phosphorylation, 
and remains essentially trapped within the cerebral tissues. When the
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rad io - labe lled  analogue, [14C ]-deoxyg lucose , is a d m in is te re d  
intravenously to animals, it is taken up and phosphorylated rapidly 
within the tissues; thence it is possible to produce autoradiograms of 
deoxyglucose uptake by exposure of brain sections to radiation-sensitive 
film. In order to measure precisely local cerebral glucose utilisation 
within discrete CNS regions, Sokoloff and colleagues (1977) developed a 
mathematical model which incorporates the biochemical properties of 
deoxyglucose and glucose, the plasma history of the tracer uptake within 
the animal, and the concentration of 14C in the CNS as measured by 
densitometric analysis of the autoradiograms (see Methods Section 1 for 
details of mathematical model and autoradiographic routines). Thus the 
advent of this technique has provided an opportunity  to investigate, 
within defined physiological parameters (Sokoloff et al., 1977; Sokoloff, 
1981), the functional consequences of pharmacological, physiological and 
pathological manipulations within the CNS.
Pharmacological Investigations
Analysis of cerebral glucose utilisation in response to a variety of 
pharmacological agents has revealed in many cases striking patterns of 
functional activation or depression (for review, see McCulloch, 1982). 
For example, dopaminergic influences upon cerebral glucose utilisation 
have been studied extensively, and alterations in glucose use appear to be 
restricted in their distribution to a few neuronal circuits. However, 
altered glucose .use is not confined to those regions which receive 
dopaminergic innervation (Moore & Bloom, 1978). Further, in regions 
known to contain dopaminergic receptors, there is no direct relationship 
between the magnitude of alterations in glucose use and the density of 
dopaminergic receptors within those regions.
Similar pa tte rn s  have been observed in response  to other 
pharmacological agents. Kurumaji and colleagues (1989) demonstrated 
that administration of the non-competitive NMDA antagonist MK-801
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effected large alterations in glucose use in areas of cortex associated with 
limbic function known to contain high densities of NMDA receptors. 
However, regions of sensory cortex were unaffected. Additionally, 
alterations in glucose use in the hippocampus were not localised within 
those regions which display high densities of NMDA receptors. 
Therefore cerebral glucose use appears to reflect the functional 
consequences of pharmacological agents not only directly at the site of 
drug action, but also within remote sites which are neuroanatomically 
connected with the site of drug-receptor interaction.
Physiological Investigations
W hereas adm in istra tion  of pharm acological agents has been 
demonstrated to produce marked alterations in cerebral glucose use, 
responses to physiological challenges are mostly subtle alterations in 
glucose use. [14C]-Deoxyglucose autoradiography has been used to 
measure subtle circadian variations in glucose use in unrestrained rats 
(Room & Tielemans, 1989). The authors reported that glucose use was 
altered in cortical and extrapyramidal regions, and in the suprachiasmatic 
nucleus, which has been suggested to play a role in maintenance of 
c ircadian  rhythm s. Friedm an & G oldm an-Rakic  (1988) used 
deoxyglucose autoradiography to investigate responses to cognitive 
memory tasks in primates, and measured subtle increases in glucose use 
in specific layers of the dentate  gyrus and CA1 regions of the 
hippocampus; in contrast, glucose use was unaltered in the amygdalar 
nuclei, which are known to be involved in learning and memory 
(Mishkin, 1978). Finally, Porrino et al. (1990) have demonstrated
alterations in glucose use in a number of brain regions following self­
stimulation of electrodes previously implanted in the medial forebrain 
bundle: this regime is believed to be an artificial activation of brain 
systems that normally mediate the reinforcing effects of natural rewards. 
The authors reported alterations in a number of limbic brain regions
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such as the diagonal band nucleus, nucleus accumbens, lateral septum  
and cingulate cortex. Thus deoxyglucose autoradiography is a potentially 
pow erful technique in estim ating the extent of cerebral activation in 
response to a range of physiological challenges.
Pathological M anipulations
The deoxyglucose technique has also been used  extensively to 
illustra te  alterations in cerebral glucose utilisation during  types of 
pathological insult. For example, a large body of work has examined the 
alterations in glucose use which occur following cerebral ischaemia, and 
has provided evidence for dynamic functional disturbances w ithin the 
brain (for review see Ginsberg et al., 1990). A lthough the effects of 
pathological insult on the stability of the kinetic data incorporated into 
the deoxyglucose operational equation m ust be considered, use of the 
deoxyglucose technique has dem onstrated that increased deoxyglucose 
uptake may be observed in the region surrounding the infarct, or the 
penum bral region (Nedergaard et al., 1986; Shiraishi et al., 1989). Thus 
the suggestion has been m ade that infarction is a dynamic, progressive 
event, in which the cells in the penum bral region are compromised, and 
finally infarcted.
Several attem pts have been m ade to demonstrate subtle alterations in 
glucose use in the CNS following lesions specific neuronal pathw ays. 
Local cerebral glucose utilisation has been m easured at several time- 
points following unilateral ocular enucleation in the rat (Chalmers & 
McCulloch, 1989). The authors reported that w hile glucose use fell 
dramatically in structures associated with visual processing directly after 
enuclea tion , functional recovery occurred , in ferring  th a t p lastic  
m echanism s exist w ithin the CNS. It was also possible to correlate 
alterations in glucose use with alterations in receptor densities in those 
areas (Chalmers, D. T., Ph. D. Thesis, University of Glasgow, 1989), 
dem onstrating that deoxyglucose m ay be used to illustrate functionally
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the plastic processes which occur in response to denervation.
More subtle alterations have been measured in response to discrete 
lesions of specific nuclei or fibre tracts. Harrell and Davis (1984) report 
alterations in hippocampal glucose use following electrolytic lesions of 
the medial septal area, and found evidence for long-term functional 
recovery within the hippocampus. In contrast, Kelly et al. (1985b) 
demonstrated that decrements in glucose use in the hippocampus did not 
recover with time following fimbria fornix transection, bu t that the 
decrements could be ameliorated by grafting septal tissue; the authors 
suggested therefore that sprouting of grafted cholinergic cells are able to 
make synaptic contacts with hippocampal cells, and thus restore 
functional activity within the hippocampus, using fluoro-deoxyglucose 
in a positron emission tomography (PET) study of primates, Kiyosawa 
and colleagues (1989) found that amelioration of nucleus basalis-induced 
decreases in cortical glucose use are not accompanied by recovery of 
choline acetyltransferase activity in the cortex; the authors suggested 
therefore that functional plasticity within the cortex was due to non- 
cholinergic mechanism, rather than recovery of cholinergic neuronal 
connections from the nucleus basalis.
Deoxyglucose autoradiography therefore has proved to be pivotal in 
demonstration of functional relationships between specific populations 
of neurones in the CNS, and has provided novel insights into the effects 
in vivo of pharmacological, physiological and pathological manipulation 
of neurotransmitter systems in the brain.
6.2. QUANTITATIVE LIGAND-BINDING AUTORADIOGRAPHY
While deoxyglucose autoradiography has provided novel insights 
into the state of functional state of discrete CNS regions, ligand-binding 
autoradiography has been readily employed in the estimation of receptor
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densities in the CNS. The development of radio-labelled ligands specific 
for receptors w ithin the CNS has enabled high-resolution anatomical 
m apping of receptor distributions in the brain. The technique relies on 
knowledge of receptor ligand kinetics (see M ethods Section 2 for theory 
and methodology); brain sections are incubated for a fixed period in the 
presence of radio-labelled ligand, rinsed and dried, and opposed to 
radiation-sensitive film in order to produce an autoradiographic image of 
receptor densities in anatomically (discrete areas.
Ligand-binding kinetics have been determ ined for a large range of 
receptors and receptor sub-types. The use of these techniques has 
perm itted quantitative anatomical m apping of receptors in the CNS. A 
large body of w ork has been dedicated to elucidating alterations in 
receptor densities in a num ber of CNS diseases such as Alzheimer's 
Disease (Geddes et al., 1985; see Greenamyre et al., 1987; Mash et al., 1985; 
Perry et al., 1986). A dditionally, ligand-binding autoradiography in 
animal models of disease states has been crucial in the estimation of the 
degree of plasticity of specific neurotransm itter systems (for example see 
Joyce et al, 1989; M ash et al., 1985; Ulas et al., 1990a,b), confirming or 
reforming hypotheses which may explain alterations in receptor density 
following the onset of neurodegenerative disease.
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7. AIMS OF THESIS
The aims of this thesis are firstly to investigate functional activity in 
the h ippocam pal formation in response to pharm acological and 
pa th o lo g ica l  m an ip u la t io n  of cho linerg ic  and  g lu tam ate rg ic  
transmission, and secondly to investigate the plastic modification of 
hippocampal cholinergic and glutamatergic receptors after removal of the 
cholinergic input.
Q uan tita tive  in vivo [14C ]-deoxyglucose  a u to ra d io g ra p h y  and  
quantitative in vitro ligand-binding autoradiography have been used 
extensively in order to examine critically the role of glutamatergic and 
cholinergic neurotransmitter systems in the hippocampus, and associated 
limbic regions. These aims are discussed specifically below.
7.1. EFFECTS OF GLUTAMATERGIC AND CHOLINERGIC AGENTS ON 
CEREBRAL GLUCOSE UTILISATION
Deoxyglucose autoradiography has been employed to estimate the 
effects of three pharmacological agents on local cerebral glucose 
u tilisa tion  in the conscious, lightly res tra ined  rat. Detailed 
measurements of glucose use in the hippocampus have provided a focus 
for discussion. In addition, glucose use in limbic structures associated 
closely with hippocampal have been examined. Finally, measurements 
have been compared to alterations in glucose use in other, non-limbic 
regions in order to provide a full profile of drug action.
7.1.1. D-CPP-ene, a Novel Competitive NMDA Antagonist
The novel competitive NMDA antagonist, (E)-4-(3-phosphonoprop-2- 
enyl)- piperazine-2-carboxylic acid (D-CPP-ene) is a d rug  with high
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potency, and is potentially therapeutic in the prevention of neuronal 
dam age follow ing ischaem ia (Aebischer et al., 1989). Recently, 
adm inistration of the non-competitive NMDA antagonists MK-801 and 
phencyclid ine have been show n to resu lt in pathom orphological 
alterations in areas of cortex and hippocam pus (Olney et al., 1989); 
fu rther, deoxyglucose au to rad iog raphy  has dem onstra ted  m arked 
functional disturbances in these areas following adm inistration of MK- 
801 (Kurumaji et al., 1989).
In the present study, cerebral glucose utilisation have been m easured 
in conscious, lightly restrained rats following adm inistration of saline or 
D-CPP-ene (0.3, 3 or 30mgkg_1), in order to assess fully the functional 
effects of D-CPP-ene. The pattern of alterations in glucose utilisation are 
d iscussed  w ith  reference to the neuroanatom ical organ isation  of 
glutam atergic pathw ays in the CNS; further, the patterns of altered 
glucose use are discussed w ith reference to the functional alterations 
elicited by other NMDA antagonists.
7.1.2. L-679-512, a Novel Muscarinic Agonist
L-679-512 is a novel muscarinic agonist with high efficacy which is 
able to pass the blood-brain barrier freely, and stim ulate m aximally 
phosphoinositide turnover in the brain (Saunders & Freedm an, 1989; 
Freedm an et al., 1990). There is considerable interest in cholinomimetic 
com pounds as therapeutic agents in the treatm ent of the dem entia of 
Alzheimer's Disease. Previously, only quaternary com pounds, such as 
carbachol and  m uscarine have been able to stim ula te  m axim al 
phosphoinositide turnover; how ever, these com pounds have only a 
limited ability to cross the blood-brain barrier, thus limiting their central 
effects.
The aim of this series of experiments was to estim ate the functional 
consequences, as m easured by [l4C]-deoxyglucose autoradiography, of
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administration of L-679-512. Local cerebral glucose utilisation was 
m easured  in fully conscious, lightly res tra ined  rats, following 
administration of L-679-512 (3, 10 or SOpgkg'1) or saline. The patterns of 
cerebral glucose use have been compared to those patterns produced by 
o ther cholinom im etic  agents, and evidence for neuroanatom ical 
organisation of alterations in function is reviewed.
7.1.3. 9-Am ino-l,2,3,4-Tetrahydroacridine (THA), a Cholinesterase Inhibitor 
w ith Potential Glutamatergic Activity.
THA is a cholinesterase inhibitor, which has been suggested to be 
efficacious in the amelioration of cognitive deficits in Alzheimer's 
Disease (Summers et al., 1986). The drug has recently been introduced 
into clinical trials; however, to date, there has been no study of its effects 
on functional activity/?? vivo.
The therapeutic effects of THA have been attributed not only to its 
effects at cholinergic synapses, but also to an action at glutamatergic 
synapses (Albin et al., 1988). Using deoxyglucose autoradiography, the 
patterns of cerebral glucose utilisation in response to THA (2.5mgkg_1) or 
saline administration were measured in the conscious rat. Patterns of 
glucose utilisation are discussed in comparison to those produced by 
other cholinergic or glutamatergic drugs.
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7.2. FUNCTIONAL PLASTICITY OF THE HIPPOCAMPUS IN RESPONSE TO 
LESIONS OF THE MEDIAL SEPTUM
Quantitative [14C]-deoxyglucose autoradiography and quantitative 
receptor autoradiography has been employed three weeks after ibotenate 
lesions of the medial septum  in order to estimate the effects of 
cholinergic denervation on transmission in the hippocam pus. In 
a d d it io n ,  the  in teg rity  of m uscarin ic  recep to r  co u p lin g  to 
phosphoinositide turnover was investigated using biochemical assay 
three weeks after medial septal lesions.
7.2.1. Functional Activity in the Hippocampus After Ibotenic Acid Lesions of 
the Medial Septum
In contrast to previous investigations which involved the use of non­
specific lesion techniques (Harrell & Davis, 1984; Kelly et al., 1985b), this 
study examines the functional consequences of discrete ibotenate-induced 
lesions of the medial septal area in rats. M easurements of glucose 
utilisation have been made three weeks after medial septal lesions in 
discrete h ippocam pal regions and limbic areas associated with 
hippocampal function.
7.2.2. A ltera tions in .L igand-B inding  to H ippocam pal C holinerg ic  and 
Glutam atergic Receptors After Ibotenic Acid Lesions of the Medial 
Septum
The effects of cholinergic denervation on the hippocampal cholinergic 
and glutamatergic receptor binding have been assessed three weeks after 
lesions of the medial septum. Sub-types of glutamate receptor densities 
were measured using [3H]-AMPA, [3H]-kainate, and NMDA-sensitive 
[3H]-glutamate binding, to image AMPA-sensitive quisqualate, kainate
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and NMDA receptors respectively. Muscarinic receptor densities were 
measured using [3H]-QNB. The aim of this approach was to determine 
firstly, whether discrete, axon-sparing lesions of the medial septum 
would result in alterations in hippocampal muscarinic receptor densities; 
and secondly, whether hippocampal glutamatergic receptor integrity is 
altered by removal of the modulatory cholinergic input. The results of 
this study are discussed in relation to the role of cholinergic and 
glutamatergic receptors in hippocampal function; the significance of 
plastic mechanisms is discussed with respect to current theories regarding 
the neurochemical deficits in Alzheimer's Disease.
7.2.3. Muscarinic-Mediated Phosphoinositide Hydrolysis in the Hippocampus 
Following Ibotenic Acid Lesions of the Medial Septum
The final aim addressed in this series of experiments was to assess 
whether muscarinic-coupled second messenger turnover was preserved 
in the hippocampus. Carbachol-stimulated phosphoinositide hydrolysis 
was assayed biochemically in hippocampal slices from rat brains three 
weeks after lesions of the medial septum. The results are discussed with 
respect to measurements of muscarinic receptor density within the 
lesioned hippocampus.
7.3. THE CEREBRAL METABOLIC EFFECTS OF ACUTE SUBDURAL 
HAEMATOMA IN THE RAT.
The aims of this series of experiments were firstly to measure the 
effects on local cerebral glucose utilisation of a novel cortical ischaemic 
insult, acute subdural haematoma in the rat, and secondly to assess the 
ability of the competitive NMDA antagonist D-CPP-ene to ameliorate 
these effects.
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Local cerebral glucose use was measured in the conscious rat, two 
hours after acute subdural haematoma had been induced by injection of 
autologous venous blood. Cerebral glucose use was estimated in areas 
directly vulnerable to ischaemic damage, such as the underlying cortex, 
and discrete hippocampal regions remote from the site of infarct. 
Additionally, rates for cerebral glucose use were estimated in limbic areas 
associated with hippocampal function and sensory regions. These were 
compared with rates for local cerebral glucose utilisation in sham- 
operated control rats, and rats which had received D-CPP-ene prior to 
acute subdural haematoma.
Alterations in local cerebral glucose use, and the ability for D-CPP-ene 
to ameliorate these alterations are discussed with reference to the 
excitotoxic hypothesis of ischaemia; the role of glutamatergic circuitry in 
the vulnerability of hippocampal ischaemic damage is discussed. Finally, 
the results of this study are compared with those of similar studies of the 
functional consequences of ischaemia, and the impact of the results on 
the attempts to elucidate the mechanisms which underlie ischaemic 
damage are discussed.
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CHAPTER II 
METHODS
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1. QUANTITATIVE AUTORADIOGRAPHY
1.1. IN  VIVO  [14C]-2-DEOXYGLUCOSE AUTORADIOGRAPHY
1.1.1. Theory: Mathematical Model and the Operational Equation
Sokoloff and colleagues made use of an operational equation to 
calculate rates of cerebral glucose utilisation in the conscious albino rat. 
This equation is derived mathematically from a theoretical model which 
incorporates the rate constants of uptake and phosphorylation of glucose 
and deoxyglucose (Figures 4 & 5). The operational equation describes the 
rates of cerebral glucose use (Rj) ,  following injection of a bolus of 
intravenous [14C]-2-deoxyglucose, in terms of the concentrations of [14C]- 
2-deoxyglucose and glucose in arterial plasma (Cp* and Cp) and the total 
concentra tion  of 14C  within the CNS (C j* ) .  The equation also 
incorporates a "lumped" constant, which represents the relative 
distribution volume of deoxyglucose and glucose, the Michaelis-Menten 
constants and maximal velocities of hexokinase for phosphorylation of 
deoxyglucose and glucose, and a factor which predicts the fraction of 
glucose which, once phosphorylated, will continue to be metabolised via 
the glycolytic pathway.
In the application of the operational equation , a num ber of 
assumptions are necessary:-
1. Measurements may only be made within a localised area in 
which rates of blood flow and rates of uptake and phosphorylation 
of deoxyglucose and glucose are constant.
2. The concentrations of deoxyglucose and glucose within each 
element of tissue are constant, and deoxyglucose and glucose are 
present in a single compartment, and may exchange freely between 
plasma and tissue.
3. The arterial plasma concentrations of deoxyglucose and glucose
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PLASMA BRAIN TISSUE
[14 C]Deoxy glucose-6
(CM*>
[ 14C]Deoxy glucose 
(Co*)
14C]Deoxyglucose ^ 
(Cp*) ^
Glucose Glucose Glucose-6-Phosphate
Precursor Pool i Metabolic Products
k*‘
— -phosphate
■3
I
I
I
co2 + h 2o
TOTAL TISSUE 14C CONCENTRATION : Cj* = C,? + C *
1 t  M
FIGURE 4: THEORETICAL MODEL OF DEOXYGLUCOSE UPTAKE IN 
THE BRAIN
Cp* and Cp represent the concentrations of [14C]-2-deoxyglucose and 
glucose in a rteria l plasm a; CE* and CE rep resen t their respective 
concentrations in the tissue precursor pool. CM* is the concentration of 
[14C]-2-deoxyglucose-6-phosphate in the tissue. The total 14C concentration 
w ithin a hom ogeneous region of tissue is represented by Cj*. The rate 
constants kj*, k2*, and k3* are the rate constants for uptake and subsequent 
phosphorylation of [14C]-2-deoxyglucose by hexokinase, while kj, k2, and k3 
are the equivalent constants for glucose. Possible glucose-6-phosphatase 
activity is represented by a broken line (Sokoloff et al., 1977).
represent accurately their cerebral capillary concentrations.
4. Carbohydrate metabolism is in a steady state.
A dditionally , [14C]-2-deoxyglucose and [14C ]-2-deoxyg lucose-6 - 
p h o sp h a te  m ust be present in tracer am ounts, and  m ust be 
pharmacologically inactive.
A criticism of the deoxyglucose technique is that it does not account 
for the breakdown of deoxyglucose-6-phosphate to deoxyglucose by 
glucose-6-phosphatase (Hawkins & Miller, 1978). However, glucose-6- 
phosphatase  is believed to be contained within the endoplasm ic 
reticulum, and is not free within the cytosol; Sokoloff and colleagues 
have demonstrated that its activity in the brain is so low that in the 45 
minute experimental period the effect of the enzyme on the total amount 
of phosphorylated deoxyglucose is negligible (Sokoloff, 1979).
Using a 45 m inute period also diminishes the errors involved in 
using the fixed rate constants k-,*, k2*, and k3*, which define the 
distribution of tracer within the various compartments of the model 
(Figure 4). A possible source of error in calculating local cerebral glucose 
utilisation with the operational equation exists in the assumption that 
the constants for transfer of [14C]-2-deoxyglucose between plasma and 
tissue (kj*, k2*), and its subsequent phosphorylation in cerebral tissue 
(k3*), do not change over a given range of physiological conditions. 
Since, how ever, Cp* diminishes with time, the elements of the 
operational equation which contain the term Cp* will likewise diminish 
with respect to time, and hence if the experimental period is lengthened, 
the error inherent in these elements will also be reduced. This has been 
demonstrated by Sokoloff and colleagues experimentally (Sokoloff et al., 
1977; Sokoloff, 1979).
92
*co
+
*CM
X
CD
*CX
u H
* roX
+
*<NX
COX
+*CN
X
cd
<d
* r-
H
• H
u
2
£op
3
a
w
hJ
<
01
wPX
O
w
ID
w
&
p
OHHCX
CD 4-» CD
c
44
cd 3cd X44>4 4-» CA
CD
X4—>
CAr—s/-N
H
3
O
• pH
-Q-
CJ
* CD
• d
<D
CD
C T
Vh
cd
CA
o
4-»
§
*
CO
X
e x
S
^d
CJ
^d
'b b
s X T3• H 3 a> 3
CD cd X cd
CX V* H Q>X CN| CACD X o
CD CD CJ
X * rH
to
cd J 3
<Hh
o
X 3♦H
'b b
*d /^ s O o
3
<D
X CD
'ey CD • d
a> >  • H
1
CN
X! H-* 1t "H4-* u
<y X u44
(d CXCO
a>
CD r-H
0) d l—“ ‘
d Ih (ACA s(ACO a • pH•4-» <4-1
•43 U 3
CA
CD
3 • d • pH 3• H
3
3
cd 3o
H
^d
O• H H-J ★ CX
• H
cd
'o
>
nJ
H->
3
8
U>w'
cd
r ;
pH
in
O
X
3
O
• x
d
3
O
o
U
3CO
cdp 4
CX
<-•
e x
CA
o
X
CX
X• H
£CA• pH
• d
f-H • H 44 CD
3 d<3 CD CD CAH-H
O4-*
to
OCJ
^d
'b b
d
c r
CA
X
CD
X4->
* » .
CDCA
X
d
<44
o
o
O • d CA *44cd
to
g
3 CA
cd 44 • pH <DH>H
CD CD(A • d
X44
4-> o 3 to
c u cd • pH• H
x
j3
'bO
(DCA i
a>44
cd
3
X
o
CD
o
CJ
J3
b b
to44
3
CD
CJ • d
3 iCNi
X <Do o %
b o
CO u CD" d
2 rH U-(o
3
•pH>
3
O
M-h
o CDX p-H• H H-» CA cd O44 <44
cn33 O■4-*
CX
d QJXH-H
d cdin4-i
I-
o
44
CA
CDto
Q
3
CD
u
M-i
CA44
Q44
cd>4CD
d
3
3 3 o
O
u
cd
44
CA
ex(4
oCD 3 CJX4-< OCJ 3•pH
X
§
• NX 
cd
£X-MCdex
cj X
rHO u
'bb xj
cd
«
a
£
o
X
0)
3*43
3
o
cj
x
CD
•4-*
Cdr ■<
&
OXCXto
OXCX
a>
<j
3
O
VX
cj
•  pHX
£
O
■8
cds
cd
44Cd
44
(A
x
<3
CD
44
to
bO
{3
• H
3
x
CD
(A
ouj3
'bb
S3
o33
cj
cd
.i-i
j- i
o
<D
to
cd
3
• HX
O
X
CDX
to
CD
s  «
.52 S
u
Op^ H
<D>
fH
cd
S
•  p H
X
cds
a>
X
44
x
3
cd
3
(34->
CO
3
Ou
3
CD44
3
CD
5* ^. £>
• H CT\
0) ^
X <aU
CDX
CD
»4
(0
6>
x
3
cd
s
w
x
3
cd
*fi>
x
3
cd
*s
o
x
o
CD
<D
>
• H H-»u
CDCXto
CD
S-I
CD
CO
O
cj
'bb
x
3
cd
CD
CO
OoJ3
'bb
> v
X
o
CD
x
1.1.2. Methodological Considerations
A lthough the constants incorporated in the operational equation 
appear to be stable for a range of physiological values, in theory the value 
of the rate constants and lum ped constants m ight be expected to be 
altered by factors producing an imbalance between glucose supply and 
utilisation.
O utw ith normoglycaemia, the ratio of distribution between glucose 
and deoxyglucose is altered: in hyperglycaemia decreases in the brain 
distribution spaces of deoxyglucose and glucose occur; thus X, the ratio of 
distribution volumes for glucose and [14C]-2-deoxyglucose, will decrease. 
The consequential decrease in the absolute value of the lumped constant 
ren d e rs  the opera tional equation  inaccura te , and  leads to an 
underestim ation of cerebral metabolic rate.
Conversely, in hypoglycaemia, the distribution volume of glucose is 
decreased, while that of deoxyglucose is increased, leading to a marked 
elevation in the value of the lumped constant. This in turn leads to an 
overestimation of cerebral metabolic rate.
The former case is particularly im portant in situations where stress- 
induced hyperglycaemia is evident; the latter is likely to occur if food has 
been w ithheld for a num ber of days, or if experim ental procedures 
disable the animal sufficiently to prevent it feeding normally over an 
extended period.
W hile it is often possible to m aintain norm oglycaem ia by sim ple 
adjustm ent of experim ental procedures (for exam ple see M ethods 
Section 1.1.8., THA), m ore caution m ust be applied in situations where 
regional supply  and utilisation of glucose may be altered. In focal 
cerebral ischaemia, marked reductions of blood flow, and hence glucose 
supply , m ay in terfere with the quantitative estim ation of cerebral 
metabolism. In the present study, deoxyglucose autoradiography was 
used to m easure cerebral glucose use in response to acute subdural 
haematoma in the rat. The effects of ischaemia on the rate and lum ped
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constan ts are discussed w ithin the relevant section (Results and 
Discussion Section 3).
1.1.3. Anim als
All deoxyglucose investigations w ere perform ed on adu lt male 
Sprague Dawley rats (H arlan Olac, O xfordshire, UK). Prior to 
investigations, the rats were housed in a naturally  lit, tem perature- 
controlled environm ent, and unless stated o therw ise (see M ethods 
Section 1.1.8, THA) all had free access to food and water.
1.1.4. Surgical Preparation
Rats were placed in a perspex cham ber into which flowed an 
anaesthetic gas composed of 5% halothane in a nitrous oxide: oxygen 
m ixture (70%: 30%). Once anaesthesia was induced, halothane was 
reduced to 1-1.5%, and rats were maintained, spontaneously breathing, in 
an unconscious state for the implantation of femoral arterial and venous 
cannulae. The femoral vessels were exposed bilaterally through a small 
incision in the skin overlying the pelvic muscles, proximal to the femur. 
A polyethylene cannula (Portex, external diam eter 0.96mm, internal 
diam eter 0.58mm), 15cm in length and filled with heparinised saline (10 
IUm P1), was inserted approximately 2cm into the vessel. The cannulae 
were tied in place with fine su ture m aterial, and the w ound  was 
infiltrated with local anaesthetic gel (lignocaine hydrochloride, 2%) and 
sutured.
Externally, the w ound was smeared with local anaesthetic gel, and 
covered in gauze pads. The lower torso was enveloped in a surgical 
stocking, and a plaster cast was applied loosely around the hindlimbs and 
abdomen. The plaster cast and the hindlimbs of the animal were taped 
to a lead brick for purposes of restraint, anaesthesia was term inated, and
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the rats allowed to regain consciousness. A recovery period of at least 
two hours was given, prior to autoradiographic m easurements to allow 
dissipation of anaesthetic; during this period, arterial blood pressure was 
m onitored continuously, and norm othermia m aintained w ith a heating 
lam p.
1.1.5. Autoradiographic Sampling and Preparation of Autoradiograms
The autoradiographic procedure was initiated by the intravenous 
infusion over 30 seconds of [14C]-2-deoxyglucose (125pCi in 0.7ml saline). 
Concurrent with the start of isotope injection, a 45 m inute experimental 
period commenced, in which 14 timed arterial samples were collected 
and immediately centrifuged. The plasma from each sample was assayed 
for 14C activity by liquid scintillation and for glucose concentration 
(Glucose A nalyzer 2, Beckman, High W ycombe, UK), in o rder to 
calculate the history of the isotope. At 45 minutes, the animal was killed 
by decapitation, and the brain wholly dissected out and frozen in 
isopentane cooled to -45°C in dry ice. The brain was m ounted on a 
sw ivel-headed microtom e chuck using em bedding m atrix (Tissue-Tek, 
Miles Inc., Elkhart, USA), and coronal sections 20pm thick were cut 
serially in a cryostat. Three adjacent sections were thaw -m ounted onto 
glass coverslips, and rapidly dried on a hot-plate. The following ten 
sections were discarded. This cycle was repeated throughout the brain 
(medulla to frontal lobes).
The coverslips w ere glued to card, and placed in X-ray cassettes, 
adjacent to 14C-sensitive film, along with a set of pre-calibrated epoxy­
resin standards (concentration range 44-1475 nCi g_1), for approxim ately 
two weeks. Films were processed using a standard Kodak autom atic 
processor, in order to generate deoxyglucose autoradiograms.
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1.1.6. Liquid Scintillation Analysis
The concentration of 14C in plasma was estim ated for each animal 
during the [14C]-2-deoxyglucose autoradiographic routine. A 20(0.1 aliquot 
was pipetted into a scintillation vial containing 1ml of water. To each 
vial was added 10ml of scintillation fluid (Ecoscint, National Diagnostics, 
New Jersey, USA), and the vials shaken thoroughly. The radioactivity in 
each vial was counted in a refrigerated scintillation counter using an 
external standard  channels-ratio m ethod (Peng, 1977) together w ith a 
standard calibration curve for quench correction. Vials were counted on 
three separate occasions, and the mean values for disintegrations per 
m inute used in the calculation of the plasma integral.
1.1.7. Calculation of Local Cerebral Glucose Utilisation
Local tissue concentrations of 14C were m easured in each region of 
interest, using computerized densitometry (Methods section 1.3.). Local 
cerebral glucose utilisation for each region was calculated from these 
values and the plasm a values for tracer and glucose concentration, by 
application of the deoxyglucose operational equation derived by Sokoloff 
et al. (1977).
1.1.8. Drug A dm inistration
In three series of anim als, deoxyglucose au to rad iog raphy  was 
p e rfo rm e d  a fte r  a d m in is tra tio n  of one of the  fo llo w in g  
pharmacologically active agents, in order to assess its effects on cerebral 
metabolism.
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1. D-(E)-4-(3-phosphonoprop-2-enyl)-piperazine-2-carboxylic acid (D-
CPP-ene), a competitive glutam ate antagonist
Com petitive antagonists such as D-CPP-ene are highly hydrophilic, 
and therefore the rate at which they penetrate the blood brain barrier is 
slow, and the CNS concentration they achieve is low relative to their 
plasm a concentration. The blood-brain barrier permeability-surface area 
product (PS) of D-CPP-ene has been estim ated  to be less than 
O.OOOlml/min/g (Pardridge et al., 1990), a figure in agreem ent with its 
octanol/w ater partition coefficient (Rapoport et al., 1979). The entry into 
the brain of drugs with low blood-brain barrier perm eability may be 
estimated by the equation:-
Cb (T) = PS JoT CA(t)dt
where CB is the concentration of drug in the brain at time T, and CA(t) is 
the arterial plasma concentration of the drug at variable time t after its 
adm inistration into the bloodstream. This equation has been used to 
suggest that the CNS concentration of D-CPP-ene reaches a plateau at 120 
m inutes after adm inistration  into the bloodstream  (M cCulloch & 
Iversen, 1991). Therefore, in order that the effects of D-CPP-ene on 
cerebral metabolism could be assessed at steady-state conditions in terms 
of drug concentration, D-CPP-ene was adm inistered intravenously two 
hours prior to administration of isotope, at a dose of 0.3, 3 or 30 m gkg'1.
2. L679-512, a novel muscarinic agonist
L679-512, a novel m uscarin ic  agonist of high efficacy, was 
adm inistered intravenously 15 minutes prior to adm inistration of [14C]- 
2-deoxyglucose, at a dose of 3,10, or 30mgkg_1.
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3. 9 -A m ino-l,2 ,3 ,4 -te trahydroacrid ine  (THA), a C ho lineste rase  
Inhib itor w ith Potential Glutamatergic Activity
9 -A m in o -l,2 ,3 ,4 -te trah y d ro ac rid in e  (THA) w as ad m in is te red  
intravenously 15 minute prior to isotope injection at a dose of 2.5mgkg_1. 
In this series, it was found that THA induced a degree of hyperglycaemia; 
in order that plasma glucose levels did not exceed those values for which 
the operational equation is accurate, food was w ithdraw n from these 
animals 12 hours prior to autoradiographic measurement.
1.1.9. Chemicals
[14C]-2-deoxyglucose (50Ci m m ol'1) was supp lied  by A m ersham  
International, Buckinghamshire, England.
D-(E)-4-(3-phosphonoprop-2-enyl)-piperazine-2-carboxylic acid (D-CPP- 
ene) was obtained from Sandoz Research Institute Berne Ltd., Berne, 
Switzerland.
9 -A m in o -l,2 ,3 ,4 -te trah y d ro acrid in e  h y d ro ch lo rid e  (THA) w as 
purchased from Sigma Chemical Company Ltd., Poole, Dorset, UK.
L679-512 was obtained from Merck Sharpe Dohme, Harlow, Essex, UK.
1.2. IN VITRO LIGAND-BINDING AUTORADIOGRAPHY
1.2.1. Theory
Ligand-binding autoradiography involves the interaction of a radio­
labelled d rug  with a receptor, according to classical ligand-receptor 
kinetics. A simple model is described by the bimolecular action:-
[L] + [R] ^  [RL] (1)
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RL, the product is more commonly known as B, the am ount bound. At 
equilibrium :-
[R] [L]
Kh = (2)
[B]
where is the dissociation constant. The total num ber of receptors, 
Bmax' W^1 be equal to the amount of free receptors plus the am ount 
bound, i.e.:-
Bmax = [R] + [B] (3)
Substitution for [R] in equation (2) yields:-
(Bmax - [B] ) [LI
Kd = --------------------  (4)
[B]
Rearrangement of equation (4) gives:-
Bmax [LI
[B] =   (5)
[L] + Kd
This equation is used in saturation analysis to provide estimates of 
and Bmax- IB] is measured as a function of the radio-ligand, and will 
increase as [L], the concentration of the ligand, is increased. K^, the 
dissociation constant, which describes the equilibrium  condition of
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binding, will be equal to 1/2 Bniax.
Non-specific binding, that is, binding to com ponents of the tissue 
o ther than the receptor, is non-saturable, and proportional to the 
concentration of the radio-ligand. The portion of non-specific binding 
may be estimated by displacement of the radio-ligand with a non-labelled 
ligand specific for the receptor.
Analysis of b inding data is more commonly perform ed using a 
Scatchard plot. Further rearrangement of equation (4) yields:-
[B] Bmax [B]
—  =    +  —  (6)
[L] Kd Kd
When the ratio of the concentrations of bound (B) and free (L) ligand 
is plotted against the concentration of bound ligand, a straight line is 
produced, with a gradient equal to -l/K ^. The intercept of the line on the 
x-axis is Bmax (Scatchard, 1949). This analysis allows estimation of Bmax 
by ex trapo lation , and  hence negates the need to use sa tu ra ting  
concentrations of ligand.
This method has been used extensively in the calculation of receptor- 
binding kinetics, in order to establish protocols for binding w ith each 
radio-ligand. The present study employs kinetic analysis of ligand- 
binding which has been calculated elsewhere (M onaghan & Cotman, 
1985; Walmsley e t al., 1984; W esterberg et al., 1987); details of m ethods 
used, and the source reference are found in Table 2.
1.2.2. Preparation of Sections for Ligand-Binding Autoradiography
Adult male Sprague Dawley rats were killed by decapitation, and the 
brains rapidly dissected out and frozen in isopentane cooled to -42°C. 
Coronal sections, 20|U.m thick were cut in a cryostat, and collected on
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gelatin-coated microscope slides: three adjacent sections in 27 were 
serially collected throughout the brain (cerebellum to frontal lobes) for 
each ligand-binding experiment.
The sections were dried at room tem perature, and stored at -20°C, in 
enclosed containers for up to 12 months prior to autoradiography.
1.2.3. Procedure
A genera l o u tlin e  of the m eth o d  em p loyed  in recep to r 
autoradiography is given in Figure 6, and the protocol em ployed for 
binding experiments with each ligand is found in Table 2, together with 
details of the publication which describes the particular m ethod used.
Briefly, tissue sections were incubated in the appropriate buffer for a 
period  of tim e (the pre-incubation  period) in o rder to rem ove 
endogenous ligands which might inhibit or displace the binding of the 
radio-ligand. Tissue sections were then incubated with the radio-ligand 
for a given period; non-specific binding was estim ated in adjacent 
sections by inclusion of a non-radio-labelled displacer in the incubation 
medium. At the end of the incubation period, the sections were washed 
in buffer and rinsed in water to remove unbound radio-ligand, and dried 
in a stream  of cool air. Because of the short dissociation time of 
glutam ate receptor ligands, sections incubated w ith these ligands were 
d ried  rap id ly  by application of 2.5% g lu ta ra ldehyde  in acetone 
(approxim ately .1ml per section). Finally, sections were apposed to 
radiation-sensitive film in sealed X-ray cassettes for an appropriate  
length of time, to produce autoradiogram s. Films were developed 
m anually in Kodak D-19 developer for five m inutes at 17°C, w ith 
interm ittent agitation. Developm ent was term inated by placing the 
films in de-ionised water at 20°C for 30 seconds, and the films were fixed 
in Kodak Kodafix at 20°C for ten minutes. Finally, films were washed 
with running water and rinsed in de-ionised water, and suspended in a
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RECEPTOR AUTORADIOGRAPHYI --------------------------------------------------
SECTIONS PREINCUBATED 
IN BUFFER
SECTIONS RINSED AND DRIED
SECTIONS APPOSED TO [ H]-SENSITIVE FILM
SECTIONS INCUBATED WITH RADIOLIGAND 
WITH OR WITHOUT COMPETITIVE DISPLACER
IMAGES ANALYSED USING COMPUTER-ASSISTED 
DEN SITOMETRIC MEASUREMENT
FILM DEVELOPED AFTER APPROPRIATE EXPOSURE
TISSUE SECTIONS CUT ON CRYOSTAT MICROTOME 
AND MOUNTED ON GLASS SLIDES
FIGURE 6: GENERAL PROCEDURE FOR QUANTITATIVE 
RECEPTOR AUTORADIOGRAPHY IN  VITRO
drying cabinet.
L igand concentrations (pmoles of ligand b o u n d /g  tissue) were 
estim ated from the autoradiogram s using com puterised densitom etry 
(Methods Section 1.4.), with reference to pre-calibrated tritium  standards 
of known radioactivity (range 1060-17720 nC i/g  tissue equivalent.
1.2.4. Chemicals
[3H ]-Q uinuclidinyl benzilate ([3H]-QNB, 44 Ci m m ol-1) and [3H ]- 
g lu tam ate  (46 Ci m m ol"1) w ere p u rch ased  from  A m ersham  
International, Buckinghamshire, UK. [3H]-Kainate (59 Ci mmol"1) and 
[3H]-a-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]-AMPA, 29.2 Ci 
m m o l'1) were obtained from New England Nuclear, Herts., UK.
A tropine sulphate, N-m ethyl-D-aspartate, kainate, quisqualate and 
potassium  thiocyanate were purchased from Sigma Chemicals, UK. 4- 
A cetam ido-4 '-iso th iocyanostilbene-2 ,2 '-d isu lfon ic  acid  (SITS) was 
obtained from Fluka, Buchs, Switzerland.
1.3. ANALYSIS OF AUTORADIOGRAMS
Two com puter-based densitom etry systems were em ployed in the 
analysis of the autoradiograms. For most optical density measurements, 
a Quantim et 970 image analyser (Cambridge Instrum ents, England) was 
used. The autoradiograms were suspended on a fixed glass plate above a 
w hite stage, illum inated by four 24W lam ps, w hose in tensity  was 
controlled by the computer. Light from the lamps was reflected by the 
white stage, through the glass plate and autoradiogram, and was detected 
by a video camera. The image was digitised into pixels with a grey level 
in the range of 0-255 (grey-level of 255 corresponds w ith an optical 
density of 0; grey level of 1 corresponds to an optical density of 2.41). The
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image was projected onto a live video screen for the user's reference.
The system was calibrated against each film, so that a calibration curve 
betw een 100% transmission (obtained when a blank part of film was in 
view) and zero transmission (measured when the lens cap was in place) 
was achieved.
Once the system had been calibrated, optical densities of the images 
produced by the pre-calibrated standards were m easured, to provide a 
calibration curve of optical density versus radioactivity (nC i/g  tissue 
equivalent). The optical densities of the images produced by the radio­
labelled sections were subsequently quantified in term s of isotope 
concentration by reference to the standard curve. For each anatomical 
region of interest, the image analyser calculated three integrated optical 
density measurements, within a given frame of reference superim posed 
upon the region. The size of the reference frame could be altered 
between 9 and 900 pixels/fram e (900 pixels represented 9mm2), but was 
kept constant between animals for each particular structure. Structures 
were defined anatomically with reference to a stereotaxic atlas (Paxinos 
and W atson 1986), and for each animal 3-6 sections were m easured to 
give a mean optical density value for a given structure.
A m odified densitom etric approach was used in the analysis of 
several series of films in order to m easure discrete regions of the 
hippocam pus (Room & Tielemans, 1989). Following the production of 
autoradiogram s, the radio-labelled sections were histologically stained, 
and superimposed on the autoradiographic image: this allowed detection 
of discrete "cortical" layers, which would not have been possible from 
the autoradiogram s alone. For this procedure the IBAS 2000 analyser 
(Kontron, Munich, Germany) was used. This system differs substantially 
from the Quantim et 970 in its method of analysis. A light-box provided 
a diffuse light source upon which the autoradiogram  or histological 
section was placed. The host computer was connected to a video camera 
suspended above the light-box: using the light-box as a reference the
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system was calibrated, by detecting the grey level (range 0-255) of each 
pixel in view (field of view: 1.75 x 1.25cm, equal to 512 x 768 pixels). Thus 
a maximal transmission level was set for each pixel, and an allowance 
m ade for the possibility of uneven illum ination from the light-box. 
Once the system had been calibrated, the autoradiogram  was placed on 
the light-box. The whole image was digitised by averaging over 10 
successive measurements, and the grey level for each pixel was stored. 
The autoradiogram  was replaced by the corresponding histologically- 
stained section, the image of which in turn was stored. A H elm ert 
transform ation technique was used to m easure the positions of at least 
four markers (such as bubbles in the section, etc.) and then rotate and 
m agnify the histological image, with respect to the autoradiographic 
image, so that the two were aligned.
Densitometric measurements were m ade by draw ing the outlines of 
distinct histologically-defined layers and regions on a digitiser tablet; the 
path of the pen was observed as a red line on the histological image 
stored and displayed on the video screen. Concurrently, the grey level of 
the outlined area was calculated from the stored autoradiographic image. 
Following measurement of each section, transmission from the light-box 
was re-measured, as a control against changing levels of light.
O ptical density  m easurem ents w ere quan tified  in term s of 
radioactivity, as previously, with reference to pre-calibrated standards 
which were m easured prior to analysis of each section. A total of 3-6 
sections were measured for each given region of interest, and the mean 
values of radioactivity calculated.
1.4. STATISTICAL ANALYSIS
In studies w ith two groups, statistical analysis of results was 
perform ed using a two-tailed, unpaired Student's t-test. In studies with 
three or more groups, Bonferroni correction was used for multiple group 
com parisons (W allenstein et al., 1980). Statistical significance was 
deemed to be achieved when p<0.05.
2. LESIONS OF THE CNS
2.1. STEREOTAXIC LESIONS OF THE MEDIAL SEPTAL NUCLEUS
2.1.1. Theory: The Use of Ibotenic Acid as a Neurotoxin
Ibotenic acid is an analogue of glutamate with neurotoxic actions, and 
which has been employed widely to lesion specific cellular populations 
w ithin the CNS (Fisher & Hanin, 1986; Smith, 1988). Injection of 
ibotenate has been shown to produce m arked destruction of neurones, 
while axons of passage are spared (Schwarcz et al., 1979).
Ibotenic acid-induced lesions of the hippocam pal afferents are now 
well established models of amnesia (Fisher & Hanin, 1986; Hagan & 
M orris, 1988; Smith, 1988); the advantage of ibotenic acid in this 
particular field of study is the lack of epileptogenic effects known to occur 
in glutamatergic systems following injection of kainic acid.
2.1.2. A nim als
Surgery was perform ed on either adult male Sprague Dawley rats 
(Harlan Olac, Oxfordshire, UK), and W istar rats (Cpb: Wu, TNO Zeist, 
N etherlands). Prior to surgery, rats were kept in a tem perature- 
controlled environment, and fed ad libitum.
2.1.3. Chemicals
Ibotenic Acid (Cam bridge Research Biochemicals Ltd, or Sigma 
Chemical Company Ltd, England) was dissolved in phosphate-buffered 
saline (0.1M, pH7.2) at a concentration of lOmg m b1. Once prepared, the 
solution was stored frozen until use, for a m axim um  period of two 
m onths.
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2.1.4. Surgical Procedure
Injection into the medial septum of the buffered ibotenic acid solution 
was achieved using stereotaxic procedures. The rat was anaesthetised 
w ith chloral hydrate (400mgkg_1) and d iazepam  (Valium , Roche 
England) (2mgkg_1) injected intraperitoneally. The scalp was shaved and 
cleaned with an antiseptic surgical swab, and the rat was placed in a 
stereotaxic frame and restrained by use of ear bars and an incisor bar. The 
incisor bar was lowered 3.3mm, according to Paxinos and Watson (1986). 
The scalp was incised, and the underlying tissue retracted from the skull. 
Using a dental drill, a burrhole was m ade anterior to Bregma. The 
buffered ibotenic acid solution was delivered into the medial septum  
through a lp l syringe (SGE, Ring wood, Australia), the needle of which 
had been placed 0.8mm anterior to Bregma, at the midline, and lowered 
5.8mm below the surface of the dura. These coordinates have been 
previously defined (Wenk et al., 1984).
A total volume of 0.6pl (6pg ibotenic acid) was injected into the 
medial septum  at a rate of O.lfil m in '1. Following completion of the 
injection, the syringe was left in place for five m inutes, to allow 
diffusion of the toxin away from the injection site; the syringe was then 
slowly withdrawn. Antibiotic powder (neomycin sulphate) was applied 
to the exposed skull and scalp, and the wound was sutured. The animal 
was rem oved from the frame, and m aintained on a therm al blanket 
until recovery from anaesthesia was complete.
In order to control for surgical damage to the medial septum  and 
surrounding tissues, sham-operated rats underw ent a surgical procedure 
identical to that outlined above, but phosphate buffered saline m edium  
only was injected into the medial septum.
2.1.5. Quantification of Extent of Lesion
The size and position of the lesion were assessed using the following 
histological methods.
Initially, a series of rats w ere placed in the stereotaxic fram e as 
described, with the exception that no vehicle was injected; the rats were 
sacrificed immediately following the surgical procedure. The brains were 
rapidly dissected out and frozen, and the frontal portion was cut into 
20pm sections in a cryostat. Sections were thaw -m ounted on glass 
microscope slides, and the tissue was fixed and stained using thionine, 
cresyl v iolet/luxol fast blue, or haem atoxylin and eosin. U nder light 
microscopy, the position of the syringe was identified by a straight line of 
disrupted cells and fibres. Thus the accuracy of the chosen coordinates, 
was confirmed. A second series of experim ents was perform ed to 
estim ate the reproducibility of the lesion. Animals were allowed to 
survive post-operatively for three weeks. After this time, the animal 
was placed under deep halothane anaesthesia, and the brain was fixed by 
perfusion of approxim ately 200ml of 40% form aldehyde: acetic acid: 
methanol mixture (1:1:8 v /v /v ) . The brain dissected out and cryostat- 
sectioned, and alternate tissue sections were stained w ith either 
haematoxylin and eosin, or cresyl violet-luxol fast blue. The lesion site 
was quantified by light microscopy in order to determine both the size 
and position of the lesion. In two brains: one sham and one ibotenate- 
lesioned, staining for glial fibrillary acidic protein (GFAP) was performed 
by an independent neuropathologist (Professor D. I. Graham, Institute of 
Neurolocial Sciences, Southern General Hospital, Glasgow) to confirm 
the presence of glial cells within the lesioned tissue.
In subsequent series, rats were prepared surgically as described, and 
killed by decapitation, and the brains dissected out and frozen rapidly. 
The method of collection of material for histology was dependent on the 
protocols subsequently applied to the lesioned animals. In those brains 
which were used in autoradiographic investigations, cryostat cut sections
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were collected adjacent to those sections used for autoradiography 
(Methods Section 1.2.2.). For all other brains, the portion rostral to the 
optic chiasma was separated and frozen. This portion was cryostat-cut 
into 20pm sections, and stained using one of the m ethods previously 
used. The extent of the lesion was assessed using light microscopy.
2.2. ACUTE SUBDURAL HAEMATOMA: A RAT MODEL OF FOCAL 
CEREBRAL ISCHAEMIA
2.2.1. Surgical Preparation
U nder halothane anaesthesia, femoral arterial and venous cannulae 
were implanted in adult, male Sprague Dawley rats, in preparation for 
autoradiographic measurements (Methods Section 1.1.4). The rats were 
then turned prone, and a midline incision was made in the scalp. Using 
a dental drill, a 3mm burrhole was drilled approximately 2mm left of the 
sagittal suture and 3mm anterior to Bregma, over the parietal cortex. The 
dura was incised, and a J-shaped 23 gauge needle inserted into the 
subdural space. The burrhole was sealed around the needle with rapidly- 
setting glue. A haematoma was produced by injection of 0.4ml of non- 
heparinised autologous venous blood into the subdural space: the total 
injection time was seven minutes. The needle was then cut and the 
open end sealed to prevent back-flow of injected blood. Local anaesthetic 
gel was applied.to the scalp and the wound was sutured. Animals were 
restrained  and allowed to regain consciousness in preparation  for 
au toradiography. Sham -operated control rats underw ent the same 
surgical procedure, including placem ent of the needle, w ith the 
exception that no blood was injected into the subdural space.
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2.2.3. Experimental Routines and Drug Administration
Two hours following production of ASDH, [14C ]-2 -deoxyg lucose  
(125pCi in 0.7ml saline) was adm inistered , and the deoxyglucose 
autoradiographic procedure was initiated. Prior to comm encem ent of 
autoradiography, arterial blood pressure and rectal tem perature were 
m onitored continually. Arterial blood gases were sampled regularly, and 
norm otherm ia was maintained with the use of a heating lamp.
In a series of animals, adm inistration of the competitive glutam ate 
antagonist, D-CPP-ene (Sandoz Research Institute Bern Ltd, Switzerland) 
was adm inistered intravenously, at a concentration of 15mgkg_1 in 
saline, 15 minutes before the ASDH was produced. Despite its apparently 
lim ited penetration of the CNS at short times after adm inistration  
(McCulloch & Iversen, 1991) D-CPP-ene adm inistration according to this 
regime has been shown to be neuroprotective in focal cerebral ischaemia 
in the cat (Bullock et al., 1990). Deoxyglucose autoradiography was 
perform ed two hours after production of the haematoma; at this time D- 
CPP-ene is predicted to reach its maximal CNS concentration, and the 
effects of D-CPP-ene could be compared w ith those produced in control 
animals (Methods Section 1.1.8.)
Twenty five minutes after the administration of deoxyglucose, 6.1 mCi 
of the blood flow tracer, 99m -technecium -labelled H exam ethethyl- 
propyleneam ine oxime ([99rrTC]-HMPAO; half life 6 hours) was injected 
intravenously, in order to m easure blood flow and cerebral glucose use 
co n cu rren tly  (K uroda et al., 1992). Fo llow ing  deoxyg lucose  
a u to ra d io g ra p h ic  m easu rem en ts , the  an im als w ere  k illed  by 
decapitation, and the brains rapidly dissected and frozen in isopentane at 
-45°C and  cut in to  20|im sections in a cryostat. Blood flow 
autoradiogram s of [99rnTC]-HMPAO w ere prepared  by exposing the 
sections to radiation-sensitive film (LKB-Ultrafilm) for six hours. The 
sections were set aside for 72 hours to allow for decay of 99mTC, then re­
exposed to 14C -sensitive  film  for tw o w eeks. D eoxyglucose
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autoradiogram s were analysed as described previously; the results of 
blood flow measurements have been described elsewhere (Kuroda et al., 
1992), and are not included as part of this study.
2.2.4. Quantification of Ischaemic Lesion
Quantitative neuropathological studies have been described in detail 
(Miller et al., 1990). At four hours after production of the haematoma, 
the region of infarct is clearly visible in sections sta ined  w ith 
haematoxylin and eosin. The infarcted area can be defined as a sharply 
delineated region of pallor, bordering norm al, densely stained tissue 
(Figure 7). W ithin the infarcted area, there is vacuolation of the 
neuropil and swelling of astrocytes. H ippocam pal dam age was not 
observed up to 24 hours following production  of the haem atom a; 
how ever, after four days, gross u ltrastructu ral abnorm alities were 
apparent in the nucleus, cytoplasm and endoplasmic reticulum (Bullock 
et al., 1991b).
Following production of autoradiograms in the present study, coronal 
sections were stained with haem atoxylin and eosin, and the damage 
assessed by an independent neuropathologist (Professor D. I. Graham, 
Institute of Neurological Sciences, Southern General Hospital, Glasgow).
11 2
LEGEND TO FIGURE 7: HISTOLOGICAL ANALYSIS OF ACUTE 
SUBDURAL HAEMATOMA IN THE RAT
A. D iagram  of the d istribution  of ischaemic dam age at various 
stereotaxic planes through the rat brain.
B. & C. Coronal sections stained with hematoxylin and eosin after acute
subdural haematoma in the rat. Sections at the level of the frontal 
cortex (B) and the hippocampus (C) in a rat four hours after acute 
subdural haematoma. Note the region of pallor w ith a clearly 
defined margin beneath the haematoma.
Reproduced with kind perm ission from Mr Ross Bullock and 
colleagues (Miller et al., 1990).
F I G U R E  7:  H I S T O L O G I C A L  A N A L Y S I S  O F  A C U T E  S U B D U R A L  
H A E M A T O M A  I N  T H E  R A T
3. BIOCHEMICAL ANALYSIS OF SECOND MESSENGER SYSTEMS IN 
THE HIPPOCAMPUS: ESTIMATION OF PHOSPHOINOSITIDE  
TURNOVER
3.1. Theory and Background to Assay
There are now known to exist several second m essenger systems, 
which are activated by the association of a specific receptor and its 
neurotransm itter, resu lting  in the m odification of cellular responses. 
One of these is the phosphoinositide cycle, (Figure 8) and activation of a 
num ber of receptor types and sub-types is thought to be linked to 
phosphoinositide metabolism.
When an agonist binds to a receptor linked to the phosphoinositide 
signalling system, the resultant agonist-receptor complex leads to the 
stimulation of a phosphoinositide-specific phospholipase C. Activation 
of this enzym e results in the hydrolysis of phosphatidyl-inositol 4,5- 
b isphosphate (PIP2) to form diacylglycerol (DAG) and inositol 1,4,5- 
trisphosphate (IP3). Both products have second messenger actions: IP3 
has been dem onstrated to mobilise calcium ions from endoplasm ic 
reticulum , the pu tative  stim ulus for m any enzym es and cellular 
reactions, while DAG activates protein kinase C thus resulting in protein 
phosphorylation, and further modification of cell function.
DAG is inactivated by its conversion to phosphatidic acid by DAG 
kinase; phosphatidic acid reacts w ith 'cytidine triphosphate, resulting in 
the formation of cytidine diphosphodiacylglycerol (CDP-DAG), which is 
ultimately used in the re-synthesis of PIP2. IP3 is broken down and thus 
inactivated by a phosphatase, yielding inositol 1,4-bisphosphate (IP2). 
Further metabolism of IP9 leads to formation of inositol phosphate and 
subsequently myo-inositol, which combines with CDP.DAG in the re­
synthesis of PIP2. Re-synthesis involves a num ber of interm ediary 
s ta g e s : C D P.D A G  an d  m y o -in o s ito l c o m b in e  to fo rm
p h o s p h a t id y l in o s i to l ,  w h ich  is P h o s p h o ry la te d  to fo rm
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LEGEND TO FIGURE 8: THE PHOSPHOINOSITIDE CYCLE
Schematic diagram  of agonist-dependent phosphoinositide hydrolysis. 
Activation of phospholipase leads to hydrolysis of phosphatidylinositol 4,5 
bisphosphate (PIP2)/ resulting in the formation of diacylglycerol (DAG) and 
inositol 1,4,5 trisphosphate (IP3). DAG and IP3 have second messenger 
activities: DAG activates protein kinase C (PKC), while IP3 m obilises 
intracellular Ca2+ stores, resulting in phosphorylation of phosphoproteins 
(PP) such as membrane channels. DAG is converted to phosphatidic acid 
(PA) via DAG kinase; PA reacts with cytidine diphosphate (CDP) to form 
cytidine diphosphodiacylglycerol (CDP-DAG). IP3 is metabolised to myo­
inositol via inositol b isphosphate (IP9), and inositol phosphate (IP); 
lithium chloride prevents the breakdown of PI to myo-inositol. IP3 may 
also be metabolised to other inositol phosphates with second messenger 
activity, such as IP4.
DAG
PKC
PA
CDP-DAGPP
PLC
PIPPIP0  = P - 0
Myo­
inositolADP
LiCl
Endoplasmic
Reticulum
FIGURE 8: THE PHOSPHOINOSITIDE CYCLE
phosphatidylinositol 4-phosphate (PIP), and then further phosphorylated 
to PIP2 by two distinct kinases. Thus, the cyclic breakdow n and re­
synthesis of PIP2 in response to receptor-agonist interaction represents a 
complex second m essenger signalling system  which results in the 
m odulation of cell function.
The discovery that lithium inhibits the phosphatase enzym e which 
mediates the breakdown of inositol phosphate to myo-inositol provided 
an ind irect m ethod for the estim ation  of the total am ount of 
phosphatidyl hydrolysis in a given period (Gonzales & Crews, 1984; 
Janowsky et al., 1984). Briefly, tissue slices are incubated with [3H ]- 
labelled myo-inositol, which is incorporated into phosphatidylinositol, 
and further m etabolised to PIP2. To the m edium  is added lithium  
chloride, and an agonist known to exert its effects through activation of 
the phosphoinositide cycle. Agonist-receptor interaction will thus result 
in the breakdow n of PIP2, and stim ulation of phosphatidylinosito l 
turnover, as described. The presence of lithium, however, prevents the 
hydrolysis of inositol phosphate and results in accum ulation of [3H ]- 
inositol phosphate, which may be separated from other inositol lipids by 
ion-exchange chromatography, and quantified using liquid scintillation 
analysis. The total accumulation of [3H]-inositol phosphate may thus be 
used as an indication of agonist-induced activity of the phosphoinositide 
cycle.
3.2. M ethod
Experiments were perform ed on adult male W istar rats (Cpb: Wu, 
TNO, Zeist, Netherlands), which had previously undergone surgery to 
lesion the medial septal nucleus of the brain (Methods Section 2.1.4.). 
Rats were killed by decapitation, and the brains rapidly rem oved and 
placed on ice. The frontal portion of the brain was rem oved and 
p rocessed  h isto logically  for quan tifica tion  of the lesion. The
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hippocampus was dissected out and chopped into 0.35mm2 slices using a 
M cllw ain tissue chopper, and suspended  in 50ml Kreb's R inger 
bicarbonate buffer (KRBB) at room tem perature. Sections were washed 
once with KRBB at 37°C and re-suspended in 50ml fresh KRBB. To 
rem ove endogenous agonists, slices were incubated for 30 m inutes at 
37°C in a shaking waterbath, under a constant stream of 95% oxygen: 5% 
carbon dioxide. Following the incubation, the buffer was aspirated, and 
50ml aliquots of the remaining slurry (containing approxim ately 15mg 
tissue) were transferred to glass m icrom edia tubes (Otan, Rijsbergen, 
Netherlands). For each brain, a total of four samples were collected. To 
each sample was added 200pl [3H]-myo-inositol (final concentration 250 
nM), and the samples were incubated as previously for 45 m inutes. 
Following the incubation, 25pl of lithium  chloride solution (final 
concentration lOmM) was added, and the sections further incubated for 
10 minutes. Agonist-induced phosphoinositide turnover was estim ated 
in two of the four samples for each brain, by the addition of the 
muscarinic agonist carbachol (25pl, final concentration 500pM). Basal 
phosphoinositide turnover was estimated in the remaining two samples, 
following the addition of 25pl KRBB. The final incubation solutions 
were incubated under the conditions described for 60 minutes.
Accumulation of inositol phosphate was terminated by the addition of 
2.5ml ice-cold KRBB to the m edium . The buffer and incubation 
solutions were aspirated, and the slices were washed twice with 2.5ml 
ice-cold KRBB. Following the second wash the KRBB was aspirated and 
0.9ml of a chloroform and methanol m ixture was added to elute the 
inositol com pounds from the tissue slices. After 10 m inutes, 0.3ml 
chloroform and 0.3ml ultrapure water (Milli-Q 200pm filter) were added, 
and the mixture was centrifuged at 500gavc for 15 minutes. This resulted 
in a separation of the solution into aqueous and organic layers: 0.8ml of 
the aqueous supernatan t, containing the inositol com pounds, was 
transferred to a polypropylene column filled with 1ml anion exchange
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resin (AG1-X8 formate form, 100-200 mesh, and Econo-Column, Bio-Rad, 
California, USA). The column was washed with 10ml ultrapure water to 
rem ove uncharged moieties, and 0.6ml am m onium  form ate to elute 
non-metabolised [3H]-myo-inositol. Finally, [3H]-inositol phosphate was 
eluted with 1.6ml ammonium formate, and the filtrate was collected in 
scintillation vials. To each vial was added  8ml liquid scintillant 
(Picofluor 30), and the concentration of isotope was determ ined by liquid 
scintillation analysis. Finally, choline acetyltransferase (ChAT) activity 
was m easured in hippocam pal slices according to the m icro-assay 
developed by Fonnum (1975).
Analysis of Results
[3H]-inositol phosphate accumulation for each animal was calculated 
from the data obtained by liquid scintillation analysis and expressed in 
DPM. Basal and carbachol-stim ulated [3H ]-in o sito l p h o sp h a te  
accumulation in sham and lesioned rats, and the percentage of carbachol 
stim ulation of [3H]-inositol phosphate accum ulation for sham  and 
lesioned rats, were com pared statistically using unpaired , 2-tailed 
Student's t-test. ChAT activity in lesioned and sham -operated animals 
was compared statistically using Student's t-test, and the relationship 
between ChAT activity and basal and stimulated [3Fl]-inositol phosphate 
accumulation were determined using linear regression analysis.
Materials
Kreb's Ringer bicarbonate buffer (KRBB; NaCl, 118mM; KCl,5mM; 
C aC l2-2H20 , 2.5mM; KH9.P 0 4, 2mM; M gS04.7H20 , 2mM; N a2 EDTA,
0.2mM; N aH C 03, 24mM; glucose, lOmM) was prepared using ultrapure 
water (MilliQ). All reagents were of analytical grade, and were obtained 
from Baker Chemicals, Netherlands.
M yo-inositol (Sigma Chemical Co., St. Louis, USA), Carbachol 
(Brocacef, M aarsden, N etherlands), and L ithium  chloride (Baker 
Chemicals, Deventer, Netherlands) were dissolved in KRBB.
[2-3H(N)]-myo-inositol (specific activity 16Ci/m m ol) was obtained 
from New England Nuclear, Boston, USA.
The liquid scintillation fluid used was Picofluor 30 and was obtained 
from Packard Instruments, Downer's Grove, Illinois, USA).
CHAPTER III 
RESULTS
1. EFFECTS OF GLUTAMATERGIC AND CHOLINERGIC AGENTS ON 
CEREBRAL GLUCOSE USE
1.1. GENERAL OBSERVATIONS
Administration of the competitive glutam ate antagonist D-CPP-ene 
resulted in a m arked dose-dependent sedation in conscious, restrained 
rats: exploratory behaviour, present in saline-treated control anim als 
was abolished following adm inistration of 30mgkg_1 D-CPP-ene. In 
these animals a slight tail trem or was present. Mean arterial blood 
pressure was seen to increase slowly over a two hour period; however, 
neither the mean arterial pressure nor the average increase in blood 
pressure was significantly different in the D-CPP-ene t re a ^ d  rats 
compared to control animals (Appendix I, Table 1). Finally, two hours 
and 35 minutes after administration of 30mgkg_1 D-CPP-ene, rats had 
significantly lower arterial pH than saline-treated controls. O ther 
physiological param eters remained unchanged after adm inistration of 
D-CPP-ene.
Animals treated with the muscarinic agonist L-679-512 show ed a 
m arked accentuation of exploratory behaviour, coupled with signs of 
stress: sniffing and chewing became more frequent, and lacrim ation 
was apparent. M uscle fasciculation and a tail trem or w ere also 
observed. These responses were dose-dependent, and most evident 
following the highest dose of SOpgkg'1. In rats which received SOpgkg'1 
L-679-512, a p rofound bradycardia occurred w ithin a m inute of 
intravenous adm inistration of the drug; this was accompanied by a 
transient decrease in blood pressure. At the time of deoxyglucose 
adm inistration, however, the mean arterial pressure and the average 
change in blood pressure were not significantly different to that 
m easured prior to drug injection (Appendix II, Table 1). A decrease in
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arterial C 0 2 (PaC 02) was apparent following adm inistration of L-679- 
512 (3 and SOpgkg'1). Additionally, L-679-512 (10 and 30jigkg_1) induced 
an increase in plasma glucose, which persisted until the end of the 
experiment. Other physiological param eters were unaltered after drug 
adm inistration.
The cholinesterase inhibitor am ino-tetrahydroacridine (THA) also 
induced a m arked accentuation of exploratory behaviour, sniffing, 
chewing and lacrimation. In addition, muscle fasciculation and a tail 
tremor were also present. Mean arterial pressure increased in response 
to THA adm inistration, and was significantly elevated at the time of 
deoxyglucose adm inistration; furtherm ore, the average change in 
arterial pressure was found to be significantly increased in the THA- 
treated group (Appendix III, Table 1). A decrease in arterial C 0 2 (PaC 02) 
and an increase in arterial plasma glucose was observed in response to 
THA adm inistration. Other physiological param eters were unaltered 
following drug administration.
1.2. LOCAL CEREBRAL GLUCOSE UTILISATION
Local Cerebral Glucose Utilisation was estimated in 76 anatomically 
defined areas following intravenous administration of D-CPP-ene (0.3, 3 
or 30 mgkg-1), L-679-512 (0.3, 10 or 30 H-gkg"1), am ino-tetrahydroacridine 
(THA, 2.5 m gkg'1). Patterns of glucose utilisation produced by each drug 
were compared with glucose use in groups of contemporaneous saline- 
treated control rats. Details of mean rates of glucose utilisation in each 
structure are given in Appendices I-III.
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1.2.1. D-CPP-ene, a Competitive NMDA Antagonist
D-CPP-ene, a com petitive  g lu tam ate  an tag o n is t, in d u ced  
heterogeneous alterations in glucose use (Appendix I). In 52 of the 76 
regions analysed, D-CPP-ene administration did not at any dose produce 
significant alterations in glucose utilisation compared to saline-treated 
controls. Of the remaining 24 regions, significant functional alterations 
were measured only in those animals which received 3 or 30mgkg-1 D- 
CPP-ene. Significant decreases in glucose use occurred in twelve 
regions of brain: these were m ostly cortical areas, or subcortical 
structures involved in processing sensory inform ation. In contrast, 
significant increases in glucose use were m easured in four regions 
involved in olfaction. In another eight regions involved m ostly in 
limbic function, a biphasic response to D-CPP-ene was observed: glucose 
use was significantly depressed after the interm ediate dose of 3mgkg-1 
D-CPP-ene, but was not significantly different from control value in 
those animals which received 30 m gkg'1 D-CPP-ene.
Hippocampal Region
Following the intermediate dose of 3 mgkg-1 D-CPP-ene, glucose use 
was decreased significantly in two hippocampal areas (Appendix I, Table 
2 and Figures 9 & 10): rates of glucose utilisation were decreased in the 
subiculum and the pyramidal layer of the CA4 region by 22% and 31% 
respectively . G lucose utilisation in these struc tu res rem ained  
unchanged with respect to control values following adm inistration of 
0.3 or 30mgkg-1. Although there were no other significant alterations in 
the hippocampus in response to D-CPP-ene administration, it was noted 
that the mean value for glucose use in response to 3mgkg-1 in each 
hippocam pal area m easured was lower than the control value, while 
rates of glucose use following 3 or 30mgkg-1 D-CPP-ene were comparable 
to control values.
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LEGENDS TO FIGURES 9 A N D  10
FIGURE 9: Local cerebral glucose utilisation in the hippocam pus following 
D-CPP-ene adm inistration: Ammon's Horn.
FIGURE 10: Local cerebral glucose utilisation in the hippocam pus following 
D-CPP-ene adm inistration: Dentate gyrus, presubiculum  and 
subiculum .
Data are presented as mean glucose utilisation (jimol lOOg'1 m in '1) ± S.E.M. 
*p<0.05 relative to control (Student's unpaired  t-test, tw o-tailed, w ith 
Bonferroni correction for m ultiple group comparison).
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FIGURE 9 : LOCAL CEREBRAL GLUCOSE UTILISATION IN THE
HIPPOCAMPUS FOLLOWING D-CPP-ENE ADMINISTRATION: 
AMMON'S HORN
LC
GU
 
lu
no
l/l
OO
g/
m
in
 
LC
GU
 
pm
ol
/lO
O
g/
m
in
DENTATE GYRUS MOLECULAR 
LAYER (SUPERIOR BLADE)
DENTATE GYRUS 
POLYMORPHIC LAYER
80 -i 80
4 0 -
20 -
Control 0.3 3 30 Control 0.3 3 30
D-CPP-ene (mg/kg) D-CPP-ene (mg/kg)
PRESUBICULUM SUBICULUM
Control 0.3 3 30 Control 0.3 3 30
D-CPP-ene (mg/kg) D-CPP-ene (mg/kg)
FIGURE 10: LOCAL CEREBRAL GLUCOSE UTILISATION IN THE
HIPPOCAMPUS FOLLOWING D-CPP-ENE ADMINISTRATION: 
DENTATE GYRUS , PRESUBICULUM AND SUBICULUM
PC
CONTROL
FIGURE 11: AUTORADIOGRAMS OF GLUCOSE UTILISATION IN THE
RAT BRAIN FO LLO W IN G  D-CPP-ENE: H IP P O C A M P U S ,  
AUDITORY A N D  VISUAL REGIONS
Representative au torad iogram s of glucose use in the rat  brain at the level of 
the ventral  h ippocam pus ,  aud i to ry  and  visual regions following D-CPP-ene 
a d m in i s t r a t io n .  Left: con t ro l  an imal .  H i p p o c a m p u s  (Hi), pos te r io r  
c ingula te  cortex (PC), aud i to ry  cortex (Au), and  media l  genicula te  nucleus  
(MG) are  ind ica ted  by solid lines. Right: D-CPP-ene- t rea ted  (30 m g k g ' 1) 
animal.  No te  the increased deoxyglucose  up take  in the en torh ina l  cortex 
(Ent) and decreased  deoxyglucose  u p take  in aud i to ry  and  visual s tructures  
in the D-CPP-ene- t rea ted  an im al  c o m p a r e d  to control .  Scale bar equals  
2 m  m .
D-CPP-ENE
Areas Associated with Limbic Function
Rates of glucose use following D-CPP-ene adm inistration in limbic 
structures other than the hippocam pus are given in Appendix I, Table 
3. Heterogeneous functional alterations were recorded in response to 3 
and SOmgkg'1 D-CPP-ene. In three cortical areas, the anterior cingulate, 
frontal and parietal cortices, a m arked dose-dependent decrease in 
glucose utilisation was observed: a dose of 30mgkg_1 D-CPP-ene effected 
a reduction in glucose use of 44% in the parietal cortex relative to the 
control value. In contrast, glucose utilisation in the posterior cingulate 
cortex was not significantly altered with respect to the control value 
(Figure 12).
In four limbic subcortical structures, the dorsal tegmental nucleus, 
the m edial and lateral portions of the m am illary body, and the 
nucleus accumbens, glucose use was significantly suppressed following 
Smgkg'1 D-CPP-ene, but not different from control values following 0.3 
or 30m gkg'] D-CPP-ene. Finally, glucose utilisation in the lateral 
am ygdalar nucleus decreased in a dose-dependent m anner, and was 
significantly lower than the control value after adm inistration  of 
30mgkg_1 D-CPP-ene (Figure 13).
Olfactory Areas
D-CPP-ene effected the largest increase in glucose utilisation in areas 
involved in the processing of olfactory information (Appendix I, Table 
4). Of six olfactory regions m easured, significantly increased glucose 
utilisation was observed in four regions following adm inistration of 
30mgkg_1 (Figures 15 & 16). In two, the lateral olfactory tract and the 
posterior piriform  cortex, there was evidence of a dose-dependent 
m echanism  of drug action. In the lateral olfactory tract the largest 
elevation in glucose use was recorded: 30mgkg_1 D-CPP-ene induced a 
62% increase with respect to control values. In the entorhinal cortex 
and anterior olfactory nucleus significant increases in glucose use (43%)
1 22
LEGENDS TO FIGURES 12 A N D  13
FIGURE 12: Local cerebral glucose utilisation in cortical areas associated 
with limbic function following D-CPP-ene adm inistration.
FIGURE 13: Local cerebral glucose utilisation in subcortical limbic areas 
following D-CPP-ene administration.
Data are presented as mean glucose utilisation (pmol lOOg'1 m in-1) ± S.E.M. 
*p<0.05, **p<0.01 relative to control (Student's unpaired t-test, two-tailed, 
w ith Bonferroni correction for m ultiple group comparison).
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FIGURE 12 : LOCAL CEREBRAL GLUCOSE UTILISATION IN CORTICAL
AREAS ASSOCIATED WITH LIMBIC FUNCTION FOLLOWING 
D-CPP-ENE ADMINISTRATION
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FIGURE 14: AUTORADIOGRAMS OF GLUCOSE UTILISATION IN THE
RAT BRAIN FOLLOWING D-CPP-ENE: PARIETAL CORTEX
Representative  au torad iogram s  of glucose use in the rat brain at the level of 
the parietal  cortex in response  to D-CPP-ene adminis t ra t ion .  Left: control  
animal .  Ante r io r  cingula te  cortex (AC), par ie tal  cortex (Par) and  cauda te  
(Cau) are indica ted  by solid lines. Right: D-CPP-ene- t rea ted  (30 m g k g ' 1) 
an im al.  N o te  the reduc t ion  in optical dens i ty  in par ie ta l  a n d  an te r io r  
cingulate  cortices in the D-CPP-ene-treated animal co m pared  to control.  In 
contrast , the optical densi ty  of the p r im ary  olfactory cortex (PO) is increased 
in the D-CPP-ene-t rea ted  an imal  c o m p ared  to control.  Scale bar equa ls  
2mm.
were evident after administration of SOmgjkg'1 D-CPP-ene (Figure 15).
Auditory and Visual Structures
Administration of D-CPP-ene produced profound dose-dependent 
a lterations in glucose u tilisa tion  witlhin struc tu res involved in 
processing auditory and visual inform ation (Appendix I, Table 5 and 
Figures 11 &17). Significantly decreased glucose utilisation was 
observed after adm inistration of SOmgkg'1 D-CPP-ene in eight out of 
fourteen regions in this group; in six of tthese, glucose utilisation was 
also suppressed significantly following 3m gkg'] D-CPP-ene. The largest 
reductions in glucose utilisation were m easured in cortical areas: in 
layer IV of the auditory and visual cortices, in which 30mgkg_1 D-CPP- 
ene induced 49% and 41% reductions respectively, and in layer II of the 
auditory cortex a decrease of 40% was m easured. The medial geniculate 
body and the inferior colliculus were also greatly  affected, w ith 
respective reductions of 39% and 35% in response to 30mgkg_1 D-CPP- 
ene. O ther alterations in glucose use occurred in the dorsolateral 
geniculate body, the anterior pretectal nucleus, and the superficial layer 
of the superior colliculus following 3 and 30mgkg_1 D-CPP-ene.
Extrapyramidal and Sensorimotor Areas
Few a ltera tions in glucose u tilisa tion  could be evoked in 
extrapyram idal and sensorimotor regions by D-CPP-ene (Appendix I, 
Table 6). Administration of D-CPP-ene at a dose of 3mgkg_1 evoked a 
decrease in glucose use in two structures, the cerebellar hemisphere, 
and the inferior olive. Adm inistration of 3 or 30mgkg_1 D-CPP-ene, 
however did not produce a significant deviation from the control value 
for either structure. Glucose use was unchanged by D -C P P -ene  
adm inistration at any dose in ten other structures within this group.
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LEGEND TO FIGURE 15
FIGURE 15: Local cerebral glucose utilisation in olfactory areas in response 
to D-CPP-ene administration.
Data are presented as mean glucose utilisation (pmol lOOg'1 m in '1) ± S.E.M. 
**p<0.01 relative to control (Student's unpaired  t-test, tw o-tailed, w ith 
Bonferroni correction for m ultiple group comparison).
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FIGURE 15 : LOCAL CEREBRAL GLUCOSE UTILISATION IN OLFACTORY 
AREAS FOLLOWING D-CPP-ENE ADMINISTRATION
CONTROL d-CPP-ENE
FIGURE 16: AUTORADIOGRAMS OF GLUCOSE UTILISATION IN THE
RAT BRAIN F O L L O W IN G  D -C PP -EN E:  O LF A C T O R Y  
CORTEX
Representative au torad iogram s of glucose use in the rat brain at the level of 
ol factory  areas  in response  to D-CPP-ene  a d m in is t r a t io n .  Left: contro l  
animal. Right: D-CPP-ene-treated (30 m g k g '1) animal.  Optical  densit ies of 
the lateral olfactory tract (LOT) and  the anter io r olfac tory nuc leus  (AON), 
ind ica ted  by solid lines, are  increased in the D -C P P -en e - t r ea te d  a n im a l  
com pared  to control. Scale equals 2mm.
LEGEND TO FIGURE 17
FIGURE 17: Local cerebral glucose utilisation in auditory and visual 
structures in response to D-CPP-ene administration.
Data are presented as mean glucose utilisation (pmol lOOg'1 min’1) ± S.E.M. 
*p<0.05, **p<0.01 relative to control (Student's unpaired t-test, two-tailed, 
with Bonferroni correction for multiple group comparison).
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FIGURE 17 : LOCAL CEREBRAL GLUCOSE UTILISATION IN VISUAL 
AND AUDITORY STRUCTURES FOLLOWING D-CPP-ENE 
ADMINISTRATION
Myelinated Fibre Tracts
Glucose use was measured in five regions of white m atter to 
examine the metabolic effects D-CPP-ene on fibre tracts of the brain 
(Appendix I, Table 7). D-CPP-ene had no effects at any dose on glucose 
utilisation in five regions of white matter.
1.2.2. L-679-512, a Novel Muscarinic Agonist
The effects of L-679-512 on cerebral glucose utilisation are given in 
Appendix II. Alterations in glucose utilisation were observed in only 
twelve of the 76 regions of brain analysed, and in every case glucose 
utilisation decreased following L-679-512 administration. These effects 
were concentrated particularly in hippocampal and limbic structures, 
and regions of the brain involved in olfactory transmission.
Hippocampal Region
A dm inistration of L-679-512 resulted in essentially the same 
biphasic depression of glucose use in the hippocampus: in most cases a 
dose of lOpgkg'1 L-679-512 resulted in a suppression of glucose 
utilisation, while administration of 3 or 30pgkg_1 did not result in 
deviation from control values (Figures 18 & 19). Glucose use was 
sigmficantly lowered by L-679-512 in three hippocampal areas, in the 
stratum lacunosum moleculare of the CA1 and CA2/3 sectors (11% and 
14%, respectively) and in the stratum oriens/pyramidale of CA2 (15%). 
No other significant decreases in glucose utilisation were observed.
Areas Associated with Limbic Function
L-679-512 induced alterations in five of 25 limbic structures 
measured (Appendix II, Table 3). In one cortical area, the parietal cortex, 
a dose-dependent decrease in glucose utilisation was observed; glucose 
use was decreased significantly in response to a dose of 30(J.gkg_1 L-679-
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LEGENDS TO FIGURES 18 AND 19
FIGURE 18: Local cerebral glucose utilisation in the hippocampus following 
L-679-512 administration: Ammon's Horn.
FIGURE 19: Local cerebral glucose utilisation in the hippocampus following 
L-679-512 administration: Dentate gyrus, presubiculum and 
subiculum.
Data are presented as mean glucose utilisation (pmol 100g_1 min'1) ± S.E.M. 
*p<0.05 relative to control (Student's unpaired t-test, two-tailed, with 
Bonferroni correction for multiple group comparison).
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FIGURE 18 : LOCAL CEREBRAL GLUCOSE UTILISATION IN THE
HIPPOCAMPUS FOLLOWING L-679-512 ADMINISTRATION 
AMMON'S HORN
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512. In the medial and lateral portions of the | mamillary body, glucose 
use decreased significantly following 3 and 30|igkg_1 L-679-512 and in 
the lateral portion glucose use remained significantly lower than the 
control value after lOpgkg'1 L-679-512 (Figure 20). In the medial 
forebrain bundle and the horizontal limb of the diagonal band glucose 
utilisation decreased in a dose-dependent manner, and was significantly 
lower than the control value after SOpgkg"1 L-679-512.
Olfactory Areas
L-679-512 produced functional changes in glucose utilisation in 
olfactory areas: in three of the six structures, decreases in glucose 
utilisation were observed in response to SOpgkg'1 L-679-512 (Appendix 
II, Table 4). In the lateral olfactory tract, the primary olfactory cortex, 
and the entorhinal cortex, decreases were measured of 23%, 25% and 
20% respectively (Figure 21). In every other structure, glucose use was 
suppressed, though not significantly, following 30|igkg_1 L-679-512. 
Doses of 3 or lOpgkg'1 did not result in functional alterations in any 
olfactory region.
Auditory and Visual Structures
L-679-512 evoked significant alterations in glucose utilisation in 
only two structures (Appendix II, Table 5). A dose of SOpgkg'1 L-679-512 
caused a reduction in glucose use of 23% in the medial geniculate body 
and 27% in layer IV of the visual cortex; lower doses of drug failed to 
produce  significant functional alterations in aud ito ry  or visual 
structures. In auditory structures, although no further significant 
alterations were observed, there was evidence of a dose-dependent 
mechanism of suppression of glucose use (Figure 22). This pattern of 
alteration was not evident in visual structures.
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LEGENDS TO FIGURES 20 & 21
FIGURE 20: Local cerebral glucose utilisation in regions associated with 
limbic function following L-679-512 administration.
FIGURE 21: Local cerebral glucose utilisation in olfactory structures 
following L-679-512 administration.
Data are presented as mean glucose utilisation (pmol lOOg'1 min-1) ± S.E.M. 
*p<0.05 relative to control (Student's unpaired  t-test, two-tailed, with 
Bonferroni correction for multiple group comparison).
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LEGEND TO FIGURE 22
FIGURE 22: Local cerebral glucose utilisation in auditory and visual regions 
following L-679-512 administration.
Data are presented as mean glucose utilisation (jimol 100g_1 min"1) ± S.E.M. 
*p<0.05 relative to control (Student’s unpaired t-test, two-tailed, with 
Bonferroni correction for multiple group comparison).
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FIGURE 22 : LOCAL CEREBRAL GLUCOSE UTILISATION FOLLOWING 
L-679-512 ADMINISTRATION: AUDITORY AND VISUAL 
STRUCTURES
Extrapyramidal and Sensorimotor Areas
L-679-512 administration produced only one significant functional 
alteration in this group of structures: in the caudate nucleus, glucose 
use was reduced by 22% in response to SOfigkg'1 L-679-512. Glucose use 
remained unchanged in all other structures in the group in response to 
L-679-512 administration.
Myelinated Fibre Tracts
L-679-512, had no effects at any dose on glucose utilisation in five 
regions of white matter.
1.2.3. 9-Amino-l,2,3,4-tetrahydroacridine (THA), a Cholinesterase Inhibitor 
with Potential Glutamatergic Activity
Despite the overt changes in behaviour and physiological 
param eters which accompanied THA adm inistration , functional 
alterations in response to the drug were observed in only eight of the 76 
regions analysed. In seven of these regions, glucose utilisation 
increased following THA administration, while in one other structure 
there was a significant decrease in glucose use. The most marked 
alterations in function occurred in regions involved in visual 
processing.
Hippocampal Region
Glucose utilisation was increased significantly in the subiculum 
following THA administration; there were no significant alterations in 
glucose use in other hippocampal regions (Appendix III, Table 2, and 
Figure 23).
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LEGENDS TO FIGURES 23 AND 24
FIGURE 23: Local cerebral glucose utilisation in hippocampal and limbic 
structures following THA administration.
Abbreviations: Or: stratum oriens; Rad: stratum radiatum; 
Mol: molecular layer; Subic: subiculum; PCC: posterior 
cingulate cortex; Mam B (Med): ! mamillary body, medial 
portion; Thai AVN: thalamus, anteroventral nucleus; N  Acb: 
nucleus accumbens.
FIGURE 24: Local cerebral glucose utilisation in auditory and visual 
structures following THA administration.
Abbreviations: Aud (IV): auditory cortex, layer IV; IC: inferior 
colliculus; MGB: medial geniculate body; Co N: cochlear 
nucleus; SON: superior olivary nucleus; Vis (IV): visual cortex, 
layer IV; SC (Sup): superior colliculus, superficial layers; SC 
(Deep): superior colliculus, deep layers; DLG: dorsolateral 
geniculate body; APN: anterior pretectal nucleus.
Data are presented as mean glucose utilisation (pmol lOOg'1 min"1) ± S.E.M. 
*p<0.05, **p<0.01 relative to control (Student's unpaired t-test, two-tailed).
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Areas Associated with Limbic Function
THA adm inistration resulted in significantly altered glucose 
utilisation in two regions of brain involved in limbic function. Glucose 
utilisation was decreased in the dorsal raphe nucleus by 15% following 
THA; this represented the only region to exhibit reduced glucose 
utilisation in response to THA. THAI elicited a significant functional 
increase in the anteroventral thalamus: glucose use was increased by 
25%.
Olfactory Areas
In contrast to the extensive effects of D-CPP-ene and L-679-512 on 
local glucose utilisation within olfactory areas, THA administration did 
not produce significant alterations in glucose utilisation within these 
regions, in comparison to saline-treated controls.
Auditory and Visual Structures
The effects of THA on cerebral glucose utilisation in auditory and 
visual s tructures were qualitatively different from those which 
accompanied D-CPP-ene or L-679-512 administration (Appendix III, 
Table 5). No alterations in glucose use occurred in response to THA in 
any of seven auditory structures measured. However, in three regions 
involved in visual function increases in glucose utilisation were 
observed. THA effected a 40% increase in glucose use in the superficial 
layer superior, colliculus (Figures 24 & 25). Glucose use was also 
elevated in the dorsolateral and ventrolateral portions of the geniculate 
body by 28% and 25% respectively, relative to control values. In four 
other structures involved in visual processing, glucose use remained 
unchanged.
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C O N T R O L  T H A
FIGURE 25: AUTORADIOGRAMS OF GLUCOSE UTILISATION IN THE
R A T BRAIN F O L L O W I N G  T H A :  H I P P O C A M P U S ,
AUDITORY A N D  VISUAL REGIONS
Representat ive  au torad iogram s  of glucose use  in the rat  brain at the level of 
the ventra l  h ippocam pus ,  aud i to ry  and  visual regions in response  to THA 
adminis t ra t ion .  Left: control animal.  H ip p o c a m p u s  (Hi), au d i to ry  cortex 
(Au), and  m edia l  genicula te  nuc leus  (MG) are  ind ica ted  by solid lines. 
Right: TTIA-treated (2.5 mgkg"1) animal.  N o te  the increased  deoxyglucose  
u p take  in the superficial layers of the super io r  colliculus (SC) c om pared  to 
control. Scale equals  2mm.
Extrapyramidal and Sensorimotor Areas
THA effected only one alteration in glucose utilisation within this 
group of structures: in the cerebral hemisphere, a significant increase in 
glucose use was measured in response to 2.5mgkg‘1 THA.
Myelinated Fibre Tracts
THA however evoked a significant increase in glucose use in the 
genu of the corpus callosum. Although glucose use was slightly 
increased in the four other regions, these increases were not 
significantly different from control values.
2. FUNCTIONAL PLASTICITY OF THE HIPPOCAMPUS IN RESPONSE 
TO LESIONS OF THE MEDIAL SEPTUM
2.1. CHARACTERISATION OF IBOTENIC ACID-INDUCED LESIONS OF 
THE MEDIAL SEPTUM
Ibotenate infusion into the medial septum resulted in a loss of 
neuronal cell bodies in the medial septal area revealed with light 
microscopy. Lesions involved typically the entire medial septal 
nucleus, rostral to the anterior commissure through to its termination 
caudal to the septo-hippocampal nuclei (Paxinos and Watson, 1986), 
with minimal damage to the surrounding lateral septum or vertical 
diagonal band nucleus (Figure 26).
Quantitatively, the lesion extended to the extreme dorsal regions of 
the lateral septum bordering the medial septum, while the diagonal 
band was largely intact. The corpus callosum suffered consistent but 
discrete damage, probably due to the passage of the syringe needle. A 
needle tract lesion was frequently visible in the cingulate cortex 
overlying the septal region, possibly due to diffusion of ibotenate up the 
syringe barrel tract upon removal of the syringe. In some cases, damage 
was recorded in more ventral portions of the lateral septum and in the 
dorsal extremity of the vertical diagonal band. These nuclei, however, 
were largely conserved. Only in a very small number of animals did 
the lesion lie .outwith these limits. Animals with more extensive 
lesions, or incomplete lesions of the medial septum, were discarded. 
Brains in which the lesion appeared to be unilateral fell naturally into 
either of these categories, and were also excluded. In no animal was 
there histological evidence at the light microscopy level to indicate 
direct ibotenate-induced damage of the hippocampus or other structures 
distant from the septal area.
The lesion could be identified easily from the surrounding non-
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LEGEND TO FIGURE 26
QUANTIFICATION OF IBOTENATE LESIONS OF THE MEDIAL SEPTUM
Diagrammatic illustration of coronal sections at the level of the medial 
septal region, illustrating the extent of a representational ibotenic acid- 
induced lesion.
(A) 0.2 mm, (B) 0.7 mm, and (C) 1.00 mm anterior to bregma. The lesioned 
area, which encompassed the entire medial septal nucleus, is represented by 
the blackened area.
A bbrev ia tions: LS: Lateral septum; VDB: vertical diagonal band; HDB: 
horizontal diagonal band; CP: Caudate Putamen.
LS
C P
VDB
LS
C P
LS
C P
FIGURE 26: QUANTIFICATION OF IBOTENATE LESIONS OF THE
MEDIAL SEPTUM
LEGEND TO FIGURE 27: HISTOLOGICAL PROFILE OF IBOTENATE
LESIONS OF THE MEDIAL SEPTUM
A.-D. Cresyl violet-stained coronal sections taken at the level of the 
medial septum three weeks after injection of phosphate buffered 
saline (A & C) or ibotenic acid (B & D).
A and B: gross histological evaluation  of lesioned area 
(Magnification approximately x 30). CC, corpus callosum; MS, 
medial septum; LS, lateral septum; lv, lateral ventricle. Note the 
presence of magnocellular, putatively cholinergic cells in the medial 
septal area of the sham-operated control rat (A). In contrast, the 
ibotenate-lesioned septum  (B) is devoid of magnocellular cells; 
instead, intense gliosis is present. The small arrowheads indicate 
the border between lesioned and normal tissue.
C and D: photographs of medial septal tissue (magnification 
approximately x 185). Magnocellular cells in the normal (sham- 
operated) septum (C) are indicated by large arrowheads. Note the 
absence of magnocellular cells, and the large numbers of glial cells 
(tailed arrows) in the lesioned tissue (D).
E.-F. Sections from the medial septum stained for glial fibrillary acidic 
protein (GFAP). E: sham-operated control rat. F: the lesioned 
septum  is densely stained, indicating the presence of reactive 
astrocytosis, and inherent cell loss (Hume-Adams & Graham, 1988).
.*’*•'* v- - ■ '■•.-w. v - ' ' v  ?  i V* • ■'
• v  • . r i »:•*, r.-..1. / 1- > -r • ■*V.r.i.’c:
#  X • a  k i
t
* • y
% • • «u* V *  *
* I . ','»***•»» ^   ^. »• 'V *' t • 'f‘ * v'' *
5 M
1 iC •»«. £> '  i ^ ° '  «
* • ^ V .  . a '  1
* 4® -
V  " ‘ T *
. *> / .  A
* •  •
. t «.;
v ■
A  *
« • $ :
1
. . * *
,■ *. »« '• * • • 
i V , . .
•’■ • *■ .|S4 * '*'* ■’ •• ' * [
\  v  v
,* ' d.
: v . a
jr«t-* •> , ' »>*. •*. 'kL- >v■■; > • .
, -V .7 • • «v V c .jU  ■" .>
: . v : \ /  , V ; ■
V v ’,V 'V' tv *  •••; A1»c r - A r  i  • f • k • .
'■ '* ' f V ' ^ ww A/ ' •'* * /• ' ’ :
l. A ' - . 'V  , ■ ■ ■• v > -
FIGURE 27: HISTOLOGICAL PROFILE OF IBOTENATE LESIONS 
OF THE MEDIAL SEPTUM
lesioned tissue. The lesion site was bordered by a wall of typically small 
glial cells, and the lesioned tissue was characteristically devoid of large, 
putatively cholinergic cell bodies; instead, the area was infiltrated with 
glial cells and irregular shaped macrophages (Figure 27). In two brains, 
staining for glial fibrillary acidic protein (GFAP) confirmed the presence 
of glial cells within the lesioned tissue (Figure 27).
2.2. LOCAL CEREBRAL GLUCOSE UTILISATION FOLLOWING LESIONS 
OF THE MEDIAL SEPTUM
2.2.1. Local Cerebral Glucose Utilisation Within the Hippocampus
The heterogeneous pattern of glucose utilisation within the normal 
rat h ippocam pus is illustrated in Figure 28. Glucose utilisation is 
generally higher within the CA region, particularly CA2, than in the 
dentate gyrus, although glucose use within the CA region is highly 
stratified: high levels of glucose utilisation are measured within the
stra tum  lacunosum  moleculare, and the pyram idal layer exhibits 
greater levels of glucose utilisation than in the bordering strata oriens 
and radiatum. Within the dentate gyrus, glucose utilisation is higher 
in the granular and molecular layers than in the infragranular region.
In comparison to the diversity of functional activation in the CA 
and  d e n ta te  regions, glucose use w ithin the sub icu lum  and  
presubiculum  is more heterogeneous. Additionally, in the entorhinal 
cortex, glucose utilisation varies little within specific layers, although 
higher levels of functional activity are observed superficially compared 
to deep levels.
130]
FIGURE 28: A U TO R A D IO G R A M  OF GLUCOSE UTILISATION IN THE
RAT H IPP O CA M PU S
Representa tive  au to rad iog ram  of glucose use in the rat brain at the level of 
the dorsal  h ip p o c am p u s  . Abbreviations:  o r /p y r :  strata o r iens /py ram ida le ;  
rad: s t ra tum  rad ia tum;  lac. mol: s t ra tum  lacunosum moleculare;  DG mol: 
d e n ta te  m olecu la r  layer;  DG mol: d e n ta te  molecu lar  layer; DG infra: 
denta te  infragranula r  layer. Scale equals  2mm.
LEGEND TO FIGURE 29
FIGURE 29: Local cerebral glucose utilisation in hippocampal and limbic 
regions following lesions of the medial septum.
Abbreviations: or: stratum oriens; rad: stratum radiatum; DG 
Mol (sup): dentate gyrus, molecular layer, superior blade; DG 
Gran (sup): dentate gyrus, granular layer, superior blade; Ent L 
I-II: entorhinal cortex, lateral portion layers I-II; Ent L III-VI: 
entorhinal cortex, lateral portion, layers III-VI; MS: medial 
septum; LS: lateral septum; Amyg BL: amygdala, basolateral 
nucleus; Thai AVN: thalamus, anteroventral nucleus; PCC: 
posterior cingulate cortex; Par C: parietal cortex.
Data are presented as mean glucose utilisation (pmol lOOg'1 m in '1) ± S.E.M. 
There were no significant differences between sham-operated control and 
lesioned animals (Student's unpaired t-test, two-tailed).
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FIGURE 29 : LOCAL CEREBRAL GLUCOSE UTILISATION FOLLOWING 
LESIONS OF THE MEDIAL SEPTUM: HIPPOCAMPAL AND 
LIMBIC AREAS
2.2.2. Cerebral Glucose Utilisation in Hippocampal and Limbic Regions 
Following Lesions of the Medial Septum
Local cerebral glucose utilisation was measured in rats three weeks 
after medial septal lesions or sham operation in 57 anatomically 
defined regions of brain: these comprised of 22 hippocampal regions, 23 
structures associated with limbic function, and twelve other brain 
regions. In each case, glucose utilisation was unaltered in response to 
lesions of the medial septum in comparison to sham-operated control 
animals (Figure 29).
2.3. MUSCARINIC AND GLUTAMATERGIC RECEPTOR BINDING IN 
HIPPOCAMPAL REGIONS FOLLOWING LESIONS OF THE MEDIAL 
SEPTUM
2.3.1. Anatomical Distribution of Muscarinic and Glutamatergic Binding Sites 
Within the Hippocampus and Associated Regions.
The regional distributions of glutamatergic and muscarinic binding 
sites within the hippocampus are illustrated in Figure 30.
[3H]-QNB Binding Sites
The observed distribution of muscarinic receptors, as measured by 
[3H]-QNB binding, was generally in agreement with previous reports 
(Mash & Potter, 1986; Tonnaer et al., 1988). [3H]-QNB binding to 
muscarinic receptors was highest within the CA1 strata radiatum and 
pyramidale, and dense labelling was also present in CA1 strata oriens 
and lacunosum moleculare and throughout the dentate gyrus. In the 
CA2 and CA3 regions, [3H]-QNB binding was slightly lower.
The entorhinal cortex contained high levels of binding sites, which 
were distributed more densely in superficial layers: this contrasts with 
the pattern of binding in other cortical regions in which dense bands of
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P H ] - Q N B  [3H]-AMPA
[3HJ-KAINATE [3H] -G LU T AM A T E
FIGURE 30: A U T O R A D I O G R A M S  O F  L I G A N D  B I N D I N G  TO 
G LU T A M A T E RG IC  A N D  M U S C A R IN IC  RECEPTORS IN 
THE RAT HIPPOCAMPUS
R epresen ta t iv e  a u to r a d io g r a m s  of [3H]-QNB (A), [3H]-AM PA (B), [3H ]- 
kainate (C) and  [3H]-g lu tamate  (D) b inding  in the rat brain at the level of the 
dorsa l  h ip p o c a m p u s .  Abbrevia t ions:  or: s t r a tu m  oriens;  pyr:  s t r a tu m  
p y ra m id a le ;  rad: s t r a tu m  rad ia tu m ;  luc: s t r a tu m  luc idum ;  DG mol: 
den ta te  molecular  layer. Scale equals 2mm.
labelling in superficial and deep layers border an intermediate band of 
more diffuse binding.
In agreement with Tonnaer et al. (1988), [3H]-QNB binding was 
dense in the subiculum, and less dense in the presubiculum. In the 
septal area, m oderate  levels of binding occurred, and these were 
concentrated in the lateral septum.
[3H]-AMPA Binding Sites
[3H]-AMPA binding sites are dense w ith in  the h ippocam pal 
formation. In contrast with a previous report that [3H]-AM PA-binding 
is highest in the stratum pyramidale (Cotman et al., 1987), the use of 
histological overlay in the present series demonstrated that binding was 
most dense in the stratum radiatum, with moderately less binding in 
the stratum pyramidale. Other CA1 regions were also densely labelled. 
Within CA2/3 [3H]-AMPA binding was also highest in the stratum 
radiatum, although binding is generally lower than in CA1. In the 
dentate gyrus, [3H]-AMPA binding was concentrated w ithin  the 
molecular layer. In the cortex, [3H]-AMPA binding was distributed 
evenly throughout superficial and deep cortical layers. Dense [3H]- 
AMPA binding was also measured in the subiculum; in the septal area, 
binding was dense in the lateral septum, and moderate within the 
medial septum.
[3H]-Kainate Binding Sites
The distribution of [3H]-kainate binding was observed to be 
m arkedly different to that of [3H]-AMPA binding. In the stratum  
lucidum, situated lateral to the CA2/3 pyramidal cell layer, [3H]-kainate 
binding sites were extremely dense, and the CA4 pyramidal layer also 
exhibited relatively high amounts of binding. Little binding occurred 
e lsew here  within the hippocampus, although the den ta te  gyrus, 
particu larly  the infragranular layer and the inner portion of the
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molecular layer, was generall} more densely labelled than the CA 
sector. Low levels of kainate binding were measured in the subicular 
complex.
W ithin cortical regions, [3H]-kainate  b ind ing  was generally  
associated with deep cortical layers; however, this trend is absent in the 
entorhinal cortex, which contained higher densities of binding within 
superficial layers. In the septal area, low amounts of [3H ]-k a in a te  
binding occurred throughout the septal nuclei and diagonal band.
NMDA-Displaceable [3H]-L-Glutamate Binding Sites
NM DA-displaceable [3H]-glutamate binding sites were found in 
extremely high quantities in the hippocampus, and were concentrated 
in CA1 strata oriens and radiatum. The inner portion of the dentate 
molecular layer was also densely labelled, while binding was lower in 
the outer portion and in CA2 and CA3.
NMDA-sensitive [3H]-glutamate binding was dense within cortical 
areas, and was particularly dense within the entorhinal cortex; binding 
sites were concentrated in the outer cortical layers. The subiculum and 
presubiculum were observed to contained moderate levels of NMDA- 
sensitive binding sites, while in the septal area NMDA-sensitive 
binding was low.
2.3.2. Alterations in Muscarinic and Glutamatergic Receptor Binding W ithin 
Hippocampal and Associated Regions Following Lesions of the Medial 
Septum
Exact values for [3H]-QNB, [3H]-AMPA, [3H]-kainate and NMDA- 
displaceable [3H]-glutamate binding to muscarinic, AMP A, kainate and 
NMDA receptors respectively are found in Appendix V, Tables 1-4.
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LEGENDS TO FIGURES 31 & 32
FIGURE 31: [3H]-Quinuclidinyl Benzylate ([3H]-QNB) binding in the
hippocampal formation and associated regions following 
lesions of the medial septum: Ammons horn and the 
dentate gyrus.
Abbreviations: or: stratum oriens; pyr: stratum pyramidale; 
rad: stra tum  radiatum ; lac mol: s tra tum  lacunosum  
moleculare; mol (outer): molecular layer, outer portion; 
mol (inner): molecular layer, inner portion; gran: granular 
layer; infragran: infragranular layer.
FIGURE 32: [3H]-Quinuclidinyl Benzylate ([3H]-QNB) binding in the
hippocampal formation and associated areas following 
lesions of the medial septum: subicular area, entorhinal 
cortex and septal area.
Abbreviations: Sub: subiculum; Pres: presubiculum; Medial: 
Entorhinal cortex, medial portion; Lateral: entorhinal cortex, 
lateral portion; I-II: cortical layers I-II; III-VI: cortical layers 
III-VI; LS: lateral septum; MS: medial septum; VDB: 
vertical diagonal band nucleus.
Data are presented as mean ligand bound (pm ol/g tissue) ± S.E.M. *p<0.05, 
**p<0.01 relative to control (Student's unpaired t-test, two-tailed).
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LEGENDS TO FIGURES 33 & 34
FIGURE 33: [3H]-AMPA binding in the hippocampal formation and
associated regions following lesions of the medial septum: 
Ammons horn and the dentate gyrus.
Abbreviations: or: stratum oriens; pyr: stratum pyramidale; 
rad: stra tum  radiatum ; lac mol: stra tum  lacunosum  
moleculare; mol (outer): molecular layer, outer portion; 
mol (inner): molecular layer, inner portion; gran: granular 
layer; infragran: infragranular layer.
FIGURE 34: [3H]-AMPA binding in the hippocampal formation and
associated areas following lesions of the medial septum: 
subicular area, entorhinal cortex and septal area.
Abbreviations: Sub: subiculum; Pres: presubiculum; Medial: 
Entorhinal cortex, medial portion; Lateral: entorhinal cortex, 
lateral portion; I-II: cortical layers I-II; III-VI: cortical layers 
III-VI; LS: lateral septum; MS: medial septum; VDB: 
vertical diagonal band nucleus.
Data are presented as mean ligand bound (pmol/g tissue) ± S.E.M. *p<0.05, 
**p<0.01 relative to control (Student's unpaired t-test, two-tailed).
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[3H]-QNB Binding
In Ammon's Horn and the dentate gyrus, muscarinic binding sites, 
measured by [3H]-QNB binding were unaltered following lesions of the 
medial septum (Appendix V Table 1; Figures 31 & 32). In the 
subiculum, however, a significant decrease (14%) was observed in the 
lesioned group. In the septal area, further reductions in [3H ]-Q N B  
binding were apparent: binding was reduced in the medial septum by 
32% and in the lateral septum by 13% relative to control values.
[3H]-AMPA Binding to Quisqualate Receptors
Significantly decreased [3H]-AMPA binding was m easured in a 
number of hippocampal and associated regions in response to lesions of 
the medial septum (Appendix V, Table 2). Within the CA region, 
significantly decreased levels of binding occurred in the stratum  
pyramidale of CA1-3. The largest decrease, which represented 18% of 
the control value, occurred in CA2 (Figure 33). Significant decreases in 
[3H]-AMPA binding were also measured in the stratum radiatum  of 
CA1 and the strata oriens and lacunosum moleculare of CA2. No 
significant alterations in binding were measured in the dentate gyrus or 
subicular area.
In the entorhinal cortex, [3H]-AMPA binding was significantly 
decreased in layers III-VI of the medial portion, and in layers I-II of the 
lateral portion following medial septal lesions. In the septal area, 
binding was decreased by 49% in the medial septal nucleus, but was 
unaltered in the lateral septal nucleus and diagonal band (Figure 34).
[3H]-Kainate Binding
In contrast to the localised alterations in [3H]-AMPA binding in 
response to lesions of the medial septum, there were no significant 
alterations in [3H]-kainate binding in the 29 hippocampal and associated 
areas following septal lesions (Appendix V, Table 3, and Figures 35 &
1 34
LEGENDS TO FIGURES 35 & 36
FIGURE 35: [3H]-Kainate binding in the hippocampal formation and
associated regions following lesions of the medial septum: 
Ammons horn and the dentate gyrus.
Abbreviations: or: stratum oriens; pyr: stratum pyramidale; 
rad: stra tum  radiatum ; lac mol: s tra tum  lacunosum  
moleculare; mol (outer): molecular layer, outer portion; 
mol (inner): molecular layer, inner portion; gran: granular 
layer; infragran: infragranular layer.
FIGURE 36: [3H]-Kainate binding in the hippocampal formation and
associated areas following lesions of the medial septum: 
subicular area, entorhinal cortex and septal area.
Abbreviations: Sub: subiculum; Pres: presubiculum; Medial: 
Entorhinal cortex, medial portion; Lateral: entorhinal cortex, 
lateral portion; I-II: cortical layers I-II; III-VI: cortical layers 
III-VI; LS: lateral septum; MS: medial septum; VDB: 
vertical diagonal band nucleus.
Data are presented as mean ligand bound (pm ol/g tissue) ± S.E.M. There 
were no significant differences between control and lesioned animals 
(Student's unpaired t-test, two-tailed).
CA
1 
CA
2 
C
A
3
< c/3
X Cd c/3 X
□  m
P i i i i i l P i i
 ^I
“  o
5
X
UJxz
ooc
1  sE c
o  a
E 3 c  o
X
<
QUJ
UJ
X
H
x
O
C/3zot-HC/3UJX
Oz
I" _ _ _ _ J
c r  ioc
________________________________
o8 or*\ r i
—5
( d n s s j i  o / | 0 i u d )  
ciMfiOH a i v i s i i v M - H f
C/3 UJX x  X < 
>  X
w -
X
H c
U j
r~
oc
;:r&^MMUWUiAtt
X
h-
8
r -
o
—r
o
o a
E §
h '
C l
O O CD or i  — — 8  8
( d n s s j j  8 / | o i u d )  
(INilOil aJLVNIV>I-Hc
C/3
X X
w
X
C/3z 
cI—<
o
X 
X ^  
XX
X r*
^ X
C E— X Z 
&W
£ q
z 9i—i z
o  ^  z z
3 9
w “
H <
= H^c/3
1/3r*^
X
X
X
c
X
<
uj
a:
<
•j
<
£
UJ
C/3
r i
CQQ>
c/5
2
oo-J
XUJ
HC£
CJ
-J
XC£
HZ
UJ
III1IISIII1
__
r  ) r )
! >
3 s
2 _O —
- > 
s 2 ^  =
< * 
oicc w ............................
-t r  i
o
L-
Q-
( r > H S S |)  t f / ) < H l K l )
f lNi i lOJI J X V N I I Y M H
FI
GU
RE
 
36 
: [
3 H
l-K
AI
NA
TE
 
BI
ND
IN
G 
IN 
TH
E 
H
IP
PO
CA
M
PA
L 
RE
G
IO
N:
 S
UB
IC
UL
AR
 
C
O
M
PL
EX
, 
EN
TO
RH
IN
AL
 
C
O
R
TE
X
 
AN
D 
SE
PT
AL
 
A
R
EA
LEGENDS TO FIGURES 37 & 38
FIGURE 37: N M D A -d isp la ce ab le  [3H ]-g lu tam ate  b ind ing  in the
hippocampal formation and associated regions following 
lesions of the medial septum: Am m ons horn and the 
dentate gyrus.
Abbreviations: or: stratum oriens; pyr: stratum pyramidale; 
rad: stra tum  radiatum ; lac mol: stra tum  lacunosum  
moleculare; mol (outer): molecular layer, outer portion; 
mol (inner): molecular layer, inner portion; gran: granular 
layer; infragran: infragranular layer.
FIGURE 38: N M D A -d isp la ce ab le  [3H ]-g lu tam ate  b ind ing  in the
hippocam pal formation and associated areas following 
lesions of the medial septum: subicular area, entorhinal 
cortex and septal area.
Abbreviations: Sub: subiculum; Pres: presubiculum; Medial: 
Entorhinal cortex, medial portion; Lateral: entorhinal cortex, 
lateral portion; I-II: cortical layers I-II; III-VI: cortical layers 
III-VI; LS: lateral septum; MS: medial septum; VDB: 
vertical diagonal band nucleus.
Data are presented as mean ligand bound (pm ol/g tissue) ± S.E.M. There 
were no differences between control and lesioned animals (Student's 
unpaired t-test, two-tailed).
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36). The largest deviations from sham operated control values occurred 
in the stratum lacunosum moleculare, where increases of 17% and 16% 
were measured in the CA1 and CA2 regions respectively in response to 
septal lesions. Binding was unaltered in the lesioned medial septal 
area.
NMDA-Displaceable [3H]-Glutamate Binding
There were no significant alterations in NMDA-sensitive [3H ]- 
glutamate binding sites in any of 29 structures measured (Appendix V, 
Table 4 and Figures 37 & 38). In the presubiculum, binding was 
increased by 68%, and in the vertical limb of the diagonal band nucleus, 
binding was increased by 92% in lesioned animals compared to values 
for sham operation; however, the variability of binding ^  these 
animals was high, reflected by the relatively large standard errors, and 
these results were not significant.
2.4. MEASUREMENT OF PHOSPHOINOSITIDE TURNOVER FOLLOWING 
LESIONS OF THE MEDIAL SEPTUM
Accumulation of [3H]-inositol phosphate was m easured in the 
presence of lithium in rat hippocampal slices 21 days after lesions of the 
medial septum or sham operation. Choline acetyltransferase activity 
was assayed in.homogenate preparations from the hippocampus of each 
rat.
Mean values for phosphoinositide hydrolysis, as indicated by 
inositol phosphate accumulation, and choline acetyltransferase activity 
are given in Table 3. Following lesions of the medial septum, a decrease 
in choline acetyltransferase activity of 25% was m easured in the 
hippocampus; this reduction was statistically significant. However, no 
significant difference in either basal or carbachol-stimulated inositol
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LEGEND TO FIGURE 39
FIGURE 39: Phosphoinositide hydrolysis in the rat hippocampus following 
lesions of the medial septum
A. [3H]-Inositol phosphate accumulation: Basal and carbachol-
stimulated [3H]-inositol phosphate accumulation is expressed 
as DPM for lesioned (n=10) and control (n=10) rats. There were 
no significant differences between control and lesioned rats 
(Student's unpaired t-test, two-tailed).
B. & C. Basal (B.) and carbachol-stimulated (C.) [3H]-inositol phosphate
accumulation (DPM) vs. ChAT activity. [3H ] - in o s i to l  
phosphate  accumulation (DPM) is plotted against ChAT 
activ ity  ( n m o l /h /m g  protein) within the h ippocam pus. 
C orre la tion  coefficients for [3H ]- in o s i to l  p h o s p h a te  
accumulation vs. ChAT activity in sham-operated control and 
lesioned animals are given as r2 values. There was no 
correlation between ChAT activity and [3H]-inositol phosphate 
accumulation. Note the relative loss of ChAT activity in 
lesioned animals.
ChAT: Choline acetyltransferase
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phosphate accumulation occurred in the hippocampus following septal 
lesions (Figure 39). Finally, there was no correlation between 
phosphoinositide hydrolysis and ChAT activity in control or lesioned 
animals.
3. THE CEREBRAL METABOLIC EFFECTS OF ACUTE SUBDURAL 
HAEMATOMA IN THE RAT.
3.1. EFFECTS OF ACUTE SUBDURAL HAEMATOMA ON LOCAL 
CEREBRAL GLUCOSE UTILISATION
Local cerebral glucose utilisation two hours after acute subdural 
haematoma alone, haematoma with prior administration of D-CPP-ene, 
or sham surgery are given in Appendix V. Rates of cerebral glucose use 
were calculated using the rate and lumped constants described by 
Sokoloff et al. (1977). Glucose use was measured in twelve hippocampal 
regions, nineteen other regions associated with limbic function, and 
nine additional regions of interest.
Visual inspection of the autoradiograms (Figure 40) from animals 
with subdural haematoma alone revealed an area of hypometabolism, 
presumably caused by loss of perfusion, and thence impeded tracer 
delivery, in the region of infarct, which extended from the posterior 
parietal cortex to the occipital cortex; in some animals, a lack of 
deoxyglucose uptake was observed in in visual cortical areas. The lack 
of deoxyglucose uptake was limited to the cortex; there was no evidence 
of impeded uptake in the underlying hippocampal formation in any 
animal. Surrounding the area of diminished deoxyglucose uptake was 
a r im  of ap p a ren t | hyperm etabolism ,! p re su m ed  to be the 
ischaemic penumbral region. In those animals which had received 
acute subdural haematoma with prior administration of D-CPP-ene, the 
area of decreased deoxyglucose uptake was on inspection smaller than 
in the non-pretreated group. Additionally, D-CPP-ene abolished the 
appearance of the rim of increased deoxyglucose phosphorylation 
bordering the infarcted area. In the sham -treated rats, a slight 
depression of glucose utilisation was observed in the area directly below 
the inserted needle, and was probably due to heat-damage in the course
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FIGURE 40: AUTORADIOGRAMS OF GLUCOSE UTILISATION IN THE
RAT BRAIN H I P P O C A M P U S  F O L L O W I N G  A C U T E 
SUBDURAL H A EM A TO M A
Representa tive  au torad iogram s of glucose use in the rat brain at the level of 
the  do rsa l  h ip p o c a m p u s .  Left: s h a m - o p e r a t e d  contro l .  Right: acute  
su b d u ra l  haem atom a.  Note  the large parietal  cortical region of m arked ly  
red u ced  deoxyglucose  up tak e  and  the degree  of increased deoxyglucose  
u p take  th ro u g h o u t  the h ippocam pal  format ion in response  to haem atom a.
Abbrevia tions:  CA1 o r /p y r :  CA1 strata o r ie n s /p y ra m id a le ;  CA1 rad: CA1 
s t ra tum  rad ia tum;  CA1 mol: CA1 s t ra tum  leculosum moleculare;  DG mol: 
denta te  molecular layer. Par: parietal  cortex; Pen: penum bra l  region. Scale 
bar equals  2mm.
of drilling through the skull. No hypermetabolism was evident in the 
surrounding cerebral tissues.
Following acute subdural haem atom a, glucose utilisation was 
markedly increased in the hippocampus bilaterally. When compared 
statistically to rates of glucose utilisation in sham-operated rats, all 
values for glucose utilisation in the hippocampal CA and dentate gyrus 
ipsilateral to the haematoma were significantly increased: in the CA1 
stratum radiatum the largest increase of 142% was measured (Figure 41). 
Contralaterally, glucose utilisation was increased less than ipsilaterally; 
the largest increase occurred in the CA1 radiatum. Variability was 
greater contralaterally, and consequently, increases were significant in 
only three hippocampal regions: the CA3 stratum oriens, the CA1 
stratum lacunosum moleculare, and the dentate molecular layer. In 
animals which had received D-CPP-ene prior to the haematoma, 
glucose utilisation was lower than in the group with haematoma alone 
(Figure 41). Significant difference in comparison to the haematoma 
group was achieved in three hippocampal regions, the CA3 stratum 
oriens, and the stratum radiatum of CA1 and CA3. D-CPP-ene also 
induced an increase in glucose utilisation in the presubiculum  
contralaterally to the haematoma.
In other regions associated with limbic function, a num ber of 
alterations were observed, which can be rela ted  to either the 
haematoma or the action of D-CPP-ene. In the group of animals with 
the haem atom a alone, glucose utilisation was increased in the 
laterodorsal thalamic nucleus in comparison with sham-treated rats. In 
contrast, glucose utilisation was significantly increased  in the 
anteroventral thalamic nucleus in the D-CPP-ene p re trea ted  group 
compared with values for acute subdural haematoma alone. A number 
of cortical regions were likewise affected: glucose utilisation was raised 
significantly in the entorhinal cortex and lateral olfactory tract 
contralaterally, and in the posterior cingulate cortex bilaterally,
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LEGEND TO FIGURE 41
FIGURE 41: Local cerebral glucose utilisation in hippocampal regions 
following acute subdural haematoma.
Abbreviations: ASDH: acute subdural haematoma; or: stratum 
oriens; rad: stratum radiatum; pres: presubiculum; subic: 
subiculum; DG Mol (sup): dentate gyrus, molecular layer, 
superior blade; DG Infra (sup): dentate gyrus, infragranular 
granular layer, superior blade; Ent L I-II: entorhinal cortex, 
lateral portion layers I-II.
Data are presented as mean glucose utilisation (pmol lOOg'1 m in '1) ± S.E.M. 
All measurements were made ipsilateral to the haematoma. *p<0.05, 
**p<0.01 for comparisons of ASDH with controls; tp<0.05 for comparisons 
of ASDH alone with D-CPP-ene pre-treated ASDH (15 mgkg*1) (Student's 
unpaired t-test, two-tailed, with Bonferroni correction).
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FIGURE 41 : LOCAL CEREISRAL GLUCOSE UTILISATION FOLLOWING
ACUTE SUBDURAL HAEMATOMA : HIPPOCAMPAL
FORMATION
following D-CPP-ene pretreatment. In one cortical area, layer IV of the 
frontal cortex, glucose utilisation was reduced significantly following D- 
CPP-ene treatment.
Finally, acute subdural haematoma was seen to alter glucose 
utilisation in several other regions (Figure 42). In auditory and visual 
regions, values for glucose utilisation were significantly lower 
following acute subdural haematoma in the ipsilateral medial and 
dorsolateral geniculate bodies, and a depression of glucose use, though 
not significant, was observed in the auditory cortex. In the caudate 
nucleus ipsilateral to the haematoma, glucose utilisation was lower 
than in sham-treated rats, but this result was not significant. D-CPP-ene 
pretreatment failed to alter significantly rates of glucose utilisation in 
any of these structures, although values for the medial and dorsolateral 
geniculate bodies were higher than in the group which had received the 
haematoma alone.
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LEGEND TO FIGURE 42
FIGURE 42: Local cerebral glucose utilisation in limbic, auditory and visual 
regions following acute subdural haematoma.
Abbreviations:  ASDH: acute subdural haematoma; Thai
AVN: thalamus, anteroventral nucleus; MS: medial septum; 
LS: lateral septum; PCC: posterior cingulate cortex; FC: frontal 
cortex; Aud C IV: auditory cortex layer IV; MGB: medial 
geniculate body; DLG: dorsolateral geniculate body; SC (sup): 
superior colliculus, superficial layer.
Data are presented as mean glucose utilisation (pmol lOOg'1 m in '1) ± S.E.M. 
All m easurements were made ipsilateral to the haematoma. *p<0.05, 
**p<0.01 for comparisons of ASDH with controls; tp<0.05 for comparisons 
of ASDH alone with D-CPP-ene pre-treated ASDH (15 m gkg '1) (Student's 
unpaired t-test, two-tailed, with Bonferroni correction).
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CHAPTER IV 
DISCUSSION
1. EFFECTS OF GLUTAMATERGIC AND CHOLINERGIC AGENTS ON 
CEREBRAL GLUCOSE USE
1.1. THE COMPETITIVE NMDA ANTAGONIST D-CPP-ENE
The development of antagonists specific for the NMDA receptor 
and its associated ion channel (Figure 3), and the use of the 
deoxyglucose technique has provided considerable insight into the 
function of glutamatergic systems in the brain (McCulloch & Iversen, 
1991). Further, the deoxyglucose autoradiographic technique has 
proved informative in the study of differences between competitive 
and non-competitive antagonists: while the general distribution of 
a lterations is similar, the functional effects of non-com petitive 
antagonists differ greatly in their magnitude. While non-competitive 
antagonists such as MK-801 (Kurumaji et al., 1989) and phencyclidine 
(Weissman et al., 1987) produce marked increases in glucose use in 
limbic and olfactory regions, the competitive NMDA antagonists 3-(2- 
carboxypiperazin-4-yl)-propyl-l-phosphonic acid (CPP, Kurumaji et al., 
1989) and 2-amino-7-phosphonoheptanoate (AP7; Chapman et al., 1989) 
produce few significant alterations in cerebral glucose use.
Kurumaji and colleagues (1989) suggested that the difference in 
patterns of altered glucose use produced by MK-801 and CPP was due to 
the different modes of action of the drugs: the action of non­
competitive antagonists, because of their use-dependency, is potentiated 
in areas of high glutamatergic activity, while in these regions, 
competitive antagonists which bind to the recognition site for 
glutamate are readily displaced by the endogenous agonist during 
intense glutamatergic activity. Thus, the increased functional activity 
in limbic and olfactory regions in response to MK-801 was interpreted as 
a futile attem pt to overcome the non-com petitive glutam atergic  
blockade within these regions.
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In contrast to previous studies, D-CPP-ene administration resulted 
in much less overt alterations in glucose utilisation in limbic regions 
including the Papez circuit (hippocampal formation, | mamillary 
bodies, anterior thalamic nucleus and cingulate cortex), but produced 
marked dose-dependent reductions in glucose use in areas involved in 
sensory processing, such as auditory and visual structures. Therefore, 
the results presented here are notably different to those of glucose use 
following administration of classical competitive antagonists. Indeed, 
while non-competitive antagonists produce largely similar patterns of 
; altered glucose use (Crosby et al., 1982; Hammer et al., 1982; Kurumaji
et al., 1989; Weissman et al., 1987), competitive antagonists display 
heterogeneity in their ability to produce functional alterations in 
discrete CNS regions. It might be presumed that the present results 
differ from previous reports of competitive NMDA antagonists on the 
basis of the high potency of D-CPP-ene (Chapman et al., 1990; Lowe et 
al., 1990). However, a recent study of the effects of CGP39551 (2-amino- 
4-methyl-5-phosphono-3-pentenoic acid 1-ethyl ester), an orally active, 
unsaturated analogue of AP7 with high potency (Schmutz et al., 1989), 
demonstrated large increases in glucose utilisation in the Papez circuit, 
extrapyramidal system and olfactory regions (Chapman et al., 1991), 
while sensory regions were largely unaltered.
Different patterns of functional activity may represent the affinities 
which some drugs have for other classes of receptor such as the p- 
adrenergic, dopaminergic, and sigma-opiate receptor (Snell et al., 1988, 
Kozlowski, 1986). The non-competitive antagonist phencyclidine has 
been shown to interact with the sigma-opiate binding site in the brain, 
for which MK-801 has little affinity (Wong & Nielsen, 1989), and 
phencyclidine also displays some dopamine agonist properties (Snell et 
al., 1988). In addition to the functional activation of the Papez and 
olfactory structures, phencyclidine has been shown to increase glucose 
use in regions such as the anterior cingulate cortex, amygdala, caudate
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nucleus and globus pallidus, while MK-801 has no effect: and it has 
been suggested  that these differences represent the action of 
phencyclidine at opiate or dopamine receptors. While there is little 
evidence from deoxyglucose studies that selective sigma-opiate ligands 
induce altered glucose use in these areas (della Puppa & London, 1989; 
K oz low sk i 1986), the  d o p a m in e rg ic  a g o n is t  a p o m o rp h in e  
increases glucose utilisation in striatal regions (Kelly & McCulloch, 
1987). It is possible, therefore, that the ability of CGP39551 to activate 
dopaminergic areas such as the caudate nucleus, substantia nigra, and 
globus pallidus may be due to the actions of the drug at dopaminergic 
sites. In contrast, Lehmann et al. (1987) have shown that CPP has little 
affinity for dopaminergic receptors, and none at all for p -adrenerg ic  
receptors, at a concentration which maximally displaces [3H ]-A P5 
binding (Davies et al., 1986).
Additionally, variant patterns of glucose use produced by different 
competitive NMDA antagonists may be explained by the existence of 
sub-populations of NMDA receptors within the brain. Comparisons 
between the distribution of [3H]-CPP, [3H]-AP5, and NMDA-displaceable 
[3H]-glutamate binding have lead to the speculation that at least two 
sub-types of NMDA receptor exist (Cotman et al., 1987): both [3H]-CPP 
and [3H]-AP5 bind in relatively higher amounts in the thalamus, and 
lower amounts in the striatum, septal area and cerebellum compared to 
NMDA-displaceable [3H]-glutamate. Recently it has been shown that 
[3H]-MK-801 binds differentially in a number of brain regions, including 
regions of the hippocampus and entorhinal cortex, and this suggests the 
existence of at least two active subpopulations of NMDA receptors 
(Monaghan, 1991). Therefore, the discrepancies in patterns of in vivo 
action of D-CPP-ene compared with other NMDA antagonists may be 
explained by different affinities for subpopulations of NMDA receptors 
within different regions of the brain.
Comparisons of the functional responses to D-CPP-ene and other
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NMDA antagonists thus provides an insight into the diversity of 
NMDA-mediated cerebral events, and illustrates a complex relationship 
between glucose use and NMDA receptor occupancy. The regional 
changes in glucose utilisation in response to D-CPP-ene, and their 
implications for the local function of NMDA receptors are discussed in 
further detail below.
The Hippocampal Formation and Limbic Areas
The highest density of NMDA-displaceable glutamate binding in the 
entire brain occurs in the hippocampus, in the strata oriens and 
radiatum (Monaghan & Cotman, 1985; Monaghan et al., 1983). On this 
basis alone it would be expected that NMDA antagonists such as D-CPP- 
ene would produce substantial alterations in hippocampal function. 
On the contrary, D-CPP-ene had little effect on glucose utilisation 
within the hippocampus, and indeed resulted in decreased glucose use 
in two areas of the hippocampal formation -  the CA4 pyramidal layer 
and the subiculum -  which show little affinity for NMDA-sensitive 
glutamate binding. There is much evidence, however, to suggest that 
while NMDA receptors are involved in the high-frequency synaptic 
transm ission  which results in the estab lishm ent of long-term  
potentiation (LTP; Collingridge, 1985), under normal low frequency 
cell-firing, the NMDA-associated channel is blocked by magnesium and 
hence contributes little to synaptic activity (Collingridge & Bliss, 1987; 
Collingridge et al., 1988).
In contrast to the present results are reports by a number of authors 
that both competitive and non-com petitive NMDA antagonists 
increase glucose utilisation in the hippocampal CA region (Chapman et 
al., 1991; Hammer et al., 1982; Hammer & Herkenham, 1983; Lund et al., 
1981; Oguchi et al., 1982) and dentate gyrus (Chapman et al., 1991; 
Kurumaji et al.,1989; Weissman et al., 1987). It has been noted also that 
alterations in glucose use were not related simply to the density of
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NMDA receptors within a particular region: for example, both CPP and 
MK-801 administration increased glucose use in the relatively NMDA 
receptor-sparse hippocampal CA stratum lacunosum moleculare, while 
glucose use in the stratum radiatum, which contains high densities of 
NMDA receptors, was unaltered Kurumaji et al., 1989). In view of the 
pattern of functional alterations in the limbic system, Kurumaji and 
colleagues suggested that contrary to electrophysiological evidence, 
antagonism of hippocampal NMDA receptors is probably responsible 
for the marked alterations in glucose utilisation throughout the Papez 
circuit following MK-801 administration: the Papez circuit represents a 
network of fibres between the hippocampal formation, diencephalon 
and the cingulate cortices and thus forms an anatomical basis for a relay 
circuit between the anterior and posterior limbic areas and the 
hippocampus. However, the authors observed in a subsequent series of 
experiments that intrahippocampal injection of MK-801 resulted in 
altered glucose use throughout the stratum lacunosum moleculare and 
the dentate gyrus ipsilateral to the site of the injection, but functional 
activity in major hippocampal efferents was unaltered (Kurumaji & 
McCulloch, 1990a). This would imply that blockade of NMDA receptors 
in the hippocampus was not responsible for the altered function 
m easured in the Papez circuit and rhinencephalon in response to 
systemic administration of MK-801 and other NMDA antagonists.
The pattern of intrahippocampal association fibres is complex and 
highly organised (Swanson et al., 1987): the afferents and efferents of the 
hippocampal formation are highly interconnected ipsilaterally and 
contralaterally. The medial and lateral portions of the entorhinal 
cortex, which give rise to the medial and lateral perforant pathway 
respectively, innervate distinct areas of the dentate gyrus to form the 
first synapse in the trisynaptic path. Fibres from the lateral entorhinal 
cortex synapse within the CA stratum lacunosum moleculare (Gottlieb 
& Cowan, 1972) and the outer two thirds of the dentate molecular layer
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(Storm-Mathisen, 1977); these inputs account for 85% of the synapses 
w ith in  the den ta te  molecular layer area and are pu ta tive ly  
glutamatergic (Matthews et al., 1976). In contrast, synaptic contacts from 
the medial perforant path are restricted to the inner third of the dentate 
molecular layer. The medial and lateral entorhinal cortex are 
innervated by separate structures: the lateral entorhinal cortex receives 
a major afferent from the olfactory cortex, which terminates in layers I 
and II of the entorhinal area, and is thus in a position to influence 
events in the deeper layers of the cortex through an extensive system of 
interneurons (Kohler et al., 1986). The medial entorhinal cortex, on the 
other hand, receives dense inputs particularly in layers I and III from 
the pre- and parasubiculum (Kohler et al, 1978; Swanson & Cowan, 
1977), which in turn are innervated to a greater extent by visual areas. 
In functional terms, therefore, the two portions of the perforant path 
provide the hippocampus with information from two distinct sensory 
systems.
Glucose utilisation in the entorhinal cortex has been demonstrated 
to increase in response to a variety of NMDA antagonists: for example, 
a three-fold increase in glucose use occurred in the posterior entorhinal 
cortex in animals treated with MK-801 (Kurumaji et al., 1989), and D- 
CPP-ene OOmgkg*1) induced a 43% increase in the same area. Since the 
functional activation in response to each drug occurred in the outer 
layers of the entorhinal cortex, it may be surmised that they were 
associated w ith olfactory transmission; and further evidence for this is 
p rov ided  by the increased glucose utilisation th roughou t the 
rhinencephalon and lateral olfactory tract. In the hippocampus, the 
terminal regions for projections of the lateral perforant pathway, that is 
the CA lacunosum moleculare and the dentate molecular layer, were 
functionally activated following MK-801 administration, bu t were 
unchanged in response to D-CPP-ene.
In a further series of experiments, Kurumaji and McCulloch (1990b)
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attem pted  to determine whether the functional integrity of the 
entorhinal cortex was required for activation of the hippocampus by 
MK-801. Systemic administration of MK-801 in animals with lesions of 
the entorhinal cortex resulted in a pattern of glucose utilisation 
different to that seen in sham-operated rats. While increased glucose 
use was measured in the CA lacunosum moleculare and dentate gyrus 
contralateral to the lesion, these regions were functionally unaltered by 
MK-801 ipsilaterally. This suggests that cell firing in the entorhinal 
cortex in response to NMDA antagonists leads to the functional changes 
observed in the hippocampus.
In contrast, the lack of alterations in the hippocampus in response 
to D-CPP-ene are surprising. However, D-CPP-ene induced a much 
smaller increase in glucose utilisation in the entorhinal cortex, and this 
putative increase in cell firing may have a much lesser impact on 
hippocampal function. Additionally, competitive blockade of NMDA 
receptors may be overcome by an increase in the release of the 
endogenous agonist glutamate, presumably without significant increase 
in functional activity. If the functional alterations observed in the 
entorhinal cortex represent an attem pt to su rm ount the NMDA 
receptor blockade by increased activity, it follows that the difference in 
magnitude of the increase in glucose use effected by the two drugs will 
be due to the distinction between their com petitive and non­
competitive action. However, the competitive NMDA antagonist 
CGP39551 did. not alter significantly glucose use in the entorhinal 
cortex, but resulted in significantly increased glucose use in the piriform 
cortex and the hippocampus: thus the reason for the activation of the 
hippocampus in response to some, but not all, NMDA antagonists is 
obscure.
There is g row ing  su pport for existence of g lu tam aterg ic  
autoreceptors within the CNS; thus, blockade of these may contribute to 
the sustained neuronal firing in limbic areas following administration
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of NMDA antagonists. Using electrophysiological recording techniques, 
Coan & Collingridge (1987) measured the response of CAl neurons in 
h ippocam pal slices to high-frequency stimulation of the Schaffer 
collateral fibres, and observed that in the absence of magnesium, 
application of AP5 or magnesium to the hippocampal slice resulted in 
an increase in the size of the population spike. The authors suggested 
that NMDA receptors therefore may be involved in presynaptic 
autoregulation, and removal of this component resulted in an increase 
in cell firing. Further, it has been dem onstra ted  that MK-801 
administration increases extracellular glutamate levels, measured with 
high performance liquid chromatography (HPLC) within distinct brain 
regions including the olfactory bulb and piriform cortex (Loscher et al., 
1991), while CGP39551 did not have significant effects on glutamate 
release in these areas. These observations would support the view that 
increased neuronal activity represents an attempt to overcome the 
glutam atergic blockade, and that in the case of the competitive 
antagonist, the blockade is readily overcome by moderate increases in 
glutamate release. The authors also demonstrated that in these and 
other areas such as the hippocam pus, release of the inhibitory 
transmitter y-amino-butyric acid (GABA) is significantly increased by 
MK-801 but not by CGP39551; this may be due to either the activation of 
recurrent GABAergic inhibitory neurones (Andersen et al., 1964a, b; 
W o u te r lo o d  et a l., 1985), or e n h a n c e d  turnover of 
glutamate in these areas.
There is, however, little other evidence to support such a feedback 
mechanism. The concentration of glutamate within the synaptic cleft is 
controlled rapidly by presynaptic regulatory mechanisms and uptake 
sites (Nicholls & Attwell, 1990), and other authors have reported that 
pharmacological blockade of the NMDA receptor in the hippocampus 
inhibits glutamate release (Chapman & Bowker , 11987; Connick & 
Stone, 1988; Crowder et al., 1987; Nadler et al., 1990).
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D-CPP-ene significantly reduced glucose utilisation in the CA4 
region and subiculum following the intermediate dose of 3mgkg-1' and 
in the mamillary body following 3 and 30mgkg_1; the subiculum  
appears to perform an important role in the relay of information from 
the hippocampus to many cortical and sub-cortical regions such as areas 
involved in visual processing (Swanson et ah, 1987). Subicular fibres 
project to the j mamillary body and nucleus accumbens, and a 
glutamatergic mechanism has been implicated (Walaas & Fonnum,
1980). Further, in the nucleus accumbens, glucose utilisation was 
affected in a similar manner to that in Papez areas; functional 
suppression occurred following 3mgkg_1 but not 30mgkg_1 D-CPP-ene. 
The failure of D-CPP-ene to produce increased glucose utilisation in 
Papez structures, such as the posterior cingulate cortex and mamillary 
bodies, is in contrast with the report that MK-801 produced marked 
increases in glucose use in these structures (Kurumaji et al., 1989), but 
accords with the lack of alterations reported in these areas in response 
to other competitive antagonists (Chapman et al., 1989, 1991; Kurumaji 
et al., 1989). Kurumaji and McCulloch (1990a) noted that Papez 
structures were functionally activated by MK-801 despite removal of the 
entorhinal cortex, supporting an additional mechanism for functional 
activation of the Papez circuit. Bearing in m ind the anatomical 
complexity of subicular (and hippocampal) connections, it is not 
unlikely that this response is due to two distinct mechanisms of 
functional alteration. It is possible that the initial decrease in glucose 
utilisation reflects a local inhibition of cell firing due to the action of D- 
CPP-ene on NMDA receptors within that region. It is notable that all 
areas of the hippocampus measured are found to have a slightly 
decreased rate of glucose utilisation following 3mgkg_1 compared with 
0.3mgkg_1 or 30mgkg'] D-CPP-ene. Equally, reversal of this trend with a 
higher dose of drug might not represent a local effect, but is the result of 
increased firing within distant afferents, such as the entorhinal cortex,
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with larger doses of drug.
Olfactory Areas
Increases in glucose utilisation in olfactory regions represent the 
most consistent alterations in glucose utilisation in response to NMDA 
(an tagon is ts ,  and  occur fo llo w in g  a d m in is t ra t io n  of b o th  
competitive and non-competitive antagonists (Chapman et al., 11989, 
Chapman et al., 1991; Kurumaji et al., 1989, Weissman et al., 1987). The 
olfactory cortex, as discussed, projects extensively to the lateral 
entorhinal cortex and hence constitutes a major input of the lateral 
perforant path. Stimulation of the olfactory bulb leads to kindling in 
rats, a process which is sensitive to blockade by NMDA antagonists 
(Millan et al., 1988; Piredda & Gale, 1986). However, a large projection 
from the olfactory bulb terminates in the cortical amygdalar nuclei, 
which thence project directly to the hippocampus (Carlsen et al., 1982). 
The entorhinal cortex also projects to the basolateral and lateral 
amygdalar nuclei (Ottersen, 1982). Amygdala-induced kindling is
evidence that activation of the perforant path  by olfactory and 
entorh inal stim ulation is not necessarily requ ired  for kindling; 
furthermore, studies suggest that glutamatergic transmission exists 
between the amygdalar nuclei and the hippocampus (Petersen et al., 
1983). However, D-CPP-ene (30mgkg_1) produced a moderate decrease 
in glucose utilisation in the lateral amygdalar nucleus (Figure 13), and 
did not alter glucose use in the medial amygdalar nucleus. Thus it 
appears that NMDA receptor blockade results in diverse functional 
alterations even within structures which are functionally related.
The piriform and associated cortices contain an extensive system of 
association and commissural fibres (Haberly & Price, 1978). The 
pharmacology of excitatory transmission within the olfactory cortical 
areas is complex: kainate and AMPA receptors are believed to mediate 
transmission in the commissural fibres of the lateral olfactory tract,
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while NMDA receptors may be involved in polysynaptic excitation 
within the cortex (Collins & Howlett, 1988). The concentration of 
NMDA binding sites within the olfactory cortex is extremely high in 
comparison to other brain regions (Monaghan & Cotman, 1985). 
Additionally, the ability of the NMDA antagonist AP5 to antagonise 
transmission in the olfactory cortex when low frequency stimulation is 
applied points to evidence in this area at least of a role for NMDA 
recep to rs  in the norm al low frequency  g lu tam ate -m ed ia ted  
transmission. Although the polysynaptic nature of neuronal pathways 
merits caution in the interpretation of electrophysiological recording in 
the olfactory cortex, it may be significant that NMDA receptors in this 
region may show different characteristics from those in other limbic 
areas. A difference in the function of NMDA receptors in this area may 
underly the increases in glucose use which occur in olfactory areas in 
response to D-CPP-ene, in contrast to the marked depression produced 
in other cortical areas.
Finally, there is evidence to suggest that olfactory inputs to the 
entorhinal cortex form synapses not only directly with pyramidal cells, 
but also on GABAergic interneurons in layer I of the entorhinal area 
(Wouterlood et al., 1985). The olfactory cortex, therefore, has both an 
inhibitory and an excitatory control over entorhinal firing; blockade of 
GABAergic inhibition of entorhinal firing, may explain the metabolic 
activation to N M D A  antagonists in the entorhinal area. The entorhinal 
cortex sends reciprocal projections to olfactory areas (Swanson et al., 
1987), including the anterior olfactory nucleus, the only subcortical 
olfactory-associated region in which glucose utilisation was significantly 
increased after D-CPP-ene administration (Figures 15 & 16). Thus, 
within olfactory regions there appears to be evidence for a highly 
regulated glutamatergic transmission between adjacent cortical areas.
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Auditory and Visual Areas
Within layers of the auditory and visual cortices, high numbers of 
NMDA-sensitive binding sites are known to exist (Monaghan & 
Cotman, 1985), and glutamate has been implicated in both retino-fugal 
(Crunelli et al., 1987), and cortico-fugal fibres (Fosse & Fonnum, 1987) to 
the sup erio r  colliculus and dorso la te ra l  genicula te  nucleus. 
Additionally, glutamate is a putative transmitter in intrahemispheric 
cortico-cortical connections throughout the cerebral cortex (Baughman 
& Gilbert, 1981; Peinado & Mora, 1986), and NMDA receptors appear to 
be important in plastic responses of the visual system (Artola & Singer, 
1987; Chalmers & McCulloch, 1989; Kleinschmidt et al., 1987).
NMDA antagonists are known to possess anaesthetic, anxiolytic and 
anticonvulsant effects (Clineschmidt et al., 1982; Domino et al., 1965; 
France et al., 1990). The widespread dose-dependent reductions in 
glucose use in subcortical auditory and visual structures represent the 
most robust alterations in response to D-CPP-ene; and probably reflect 
largely the degree of sedation produced by D-CPP-ene. However, the 
competitive NMDA antagonists CGP39551 and CPP had little effect on 
auditory and visual regions, even at high doses of drug, (Chapman et 
al., 1991; Kurumaji et al., 1989), while MK-801 administration produced 
limited reductions in glucose use in auditory areas; thus heterogeneity 
exists in the responses to NMDA antagonists in these regions.
The visual system projects densely to areas of subiculum , 
presubiculum, and distinct layers of the medial entorhinal cortex, and 
thus forms a major sensory afferent to the hippocampus. Therefore, it 
is feasible that the slight depression in glucose use within hippocampal 
areas at lower doses of D-CPP-ene may reflect the degree of reduced 
firing within visual afferents, while, as discussed, the reversal of this 
trend in hippocampal areas following 30mgkg_1 D-CPP-ene possibly 
reflects functional activation of other hippocampal afferents, such as 
regions of the Papez circuit, or olfactory areas.
1 53
In sum m ary, these results provide further evidence for the 
functional heterogeneity of NMDA receptors in the brain, and illustrate 
an apparen t functional divergence between NMDA receptors in 
olfactory areas and those in other sensory systems. The bi-phasic 
alterations in glucose use observed in the hippocam pus and other 
limbic structures are perhaps indicative of the integrative role of the 
limbic system in cerebral transmission.
1.2. THE NOVEL MUSCARINIC AGONIST L-679-512
The use of the deoxyglucose autoradiographic technique has to date 
contributed minimally to the elucidation of the functional role of 
cholinergic systems within the CNS, and reflects the generally poor 
perception of the mechanisms involved in cholinergic transmission. 
While other transmitter systems have been characterised in detail in 
terms of electrophysiology, location, and anatomical circuitry, thus 
providing an interdisciplinary basis for hypotheses as to their precise 
function within the CNS, the same approach has not yet provided a 
clear understanding of cholinergic function. A num ber of factors 
contribute to this: high densities of cholinergic receptors are found in 
much of the brain, and the innervation of many such areas, especially 
cortical areas, is relatively diffuse (for a comprehensive study, see 
Lysakowski et. al., 1989), hence hindering studies which employ 
electrophysiological, deafferentation, and tract-tracing techniques. In 
addition, muscarinic and nicotinic cholinergic receptors may be sub­
divided into several sub-populations based on relative affinities of 
agonists and antagonists, structure, and transduction mechanism. A 
recent review described the existence of at least five structurally distinct 
sub-populations of muscarinic receptors (Bonner, 1989), a lthough 
functional heterogeneity has not been demonstrated for all of these.
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Therefore any systematic study of cholinergic transmission in the CNS 
is complicated by the apparent functional diversity of cholinergic 
receptors.
A number of studies have employed deoxyglucose autoradiography 
to examine the cerebral metabolic effects of muscarinic agents in the 
brain (Dam & London, 1984; Soncrant et al., 1985; Weinberger et al., 
1979). The agonists oxotremorine and arecoline have been found to 
increase glucose utilisation in areas of the brain associated with 
cholinergic function, while scopolamine, a muscarinic antagonist was 
found to reduce glucose utilisation in almost every brain region 
analysed (Weinberger et al., 1979). In each study the magnitude of 
functional alteration correlated poorly with the receptor density of that 
area. These observations possibly reflect not only the functional 
diversity of muscarinic receptors, but also the vast degree to which 
acetylcholine regulates firing throughout the brain, directly, or 
indirectly in the non-cholinergic structures by modulation of their 
cholinergic afferents.
L-679-512 is one of a series of novel muscarinic antagonists derived 
from arecoline (Saunders & Freedman, 1989; Freedman et al. 1990), with 
similar affinity for Ml and M2 receptors (R. Hargreaves, Merck, Sharp 
and Dohme, Harlow, Essex; personal communication). It is able to cross 
the blood-brain barrier freely and to stimulate maximally muscarinic 
phosphoinositide  hydrolysis in the brain. Previously, the only 
m u scar in ic  agonis ts  w hich  w ere  able to induce  m axim al 
phospho inositide  hydrolysis were qua ternary  am m onium -based  
agonists such as carbachol, oxotremorine-M, and muscarine (Saunders 
& Freedman, 1989). However, these are thought to have only a limited 
ability to cross the blood-brain barrier, and thus systemic administration 
limits their ability to produce centrally mediated effects. The present 
study, therefore, represents the first comprehensive examination of the 
in vivo functional consequences of maximally stimulating muscarinic
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FIGURE 44: THE NOVEL MUSCARINIC AGONIST L-679-512: 
CHEMICAL STRUCTURE
receptors in the CNS by administration of a muscarinic agonist.
In the present study, two observations are apparent immediately:- 
firstly, despite overt changes in behaviour and physiological parameters 
which are consistent with cholinomimetic effects (decreased heart rate 
and blood pressure, lacrimation, muscle fasciculation and tail tremor), 
few significant alterations in local cerebral glucose utilisation were 
observed. Secondly, while broadly speaking muscarinic agonists 
produce  in elevated glucose utilisation whereas the m uscarinic 
antagonist scopolamine causes widespread depression of glucose use, L- 
679-512 in contrast resulted in generally decreased rates of glucose use 
(Appendix II). While the different pattern of functional alterations 
observed in this study, compared to other studies may be explained 
partly in terms of the CNS penetration of L-679-512, the lack of any 
sim ilarity  between these responses and others, particu larly  in 
cholinergic regions, is surprising.
A number of factors may be important in these results. Firstly, L- 
679-512 induced a profound bradycardia, coupled with a decrease in 
blood pressure; these results were marked in animals which received 
SOpgkg'1 L-679-512. However, the effects were transient, and blood 
p ressure  had returned  to the pre-injection level by the time 
deoxyglucose was administered. Therefore decreased rates of glucose 
use are unlikely to be due to decreased perfusion within the CNS. 
Secondly, it has been observed in other studies that cholinomimetics 
may induce hypothermia. Hypothermia has been reported to reduce 
cerebral glucose utilisation in most regions of brain i (McCulloch, 
1982). However, hypothermia did not occur in response to L-679-512 
administration, and cannot account for the reductions in glucose use in 
this study. It must be concluded, therefore, that the different effects of 
L-679-512 on cerebral glucose use, in comparison to those produced by 
other cholinomimetics are due to the high potency of the compound, or 
its ability to penetrate freely the blood-brain barrier, or both.
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The effects of L-679-512 are further discussed below, with reference 
to regional changes in glucose utilisation, and their implications for the 
local function of muscarinic cholinergic receptors in the CNS.
Hippocampal and Limbic Areas
Muscarinic agonists have produced a spectrum of effects on glucose 
utilisation in the hippocampus: arecoline, which displays some affinity 
for nicotinic receptors has been found to increase glucose use in a dose- 
dependent manner in most regions in the hippocampus (Soncrant et 
al., 1985), while the partial muscarinic agonist oxotremorine evoked 
increases in glucose utilisation in the presubicular area only (Dam & 
London, 1984). Conversely, L-679-512 induced significant decreases in 
glucose use in three hippocampal regions, the stratum lacunosum 
moleculare of the CAl and CA2/3 regions and the stratum oriens/ 
pyram idale  region of CA2. As noted previously following the 
administration of glutamatergic agents, functional alterations do not 
necessarily occur in regions with high numbers of receptors: in the CA 
region, muscarinic receptors are particularly dense within the strata 
oriens and radiatum, with moderate amounts of binding in the stratum 
lacunosum moleculare. Nor do the regional functional reductions in 
the hippocampus correspond to the regional density of Ml or M2 
receptor sub-types (Mash & Potter, 1986): Ml receptors account for the 
majority of muscarinic binding sites in the hippocampus; dense M2 
receptor-binding is found in the pyramidal cell layer of the CA region, 
and the molecular layer of the dentate gyrus. In cortical areas, which 
contain dense amounts of Ml and M2 receptors, glucose utilisation was 
depressed following the highest dose of L-679-512; in contrast, in the M2 
receptor-dense medial forebrain bundle and horizontal diagonal band 
nucleus, glucose use was significantly reduced following 30|igkg'1 L-679- 
512. Finally, the mamillary bodies exhibited the m ost robust 
alterations in glucose utilisation following L-679-512, despite relatively
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low levels of both Ml and M2 receptors.
A possible reason for the discrepancies between the functional 
responses to L-679-512 and those to arecoline and oxotremorine is the 
ability of L-679-512, and the failure of arecoline and oxotremorine, to 
fully stimulate phosphoinositide activity, and presumably to abolish 
the M-current or the IAH(> in hippocampal cells. Since the maintenance 
of the membrane potential is an energy-demanding process, removal of 
this process would represent an energy saving, reflected in a decrease in 
deoxyglucose uptake. This may account for the decrease in glucose 
utilisation following low doses of L-679-512; as the concentration of 
agonist increases, it is likely that initial energy savings are offset by an 
increased energy demand to fuel the other consequences of muscarinic 
stimulation, such as phosphorylation of proteins by second messengers, 
activation of ion channels in response to an increasing frequency of 
depolarisation, or the activation of other sub-populations of muscarinic 
receptors, such as presynaptic inhibitory synapses. Indeed, recent 
evidence suggests that carbachol is able to inhibit firing of CAl 
pyramidale neurons through presynaptic mechanisms (Sheridan & 
Sutor, 1990).
Dam and London (1984) proposed that the lack of alterations in 
glucose utilisation following oxotremorine administration was due to 
the ability of muscarinic receptor stimulation to modify membrane 
excitability without producing adequate depolarisation to alter glucose 
use m easurably . In contrast, areco line-induced  increases in 
hippocampal glucose utilisation have been suggested to reflect the 
widespread metabolic activation observed throughout most of the brain 
(Soncrant et al., 1985). Although arecoline has affinity for nicotinic 
synapses, nicotine adm in is tra tion  does not alter significantly 
hippocampal glucose utilisation (London et al., 1988) and therefore 
probably does not participate locally in the metabolic activation of the 
hippocampus produced by arecoline.
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From these studies, there exists no overall evidence that alterations 
in hippocampal glucose utilisation represent altered activity in afferent 
n e u ro n  p opu la tions . A lthough oxo trem orine  d id  not a lter 
hippocampal glucose utilisation, functional activation was apparent in 
several Papez structures, while arecoline administration resulted in 
functional activation of both the Papez circuit and the hippocampus. 
The Papez circuit, as discussed, is an anatomically-defined feedback 
loop, providing a connection between the forebrain, cingulate cortices 
and hippocampus. Contrary to these observations, glucose utilisation 
following L-679-512 administration was suppressed in the hippocampus 
and mamillary bodies, while other Papez structures rem ained 
functionally unaltered.
The in vivo consequences of muscarinic receptor stimulation in 
the hippocampus and structures remain unclear, and these studies 
highlight the reliance of the deoxyglucose technique upon parallel in 
vitro and in vivo studies of receptor and cell function. Undoubtedly, 
studies of the functional alteration in the hippocampus in response to 
muscarinic stimulation, coupled with a better understanding of (1) the 
role of second messenger systems in muscarinic action, (2) the function 
of distinct muscarinic receptor sub-types in the hippocampus, and (3) 
the role of presynaptic and post-synaptic muscarinic modulation of 
hippocampal firing would lead to a better comprehension of the precise 
consequences of muscarinic receptor activation in the brain.
Olfactory Areas
L-679-512 produced significant decreases in glucose utilisation in 
three out of six olfactory regions in the brain (Figure 21). The olfactory 
system, as discussed, represents a major afferent of the lateral perforant 
path; furthermore, cholinergic mechanisms in the olfactory cortices 
have been implicated in seizure activity: pilocarpine application to the
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piriform cortex results in seizures in rats which can be prevented by 
glutamate antagonists (Millan et al., 1988), suggesting that acetylcholine 
m odula tes g lu tam ate-m ediated  transm ission in olfactory cortex. 
Pilocarpine-induced seizures, however, have been observed to increase 
markedly glucose utilisation in olfactory cortices in rats (Clifford et ah, 
1987), a result contrary to the present findings that L-679-512 induced 
decreased glucose utilisation in olfactory areas. The present results are 
also in contrast to those produced by arecoline and oxotremorine, 
which resulted in moderately increased glucose utilisation in the 
entorhinal cortex, and did not alter glucose utilisation in other olfactory 
areas (Soncrant et al., 1985; Dam et al., 1982). These observations 
therefore extend the evidence gained from the pattern of functional 
alterations in the hippocampus for a different mechanism of action of 
L-679-512 compared to other, partial muscarinic agonists.
Auditory and Visual Areas
Studies of function in the visual system have been facilitated by the 
ease of manipulating the system, for example by enucleation or light- 
deprivation, and these have lead to the belief that acetylcholine has a 
m odulatory role in neuronal firing within visual areas: for example, 
physostigmine and other cholinesterase inhibitors increase glucose 
utilisation in the superior colliculus (Nelson et al., 1978), a process 
dependen t on retinal stim ulation (Gomez-Ramos et al., 1982). 
However, the cholinergic component of visual transmission appears to 
be largely nicotinic, and this is reflected in the lack of functional 
alterations produced by L-679-512, and other muscarinic agonists (Dam 
& London, 1983). L-679-512 p ro duced  significantly  reduced
glucose utilisation in one visual and one auditory region of brain, the 
medial geniculate body and the auditory cortex; however, it was noted 
that there was a trend for glucose utilisation to decrease dose- 
dependently in auditory, but not visual, areas. There is no obvious
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reason for the different patterns of glucose utilisation in the two 
sensory systems: both systems contain predom inantly M2 receptors 
(Mash & Potter, 1986), and there was no apparent alteration in the 
conscious state of the animals, which might account for the loss of a 
particular sensory function. Nevertheless, the magnitude of altered 
glucose use in these areas does not suggest that functional alterations in 
the hippocam pus and limbic areas result from altered activity in 
auditory or visual afferents.
These results illustra te  overw helm ingly  the com plexity  of 
cholinergic systems in the brain, and the difficulties involved in 
disseminating the precise functional role of cholinergic transmission. 
However, this study has provided evidence for an important difference 
between the in vivo functional alterations produced by partial and full 
agonists of phosphoinositide turnover, and thus the results have 
important implications in the use of such drugs to treat cholinergic 
disorders such as Alzheimer's disease. The unique effect of L-679-512 
on glucose use in the rat brain in comparison to other muscarinic drugs 
may identify a possible method of cholinergic stimulation not achieved 
by administration of other muscarinic agonists.
1.3. 9-AMINO-l,2,3,4-TETRAHYDROACRIDINE (THA)
THA induced few alterations in local cerebral glucose utilisation, 
and therefore these results contribute little to existing evidence that 
THA interacts directly with glutamatergic receptors in the brain (Albin 
et al., 1988; Davenport et al., 1988). There appear to be few similarities 
between the pattern of functional alterations and the distribution of 
glutamatergic pathways in the brain: glucose use was unchanged in 
response to THA in all regions of sensory cortex, including olfactory
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cortices, and the functional activity of the hippocampus was largely 
unaltered; in the subiculum, however, glucose use was significantly 
increased.
In the Papez circuit, glucose utilisation was increased in the 
anteroventral thalamic nucleus, but unaltered in the mamillary 
bodies and cingulate cortices; therefore on the basis of functional 
activity, THA does not appear to enhance transmission in key limbic 
areas.
The alterations in cerebral glucose use within visual structures 
evoked by THA administration are indicative of the cholinomimetic 
effect of THA. Markedly increased glucose use was measured in the 
superficial layer of the superior colliculus and in the lateral geniculate 
body (Figures 24 & 25). In the anterior pretectal nucleus glucose use was 
increased moderately but not significantly. Large increases in glucose 
utilisation have been reported to occur in response to cholinesterase 
inhibitors (Dam & London, 1983; Nelson et al., 1978), a response 
prevented by exposing the retina to the excitotoxin kainate (Gomez- 
Rarnos et al., 1982), leading to the postulation that acetylcholine in these 
regions has a modulatory effect on glutamatergic transmission. The 
superior colliculus is also functionally activated by arecoline (Soncrant 
et al., 1985) and nicotine (London et al., 1988), but only slightly by the 
muscarinic agonist oxotremorine (Dam & London, 1983); thus it is 
probable that the cholinergic response in this area is largely nicotinic.
It has been.suggested that THA and physostigmine exert some of
j
their therapeutic effect in the treatment of the cholinergic dysfunction 
of Alzheimer's disease through nicotinic as well as muscarinic 
mechanisms (Nillson et al., 1987). Indeed, despite the lack of nicotinic 
involvem ent in septo-hippocam pal transmission (Cole & Nicoll, 
1984b), nicotine improves performance in learning and memory tasks 
{Flood et al., 1988; Gibson et al., 1983; Warburton & Wesnes, 1984), and 
nicotinic receptors are found to be reduced in regions which undergo
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pathological degeneration typical of Alzheimer's disease, such as frontal 
(Nordberg & Winblad, 1986; Whitehouse et al., 1986), temporal and 
occipital cortices (Whitehouse et al., 1986), and cholinergic forebrain 
structures (Shimohama et al., 1986bj. Nicotinic acid has been found to 
stim ulate  acetylcholine release in the cerebral cortex (Rowell & 
Winkler, 1984), and presynaptic nicotinic terminals have been found on 
catecholamine terminals in the brain (Schwartz et al., 1984), which are 
indicative of a modulatory role for nicotinic receptors. Moreover, the 
nucleus basalis of Meynert, a cholinergic forebrain nucleus, and a 
principal source of cholinergic fibres to the cortex, is reported to have 
the highest density of nicotinic receptors in the brain (Shimohama et 
al., 1985). In Alzheimer's disease, this region is subject to depletion of 
choline acetyltransferase activity and neuronal loss (Whitehouse et al.,
1981), coupled with significant reduction in nicotinic binding sites 
(Shimohama et al., 1986b.), An increase in nicotinic activity in this area, 
therefore may underlie in part the efficacy of THA in the treatment 
of Alzheimer's disease.
Nicotinic receptors predominate over muscarinic receptors in the 
habenulo-interpeduncular system (Clarke et, al., 1984), and nicotine 
administration leads to markedly increased glucose utilisation in rats 
(London et al., 1988). The habenular nuclei are interconnected 
extensively with the midbrain raphe nuclei, and are believed to provide 
a link between forebrain and midbrain limbic systems. Nicotine 
administration .produces antinociception in laboratory animals by an 
apparent central mechanism (Phan et al., 1973), and stimulation of the 
dorsal raphe attenuates nociceptive-evoked habenular neuronal firing 
(Dafny & Qiao, 1990). Although no alteration in glucose utilisation was 
m easured  in the habenula following THA adm inistra tion , the 
decreased glucose utilisation in the dorsal raphe nucleus may indicate a 
nicotinic-mediated functional modification of its habenular afferent.
Finally, THA has been demonstrated to block potassium channels
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(Osterreider, 1987), and thus facilitate presynaptic release of transmitter 
substance (Harvey & Rowan, 1990) and it has been postulated that this 
may contribute to the therapeutic effects of THA in Alzheimer's disease 
(Summers et al., 1986). Indeed, Stevens & Cotman (1987) observed that 
the excitation produced by THA on hippocampal pyramidal cells was 
not blocked by atropine, and therefore could not be explained by a 
cholinergic effect alone. It is possible, then, that several effects, 
including nicotinic, muscarinic and potassium  channel-inhibiting 
actions are synergistic in the eificacy of THA in Alzheimer's disease. In 
the light of functional alterations in response to THA and other 
cholinergic and glutamatergic agents, the present results provide 
evidence for a cholinergic, possibly nicotinic, mode of action for THA, 
and demonstrate the novel perspective gained from deoxyglucose 
autoradiographic studies of in vivo drug action.
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2. FUNCTIONAL PLASTICITY OF THE HIPPOCAMPUS IN RESPONSE 
TO LESIONS OF THE MEDIAL SEPTUM
2.1. GLUCOSE UTILISATION AND SYNAPTIC MODIFICATION
Previous attempts to examine functional activity in response to 
lesions of discrete neuronal populations have mostly demonstrated a 
bi-phasic response (Chalmers et al., 1989; Harrell & Davis, 1984; 
Kiyosawa et al., 1989; Yamaguchi et al., 1990): generally decreased 
glucose utilisation occurs acutely after the lesion, followed later by 
amelioration of the reduction in glucose utilisation over a variable 
period of time. The former phase of hypometabolism has been thought 
to reflect the decrease in activity of the target tissue due to the loss of its 
presynaptic input, while recovery of functional activity indicates 
synaptic reorganisation or restoration of the synaptic input within the 
target tissue.
A number of attempts have been made to examine the functional 
consequences of cholinergic denervation in the rat and primate brain. 
In baboons with unilateral lesions of the nucleus basalis of Meynert, 
decrements in glucose use have been observed in the cerebral cortex 
(Kiyosawa et al., 1989; Yamaguchi et al., 1990), linearly proportional to 
depletions in choline acetyltransferase (ChAT) activity. Although 
reduced ChAT activity persisted with time, however, glucose utilisation 
recovered gradually, to near normal levels after three months, inferring 
that functional recovery in the cortex was not dependent on the 
recovery of the deafferentated cholinergic input. Lamarca and Fibiger 
(1984) reported that nucleus basalis lesions were not associated with 
reduced cortical glucose utilisation ten days post-lesion, despite 
depletions in ChAT activity in the denervated cortex.
The functional response of the h ippocam pus in response to 
deafferentation has been less clearly defined. Harrell and Davis (1984)
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observed increases in glucose utilisation in ipsilateral hippocampal 
regions one week after unilateral electrolytic ablation of the medial 
septal area, and decreases in the same regions three weeks after the 
lesion. The authors suggested that early increases in hippocampal 
glucose use represented gliosis in the deafferentated hippocampus, and 
these initially masked reductions m glucose use due to the loss of the 
cholinergic input. The authors also reported that twelve weeks after 
denervation, hippocampal glucose utilisation was not significantly 
different from control values, suggesting that plastic responses had 
allowed restoration of h ippocam pal activity, as m easured  by 
deoxyglucose uptake. However, the lack of proper quantification within 
these experiments throws uncertainty on the validity of the results: 
these were comprised of measurements of [3H]-deoxyglucose uptake, 
estimated by counting silver grains, within very small experimental 
groups (one sham-operated and two lesioned animals); further, the 
control values reported were pooled data from the hippocam pus 
bilaterally of the sham-operated rat and the contralateral hippocampus 
of the two lesioned rats, and there was a sizeable degree of variability 
within reported values for control rats. In contrast, Kelly et al. (1985b) 
reported that significant decreases in glucose utilisation measured using 
quantitative [14C]-deoxyglucose autoradiography persisted six months 
after severe cholinergic denervation of the hippocampus via fimbria 
fornix transection. When embryonic septal tissue was grafted into the 
lesioned a re a , . functional activity recovered in the h ippocam pus, 
suggesting that the integrity of some cholinergic cells is required before 
functional recovery can occur. In comparison, the present results 
suggest that if functional alterations do occur in the hippocampus in 
response to ibotenate-induced medial septal lesion, these are 
ameliorated within three weeks after the lesion. Thus it would appear 
that the hippocampus is able to sustain the loss of part of its cholinergic 
input without significant long-term disruption of activity.
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It has been suggested that partial cholinergic denervation results in 
sprouting of other cholinergic afferent fibres, and these result ultimately 
in the recovery of function in the denervated pathway. Indeed, the 
ability of the hippocampus to recover function can be correlated roughly 
with the severity of the lesion: confined ibotenate lesions, electrolytic 
medial septal lesions and fimbria fornix lesions result, in that order, in 
an increasing am ount of d isruption  of both septal cholinergic 
hippocampal afferents and fibres of passage, while in the same order 
appear to decrease the ability of the h ippocam pus to recover 
functionally . H ow ever, the p e rs is ten t  decrease  in choline 
acetyltransferase activity following apparent recovery of glucose 
utilisation (Harrell & Davis, 1984; Kiyosawa et al., 1989; Yamaguchi et 
al., 1990) suggests that functional recovery is dependent on non- 
cholinergic mechanisms. It is possible, therefore that the lack of 
recovery of glucose use in the hippocampus following fimbria fornix 
lesions (Kelly et al., 1985b) was due in part to the removal of non- 
cholinergic fibres which passed through the fornix.
The hippocampus receives a major noradrenergic projection from 
neurons which arise in the locus coeruleus and travel via the medial 
forebrain bundle to the hippocampus. At least part of these fibres pass 
via the fornix (Ungerstedt, 1971). N oradrenerg ic  terminals are 
particularly dense within the infragranular region of the dentate gyrus 
and the stra tum  rad ia tum  of CA3 (Crutcher & Davis, 1980). 
Noradrenaline is proposed to modulate long-term potentiation in the 
hippocampus: consequently, superfusion of noradrenaline during high 
frequency stimulation of the dentate mossy fibres in an in vitro 
hippocampal slice preparation results in an increased m agnitude, 
duration and probability of induction of LTP in the CA3 sub-field 
(Hopkins & Johnston, 1984), while conversely, adrenergic antagonists 
block the production of LTP. This effect is thought to be mediated 
through p-adrenergic stimulation of adenylate cyclase (Stanton &
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Sarvey, 1985).
There is evidence that noradrenergic fibres invade the hippocampus 
following removal of the septal cholinergic input, resulting in synaptic 
formation within the dentate-CA3 region (Crutcher et ah, 1981), possibly 
due to the dendritic space vacated by the loss of septal cholinergic 
afferents. Further, in the dentate-CA3 region, an increase in [3H]- 
forskolin binding to adenylate cyclase has been measured following 
septal lesions (Horsburgh et al., 1991b), and has been attributed to axonal 
sprouting of noradrenergic fibres within this area.
In terms of functional recovery following cholinergic denervation, 
then, it is likely that an increased noradrenergic influence on the 
hippocampus would replace at least partly the modulatory role of the 
septal cholinergic afferent fibres destroyed by septal lesion. Following 
fimbria fornix lesion, however, both cholinergic fibres originating in 
the medial septum, and non-cholinergic fibres of passage, are destroyed. 
The latter include a proportion of noradrenergic fibres targetted for the 
hippocampus, and the removal of these during fimbria fornix lesion 
may explain the lack of functional recovery in the hippocampus at long 
time-points post-lesion (Kelly et al., 1985b).
Finally, a further explanation for the lack of alterations in glucose 
utilisation following ibotenate-induced lesions of the medial septum is 
that although denervation does result in synaptic reorganisation -  and 
the existence of receptor a ltera tions and significant choline 
acetyltransferase activity following medial septal lesion in the present 
series of experiments suggests that plastic alterations are in operation 
following septal lesion -  these alterations do not represent in functional 
terms a significant portion of the total activity, reflected by glucose 
utilisation, to be detected using the present techniques. In either case, 
the lack of altered hippocampal glucose utilisation following medial 
septal lesion suggests that hippocampal function is preserved three 
weeks following the lesion, either by synaptic reorganisation in the
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hippocampal formation, or by the maintenance of hippocampal activity 
by other cholinergic and non-cholinergic afferents.
2.2. MUSCARINIC RECEPTOR PLASTICITY AND MEDIAL SEPTAL 
LESIONS
The lack of consistent muscarinic receptor alterations in the cortex 
and hippocampus of Alzheimer's Disease has provided the impetus for 
expanded research into the role of muscarinic receptor plasticity in 
animals following cholinergic denervation; however, the results to date 
of these studies have not been less variable. While the small reductions 
in [3IT]-QNB binding in the present study are in agreement with some 
studies which report the loss of muscarinic receptors following 
cholinergic denervation (Mash et al., 1985; Watson et al., 1985), the 
m agnitude of these alterations does not provide convincing evidence 
for muscarinic receptor plasticity in the hippocampus following loss of 
the cholinergic input. It has been suggested that regulation of 
muscarinic receptor activity is achieved by a negative feed-back 
mechanism: administration of muscarinic agonists results in decreased 
receptor density (Gazit et al., 1979; Ehlert et al., 1980; McKinney & Coyle, 
1982), while pharmacological blockade induces increased receptor 
concentrations (Ben-Barak & Dudai, 1980; McKinney & Coyle, 1982). 
Similarly, reraoval of cholinergic innervation by deafferentation 
should lead to an increase in post-synaptic densities of muscarinic 
receptors. However, with few exceptions (Joyce et al., 1989; McKinney & 
Coyle, 1982; Westlind et al., 1981), and including the present study, there 
has been little evidence for such a mechanism in the brain (Court et al., 
1990; Kamiya et al., 1981; Mash et al., 1985; Norm an et al., 1986; 
Overstreet et al., 1980; Smith et al., 1989; Yamamura & Snyder, 1974; 
Watson et al., 1985). A number of reasons may explain the apparent
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lack of receptor plasticity in these studies. Firstly, small lesions of 
cholinergic inputs may lead to a partial denervation of the target organ, 
and consequently, only small alterations in synaptic receptor density, 
which were not detected by autoradiographic means. Secondly, discrete 
lesions resulting in an incomplete cholinergic denervation of the target 
tissue may allow presynaptic modifications, such as neuronal sprouting 
in the remaining cholinergic fibres, to replace the cholinergic function 
lost by the degeneration of lesioned cells. In the present case, there exist 
a num ber of other sources of hippocampal cholinergic innervation 
which arise in the diagonal band nucleus, immediately ventral to the 
medial septum. Cholinergic cells which project from the diagonal band 
through the fimbria fornix make synaptic contacts with all hippocampal 
fields (Nyakas et al., 1987). Additionally, two projections from the 
diagonal band reach the hippocampus: one projection courses over the 
genu of the corpus callosum and then runs caudally in or near the 
cingulum bundle (Milner et al., 1983; Swanson & Cowan, 1979). These 
fibres innervate the anterior cingulate and retrosplenial areas and 
finally end in temporal regions of the subiculum and presubiculum. 
The second projection from the diagonal band nucleus, which accounts 
for up to 10% of the cholinergic input into the hippocampal formation, 
runs ventrally through the amygdala and terminates within temporal 
hippocampal fields (Milner & Amaral, 1984; Gage et al., 1984). Thus 
restricted lesions of the medial septum afford the possibility of plastic 
modifications of the cholinergic innervation of the hippocampus.
In addition, ibotenic acid-induced lesions avoid to a large extent 
damage of fibres of passage in the lesioned area. The medial septal 
region supports fibres which arise predominantly in the hypothalamus 
and brainstem regions, and course through the medial septum and 
fo rn ix , . to term inate finally within the h ippocam pal form ation 
(Swanson et al., 1987). The present lesion system, therefore, permits 
preservation of a large body of cholinergic hippocampal afferents, which
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may be involved in plastic responses to partial cholinergic denervation.
A third reason for the lack of detectable alterations in muscarinic 
receptor binding following denervation may be due to the failure to 
d ifferentiate between different muscarinic receptor types. Using 
autoradiographic analysis, two sub-types of muscarinic receptor are able 
to be distinguished in the mammalian brain (Mash & Potter, 1986; 
Tonnaer et al., 1988; Wamsley et al., 1980), based on the selective 
affinity of Ml receptors for pirenzepine and the apparent selectivity of 
M2 receptors for carbachol. However, discrepancies exist between the 
reported Ml and M2 receptor densities in the hippocampus, which may 
be due to less specific actions of these compounds (see Introduction 
Section 4.1.4.). It has been observed that M2 receptors are found co­
localised with high densities of acetylcholinesterase and choline 
acetyltransferase, and a specific loss of M2 receptors has been observed 
in animals following cholinergic deafferentation (Mash et al., 1985, 
Watson et al., 1985) and in Alzheimer's Disease (Mash et al., 1985; Perry 
et al., 1986). On this basis it has been suggested that M2 receptors 
represent autoreceptors on the presynaptic cholinergic terminals (Mash 
& Potter, 1986), while Ml receptors have been suggested to be located 
post-synaptically. Accordingly, the Ml antagonist pirenzepine is 
ineffective at blocking acetylcholine-mediated autoinhibition (Meyer & 
Otero, 1985). Following deafferentation, therefore, Ml receptor density 
may be expected to increase, while M2 receptors would be reduced due 
to the loss of the presynaptic input. M2 receptors constitute 20% of total 
m uscarinic receptors in the h ippocam pus, and thus failure to 
demonstrate alterations in muscarinic receptors in some studies may be 
due to the use of non-specific muscarinic ligands such as QNB, whereby 
small decreases in M2 receptors are either masked by increases in Ml 
receptors post-synaptically, or represent an immeasurably small fraction 
of the total ligand-binding to muscarinic receptors. However, 
observations of decreased M2 receptor density following cholinergic
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denervation have not been replicated by others (Court et al., 1990; 
Norman et al., 1986; Smith et al., 1989), and Joyce and colleagues (1989) 
observed increases in both Ml and M2 receptors following almost 
complete cholinergic deafferentation of the hippocampus, suggesting 
that both Ml and M2 receptors were located postsynaptically.
The present study offers little evidence to support postsynaptic 
modification of muscarinic receptors. Instead, the moderate decrease in 
muscarinic binding in the subiculum is more likely to be due to the loss 
of presynaptic receptors situated on degenerating cholinergic afferents to 
the hippocampus. The use of [3H]-QNB prohibits distinction between 
M l and M2 receptors; further, due to the lack of consensus as to 
whether Ml or M2 receptors predominate in the subiculum (Mash & 
Potter, 1986; Regenold et al., 1989; Tonnaer et al., 1988) it is unclear 
which receptor sub-type is likely to be affected.
Although the alterations in muscarinic receptor binding in the 
present study are small, it is of interest to examine more closely the 
pattern of hippocampal cholinergic innervation originating in the 
septum. The results of degeneration (Mellgren & Srebro, 1973), 
autoradiographic (Swanson & Cowan, 1979) and tract-tracing (Nyakas et 
al., 1987) studies indicate that neuronal fibres from the medial septum 
innervate all fields of the hippocampal formation (Figure 45). In turn, 
Ammon's Horn and the subicular region give rise to a massive 
projection via the fimbria fornix to the lateral septum, which itself 
sends a dense body of neuronal fibres to the medial septum. This circuit 
has been proposed as a feedback loop between the hippocampus and 
septal area (Swanson et al., 1987). In the present study, reductions in 
muscarinic binding observed in the medial and lateral septal nuclei and 
subicular region represent a consistent reduction throughout at least 
one complete hippocampal circuit.
Few investigators have examined plastic mechanisms within the 
septal region in response to selective lesion of the septohippocampal
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FIGURE 45: THE CHOLINERGIC SEPTOHIPPOCAMPAL PATH
Simple diagrammatic representation of the septal cholinergic input to the 
hippocampus. Arrows from the hippocampus to the septal area represent 
possible feedback systems (transmitter unknown).
path. Consequently, the role of putative septohippocampal feedback 
system has not been studied in detail. Furthermore, many lesion 
paradigms actively preclude these types of investigation: electrolytic 
lesions may result in anterograde and retrograde degeneration of 
neurones in tissue some distance form the site of the lesion, while 
transection of the fimbria fornix disrupts both septohippocampal and 
hippocampal-septal fibres, resulting in a complete loss of feedback 
mechanisms between the septum and hippocampus. The isolation of 
the hippocam pus from the septal nuclei in this manner may itself 
provide a reason for conflicting results in terms of the muscarinic 
response to cholinergic denervation within the hippocampus, and 
advocates further investigation into the precise role of hippocampo- 
septal fibres in deafferentation-induced plasticity.
Finally, the lack of measurable alterations in muscarinic receptor 
binding in the hippocampus may be explained in part by an apparent 
m odulatory role of the entorhinal area on hippocampal receptor 
plasticity. In an early study of receptor plasticity following entorhinal 
cortex lesions, Monaghan et al. (1982) demonstrated decreased [3H]-QNB 
binding to muscarinic receptors in the stratum lacunosum moleculare 
and the outer portion of the dentate molecular layer, and suggested that 
integrity of the entorhinal cortex was required for the control of 
muscarinic receptor densities in the hippocampus. Moreover, in rats 
which received lesions of the medial septum two to four days post- 
natally, i.e. prior to establishment of of septohippocampal lesions (Ben- 
Barak & Dudai, 1980), the pattern of muscarinic binding sites was 
unaltered at maturity, compared to control rats. In the same groups of 
animals, however, a 70% deficit of acetylcholinesterase was observed 
post-lesion, in comparison to control values, and the authors concluded 
that the development of muscarinic binding sites in the hippocampal 
formation is not dependent upon normal establishment of presynaptic 
contacts. Therefore, the preservation of [3H]-QNB binding in the
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present series of results may be a result of entorhinal control of 
muscarinic receptors, regardless of the cholinergic septohippocampal 
afferents.
2.3. GLUTAMATERGIC RECEPTOR 1 LASTICITY AND MEDIAL SEPTAL 
LESIONS
The role of glutam ate in long-term potentiation (LTP) in the 
hippocampus and its involvement in learning and memory have been 
well established (Collingridge, 1985). The hippocampus, which contains 
extremely high densities of all sub-types of glutamate receptor, is 
p rofoundly  affected by severe neurodegeneration in Alzheimer's 
Disease (Hyman et al., 1984), and it has been suggested therefore that 
disruption of glutamatergic neuronal firing within the hippocampal 
formation may underlie some of the cognitive impairments associated 
with the disease.
In associational cortical regions of brain, loss of pyramidal cells is a 
prominent feature of Alzheimer's Disease pathology (Mountjoy et al., 
1983; Pearson et al., 1985; Terry et al., 1981), and has been demonstrated 
to be directly related to the level of cognitive impairment in Alzheimer 
patients (Neary et al., 1986). Thus a loss of glutamatergic function may 
contribute to the clinical manifestations of the disease.
Consequently, many groups have reported altered glutamate release 
and re-uptake, and altered ligand-binding to sub-types of glutamate 
receptors in Alzheimer brains (for review, see Greenamyre & Young, 
1989). In the hippocampus, although there exist some discrepancies 
betw een indiv idual results, possibly due to sub-popula tions of 
Alzheimer patients or different ligand-binding protocols, [3H]-glutamate 
binding to NMDA receptors or [3H]-TCP binding to the associated ion 
channels are reduced in Alzheimer hippocampus. The pyramidal cells
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of CA1 and CA2 have been reported to be particularly affected 
(Greenamyre et al, 1987), perhaps reflective of the vast cell loss 
associated with the disease. Less emphasis has been placed on 
alterations in other glutamatergic receptor sub-types in Alzheimer's 
Disease. Geddes and colleagues (1985) reported expansion of the kainate 
receptor field in the hippocampus of Alzheimer brains, and suggested 
that this represented compensatory sprouting of dentate associational 
and commissural fibres into the space vacated by the loss of the 
entorhinal perforant path input in the course of the disease. The 
authors suggested that despite the massive pathom orphological 
disruption associated with Alzheimer's Disease the brain exhibits some 
capacity for plastic modification in response to denervation. However, 
the result was not reproduced by a similar study (Represa et al., 1988) in 
which markedly reduced densities of kainate receptors were measured 
in the h ippocam pus of severely dem ented  A lzheimer patients, 
inferring that as the disease progresses, so does the inability of the 
diseased tissue to compensate for a reduction of excitatory input.
Additionally, AMPA-sensitive quisqualate receptors have been 
reported to be reduced in the hippocampus of Alzheimer patients 
(Dewar et al., 1991), and Greenamyre and colleagues (1987) have 
reported decreased hippocampal quisqualate-sensitive [3H]-glutamate 
binding in Alzheimer brains.
Severe pathological degeneration of the entorhinal cortex, in 
addition to that observed in the hippocampus, is also a prominent 
feature of Alzheimer's Disease, suggesting that atrophy of the perforant 
pathway to the dentate gyrus may account for some of the memory loss 
in Alzheimer patients. Thus, experimental lesions of the entorhinal 
cortex have been used as a model in which to investigate the plastic 
alterations in glutamatergic receptor densities in the hippocampus 
which may accompany entorhinal deafferentation in Alzheimer's 
Disease. These studies are of mixed success: Geddes and colleagues
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(Geddes et al., 1985) were able to demonstrate that entorhinal cortex 
lesions lead to an expansion of the kainate receptor field in the rat 
h ippocam pus , a result which paralle led  their observations in 
Alzheimer tissue. However, in contrast to the deficits demonstrated in 
Alzheimer brain, NMDA and quisqualate receptor densities have been 
reported to increase in the hippocampus following entorhinal cortex 
lesions; this suggests that the loss of the entorhinal perforant path 
input into the hippocampus cannot solely account for the decrements 
in quisqualate and NMDA receptors measured in Alzheimer brains.
Despite extensive evidence for the destruction  of both the 
g lu tam aterg ic  h ippocam pal perforant pa th  and the cholinergic 
septohippocampal pathway in Alzheimer's Disease, and the apparently 
m odulatory role which cholinergic systems exert upon glutamate- 
m ediated  neuronal firing in the h ippocam pus, few experimental 
approaches have examined the possibility of hippocampal glutamatergic 
receptor plasticity following removal of the cholinergic input. A 
previous report described decreases in muscarinic cholinergic receptor 
binding following lesions of the entorhinal cortex (Monaghan et al., 
1982), and suggested that the integrity of the entorhinal cortex, rather 
than the medial septal area, was required for the maintenance of 
cholinergic receptors in the hippocampal formation. In comparison, 
the results presented here provide evidence for glutamatergic plasticity 
following cholinergic deafferentation via lesions of the medial septum. 
Further, the selective nature of alterations in receptor density suggest 
that sub-types of glutamatergic receptor are modulated differently. The 
basis for the pattern of alterations in glutamatergic receptor sub-type, in 
term s of their function and anatom ical location w ith in  the 
hippocampus, is discussed in further detail below.
AMPA-sensitive Quisqualate Receptors
Electrophysiological evidence suggests that stimulation of either 
quisqualate or kainate receptors in conjunction with NMDA receptors is 
required for the production of LTP in the hippocampus, and blockade of 
the AMPA-sensitive quisqualate receptor with the selective antagonist 
CNQX prevented the formation of LTP in response to tetanic 
stimulation of the hippocampus (Kauer et al., 1988; Muller et al., 1988a).
The distribution of [3H]-AMPA binding to quisqualate receptors 
overlaps well with the distribution of NMDA-sensitive [3H]-glutamate 
binding sites in the brain (Monaghan et al., 1984; Rainbow et al., 1984): 
each ligand binds in high amounts in the hippocampal CA1 strata 
oriens and radiatum. [3IT]-AMPA-binding to quisqualate receptors and 
quisqualate-sensitive [3hl]-glutamate binding has been demonstrated to 
be reduced in the hippocampus of Alzheimer patients (Dewar et al., 
1991; Greenamyre et al., 1987); however, little priority has been given to 
the mechanism underlying the loss of quisqualate binding sites in the 
process of the disease. It has been suggested that reductions in ligand- 
binding in Alzheimer brains may represent cell loss from pathologically 
affected regions of brain; evidence for this was provided by a recent 
study which demonstrated reduced [3H]-AMPA binding and a parallel 
cell loss in the subiculum (Dewar et al., 1991); however, the authors 
failed to correlate reduced cell loss in the CA1 with reduced [3H]-AMPA 
binding in that sector, and thus deficits in ligand-binding cannot simply 
be attributed to cell loss in the course of the disease. In this respect, the 
results presented here, in terms of the location of altered [3H]-AM PA 
binding in the hippocampus following medial septal lesions, and the 
direction of these alterations, namely decreases, are of some interest.
Removal of the cholinergic input to the hippocampus would be 
predicted to result in an upregulatory response within glutamatergic 
neurones in order to compensate for the lack of potentiation of 
glutamatergic neuronal firing by the septal cholinergic afferents: thus an
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increase in glutamatergic receptor binding may be expected to occur 
following septal lesions. On the contrary, septal lesions were 
accompanied by a decrease in [3H]-AMPA binding in the entorhinal 
cortex and CA sector of the hippocampus. Thus it would appear that 
septal lesions mimic some of the glutamatergic receptor deficits which 
occur in Alzheimer's Disease. Whether these are truly representative 
of the altered glutamatergic receptor densities which accompany 
Alzheimer's Disease, however, is unclear.
In an a ttem pt to elucidate the mechanism s underly ing  the 
maintenance of LfP in the hippocampus, Davies and colleagues (1989) 
observed that induction of LTP was associated with an increase in the 
sensitivity of CA1 neurones to quisqualate and AMPA; this developed 
slowly and was maximal one hour after the onset of LTP. The effect was 
blocked by the NMDA antagonist APV, suggesting that NMDA- 
mediated transmission, or the induction of LTP, was necessary for the 
increased neuronal sensitivity. It is possible, then, that the decreases in 
[3H]-AMPA binding described in the present study represent a decrease 
in the affinity of AMPA-sensitive quisqualate receptors due to the 
reduced induction of LTP following removal of modulatory cholinergic 
fibres in the hippocampus.
However, 21 to 60 days after lesions of the entorhinal cortex, 
increased [3H]-AMPA binding has been reported in the dentate gyrus 
(Ulas et al., 1990a), suggesting that in the absence of the major 
hippocampal excitatory input, AMPA receptors are up-regulated. At 
shorter times post-lesion, the authors reported a decrease in AMPA 
binding in the inner dentate molecular layer, a region which would not 
be denervated by entorhinal cortex lesion, and thus the transient 
reduction of [3H]-AMPA binding was unlikely to be due to loss of 
presynaptic  AMPA receptors situated on the ablated entorhinal- 
hippocampal fibres. This observation would be consistent with the 
view that reduction in LTP, in this case due to the destruction of the
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perforan t path, leads to a decreased sensitivity of AMPA-sensitive 
quisqualate receptors in the hippocampus. Additionally, while activation 
of GABA receptors during neuronal discharge usually results in inhibition 
of firing (Andersen et al., 1964a, b; Wouterlood et al., 1985), it has been 
shown that during LTP in the hippocampus GABAb autoreceptors act to 
depress the release of GABA, thus facilitating the induction of LTP (Davies 
et al., 1991). If GABAergic autoreceptors are situated on septohippocampal 
fibres, the removal of GABAergic cells following medial septal lesion may 
therefore prevent the increased sensitivity in AMPA receptors observed 
during LTP.
There exist a number of other possible explanations for the decreased [3H]- 
AMPA binding observed in the present study, based on the anatomical 
organisation of neuronal pathways within the hippocampus which employ 
excitatory amino acids as transmitter substances. In addition to the dense 
innervation of the hippocampus, septal fibres terminate in all layers of the 
entorhinal cortex, and particularly in layers II, IV and VI (Swanson et al., 
1987). Thus reductions in [3H]-AMPA binding in the entorhinal cortex and 
the hippocampal CA sector following medial septal lesions may represent 
the loss of presynaptic glutamatergic receptors due to the removal of the 
septal-entorhinal input (Figure 46). However, although a significant 
proportion of cells in the medial septum have been identified as non- 
cholinergic, a large percentage of these are GABAergic (Kohler et al., 1984), 
and there is no evidence at present for the involvement of glutamate in the 
septal projection to the hippocampal and entorhinal areas.
Secondly, as has been discussed in previous sections, the hippocampal 
formation is interconnected by an extensive network of associational and 
commissural fibres (Swanson et al., 1987). While the entorhinal cortex 
provides the dentate gyrus with a major glutamatergic projection in the 
form of the perforant path, fibres from layer III of the entorhinal area 
synapse in the stratum lacunosum moleculare with what are assumed to be 
the distant dendrites of CA pyramidal neurones (Gottlieb & Cowan, 1973; 
Kohler, 1986). In turn, a projection from the pyramidal cell layer has been 
reported to innervate in particular layer IV of the entorhinal cortex 
(Swanson et al., 1978); the transmitter for this pathway has not been 
identified, but has been proposed to be an excitatory amino acid (Swanson 
et al., 1987). The significantly reduced [3H]-AMPA binding observed 
c o n s i s t e n t ly  t h r o u g h o u t  the  p y r a m id a l  cell la y e r  of
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FIGURE,46: HIPPOCAMPAL ASSOCIATION SYSTEMS
Simple diagram m atic representation of the glutamatergic projections 
between the h ippocam pus and  entorhinal cortex. The cholinergic 
septohippocampal path is also indicated.
glu: confirmed glutamatergic projection; EAA?: possible excitatory amino 
acid projection (Swanson et al., 1987).
the CA sector following septal lesions may represent therefore plastic 
modification of this particular association pathway following removal 
of the cholinergic input to the hippocampus.
It is of further interest to note that the reductions in [3H ]-A M PA  
binding occur in those parts of the entorhinal cortex which support the 
two respective portions of the perforant path: consequently, decreased 
levels of [3H]-AMPA binding in the outer layers of the lateral entorhinal 
cortex may be associated with altered excitatory amino acid transmission 
within the lateral perforant pain, whereas the reduction in [3H]-AMPA 
binding in the deep layers of the medial entorhinal cortex may 
represent modification of the medial perforant path input to the 
hippocampus.
Finally, studies of second messenger binding following medial 
septal lesions have also provided evidence for the involvement of the 
entorhinal cortex in hippocampal plasticity. [3H]-phorbol d ibutyrate  
binding to protein kinase C was increased in the outer layers of the 
entorhinal cortex, but was unaltered in the hippocampus (Horsburgh et 
al., 1991b). The present report of altered [3H]-AMPA b ind ing  to 
quisqualate receptors, and the increase protein kinase C binding sites 
observed within the entorhinal cortex therefore indicate that the 
entorhinal cortex undergoes extensive synaptic reorganisation in 
response to septal lesions; the neuronal response of the entorhinal 
cortex to cholinergic deafferentation supports further the role for both 
cholinergic and .glutamatergic mechanisms in hippocampal plasticity.
Kainate Receptors
Kainate receptors, like AMPA-sensitive quisqualate receptors, are 
involved  in fast excitatory post-synaptic  transm iss ion  in the 
hippocampus, (Jahr & Stevens, 1987). In contrast to [3H]-AMPA binding 
sites, however, which are concentrated in the CA1, co-localised with 
NMDA receptors, kainate receptors are sparse in CA1, but are found in
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high quantities in the dentate gyrus-CA3 region (Monaghan & Cotman, 
1985; Cotman et al., 1987). The stratum  lucidum, which runs 
immediately medial to the CA3 stratum pyramidale (Figure 2), and 
represents the terminal region of the dentate mossy fibres (Swanson et 
al., 1987) contains the highest density of kainate receptors in the 
mammalian brain; this almost certainly underlies the susceptibility of 
CA3 pyramidal neurones to kainate toxicity in animals (Schwob et al.,
1980) and m an (Teitelbaum et al., 1990). The cholinergic 
septohippocam pal input to the hippocampus is particularly dense 
within the dentate gyrus: thus it might be expected that medial septal 
lesions would result in upregulation of glutamatergic receptors in the 
CA3 , manifested in an increase in glutamatergic receptor binding, to 
overcome the decreased facilitation of glutamatergic firing through the 
loss of the modulatory cholinergic input.
However, the little evidence which exists for plastic modifications of 
kainate receptors is controversial: in Alzheimer's Disease, an expansion 
in the dentate gyrus kainate receptor field has been reported by one 
group (Geddes et al., 1985), while other investigators found decreased 
kainate receptor binding in the hippocampus of severely demented 
patients (Represa et al., 1988). Chalmers and colleagues reported an 
increase in kainate receptors in the frontal cortex of Alzheimer brains 
(Chalmers et al., 1990), and suggested that this represen ted  a 
"denervation supersensitivity" in the frontal cortex. While one group 
have replicated.the apparent broadening of the kainate receptor field in 
the dentate molecular layer of rats with entorhinal cortex lesions (Ulas 
et al, 1990b), the present study provides no evidence for kainate receptor 
regulation in response to cholinergic denervation of the hippocampus. 
Although there exist differences in the precise method of analysis of 
autoradiograms employed in the present study, compared to that of 
Ulas and colleagues, the use of histological overlay in the present study 
(Methods Section 1.3.) in order to determine the precise hippocampal
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layers precludes the possibility that the autoradiogram s were misread 
and tha t an a ltera tion  in kainate receptor localisation had  been 
overlooked. It is not im possible, how ever, that kainate receptor 
densities are modified w ith time following medial septal lesions: Ulas 
and colleagues report that kainate receptor densities are increased 
significantly at 30 to 60 days after entorhinal lesion, w hereas no 
significant alterations in kainate binding were observed at shorter time- 
points post-lesion. Therefore, the present study of ligand-binding 21 
days after m edial septal lesion, m ay have been perform ed before 
significant m odifications in kainate receptor densities occurred. 
However, in view of the significantly reduced densities of [3H]-AM PA 
binding to quisqualate receptors in the same brains, this study provides 
evidence for differential regulation of AM PA-sensitive quisqualate 
receptors and kainate receptors following cholinergic denervation of the 
hippocam pus.
NMDA Receptors
The involvem ent of NMDA receptors in the induction of LTP is 
well established: NMDA antagonists prevent the formation of LTP in 
the hippocam pus, and result in im paired learning and m em ory in 
behavioural paradigm s. The apparent association betw een LTP and 
m em ory, therefore, has provided the im petus for expanded research 
into the role of NMDA receptors in neurodegenerative diseases such as 
Alzheimer's Disease, in which cognitive ability is profoundly reduced.
[3H]-NMDA binds w ith low affinity and specificity to the NMDA 
receptor (Foster & Fagg, 1987 ), and therefore has not been employed 
routinely as a ligand for quantitative autoradiography. However, the 
dem onstration that chloride- and calcium -independent [3H ]-glutam ate 
binding to synaptic receptors is particularly sensitive to displacement by 
compounds specific for the NMDA receptor (Fagg et al., 1983) has lead to 
the use of [3H]-glutam ate as a ligand at this receptor. Consequently,
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reduc tions in the NMDA binding site m easured with NMDA- 
d isp laceab le  [3HJ-glutamate have been reported to occur in the 
hippocampus of Alzheimer patients (Greenamyre, 1986; Greenamyre et 
!al., 1987; Represa et al., 1988). Greenamyre et al. (1987) reported a 
loss of up to 80% of [3H]-glutamate binding in the CA1 and CA2 of 
Alzheimer hippocampus; however, this study did not account for 
chloride-dependent binding of [3H]-glutamate to glial cells (Bridges et al., 
1987). In contrast, others have found no consistent alteration in 
NMDA-sensitive [3H]-glutamate binding in Alzheimer brains (Cowburn 
et al., 1988a,b; Geddes et al.,1986). Further, Geddes and colleagues (1986) 
reported  that within their study, a single case which presented 
particularly severe neuronal cell loss was found to have markedly 
reduced NMDA receptor binding; this would infer that NMDA receptor 
density can be maintained at normal levels in the hippocampus of 
Alzheimer Patients, as long as a minimum level of cell survival is 
maintained. The existence of such a "threshold" phenomenon in the 
pathological alterations of Alzheimer's Disease would suggest that 
receptor plasticity is important in maintaining functional activity in the 
wake of cell loss which accompanies the disease.
The results of the present study do not provide evidence for NMDA 
receptor plasticity following medial septal lesions. However, the 
variability of NMDA-sensitive glutamate binding was higher than that 
for other ligands, as indicated by the larger degree of error associated 
with NMDA-sensitive [3H]-glutamate binding (Figures 37 & 38, and 
Appendix V, Table 4), and this may mask subtle alterations which 
might occur in NMDA receptor binding. In the vertical limb of the 
diagonal band and the presubiculum [3H]-glutamate binding to the 
NMDA receptor was increased by 92% and 68% respectively; however, 
these results were not significantly different from control values.
In contrast to the present study, increases in NMDA receptor 
binding (Ulas et al., 1990) have been demonstrated in the hippocampus
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following entorhinal cortex lesions in the rat; the increased NMDA 
receptor density which accompanies entorhinal cortex lesions is in 
contradiction to the reports of either decreased, or unaltered receptor 
density in Alzheimer's Disease. However, in view of the cell loss 
which affects the hippocam pus in Alzheimer's Disease, synaptic 
plasticity in response to deafferentation may underlie the maintenance 
of NMDA-sensitive [3H]-glutamate binding in the course of the disease.
As is the case with kainate receptors in the present study, an 
important consideration in evaluating the plastic response of NMDA 
receptors to medial septal lesion is the time post-lesion at which 
investigations were performed. In the studies by Ulas et al. (1990a,b), 
significantly increased kainate receptor densities were observed in the 
hippocam pus 60 days after entorhinal cortex lesion, while NMDA 
receptor densities were increased 30 days post-lesion; however, the 
elevation in NMDA-sensitive [3H]-glutamate binding was much greater 
at 60 days post-lesion, suggesting that modulation of NMDA receptors 
following deafferentation is by no means complete at 21 days. It is 
possible, therefore, that medial septal lesion, combined with a longer 
survival time than the present 21 day period, may result in significant 
altered NMDA receptors.
In sum m ary, these results provide further evidence for the 
differential regulation of glutamatergic receptor sub-types in the 
hippocampus following medial septal lesions. While the destruction of 
the medial septal input to the hippocampus has been demonstrated to 
result in modification of AMPA-sensitive quisqualate receptors, these 
results do not provide evidence for the involvement of NMDA and 
kainate receptors, at least at short survival times, in the plastic 
responses of the hippocampus to cholinergic denervation.
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2.4. PHOSPHOINOSITIDE HYDROLYSIS: RESPONSE TO MEDIAL SEPTAL 
LESIONS
Increasing interest in the role of second messenger systems in 
cellular function can be accredited in part to the elucidation of altered 
levels of second messengers or second messenger activity in a number 
of diseases, including Alzheimer's Disease (Saitoh et al., 1991) and 
ischaemia (Onodera & Kogure, 1989; Onodera et al., 1989). Thus, 
although altered receptor numbers may not be apparent in diseased 
tissue, changes in activity of second messengers and their enzymes may 
indicate altered neuronal transduction and consequently loss of normal 
neuronal function. Altered muscarinic-stimulated phosphoinositide 
turnover in response to lesions of the cholinergic septohippocampal 
pathway may therefore provide evidence of altered signal transduction 
through occupancy of muscarinic receptors in the hippocampus, even 
in the absence of altered muscarinic receptor densities.
Although a number of attempts have been made to demonstrate 
altered phospholipase C activity in terms of inositol phospholipid 
turnover in response to discrete neuronal populations, no general 
pattern of alteration has emerged. The results described presently 
indicate that muscarinic stimulated phosphoinositide turnover is 
unaltered in the hippocampus following lesions of the medial septum 
and suggest that there is no upregulatory response of muscarinic- 
mediated signal transduction However, this contrasts with a previous 
report that electrolytic lesions of the medial septal area result in 
chronically increased phosphoinositide  turnover in response to 
cholinergic, but not noradrenergic stimulation (Connor & Harrell, 
1989); in view of the sprouting of putatively noradrenergic fibres into 
the CA3-dentate region following medial septal lesions (Crutcher et al,
1981), this result is intriguing. Nonetheless, a similar study has shown 
that a !-adrenerg ic-m ediated  phosphoinositide  hydrolysis in the
1 65
hippocam pus is unaltered  following rem oval of the noradrenergic 
h ippocam pal p ro jection  from  the locus coeruleus and  dorsal 
noradrenerg ic  bundle  (Fowler et al., 1986). Thus, noradrenergic 
innervation of the hippocam pus would not seem to be associated with 
changes in phosphoinositide hydrolysis post-lesion.
The increased  phosp h o in o sitid e  hydro lysis in response  to 
cholinergic denervation  has been confirm ed, albeit w ith shorter 
survival times post-lesion, by several other groups. Fimbria fornix 
transection has been dem onstrated to result in increases in muscarinic- 
stim ulated phosphoinositide turnover in young (Smith et al., 1989) and 
in aged rats (Court et al., 1990) fourteen days after surgery was 
perform ed, despite preservation of muscarinic receptor densities in the 
hippocam pus. The authors noted that these results provide evidence 
for the post-synaptic location of the majority of muscarinic receptors in 
the hippocampus. In the cerebral cortex, Reed and de Belleroche (1988) 
observed an upregulation in m uscarinic-m ediated phosphoinositide 
turnover five days after removal of the cholinergic innervation via 
lesions of the nucleus basalis. H ow ever, the increase was largely 
dim inished fourteen days post-lesion, and abolished completely fifty 
days post-lesion, in spite of evidence of long-term reductions of choline 
acetyltransferase activity and acetyl cholinesterase associated with the 
lesion (Reed & de Belleroche, 1985; W enk & Olton, 1984). In 
com parison , phospho inositide  tu rnover has been show n to be 
unaltered one, six and twelve weeks after quinolinate lesions of the 
nucleus basalis (Scarth et al., 1989), and one and three weeks following 
ibotenate lesions of the nucleus basalis (Raulli et al., 1989) of rats. 
Furtherm ore, in the guinea pig, electrolytic destruction of the medial 
septum  did  not result in altered phospholipid turnover eight to ten 
days following surgery (Fisher et al., 1980). These results suggest that 
while the present time course of twenty one days survival following 
lesions of the m edial septum  m ay exclude the possibility of acute,
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transien tly  a ltered  phosphoinositide  hydro lysis, enhancem ent of 
cholinergic-m ediated phosphoinositide turnover in the acute period 
post-lesion is not a consistent finding.
It is likely that different lesion strategies are responsible for different 
in terpretations of the consequences in term s of phosphoinositide 
hydrolysis following lesions of cholinergic forebrain nuclei. Most 
notable is the absence of altered phosphoinositide turnover after 
selective lesions produced with neurotoxins (Raulli et al., 1989; Scarth et 
al., 1989, and the present study). As has been stressed in earlier sections 
of this discussion, excitotoxic lesions afford recovery and sprouting of 
fibres of passage, and do not result in such widespread damage as do, for 
example electrolytic or knife-cut lesions.
Finally, it is im portan t to realise tha t the m ethod currently  
em ployed for estimation of phosphoinositide turnover, which involves 
m easu ring  accum ulation  of inosito l p h o sp h a te  w ith in  w hole 
hippocam pal preparations, precludes the m easurem ent of discrete, 
localised alterations w ithin sub-fields of the hippocam pus: thus, it 
cannot be concluded from this study that phosphoinositide turnover 
remains unaltered in local hippocampal regions. However, in a parallel 
investigation to the present study, H orsburgh and colleagues (1991) 
observed that three weeks following medial septal lesions, [3H]-PDBu 
binding increased in the entorhinal cortex, but was unaltered in other 
hippocampal areas, suggesting that the distribution of protein Kinase C 
was preserved following septal lesions. Instead, the increased [3H]-PDBu 
binding in the entorhinal cortex indicates that plastic alterations are 
present in response lesions of the m edial septum , and provide further 
evidence for the involvem ent of the entorhinal cortex, rather than 
intrinsic hippocam pal neuronal circuits, in the synaptic modification 
within the hippocampus following cholinergic deafferentation.
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3. THE CEREBRAL METABOLIC EFFECTS OF ACUTE SUBDURAL 
HAEMATOMA IN THE RAT.
3.1. FUNCTIONAL ACTIVITY AND ACUTE SUBDURAL HAEMATOMA 
IN THE RAT
A large body of evidence has contributed to the currently well- 
established excitotoxic hypothesis of cerebral ischaemia: exposure to 
glutam ate or its analogues results in neurodegeneration in cell culture 
(Choi et al., 1988; Frandsen et al., 1989) and in vivo (Foster et al., 1987). 
Elevated extracellular glutam ate concentrations are dem onstrated in 
response to both global (Benveniste et al., 1984) and focal cerebral 
ischaem ia (Graham  et al., 1990; Bullock et al., 1991), and there is 
w idespread  evidence that glutam ate antagonists, particularly  those 
which act at the NMDA receptor and its associated ion channel, afford 
protection in ischaemic (Bullock et al., 1990; Frandsen et al., 1989; Gill et 
al., 1987; Ozyurt et al., 1988; Park et al., 1988; Rod & Auer, 1989; Sauer et 
al., 1988; Simon et al., 1984), hypoxic (McDonald et al., 1987), and 
glutam ate-treated neuronal tissue (Foster et al., 1987c; Goldberg et al., 
1988; O lney et al., 1987). A dditionally , the pa ttern  of selective 
vulnerability of neurones to ischaemic dam age corresponds well with 
the distribution of glutamate receptors in the brain: hippocam pal CA1 
pyram idal neurones, which contain the highest density of NMDA- 
sensitive binding sites within the brain (M onaghan & Cotman, 1985), 
are particu larly  susceptible to ischaem ia-related dam age in anim al 
models (Kirino, 1982; Pulsinelli et al., 1982a) and man (Cummings et al., 
1984; Volpe & Hirst, 1983).
The autoradiographic m easurem ent of local metabolism in cerebral 
ischaemia has proved to be a powerful strategy in the investigation of 
both the anatomical location of ischaemic damage, and the mechanisms 
underlying ischaemic damage (for review, see Ginsberg, 1990). Such
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studies have proved instrumental in a number of observations. Firstly, 
functional activity is affected in structures remote from, as well as 
s tructures directly within the infarcted region. Secondly, these 
functional changes are dynamic and progressive, and are suggestive of a 
time-course for the occurrence of ischaemic damage which determines 
the "therapeutic window" or absolute time in which compromised 
tissue may be saved from infarction. Thirdly, these techniques have 
been used recently as a basis for quantification of pharmacological 
efficacy: a number of groups have demonstrated the reduction by 
various pharmacological agents of functional disturbances produced by 
ischaemic insult.
This study has demonstrated that remote as well as local alterations 
in deoxyglucose phosphorylation occur following acute subdural 
haematoma in the rat. In addition, the vastly increased deoxyglucose 
phosphorylation around the site of infarct, and in the hippocampal area 
were prevented  by the adm inistra tion  prior to production  of 
haematoma of D-CPP-ene, a competitive NMDA antagonist with 
clinical potential. This suggests that a glutamatergic mechanism plays a 
role in the altered glucose utilisation, and subsequent ischaemic damage 
associated with this model. Evidence for this is reviewed below.
Local Mechanisms: The Ischaemic Penumbra
Several groups have reported the appearance of an "ischaemic 
penumbra" surrounding the infarcted region in models of focal cerebral 
ischaemia. The term was initially coined by Astrup and colleagues 
(1981) to describe the region immediately next to densely ischaemic 
tissue, with a higher perfusion rale than that of the densely ischaemic 
region. The concept of the ischaemic penumbra is derived initially 
from electrophysiological experiments in which baboons were subjected 
to occlusion of the middle cerebral artery (Astrup et al., 1977). Two 
ischaemic thresholds emerged: firstly, a reduction of flow sufficient to
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abolish evoked cortical potentials did not result in a large elevation of 
potassium ions; by contrast, massive flux of potassium occurred only 
with greater reductions in flow. Thus there is a disparity between the 
level of ischaemia required for electrical failure and for disruption of 
membrane homeostasis, and the ischaemic penumbral region has been 
conceptualised as an area in which cerebral bloodflow falls between 
these two levels.
This observation is of great therapeutic relevance: while the cells 
within the penumbral region are compromised, they are potentially 
retrievable, if the process of ischaemic damage were to be halted by 
pharmacological intervention.
Using deoxyglucose autoradiography, various authors have reported 
the presence of a region of diminished glucose utilisation following 
focal ischaemia, surrounded  by an area of apparently  increased 
deoxyglucose phosphorylation (Ginsberg et al., 1977a,b; Shiraishi et al., 
1989; Simon & Shiraishi, 1990). This increase is attributed to anaerobic 
glycolysis, since double-label experiments which employed [3H ]-  
antipyrine to measure local cerebral bloodflow demonstrated a decrease 
in bloodflow concurrent with increased deoxyglucose uptake in the 
penum bral region (Ginsberg et al., 1977). Recently, Shiraishi and 
colleagues (1989) used the deoxyglucose technique to examine the time- 
course for metabolic alterations in response to occlusion of the middle 
cerebral artery in rats, observed that increased deoxyglucose uptake 
preceded decreased uptake in the same area; the rim of apparent 
hypermetabolism surrounding the infarct progressed outward, leaving 
infarcted tissue in its place. The same group (Graham et al., 1990) also 
reported increases in excitatory amino acids in the extracellular fluid in 
response to the ischaemic insult, and postulated that local release of 
glutamate and other excitatory amino acids was responsible for the 
apparent hypermetabolism in the ischaemic penumbra: in the absence 
of bloodflow to the ischaemic cells, these toxic substances may be
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rem oved only by re-uptake and metabolism within neurons and glia; 
however, w ithin the ischaemic zone, the energy stores which fuel the 
process of re-uptake are depleted rapidly. Diffusion of these amino acids 
from  the centre of the ischaemic zone m ay jeopardise the cells within 
the ischaemic penumbra.
Support for this hypothesis comes from the observation in the 
present study that D-CPP-ene adm inistration prior to production of 
acu te  su b d u ra l haem atom a p reven ted  hyperm etabo lism  in the 
ischaem ic penum bral region. Further, in a subsequent series of 
m easurem ents, D-CPP-ene has been dem onstrated to reduce the size of 
infarct produced by the subdural haematoma (Inglis et al., 1991), a result 
which confirms the findings of Simon and colleagues (Shiraishi et al., 
1989; Simon & Shiraishi, 1990) w ho dem onstra ted  reduc tion  of 
ischaemic dam age in the m iddle cerebral artery occlusion model with 
the use of the competitive NMDA antagonist CGS-19755; this suggests 
th a t blockade of NMDA receptors m ay p reven t som e sp read  of 
ischaemic damage in the area surrounding the infarct, and adds weight 
to the glutamatergic hypothesis of ischaemic damage.
How ever, a second m ode of action m ay explain the efficacy of 
NM DA antagonists in the reduction of infarct size and preventing the 
hyperm etabolism  which occurs. Competitive NMDA antagonists cross 
the blood-brain barrier poorly, and therefore the CNS concentrations of 
these drugs rise slowly and remain only a fraction of the peripheral 
concentration (McCulloch & Iversen, 1991). However, in a double-label 
study Takizawa and colleagues (1991) demonstrated that treatm ent with 
CGS-19755 immediately after occlusion of the m iddle cerebral artery in 
rats corrected the ischaemia-induced decrease in local pH , and increased 
local cerebral bloodflow  in several ischaemic areas. The authors 
suggested therefore that a potent increase in cerebral perfusion m ay aid 
the removal of com pounds such as excitatory amino acids, lactic acid, 
and hydrogen ions which are present in toxic quantities as a result of
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the ischaemic process; this may complement any NMDA receptor 
blockade induced by the small amounts of CGS-19755 able to penetrate 
the blood-brain barrier in the limited time in which the process of 
ischaemic damage can be impeded. Thus in the present study, the 
ability of D-CPP-ene to prevent hypermetabolism in the penumbral 
region may arise from both blockade of glutamate receptors and an 
increased perfusion of the compromised tissue in the penumbral zone.
Remote Mechanisms: The Hippocampus.
The most striking observations of this study were the massive 
increases in glucose utilisation produced by acute subdural haematoma 
in the hippocampus, and the ability of D-CPP-ene to prevent almost 
completely, or in some cases abolish, these increases. From the latter it 
may be inferred that functional activation of the hippocam pus is 
produced by a glutamatergic mechanism; and indeed, in vivo dialysis of 
the extracellular fluid in the hippocampal area revealed elevated levels 
of glutam ate and asparta te  in the h ippocam pus following acute 
subdural haematoma, and these remained elevated for at least three 
hours (Bullock et al., 1991a).
To date, of the relatively few accounts of hippocampal glucose 
utilisation measured in response to ischaemia, both increased and 
decreased glucose utilisation have been reported in the hippocampal 
formation at some period after ischaemia (see Beck et al., 1990, for 
review). However, the majority of these describe the consequences of 
transient global ischaemia in the rat (Beck et al., 1989, 1990; Diemer & 
Siemkowicz, 1980; Kozuka et al., 1989; Pulsinelli et al., 1982b; Rischke & 
Kreiglstein, 1991) or gerbil (Izumivama et al., 1987; Suzuki et al., 1983), 
and the discrepancies between the duration of ischaemic period, and the 
length of recovery time prior to deoxyglucose autoradiography (from 
four minutes to two days) have made comparison of these results 
difficult. While global reperfusion models of ischaemia are pivotal in
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assessing the long-term consequences of ischaemia, these are 
complicated by issues such as reperfusion injury, and indicate little 
about the dynamic alterations which occur in the course of the initial 
ischaemic period. Furthermore, the susceptibility of gerbils to seizures 
introduces a confounding variable into the assessment of ischaemic 
damage in this species.
An advantage of this study is that not only does it represent a 
measure of functional alterations in the course of the ischaemic infarct, 
but these stem from an apparently confined focus; and there exists 
therefore the possibility to discuss these changes in terms of limited, 
anatomically defined circuitry. Disruption of the glutam atergic 
perforant pathway via lesions of the entorhinal cortex has been found 
to afford protection for the CA1 pyramidal cells against ischaemia 
(Weiloch et al., 1985), suggesting that over-stimulation of this particular 
hippocampal input is responsible for the ischaemia-induced neuronal 
damage within the hippocampus. In the rat, the entorhinal cortex 
receives inputs from cingulate, frontal and temporal cortices (See 
Swanson et al., 1987 for review), and also reciprocal connections from 
the hippocampal formation. The hippocampus receives a second major 
cortical connection, through the subicular complex from temporal, 
frontal and cingulate cortices, and additionally from parietal and visual 
cortical areas. Thus, the hippocampus receives extensive connections 
from many cortical areas. Glutamate is a major neurotransmitter in 
cortical synapses (Baughman & Gilbert, 1981; Crunelli et .al., 1987; Fosse 
& Fonnum, 1987; Peinado & Mora, 1986), a factor which most probably 
underlies the vulnerability of the cortex and its glutamatergic efferents 
in ischaemia. The massive disruption of metabolism in cortical areas 
following acute subdural haematoma in this study, combined with the 
functional activation of the h ippocam pus may provide further 
evidence for a cortical role in hippocampal ischaemic damage.
Buchan & Pulsinelli (1990) have shown that in rats subjected to
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transient four-vessel occlusion, fimbria fornix transection protects the 
hippocam pus against ischaemic damage more effectively than lesions of 
the perforan t path , suggesting that the cholinergic inpu t into the 
hippocam pus is more im portant in producing ischaemic dam age than 
the integrity of the glutamatergic perforant path. However, due to the 
global nature of the ischaemic insult, increased neuronal activity in any 
num ber of areas, including the septohippocam pal pathw ay itself, may 
underly  the ischaemic dam age observed in the hippocam pus in the 
intact animal, and these results may not reflect events in a focal model 
of ischaem ia such as acute subdural haem atom a. There is little 
evidence how ever from the present study as to w hether or not this 
inpu t is im portant in the functional activation of the hippocam pus in 
response to subdural haematoma.
Finally, given that acute subdural haem atom a is associated with a 
concom itant increase in in tracranial pressure, it is im portan t to 
consider w hether this global element could account for the functional 
activation observed in the hippocam pus. Glucose utilisation was not 
significantly altered in any of the three hippocampal afferents discussed 
above, and this may on first inspection be considered as evidence that 
hippocam pal activity was not m ediated through stim ulation of these 
afferents. However, in a separate group of anim als, in which the 
subdural haem atom a was replaced by an inert silicone mass injected 
underneath  the dura in the same m anner as blood, glucose utilisation 
w as no t increased  in e ither the  penum bra l reg ion  or in the 
h ippocam pus (Kuroda et al., 1992). The presence of a Cushing's 
response in these anim als indicated that intracranial pressure was 
increased in these rats. This w ould im ply that raised intracranial 
pressure is not able alone to induce the increased hippocampal glucose 
utilisation, and that blood is required for the w idespread cortical and 
hippocam pal a lterations associated w ith  the m odel. It m ay be 
speculated that a com ponent of blood, such as a vasoconstrictor, is
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responsible for the resultant ischaemic cortical damage; and indeed, 
several peptides found in the blood have been postulated to perform 
such a function (for review see Uddm an & Edvinsson, 1989). In 
conclusion, these results suggest that hippocampal activation in this 
model stems from ischaemic processes originating in the cortex due to 
injection of blood.
Increased intracranial pressure may, however, be an im portant 
secondary factor in ischaemia-induced damage of the hippocampus. In 
non~pathologically affected tissue, glucose metabolism and cerebral 
bloodflow are tightly coupled (Kuschinski et al. 1987). Thus increases in 
glucose use are usually associated with concomitant increases in local 
bloodflow, within a discrete homogeneous region of brain. Following 
subdural haematoma, as glucose metabolism increases in response to 
greater neuronal function, so will the build-up of waste-products 
continue within the tissue. However, an increased dem and for 
perfusion may be confounded by the raised intracranial pressure; if the 
energy demand cannot be met by increased perfusion, the result will be 
acidosis and consequent cellular damage (for review see Hakim & 
Shoubridge, 1989). As discussed previously, recent evidence suggests 
that NMDA antagonists may exert some therapeutic effect by increasing 
cerebral perfusion to ischaemic areas, thus facilitating clearance of 
substances present in toxic amounts. This effect is of obvious 
importance in situations where the cerebral perfusion is compromised, 
either by vasoconstriction, or by an increase in intracranial pressure.
Non-Limbic Structures
Following acute subdural haematoma, glucose utilisation was 
reduced in the dorsolateral and medial geniculate bodies, and there was 
evidence of functional depression in other subcortical auditory and 
visual areas. These are probably reflective of the extent of cortical 
damage induced by the haematoma, and are further evidence of the
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importance of glutamatergic transmission in cortical and subcortical 
neurotransm ission.
Effect of D-CPP-ene on Cerebral Glucose Utilisation in Rats with
Acute Subdural Haematoma
The cerebral metabolic effects of D-CPP-ene have been discussed 
previously in detail. However, in the present series of data, several 
differences emerged, which may be attributed to either the anaesthetic 
state of the animal, or the presence of the haematoma, at the time of 
administration of D-CPP-ene. Because of the trauma involved in the 
production of the subdural haematoma, the procedure was performed 
in anaesthetised animals, and these were therefore anaesthetised at the 
time of drug administration, prior to the induction of the haematoma. 
Most notable of these were the increased rates of glucose utilisation in 
the posterior cingulate cortex and anteroventral thalamic nucleus 
following D-CPP-ene administration. While other NMDA antagonists 
have been shown to induce large metabolit activations in certain Papez 
structures (see Discussion Section 1), D-CPP-ene had far less marked 
effects, and did not alter glucose utilisation in either structure in the 
conscious rat. Initially this may be thought to be due to the interaction 
of D-CPP-ene and halothane. However, halothane anaesthesia has been 
shown to ameliorate activation of the posterior cingulate cortex and 
anteroventral thalamic nucleus by MK-801 (Kurumaji et al., 1989), and 
therefore the reason for the discrepancy between the present two studies 
is unclear. However, it is possible that the effects of the haematoma and 
consequently the increased extracellular glutamate in cortical regions act 
synergistically with D-CPP-ene to compromise glutamatergic feedback 
mechanisms in these regions. D-CPP-ene was also observed to increase 
glucose utilisation in the entorhinal cortex and lateral olfactory tract 
and decrease glucose use in the parietal cortex contralateral, but not 
ipsilateral, to the haematoma; the lack of ipsilateral functional
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alteration is possibly due to mechanisms resulting from the presence of 
the haematoma.
In rats with acute subdural haematoma glucose utilisation was 
decreased in auditory and visual areas; these decreases were found to be 
partly diminished in D-CPP-ene pretreated animals; however, D-CPP- 
ene has been observed to decrease glucose utilisation in sensory regions 
(Results Section 1.2.1.), an effect attributed to its anaesthetic action, and 
therefore it is difficult to discern between functional alterations 
produced by D-CPP-ene and by the presence of the haematoma itself. 
Whether or not these areas benefit from D-CPP-ene p re trea tm ent, 
therefore, would require further study, possibly involving detailed 
histological analysis.
In summary, acute subdural haem atom a induced w idespread 
metabolic alterations in the rat brain, of which the most striking were 
the massive functional activation in the h ippocam pus, and the 
profound loss of deoxyglucose uptake in the cortex directly below the 
haematoma. Pretreatment with D-CPP-ene was found to reduce 
functional disturbances, particularly  in the h ippocam pus, thus 
providing evidence that this class of drug may be beneficial in the 
treatment of ischaemic damage in the clinic.
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3.2. COM MENT ON THE APPLICATION OF THE DEOXYGLUCOSE 
METHOD TO THE ISCHAEMIC BRAIN
Given that ischaemic damage is a dynamic, pathological process, it is 
im portan t to consider certain aspects underlying the validity  of the 
m athem atical model (Sokoloff et al., 1977). In a subsequent series of 
m easurem ents, it has been shown that the alterations in hippocam pal 
glucose utilisation described here are transient, and are not present at 
four hours (Kuroda et al., 1992), and thus strictly speaking, glucose 
m etabolism  w ithin regions of the brain cannot be assum ed to be in 
steady state. While it is useful to quantify rates of deoxyglucose uptake 
as rates of local cerebral glucose utilisation in order to make statistical 
comparisons, it should be noted that these rates may not represent the 
exact rates of glucose utilisation within the cerebral tissue.
In focal cerebral ischaemia, m arked reductions of bloodflow, and 
hence glucose supply, may interfere w ith the quantitative estimation of 
cerebral metabolism in several ways. A severe decrease in bloodflow to 
a particular region of brain w ould be expected to limit the rate of glucose 
utilisation w ithin that region. Tanaka et al. (1985) have show n that 
w hen bloodflow  is reduced to less than  25% of norm al values and 
hence supply of glucose and deoxyglucose is critically lim ited, local 
glucose utilisation is significantly underestim ated.
Secondly, although m easurem ent of glucose utilisation tends to be 
relatively insensitive to changes in the rate constants for uptake and 
phosphorylation of glucose and deoxyglucose, it is conceivable that in 
severely ischaemic tissue these constants will become inaccurate. Using 
fluorodeoxyglucose in o rder to m ake repeated  m easurem ents of 
metabolic rate, Nakai et al. (1988) dem onstrated that kl* and k3* were 
decreased significantly in ischaemic tissue, while large variations in k2* 
also occurred. Additionally the time at which the model w ould become 
insensitive to alterations in the rate constants increased, resulting in an
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underestimation of glucose use had the normal rate constants been 
used.
A num ber of studies have shown that the lumped constant is 
changed in ischaemic tissue. Ginsberg and Reivich (1979) observed a 
two-fold increase in the value of the lumped constant: in such a case, 
the use of the conventional value of the lumped constant would result 
in a two-fold overestimation of cerebral glucose use.
The lum ped constant might become altered for the following 
reasons: the tissue damage which accompanies cerebral ischaemia will 
disrupt cellular compartmentalisation, and hence it can no longer be 
assumed that X,  the distribution ratio of glucose and deoxyglucose is 
equal to that of normal tissue. Secondly, Sokoloff (1979) postulated that 
lysosomal acid hydrolases released during ischaemia would result in 
the hydrolysis of glucose-6-phosphate; the value of b/ the fraction of 
phosphorylated glucose which continues to be metabolised in glycolysis, 
would therefore be altered, and the lumped constant would no longer 
be accurate. This is especially important when calculating the rates of 
glucose utilisation in the penum bral region: by definition this 
represents a region in which bloodflow is compromised; Nedergaard et 
al. (1986) have shown an increase in lumped constant in areas bordering 
the infarct, and therefore the use of the conventional lumped constant 
to measure glucose utilisation leads to a potential overestimation of 
glucose utilisation within this area.
When this model is used to study changes in cerebral metabolism in 
response to ischaemia, these limitations must be borne in mind; in 
severely ischaemic tissue it is not possible to measure accurately cerebral 
glucose utilisation with the rate and lumped constants defined by 
Sokoloff et al. (1977), and hence values for the region of infarct have not 
been calculated.
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OVERVIEW: COM MENT ON TECHNIQUES FOR ANALYSIS OF 
HIPPOCAMPAL FUNCTION
The deoxyglucose technique has proved to be an extremely potent tool 
in neuroscience research (for review see McCulloch 1982). The coupling 
which has been dem onstra ted  to exist between rates of energy 
consumption and CNS activity, combined with the capacity to localise 
and quantify changes in metabolic dem and autoradiographically has 
provided the basis for expanded research into the CNS metabolic 
dem ands created by pathological, pharmacological and physiological 
challenge. Furthermore, deoxyglucose autoradiography provides a rare 
opportunity to investigate these effects in the conscious brain. However, 
while deoxyglucose autoradiographic techniques have proved to be 
particularly successful in m apping global distributions of dynamic 
functional alterations (McCulloch, 1982) such as the effects of acute drug 
administration, or the massive functional disturbances which accompany 
ischaemia (Ginsberg, 1990 and the present study), their worth has to date 
been limited in the study of the hippocampal function. Indeed, the 
complexity of the hippocampus and limbic system have restricted both 
the application of deoxyglucose autoradiography and the interpretation of 
results gained from such studies: in the present study, administration of 
the pharmacologically active cholinergic and glutamatergic agents has 
been shown to produce only slight alterations in glucose use in the 
hippocampus, despite the high numbers of hippocampal cholinergic and 
glutamatergic receptors within the hippocampal formation. Lack of 
functional alterations in response to cholinergic agents has been reported 
previously: the failure of the muscarinic agonist oxotremorine to alter 
significantly glucose utilisation within the hippocam pus (Dam & 
London, 1984) has been suggested to reflect the ability of muscarinic 
receptor stimulation to modify membrane excitability without producing 
adequ a te  depo la r isa t ion  to a lter g lucose u til isa tion  notably.
Alternatively, given the complexity of hippocampal circuitry, it is 
possible that alterations in response to muscarinic stimulation represent 
an immeasurably small fraction of the total synaptic activity within the 
hippocampus. However, as discussed ( Section 1.2.), the diversity of 
functional response within the hippocampus, in particular to different 
cholinom im etic agents, has done little to advance the curren t 
u n d e rs tand ing  of functional activity in relation to cholinergic 
transmission, and reflects the generally poor perception of the 
m echanism s which u n d erl ie  m uscarin ic  t ran sm iss io n  in the 
hippocampus.
Nevertheless, several investigators have em ployed deoxyglucose 
autoradiography to investigate hippocampal function with relative 
success. For example, local cerebral glucose utilisation has been shown to 
increase in specific hippocampal layers in response to cognitive challenge 
in the behaving monkey (Friedman & Goldman-Rakic, 1988): in a series 
of behavioural paradigms designed to test working memory, glucose 
utilisation was found to increase in the CA1, CA3 and the dentate gyrus, 
while glucose use in the amygdala was unaltered, demonstrating that 
cognitive processes can be seen to produce specific h ippocam pal 
alterations in function.
The complex relationship between firing of hippocampal neurones 
and local cerebral glucose utilisation has been highlighted in a study by 
Ackermann and colleagues (1984) who demonstrated that activation of 
recurrent inhibitory interneurones in the hippocam pus results in an 
increased metabolic demand; the authors suggested that the energy 
savings produced by the apparent inhibition of hippocampal firing are 
offset by the energy requirements of the inhibitory neurones; thus a net 
energy demand is observed. In polysynaptic pathw ays such as the 
hippocampus, therefore, studies of function are limited by the inability of 
the deoxyglucose technique to distinguish betw een the metabolic 
demands of different transmitter systems. Instead, the ability of the
201
deoxyglucose technique to reveal brain function maybe increased 
significantly by sim ultaneous m easurements of neurophysiological 
variables such as electrophysiological activity. Thus, while the 
deoxyglucose technique is indeed a powerful tool in neuroscience, and is 
able to provide novel in vivo insights into CNS function, its greatest 
limitation is perhaps the dependence on other techniques in parallel 
which provide information on the status of specific neurotransmitter 
systems in the CNS.
The availability of receptor-specific radio-labelled ligands, and the 
development of quantitative in vitro ligand binding autoradiography 
(Kuhar, 1981; Rainbow et al., 1982) has been instrumental in m apping 
populations of receptors and receptor sub-types within specific pathways 
of the CNS (Chang et al., 1980; Quirion et al., 1985; Wenk & Englisch, 
1986). However, despite the enormous potential of these techniques, 
little success has been achieved in the attempt to elucidate the locus of 
synaptic change in denervation studies and degenerative diseases such as 
Alzheimer's Disease.
The discovery that Alzheimer's Disease is associated with the loss of 
cholinergic neurones in the basal forebrain has fuelled expanded research 
into the functions of cholinergic transmitter systems (Bartus et al., 1982; 
Perry et al., 1978). However, despite the demonstration of consistently 
reduced presynaptic cholinergic markers in the cortex and hippocampus, 
and the profound loss of cells from the cholinergic basal forebrain nuclei, 
cholinergic receptors have not been show n to be convincingly 
and reproducib ly  dim inished (Perry et al., 1978). As a result, 
experimental lesions of the cholinergic pathways have been employed in 
order to investigate the plastic response of cholinergic receptors to 
denervation; however, the diversity of lesion methods is perhaps 
responsible for the array of conflicting reports of increased, decreased or 
unaltered cholinergic receptors following denervation (Court et al., 1990;
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Joyce et al., 1989; Kamiya et al., 1981; Mash et al., 1985; McKinney & Coyle, 
1982; N orm an et al., 1986; O verstreet et al., 1980; Smith et al., 1989; 
Watson et al., 1985; Westlind et al., 1981; Yamamura & Snyder, 1974).
W hile excitotoxins such as ibotenic acid have been em ployed as 
specific neurotoxins for cholinergic cells, it has recently become apparent 
that these also destroy non-cholinergic cells; thus the specificity of lesions 
produced by these neurotoxins has been questioned. The first suggestion 
that some of the learning and memory deficits produced by ibotenic acid 
lesions may not be due primarily to damage of cholinergic neurones was 
provided by Dunnett et al. (1987). The investigators compared the effects 
of four neurotoxins in term s of their ability to produce behavioural, 
biochemical and histological alterations when injected into the nucleus 
basalis. While ibotenate produced large deficits in behavioural memory 
tasks, ibotenate-induced depletions in choline acetyltransferase (ChAT) 
activity were m uch smaller than those produced by quisqualate. In 
contrast, quisqualate produced m uch sm aller deficits in behavioural 
memory tasks than ibotenate; the dissociation between cognitive deficits 
and ChAT depletion would suggest that ibotenate-induced disruption of 
learning and memory was not due to destruction solely of cholinergic 
neurones. Since this report, several subsequent studies have confirmed 
the dissociation of ChAT depletion and cognitive deficits (Robbins et al., 
1989a,b; W enk et al., 1989), m eriting caution in the interpretation of 
results based on studies which employ neurotoxins.
There is convincing evidence for the existence of non-cholinergic cells 
in the septohippocampal pathw ay Kohler et al, 1984); thus, denervation 
of non-cholinergic hippocam pal inputs may be responsible for m any of 
the behavioural and neurochemical deficits produced in the process of 
excitotoxic lesions of the septohippocam pal pathw ay, and may provide 
some explanation for discrepancies between studies of ligand binding to 
recep tors fo llow ing  d en erv a tio n  of the h ippocam pus. W hile 
denervation techniques, combined with the high degree of anatomical
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resolution afforded by ligand binding provide a powerful investigatory 
tool in neuroscience research, therefore, before plastic mechanisms in 
response to excitotoxic lesion can be evaluated fully, it is important that 
these excitotoxins are characterised further in terms of their specificity. 
Such an approach could be conceived to play a major role in elucidation 
of the mechanisms underlying denervation-induced plasticity, and 
ultimately, degenerative diseases such as Alzheimer's Disease.
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APPENDIX I
THE CEREBRAL METABOLIC EFFECTS 
OF THE COMPETITIVE NMDA ANTAGONIST d-CPP-ENE IN THE RAT.
Glucose utilisation was measured in conscious, lightly restrained rats 
using deoxyglucose autoradiography, following intravenous administration of 
D-CPP-ene (0.3, 3 or 30mg kg-1) or saline. The data presented in Tables 2-7 
represent mean glucose utilisation (punol I00g-1 min-1) ± SEM of 76 anatomically 
distinct regions of brain. Data in Table 1 represent physiological parameters 
following D-CPP-ene administration. *p<0.05, **p<0.01 for statistical comparison 
of drug-treated groups with saline-treated controls (unpaired Student’s t-test, 
two-tailed, with Bonferroni correction).
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APPENDIX I -  TABLE 1 
PHYSIOLOGICAL PARAMETERS
PHYSIOLOGICAL
PARAMETER CONTROL
D-CPP-ENE (mgkg- 1 )
0 .3 30
Mean A rter ia l 
Blood Pressure  
(mmHg)
A Mean A rter ia l 
Blood Pressure  
(mmHg)
A rter ia l Plasma 
Glucose (mM)
A rter ia l pH
PaCO^  (mmHg)
PaO  ^ (mmHg)
R ectal
Temperature ( ° C) 
Number of Animals
128 ± 3
4.3  ± 2 .8
8 .5  ± 0.3  
7.44 ± 0.01
42.5 ± 0.37
83.5 ± 3.0
36.9 ± 0.14 
9
128 ± 9
-5 .0  ± 2.0
7.6 ± 0.8  
7.41 ± 0.01
40.3 ± 2.9
8 6 .8  ± 3.2
36.2 ± 0.64 
5
142 ± 6
11.4 ± 7.0
7.4 ± 0.6  
7.40 ± 0.01
42.2 ± 1.5
92.8 ± 2.8
36.2 ± 0.37
149 ± 9
2 1 . 0  ± 6 . 2
8 . 2  ± 0. 1 
7.37 ± 0.01**
43 . 6 ± 0.84
92.8 ± 3.0
36.7 ± 0.54
alues are presented as mean ± SEM. **P<0.01 for s t a t i s t i c a l  comparison between 
ach drug-treated  group and sa lin e -tr e a te d  c o n tro ls . Number in  each group are 9 
sa lin e -tr e a te d  co n tro ls) or 5 (d ru g-trea ted ). A rter ia l blood gases and r e c ta l  
emperature were measured 35 minutes a fte r  [ C ] - de ox yg lu c os e  ad m in istration , 
bsolu te  values for mean a r te r ia l blood pressure are those measured two hours a fte r  
pug or sa lin e  adm in istration . A Mean a r te r ia l  blood pressure rep resen ts the change 
n blood pressure two hours a fte r  drug or sa lin e  adm inistration  r e la t iv e  to  the 
alue p rior to  in je c t io n .
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APPENDIX I -  TABLE 2 
JCOSE UTILISATION FOLLOWING D-CPP-ENE ADMINISTRATION: HIPPOCAMPAL FORMATION
D--CPP-ENE (mgkg 1
STRUCTURE CONTROL 0 . 3 3 30
Ammon's Horn
CA1 Str.  O riens/ 
Pyramidale 51 + 2 54 + 5 42 ± 4 50 ± 2
CA1 Str.  Radiatum 55 + 2 56 + 5 46 ± 4 53 ± 2
CA1 Str.  Lacunosum 
M oleculare 73 ± 2 76 + 6 63 ± 6 85 ± 7
CA2 Str.  O riens/ 
Pyramidale 69 ± 3 67 ± 4 58 ± 5 67 ± 3
CA2 Str.  Radiatum 71 ± 3 72 ± 4 60 ± 6 69 ± 3
CA2/3 Str.
Lacunosum
Molecular 80 + 3 81 + 5 68 ± 7 82 ± 3
CA3 Str.  O riens/ 
Pyramidale 69 ± 2 66 ± 4 60 ± 9 69 ± 3
CA3 Str.  Radiatum 67 + 2 70 + 4 58 ± 8 67 ± 3
CA4 Str.  
Pyramidale 62 + 2 64 + 5 47 ± 3* 61 ± 3
Dentate Gvrus
Molecular Layer 
(Superior Blade) 61 + 3 65 + 6 48 ± 8 59 ± 9
Molecular Layer 
(In fer io r  Blade) 54 ± 2 56 ± 5 50 ± 7 58 ± 4
Polymorphic
Layer 5 1 ± 2 54 + 5 41 ± 4 52 ± 3
Pre Subiculum 87 + 5 84 + 4 74 ± 8 108 ± 6
Subiculum 73 + 2 72 + 5 57 ± 5 * 77 ± 7
Data are presented as mean ± S.E.M. of 9 (con tro l) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  }imol.100g min . *P<0.05, for s t a t i s t i c a l
comparison between drug-treated  group and sa lin e -tr e a te d  co n tro ls .
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APPENDIX I - TABLE 3
GLUCOSE UTILISATION FOLLOWING D-CPP-ENE ADMINISTRATION:
AREAS ASSOCIATED WITH LIMBIC FUNCTION
D-CPP-ENE (mgkg"1)
STRUCTURE CONTROL 0 . 3 3 30
Dorsal Tegmental 
Nucleus 102 ± 5 94 ± 10 76 + 6* 92 ± 4
Dorsal Raphe 79 ± 4 76 + 5 71 + 5 77 ± 7
Median Raphe 86 ± 4 82 ± 6 72 + 5 81 ± 5
Mamillary Body 
(M edial) 101 ± 3 98 + 10 77 + 7 ** 97 ± 7
Mamillary Body 
(L ateral) 97 ± 3 91 + 10 79 + 5* 104 ± 10
Habenular 
Nucleus (Medial) 72 ± 4 87 + 6 63 + 5 68 ± 3
Habenular Nucleus 
(L ateral) 109 ± 6 117 + 11 90 + 7 104 ± 5
Thalamus:-
Mediodorsal 94 ± 6 98 + 10 82 ± 5 106 ± 7
Laterodorsal 85 ± 4 78 ± 6 70 ± 6 81 ± 3
Anteromedial 102 ± 4 97 ± 5 91 ± 8 102 ± 4
Anteroventral 95 ± 4 88 ± 13 84 ± 8 112 ± 5
Hypothalamus 56 ± 3 58 ± 4 47 ± 4 49 ± 2
Amygdala:-
Medial Nucleus 50 ± 3 44 ± 3 39 ± 4 41 ± 2
Lateral Nucleus 69 ± 3 65 ± 4 55 ± 4 50 ± 2*
B asolateral
Nucleus 76 ± 6 75 ± 6 68 ± 7 77 ± 4
Medial Septum 66 ± 3 70 ± 5 63 ± 7 84 ± 6
Lateral Septum 48 ± 2 50 ± 5 41 ± 4 46 ± 2
V ertica l Diagonal 
Band 71 ± 4 68 ± 5 59 ± 6 70 ± 6
H orizontal 
Diagonal Band 86 ± 4 82 ± 3 75 ± 7 90 ± 5
Medial Forebrain 
Bundle 89 ± 4 86 ± 6 76 ± 6 90 ± 6
Nucleus Accumbens 65 ± 2 60 ± 6 47 ± 5* 63 ± 5
C ortex:- 
Posterior  
Cingulate Cortex 91 ± 3 86 ± 7 72 ± 7 101 ± 8
Anterior 
Cingulate Cortex 112 ± 2 96 ± 6 83 ± 1 1* 81 ± 6**
P a r ie ta l Cortex 111 ± 4 103 ± 6 81 ± 7 ** 63 ± 4**
Frontal Cortex 109 ± 4 106 ± . 4 82 ± 9* 67 ± 6**
Data are presented as mean ± S.E.M. of 9 (contro l) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  ]imol. 100g-1min~ . *P<0.05, *P<0.01 for
s t a t i s t i c a l  comparison between drug-treated group and sa lin e -tr e a te d  co n tro ls .
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APPENDIX I - TABLE 4
GLUCOSE UTILISATION FOLLOWING D-CPP-ENE ADMINISTRATION:
OLFACTORY AREAS
D-CPP-ENE (mgkg )
STRUCTURE CONTROL 0 .3 3 30
Lateral O lfactory  
Cortex 120 ± 7 122 ± 1 1 102 ± 7 102 ± 9
L ateral O lfactory  
Tract 110 ± 5 121 ± 1 1 131 ± 17 179 ± 1 2**
A nterior O lfactory  
Nucleus 74 ± 4 84 ± 9 76 ± 7 106 ± 7**
Primary O lfactory  
Cortex 122 ± 4 116 ± 6 123 ± 12 141 ± 7
P oster ior  Piriform  
Cortex 73 ± 5 77 ± 5 82 ± 9 104 ± 9*
Amygdalar Nucleus 72 ± 3 73 ± 3 71 ± 7 103 + 7 * *
Data are presented as mean ± S.E.M. of 9 (con tro l) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  jj.mol.100g min . *P<0.05, *P<0.01 for
s t a t i s t i c a l  comparison between drug-treated  group and sa lin e -tr e a te d  c o n tro ls .
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APPENDIX I - TABLE 5
GLUCOSE UTILISATION FOLLOWING D-CPP-ENE ADMINISTRATION:
AUDITORY AND VISUAL STRUCTURES
D-CPP-ENE (mgkg 1
STRUCTURE CONTROL 0 .3 3 30
Auditory System
Auditory Cortex 
II 112 ± 7 109 + 1 1 80 ± 8 67 ± 3**
Auditory Cortex 
IV 133 ± 9 128 + 9 93 ± 9 68 ± 5**
Medial G eniculate  
Body 114 ± 4 100 + 5 79 ± 5** 69 ± 3**
In fe r io r  C o llicu lu s 166 ± 9 141 + 7 118 ± g** 107 ± 6**
L ateral Lemniscus 88 ± 3 87 + 6 83 ± 7 86 ± 5
Cochlear Nucleus 133 ± 7 124 ± 9 102 ± 8 110 ± 7
Superior O livary  
Nucleus 118 ± 6 104 + 10 109 ± 11 117 ± 5
V isual System
V isual Cortex IV 105 ± 6 89 + 5 75 ± 7 ** 62 ± 2**
D orso latera l 
G eniculate Body 88 ± 2 85 + 5 71 ± 5* 71 ± 3**
V en tro latera l 
G eniculate Body 70 ± 3 69 + 3 57 ± 6 58 ± 2
A nterior P re tec ta l  
Nucleus 88 ± 2 83 + 4 66 ± 6** 70 ± 6*
L ateral P ost-  
Thalamic Nucleus 92 ± 4 86 ± 6 74 ± 5 83 ± 7
Superior
C o llicu lu s  (Super) 76 ± 4 70 + 4 57 ± 3* 54 ± 2**
Superior
C o llicu lu s  (Deep) 75 ± 3 73 ± 3 65 ± 4 64 ± 4
Data are presented as mean ± S.E.M. of 9 (control) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  punol.lOOg min-1. *P<0.05, **P<0.01 for
s t a t i s t i c a l  comparison between drug-treated  group and sa lin e -tr e a te d  co n tro ls .
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APPENDIX I - TABLE 6
GLUCOSE UTILISATION FOLLOWING D-CPP-ENE ADMINISTRATION:
EXTRAPYRAMIDAL AND SENSORIMOTOR AREAS
D-CPP-ENE (mgkg 1)
STRUCTURE CONTROL 0 .3 3 30
C erebellar Nucleus 91 + 3 90 + 4 83 + 6 79 ± 5
C erebellar
Hemisphere 57 + 2 54 + 2 46 ± 3* 55 + 2
V estibu lar Nucleus 113 + 4 110 + 5 108 ± 8 101 ± 4
In fer io r  O live 73 ± 3 69 + 4 55 ± 4* 59 ± 2
Pontine Grey 52 ± 3 54 ± 4 45 ± 4 51 ± 3
Red Nucleus 65 ± 3 64 + 4 59 ± 4 66 ± 5
S u stantia  Nigra: 
Pars Compacta 54 ± 5 54 + 2 47 ± 5 55 ± 4
Pars R eticu la ta 54 ± 2 53 + 3 46 + 6 58 ± 7
Caudate Nucleus 104 ± 3 104 + 6 88 + 8 96 ± 8
Globus P a llid u s 56 ± 6 54 + 4 44 + 3 47 ± 4
Thalamus
(V entrolateral
Nucleus) 78 ± 3 82 + 4 65 + 5 61 ± 4
Subthalmic Nucleus 84 ± 2 82 ± 5 71 + 4 73 ± 5
Data are presented as mean ± S.E.M. of 9 (control) or 5 (drug-treated) animals. 
Glucose u t i l i s a t io n  i s  expressed in  )imol.100g min . *P<0.05 for s t a t i s t i c a l
comparison between drug-treated group and sa lin e -tr e a te d  co n tro ls .
APPENDIX I -  TABLE 7 
GLUCOSE UTILISATION FOLLOWING D-CPP-ENE ADMINISTRATION: 
MYELINATED FIBRE TRACTS
D--CPP-ENE (mgkg- 1)
STRUCTURE CONTROL 0.3 3 30
C erebellar White
Matter 34 ± 1 34 ± 2 30 ± 2 32 ± 1
In ternal Capsule 32 ± 2 32 ± 2 27 ± 2 27 ± 2
Fimbria Fornix 28 ± 3 ^4 ± 2 23 ± 2 25 ± 2
Corpus Callosum 38 ± 2 40 ± 3 33 ± 2 34 ± 3
Genu o f Corpus
Callosum 32 ± 1 34 ± 2 27 ± 3 28 ± 3
Data are presented as mean ± S.E.M. of 9 (con tro l) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  jjunol. 1 00g_ min-1.
APPENDIX II
THE CEREBRAL METABOLIC EFFECTS 
OF A NOVEL MUSCARINIC AGONIST, L-679-512, IN THE RAT
Glucose utilisation was measured in conscious, lightly restrained rats using 
deoxyglucose autoradiography, following intravenous administration of L-679- 
512 (3, 10 or 30pLgkg~1) or saline. The data presented in Tables 2-7 represent 
mean glucose utilisation (jjunol 100g_1 min-1) ± SEM of 76 anatomically distinct 
regions of brain. Data in Table 1 represent physiological parameters following 
L-679-512 administration. *p<0.05, **p<0.01 for statistical comparison of drug- 
treated groups with saline-treated controls (unpaired Student’s t-test, two-tailed, 
with Bonferroni correction).
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APPENDIX II  -  TABLE 1 
PHYSIOLOGICAL PARAMETERS
L-679-512 (vigkg- 1 )
PHYSIOLOGICAL
PARAMETER CONTROL 3 10 30
Mean A rter ia l
Blood Pressure
(mmHg) 128 ± 3 127 ± 9 128 ± 4 146 ± 6
A Mean A rter ia l
Blood Pressure
(mmHg) 3.0  ± 1.6 -2 . 6  ± 4.4 -5 .4  ± 7.4 8.0 ± 3.6
A rter ia l Plasma
Glucose (mM) 8 .3  ± 0 .3 8 . 6  ± 0 . 6 10.1 ± 0.7* 14.7 ± 0.7**
A rter ia l pH 7.442 ± 0.01 7.443 ± 0.01 7.438 ± 0.01 7.420 ± 0.01
PaCO^  (mmHg) 42.4 ± 0.34 38.5 ± 1.4* 43.0 ± 1.8 40.0 ± 0.88**
PaO^  (mmHg) 84.8 ± 2.3 87.5 ± 1.5 87.3 ± 2.5 86.3 ± 1.4
R ectal
Temperature ( 0 C) 36.9 ± 0.14 37.4 ± 0.31 36.4 ± 0.49 36.1 ± 0.37
Number of Animals 9 5 5 5
tlues are presented as mean ± SEM. Glucose values were measured a t the time of 
Im inistration  of [ C ]-2-deoxyglucose. A rter ia l blood gases and rec ta l
jmperature were measured 35 minutes post-deoxyglucose ad m in istration . Absolute 
ilu es for mean a r te r ia l blood pressure are those measured 15 minutes a fte r  sa lin e  
: drug adm inistration , prior to [ C]-deoxyglucose adm in istration . A Mean 
r ter ia l blood pressure represents the change in  blood pressure 15 minutes a fter  
:ug or sa lin e  in je c t io n  r e la t iv e  to  the value prior to in je c t io n .
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APPENDIX II  -  TABLE 2
JCOSE UTILISATION FOLLOWING L-679-512 ADMINISTRATION: HIPPOCAMPAL FORMATION
' '
L--679-512 (pgkg 1
STRUCTURE CONTROL 3 10 30
Ammon' s Horn
CA1 S tr . O riens/ 
Pyramidale 51 ± 2 54 ± 5 44 ± 4 48 ± 3
CA1 S tr . Radiatum 54 ± 2 58 + 4 48 ± 3 52 ± 4
CA1 S tr . Lacunosum 
M oleculare 72 ± 2 73 ± 4 63 ± 2* 64 ± 5
CA2 S tr . O riens/ 
Pyramidale 70 ± 3 70 + 6 58 ± 2* 60 ± 4
CA2 S tr . Radiatum 72 ± 3 73 ± 5 62 ± 2 64 ± 4
CA2/3 S tr .
Lacunosum
Molecular 80 ± 3 82 + 5 67 ± 1* 68 ± 4
CA3 S tr . O riens/ 
Pyramidale 69 ± 2 67 ± 5 60 ± 3 62 ± 3
CA3 Str.  Radiatum 66 ± 2 71 + 6 58 ± 3 62 ± 4
CA4 S tr. 
Pyramidale 60 ± 2 66 + 4 55 ± 2 60 ± 4
Dentate Gvrus
Molecular Layer 
(Superior Blade) 61 ± 3 66 + 4 57 ± 2 59 ± 5
Molecular Layer 
(In fer io r  Blade) 53 ± 2 59 + 5 49 ± 2 56 ± 4
Polymorphic
Layer 50 ± 2 55 + 4 48 ± 3 49 ± 4
Pre Subiculum 83 ± 3 80 + 2 85 ± 7 73 ± 2
Subiculum 71 ± 2 71 + 3 70 ± 6 64 ± 2
Data are presented as mean ± S.E.M. of 9 (con tro l) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  pmol.100g min . *P<0.05, for s t a t i s t i c a l
comparison between drug-treated  group and sa lin e -tr e a te d  c o n tr o ls .
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APPENDIX II  -  TABLE 3:
GLUCOSE UTILISATION FOLLOWING L-679-512 ADMINISTRATION: 
AREAS ASSOCIATED WITH LIMBIC FUNCTION
Ij-679-512 (jigkg- 1 )
STRUCTURE CONTROL 3 10 30
Dorsal Tegmental 
Nucleus 99 + 5 108 ± 7 98 ± 9 91 ± 2
Dorsal Raphe 76 + 3 75 ± 4 75 ± 5 69 + 2
Median Raphe 84 ± 3 86 * 5 82 ± 4 73 ± 2
Mamillary Body 
(Medial) 100 ± 2 83 ± 7* 91 ± 4 83 + 4*
Mamillary Body 
(L ateral) 96 ± 3 78 ± 5* 81 ± 4* 76 ± 5*
Habenular 
Nucleus (Medial) 73 ± 4 85 ± 8 74 ± 4 65 + 2
Habenular Nucleus 
(L ateral) 108 ± 6 107 ± 4 108 ± 6 107 ± 4
Thalamus:-
Mediodorsal 93 ± 6 104 ± 6 96 ± 4 89 ± 4
Laterodorsal 81 ± 3 89 ± 5 84 ± 6 76 + 6
Anteromedial 101 ± 4 102 ± 2 104 ± 4 95 + 8
A nteroventral 93 ± 4 102 ± 9 100 ± 4 105 + 6
Hypothalamus 55 ± 3 57 ± 4 51 ± 3 50 + 3
Amygdala:-
Medial Nucleus 47 ± 3 47 ± 4 42 ± 2 40 + 2
L ateral Nucleus 68 ± 3 68 ± 3 60 ± 2 56 ± 4
B asolatera l
Nucleus 74 + 6 74 ± 4 70 ± 6 59 + 3
Medial Septum 66 + 3 64 ± 6 58 ± 3 56 + 1
L ateral Septum 48 ± 2 49 ± 3 41 ± 2 44 + 2
V ertica l Diagonal 
Band 70 ± 4 71 ± 7 65 ± 4 63 ± 3
H orizontal 
Diagonal Band 86 + 4 82 ± 5 74 ± 5 64 ± 5*
Medial Forebrain 
Bundle 89 + 4 85 ± 6 78 ± 6 66 + 4*
Nucleus Accumbens 64 ± 2 73 ± 4 66 ± 7 64 + 1
C ortex:- 
P osterior  
Cingulate Cortex 89 + 3 87 ± 6 89 ± 8 78 + 2
Anterior  
Cingulate Cortex 105 + 8 109 ± 7 96 ± 4 88 + 3
P a r ie ta l Cortex 108 + 4 102 ± 7 100 ± 6 89 + 4*
Frontal Cortex 108 ± 4 107 ± 8 104 ± 4 91 t 2
Data are presented as mean ± S.E.M. of 9 (control) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  jimol.lOOg min . *P<0.05 for s t a t i s t i c a l
comparison between drug-treated group and sa lin e -tr e a te d  co n tro ls .
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APPENDIX II - TABLE 4
GLUCOSE UTILISATION FOLLOWING L-679-512 ADMINISTRATION: OLFACTORY AREAS
]>679-512 (jigkg ')
STRUCTURE CONTROL 3 10 30
Lateral O lfactory  
Cortex 118 + 8 122 ± 5 123 ± 7 96 ± 9
Lateral O lfactory  
Tract 107 + 5 107 ± 7 105 ± 4 82 + 5*
A nterior O lfactory  
Nucleus 73 ± 5 85 ± 12 72 ± 6 67 ± 8
Primary O lfactory  
Cortex 119 ± 4 112 ± 8 108 ± 5 89 ± 3*
P o ster ior  Piriform  
Cortex 73 ± 5 72 ± 7 79 ± 9 64 ± 2
Entorhinal Cortex 
(Layers I - I I ) 70 ± 3 72 ± 4 63 ± 6 56 ± 1*
Data are presented as mean ± S.E.M. of 9 (con tro l) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  jimol.100g min . *P<0.05 for s t a t i s t i c a l
comparison between drug-treated  group and sa lin e -tr e a te d  c o n tro ls .
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APPENDIX II - TABLE 5
GLUCOSE UTILISATION FOLLOWING L-679-512 ADMINISTRATION:
AUDITORY AND VISUAL STRUCTURES
L-679-512 (iigkg- 1 )
STRUCTURE CONTROL 3 10 30
Auditorv Svstem
Auditory Cortex 
II 1 1 1 ± 7 122 ± 9 116 + 9 97 ± 3
Auditory Cortex 
IV 133 + 9 131 ± 9 132 ± 9 107 ± 4
Medial G eniculate  
Body 113 ± 4 106 ± 5 103 ± 6 87 ± 5*
In fe r io r  C o llicu lu s 161 + 8 158 ± 12 151 + 15 134 ± 2
L ateral Lemniscus 89 + 4 88 ± 6 84 + 8 80 ± 2
Cochlear Nucleus 127 ± 6 130 ± 11 134 ± 9 112 ± 8
Superior Olivary 
Nucleus 118 ± 6 130 ± 8 116 ± 10 100 ± 4
V isual Svstem
Auditory Cortex 
IV 102 + 6 102 ± 7 99 ± 7 74 ± 6*
D orsolateral 
G eniculate Body 99 + 5 108 ± 7 98 ± 9 91 ± 2
V entro latera l 
G eniculate Body 69 ± 3 71 ± 3 70 ± 3 69 ± 4
A nterior P re tecta l 
Nucleus 87 ± 2 93 ± 4 95 ± 6 87 ± 5
Lateral P ost- 
Thalamic Nucleus 89 + 3 94 ± 5 90 ± 5 80 ± 4
Superior
C o llicu lu s  (Super) 74 + 3 76 ± 3 85 ± 7 68 ± 3
Superior
C o llicu lu s  (Deep) 74 + 2 74 ± 4 82 ± 5 70 ± 2
Data are presented as mean ± S.E.M. of 9 (con tro l) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  ymol.100g min . *P<0.05 for s t a t i s t i c a l
comparison between drug-treated  group and sa lin e -tr e a te d  c o n tro ls .
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APPENDIX II - TABLE 6
GLUCOSE UTILISATION FOLLOWING L-679-512 ADMINISTRATION:
EXTRAPYRAMIDAL AND SENSORIMOTOR AREAS
1[.-679-512 (ugkg ')
STRUCTURE CONTROL 3 10 30
C erebellar Nucleus 89 ± 3 94 ± 4 91 ± 5 83 ± 2
C erebellar
Hemisphere 56 + 1 58 + 2 64 + 6 60 ± 3
V estibu lar Nucleus 110 + 3 109 + 3 117 + 6 106 + 4
In fe r io r  O live 74 ± 4 71 ± 6 66 ± 4 60 ± 3
Pontine Grey 50 ± 2 53 ± 3 52 ± 4 53 ± 2
Red Nucleus 65 + 3 68 + 2 69 + 2 69 + 4
Su stan tia  Nigra: 
Pars Compacta 58 + 3 65 + 10 58 + 4 49 + 2
Pars R eticu la ta 52 ± 2 62 + 8 52 ± 4 50 ± 2
Caudate Nucleus 102 + 4 93 + 4 89 + 4 80 + 3*
Globus P a llid u s 56 + 6 59 + 7 49 + 3 48 + 3
Thalamus 
(V entrolateral 
N ucleus) 78 ± 3 85 + 5 77 + 5 75 ± 2
Subthalmic Nucleus 84 ± 2 86 ± 3 88 ± 4 84 ± 2
Data are presented as mean ± S.E.M. of 9 (contro l) or 5 (dru g-treated ) animals. 
Glucose u t i l i s a t io n  i s  expressed in  iimol.100g min . *P<0.05 for s t a t i s t i c a l
comparison between drug-treated  group and sa lin e -tr e a te d  c o n tr o ls .
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APPENDIX II - TABLE 7
GLUCOSE UTILISATION FOLLOWING L-679-512 ADMINISTRATION:
MYELINATED FIBRE TRACTS
L-679-512 (iigkg- 1 )
STRUCTURE CONTROL 3 10 30
C erebellar White 
Matter
Internal Capsule
Fimbria Fornix
Corpus Callosum
Genu of Corpus 
Callosum
34 ± 1 
32 ± 2 
28 ± 3 
38 ± 2
30 ± 1
36 ± 2
37 ± 3 
j 0 ± 4 
40 ± 4
31 ± 3
35 ± 3 
31 ± 2 
24 ± 2
36 ± 2
29 ± 2
36 ± 1 
31 ± 1 
28 ± 1 
35 ± 2
29 ± 1
Data are presented as mean ± S.E.M. of 9 (con tro l) or 5 (drug-treated) anim als. 
Glucose u t i l i s a t io n  i s  expressed in  y.mol.100g-lmin . Glucose u t i l i s a t io n  i s  
expressed in  iimol. 100g min .
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APPENDIX III
TH E C E R EB R A L M ETABOLIC E FF E C T S 
O F  9-A M IN O -l ,2 ,3 ,4-T E T R A -H Y D R O A C R ID IN E  (THA),
A  CO M POU ND O F PO TEN TIA LLY  M IXED CH O LIN ER G IC  A N D  
G LUTA M A TERGIC A C TIO N
Glucose utilisation was measured in conscious, lightly restrained rats using 
deoxyglucose autoradiography, following intravenous administration of THA 
(2.5mg kg-1) or saline. The data presented in Tables 2-7 represent mean glucose 
utilisation (jjLmol 100g-1 min"1) ± SEM of 76 anatomically distinct regions of brain. 
Data in Table 1 represent physiological parameters measured in response to drug 
or saline administration. *p<0.05, **p<0.01 for statistical comparison of drug- 
treated groups with saline-treated controls (unpaired Student’s t-test, two-tailed).
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APPENDIX III  -  TABLE 1 
PHYSIOLOGICAL PARAMETERS
PHYSIOLOGICAL PARAMETERS CONTROL THA ( 2 . 5mgkg“1)
Mean A rter ia l Blood Pressure (mmHg) 120 ± 2 129 ± 5
AMean A rter ia l Blood Pressure (mmHg) 1 .2  ± 2 . 4t 11.4 ± 1 .5**
A rter ia l Plasma Glucose (mM) 8.0 ± 4.7 12.3 ± 0.61**
A rter ia l pH 7.331 ± 0.01 7.303 ± 0.02
PaCO^  (mmHg) 40.7 ± 0.49 42.0 ± 1.9
PaO^  (mmHg) 91.2 ± 2.3 90.8 ± 3.4
Rectal Temperature (°C) 36.7 ± 0.2 36.0 ± 0.3
Number of Animals 6 5
a]ues are presented as mean ± SEM. Plasma glucose concentration was estimated at 
le time of adm inistration of [ C]-2-deoxyglucose. A rter ia l blood gases and 
5c t a l  temperatures were measured 35 minutes post-deoxyglucose adm inistration.  
:>solute values for  mean a r te r ia l  blood pressure represent those measured 15 minutes 
Eter in je c t io n  of THA or s a l in e ,  prior to  in jec t io n  of [ C )-deoxyglucose. AMean 
r te r ia l  blood pressure represents the change in blood pressure 15 minutes a f ter  THA 
c s a l in e  adm inistration, r e la t iv e  to the value prior to  in je c t io n .
mean of 5 animals: no data was ava ilab le  for the 6th animal.
lfP<0.01 for s t a t i s t i c a l  comparison between drug-treated group and sa l in e - tr e a te d  
l im a ls .
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APPENDIX III - TABLE 2
GLUCOSE UTILISATION FOLLOWING THA ADMINISTRATION:
HIPPOCAMPAL FORMATION
THA 
(2 . 5mgkg 1)STRUCTURE CONTROL
Ammon's Horn
CA1 Str. Oriens/Pyramidale 45 ± 3 51 ± 4
CA1 Str. Radiatum 50 ± 4 54 ± 3
CA1 Str. Lacunosum Moleculare 68 ± 5 71 ± 3
CA2 Str. Oriens/Pyramidale 62 ± 5 61 ± 3
CA2 Str. Radiatum 65 ± 5 64 ± 2
CA2/3 S tr . Lacunosum Molecular 72 ± 8 70 ± 4
CA3 Str. Oriens/Pyramidale 58 ± 4 60 ± 2
CA3 Str. Radiatum 59 ± 4 60 ± 2
CA4 Str. Pyramidale 57 ± 4 61 ± 5
Dentate Gvrus
Molecular Layer/(Superior Blade) 53 ± 7 56 ± 4
Molecular Layer/( In fer io r  Blade) 54 ± 3 62 ± 3
Polymorphic Layer 46 ± 3 51 ± 2
Pre Subiculum 83 ± 3 87 ± 8
Subiculum 69 ± 3 81 ± 3*
Data are presented as mean ± S.E.M. of 6 (control) or 5 (drug-treated)  
animals. Glucose u t i l i s a t i o n  i s  expressed in punol.lOOg min .
*P<0.05, for s t a t i s t i c a l  comparison between drug-treated group and 
sa l in e -tr e a te d  con tro ls .
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APPENDIX III - TABLE 3
GLUCOSE UTILISATION FOLLOWING THA ADMINISTRATION:
AREAS ASSOCIATED WITH LIMBIC FUNCTION
THA 
( 2 .5mgkg_1)STRUCTURE CONTROL
Dorsal Tegmental Nucleus 86 ± 5 84 ± 5
Dorsal Raphe 78 ± 3 66 ± 5*
Median Raphe 83 ± 3 76 ± 5
Mamillary. Body (Medial) 97 ± 4 102 ± 7
Mamillary Body (Lateral) 91 ± 4 100 ± 4
Habenular Nucleus (Medial) 62 + 2 69 ± 3
Habenular Nuci’eus (Lateral) 101 ± 3 104 ± 4
Thalamus:-
Mediodorsal 99 ± 6 103 ± 6
Laterodorsal 79 ± 5 88 ± 3
Anteromedial 97 ± 6 101 ± 5
Anteroventral 108 ± 5 135 ± 10*
Hypothalamus 51 ± 3 52 ± 3
Amygdala:-
Medial Nucleus 43 ± 2 46 ± 2
Lateral Nucleus 62 ± 3 61 ± 3
B asolateral Nucleus 54 ± 3 57 ± 3
Medial Septum 61 ± 4 63 ± 4
Lateral Septum 42 ± 3 43 ± 2
V ertica l Diagonal Band 65 ± 3 63 ± 2
Horizontal Diagonal Band 62 ± 9 62 ± 8
Medial Forebrain Bundle 75 ± 10 78 ± 11
Nucleus Accumb'ens 61 ± 5 58 ± 4
Cortex:-
Poster ior  Cingulate Cortex 92 ± 3 92 ± 4
Anterior Cingulate Cortex 104 ± 6 98 ± 5
P a r ie ta l Cortex 109 ± 5 111 ± 6
Frontal Cortex 99 + 2 109 + 7
Data are presented as mean ± S.E.M. of 6 (control) or 5 (drug-treated)  
animals. Glucose u t i l i s a t i o n  i s  expressed in  punol. 1 00g-1min .
*P<0.05 for s t a t i s t i c a l  comparison between drug-treated group and 
s a l in e - tr e a te d  co n tro ls .
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APPENDIX III - TABLE 4
GLUCOSE UTILISATION FOLLOWING THA ADMINISTRATION:
OLFACTORY AREAS
THA 
(2 . 5mgkg 1)STRUCTURE CONTROL
Lateral Olfactory Cortex t 
Lateral Olfactory Tract t 
Anterior Olfactory Nucleus + 
Primary Olfactory Cortex 
Post Piriform Cortex 
Entorhinal Cortex
116 ± 7 
115 ± 7  
72 ± 7 
96 ± 5 
84 ± 7 
61 ± 2
127 ± 9 
100 ± 6 
79 ± 4 
99 ± 3 
82 ± 6 
61 ± 4
Data are presented as mean ± S.E.M. of 6 (control) or 5 (drug-treated)  
animals. Glucose u t i l i s a t i o n  i s  expressed in jimol.100" min" .
t Data comprised of comparisons between 3 control and 3 drug-treated  
animals; no t i s s u e  a v a ila b le  for autoradiographic measurement within  
other animals.
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APPENDIX III - TABLE 5
GLUCOSE UTILISATION FOLLOWING THA ADMINISTRATION:
AUDITORY AND VISUAL STRUCTURES
THA 
(2. 5mgkg'STRUCTURE CONTROL ” >
Auditory Svstem
Auditory Cortex II 109 + 6 110 + 7
Auditory Cortex IV 122 + 8 126 + 8
Medial Geniculate Body 95 ± 5 98 + 7
In fer io r  C ollicu lu s 149 + 8 146 ± 7
Lateral Lemniscus 85 + 4 84 + 4
Cochlear Nucleus 103 ± 11 110 + 5
Superior Olivary Nucleus 111 ± 5 105 ± 7
Visual Svstem
Visual Cortex IV 95 + 2 94 + 7
D orsolateral Geniculate Body 74 + 3 95 + 2**
Ventrolateral Geniculate Body 63 + 4 79 + 4*
Anterior P retecta l Nucleus 88 ± 5 102 ±
Lateral Postthalamic Nucleus 83 ± 4 92 + 5
Superior C ollicu lu s  (S u p erfic ia l) 75 + 2 105 + 4**
Superior C ollicu lu s  (Deep) 72 ± 2 79 ± 5
Data are presented as mean ± S.E.M. of 6 (control) or 5 (drug-treated)  
animals. Glucose u t i l i s a t i o n  i s  expressed in }imol.100g min . 
*P<0.05/ **P<0.01 s t a t i s t i c a l  comparison between drug-treated group and 
sa l in e - tr e a te d  con tro ls .
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APPENDIX III - TABLE 6
GLUCOSE UTILISATION FOLLOWING THA ADMINISTRATION:
EXTRAPYRAMIDAL AND SENSORIMOTOR AREAS
THA 
(2 . 5mgkg"STRUCTURE CONTROL
Cerebellar Nucleus 81 ± 5 86 + 5
Cerebellar Hemisphere 49 ± 1 56 + 2*
V estibular Nucleus 92 + 2 106 + 7
In fer io r  Olive 65 + 2 67 ± 4
Pontine Grey 51 + 2 49 ± 4
Red Nucleus 58 + 3 63 ± 4
Substantia Nigra: 
Pars Compacta 57 + 4 66 + 5
Pars R eticulata 46 + 2 44 + 5
Caudate Nucleus 91 + 4 86 + 4
Globus P allidus 47 + 2 49 + 3
Thalamus (Ventrolateral Nucleus) 79 ± 5 91 ± 4
Subthalamic Nucleus 70 ± 4 74 + 2
Data are presented as mean ± S.E.M. of 6 (control) or 5 (drug-treated)  
animals. Glucose u t i l i s a t i o n  i s  expressed in  jimol.100g min . *P<0.05 for
s t a t i s t i c a l  comparison between drug-treated group and s a l in e - tr e a te d  con tro ls .
2 2 7
APPENDIX III - TABLE 7
GLUCOSE UTILISATION FOLLOWING THA ADMINISTRATION:
MYELINATED FIBRE TRACTS
THA 
( 2 . 5mgkg'-1)STRUCTURE CONTROL
Cerebellar White Matter 26 ± 2 32 ± 2
Internal Capsule 28 ± 1 34 ± 3
Fimbria Fornix 20 ± 2 26 ± 2
Corpus Callosum 32 ± 2 36 ± 2
Genu of Corpus Callosum 25 ± 1 30 ± 1*
Data are presented as mean ± S.E.M. of 6 (control) or 5 (drug-treated)  
animals. Glucose u t i l i s a t i o n  i s  expressed in ]imol.100g-1min .
*P<0.05 for s t a t i s t i c a l  comparison between drug-treated group and s a l in e -  
treated  co n tro ls .
2 2 8
APPENDIX IV
LOCAL CEREBRAL GLUCOSE UTILISATION 
IN RESPONSE TO LESIONS OF THE MEDIAL SEPTUM
Glucose utilisation was measured in conscious, lightly restrained rats using 
deoxyglucose autoradiography, three weeks after lesions of the medial septum or 
sham operation. The data presented in Tables 2 - 4  represent mean glucose 
utilisation ( j j u t i o I  100_1min_1) ± S.E.M. of 57 anatomically defined regions of brain. 
Data in Table 1 represent physiological parameters following lesion or sham 
operation. Statistical comparisons were made using unpaired Student’s t-test, 
(two-tailed).
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IAPPENDIX IV - TABLE 1
PHYSIOLOGICAL PARAMETERS FOLLOWING MEDIAL SEPTAL LESIONS
SHAM
(n=7)
LESION
(n=6 )PHYSIOLOGICAL PARAMETER
Body Weight (g) 370 ± 8 381 ± 11
Mean A rter ia l  Blood Pressure (mmHg) 136 ± 1 129 ± 3
A rter ia l Plasma Glucose (mM) 7.5 ± 0.4 . 7.9 ± 0.4
A rter ia l pH 7.44 ± 0.01 7.46 ± 0.01
PaCO^  (mmHg) 41.4 ± 1 40.1 ± 1
PaOi (mmHg) 83.9 ± 2 85.1 ± 4
Rectal Temperature (°C) 36.7 ± 0.3 37.0 ± 0.3
:an a r te r ia l  blood pressure was measured immediately prior to adm inistration of 
C]-deoxyglucose. A rter ia l plasma glucose values are those measured 1 minute 
i s t - in je c t io n  of [ C]-deoxyglucose. Rectal temperature and blood gases were 
lasured 35 minutes a f ter  deoxyglucose adm inistration.
2 3 0
APPENDIX IV - TABLE 2
LOCAL CEREBRAL GLUCOSE UTILISATION FOLLOWING MEDIAL SEPTAL LESIONS:
HIPPOCAMPAL FORMATION
LCGU (pmol/1OOg/min)
STRUCTURE SHAM (N=7) LESION (N=6 )
Ammon's Horn
CA1 Str Oriens 47 + 3 50 ± 3
Str Pyramidale 51 ± 3 53 ± 3
Str Radiatum 59 ± 7 54 ± 2
Str Lacunosum Moleculare 66 + 4 70 ± 3
CA2 Str Oriens 64 + 3 67 + 4
Str Pyramidale 74 ± 4 78 ± 5
Str Radiatum 68 ± 4 72 ± 4
Str Lacunosum Moleculare 77 ± 5 83 + 5
CA3 Str Oriens 62 ± 4 63 + 4
Str Pyramidale 68 ± 5 72 ± 5
Str Radiatum/Lacunosum Mol. 66 ± 5 71 ± 5
CA4 Str Pyramidale 56 ± 4 64 + 5
Dentate Gvrus
Superior Blade:
Molecular Layer (outer) 64 ± 3 64 ± 3
Molecular Layer (inner) 57 ± 3 57 + 3
Granular Layer 53 ± 3 53 ± 3
Infragranular Layer 52 ± 3 55 + 3
In fer io r  Blade:
Molecular Layer (outer) 47 ± 2 46 ± 2
Molecular Layer (inner) 47 ± 2 48 + 2
Granular Layer 46 ± 2 47 + 3
Subiculum 86 ± 4 84 + 6
Presubiculum 100 ± 6 97 ± 5
Entorhinal Cortex :
Lateral, Layers I - I I 77 ± 5 71 + 3
Lateral, Layers III-VI 86 ± 7 84 ± 4
Medial, Layers I - I I 81 ± 5 74 + 4
Medial, Layers III-VI 84 ± 7 83 + 5
Data are presented as mean ± S.E.M. of 7 (control) or 6 (les ioned)  
animals. Glucose u t i l i s a t i o n  i s  expressed in junol 100g-1min-1.
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APPENDIX IV - TABLE 3
LOCAL CEREBRAL GLUCOSE UTILISATION FOLLOWING MEDIAL SEPTAL LESIONS:
AREAS ASSOCIATED WITH LIMBIC FUNCTION
LCGU (junol /10  Og/min)
STRUCTURE SHAM (N=7) LESION (N=6 )
Dorsal Raphe 100 + 4 100 ± 6
Median Raphe 99 + 6 108 ± 6
Mamillary Body 111 + 6 113 ± 8
Thalamus:-
Anterodorsal Nucleus 80 ± 6 89 ± 4
Anteroventral Nucleus 121 ± 10 134 ± 3
Laterodorsal Nucleus 95 ± 7 96 ± 8
Habenular Nucleus (Medial) 83 ± 6 78 ± 3
Habenular Nucleus (Lateral) 130 ± 12 132 ± 5
Amygdala (Basolateral Nucleus) 87 ± 7 83 ± 4
Hypothalamus 55 ± 5 53 ± 3
Medial Septum 71 ± 4 67 ± 3
Lateral Septum 52 ± 4 53 ± 1
Diagonal Band, V ertica l Limb 79 ± 5 76 ± 4
Diagonal Band, Horizontal Limb 98 ± 10 96 ± 8
Nucleus Accumbens 65 ± 5 65 ± 3
Cortex (Layer IV ):
P osterior  Cingulate Cortex 107 ± 8 101 ± 6
Anterior Cingulate Cortex 1 1 1 ± 6 111 ± 6
P ar ie ta l Cortex 114 ± 12 119 ± 6
Frontal Cortex 125 ± 9 125 ± 4
Primary Olfactory Cortex 131 ± 7 127 ± 6
Data are presented as mean ± S.E.M. of 7 (control) or 6 ( les ioned)  
animals. Glucose u t i l i s a t i o n  i s  expressed in p.mol.100g-1min .
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APPENDIX IV - TABLE 4
LOCAL CEREBRAL GLUCOSE UTILISATION FOLLOWING MEDIAL SEPTAL LESIONS:
OTHER AREAS
LCGU (junol/IOOg/min)
STRUCTURE SHAM (N=7) LESION (N=6 )
Auditory and Visual Regions:-
Auditory Cortex, Layer IV 156 + 1 1 140 + 5
Medial Geniculate Body 115 + 9 117 + 6
In fer ior  C ollicu lu s 162 ± 15 159 + 8
Visual Cortex, Layer IV 114 ± 9 1 11 + 6
Dorsolateral Geniculate Body 86 ± 6 92 ± 3
Superior C o llicu lu s  (S uperfic ia l) 83 ± 5 82 ± 5
Superior C o llicu lu s  (Deep) 86 ± 6 82 + 5
Extrapyramidal & Sensorimotor Areas:
Cerebellar Hemisphere 51 ± 4 51 ± 3
Vestibular Nucleus 118 ± 6 1 17 + 7
Caudate Nucleus 108 ± 7 105 + 5
Myelinated Fibre Tracts:
Cerebellar White 30 ± 2 33 + 2
Fimbria Fornix 26 ± 3 29 + 1
Data are presented as mean ± S.E.M. of 7 (control) or 6 ( les ioned)  
animals. Glucose u t i l i s a t i o n  i s  expressed in jjimol. 1 00g-1min_1.
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A PPEN D IX  V
QUANTITATIVE LIGAND BINDING TO G LUTA M A TERGIC AND 
M USCARINIC R E C E PT O R S IN H IPPO CA M PA L AN D ASSOCIATED 
STR U C TU R ES FOLLOW ING M EDIAL SEPTA L LESIONS
[3H]-QNB, [3H]-AMPA, [3H]-kainate and NMDA-sensitive [3H]-glutamate binding 
were measured at single ligand concentrations in hippocampal and septal regions 
in sham-operated rats and rats with lesions of the medial septum. Data are 
presented as mean ligand bound (pmol/g tissue) ± S.E.M. *P<0.05, **P<0.01 for 
statistical comparisons (unpaired Student’s t-test, two-tailed).
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APPENDIX V - TABLE 1
r^U-ONB BINDING IN HIPPOCAMPAL AND
ASSOCIATED STRUCTURES FOLLOWING MEDIAL SEPTAL LESIONS
r3Hl-0NB BINDING
STRUCTURE SHAM (N=7) LESION (N=7)
1. Ammon's Horn
Str. Oriens 293 + 15
S t r . Pyramidale 362 ± 17
Str. Radiaturn 360 + 17
Str. Lacunosum Moleculare 280 + 17
Str. Oriens 203 + 12
Str. Pyramidale 259 ± 26
Str. Radiatum 243 + 16
Str. Lacunosum Moleculare 231 + 15
Str. Oriens 208 + 8
Str. Pyramidale 237 + 10
Str. Radiatum/
Lacunosum Mol. 236 ± 10
Str. Pyramidale 282 + 18
Dentate Gvrus 
Superior Blade:
Molecular Layer (outer)
Molecular Layer (inner)
Granular Layer
Infragranular Layer
In fer io r  Blade:
Molecular Layer (outer)
Molecular Layer (inner)
Granular Layer
Subicular Complex:
Subiculum
Presubiculum
Entorhirial Cortex:
Medial Portion, Layers I - I I
Layers III-VI
Lateral Portion, Layers I - I I
Layers III-VI
Septal N u c le i:
Medial Septum
Lateral Septum
Diagonal Band (V ertica l Line)
298 + 16
312 ± 13
272 ± 14
253 ± 17
324 ± 16
346 ± 17
274 ± 17
271 + 13
181 + 8
279 + 15
286 + 18
267 + 9
263 + 1 1
170 + 7
202 + 5
158 ± 8
302 + 17
354 ± 22
354 ± 20
274 ± 11
209 ± 10
249 + 7
231 + 7
218 + 3
204 + 14
229 + 7
223 ± 4
281 + 9
293 ± 1 1
305 + 12
260 + 4
261 + 7
308 + 13
346 ± 24
286 ± 17
233 ± 1 2"
184 ± 7
255 ± 12
283 ± 9
274 ± 10
253 ± 9
115 ± 13
176 ± 5
163 ± 8
Data are presented as [ H]-QNB binding, 
le s ion ed  anim als. *P<0.05, **P<0.01 for
sham and les ion ed  animals.
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pmol g 1 t i s s u e  in  7 sham or 7 
s t a t i s t i c a l  comparison between
APPENDIX V - TABLE 2
r ^ 1-AMPA BINDING IN HIPPOCAMPAL AND ASSOCIATED STRUCTURES
FOLLOWING MEDIAL SEPTAL LESIONS
[ 3H]-AMPA BINDING
STRUCTURE SHAM (N=7) LESION (N=7)
1. Ammon's Horn
CA1 Str. Oriens 379 + 1 1 345 + 12
Str. Pyramidale 442 + 14 394 + 10*
Str. Radiatum 501 + 14 458 + 11 *
Str. Lacunosum Moleculare 448 + 16 403 ± 16
CA2 Str. Oriens 297 + 10 252 ± 14*
Str. Pyramidale 341 + 10 280 ± 1 0**
Str. Radiatum 380 + 15 335 ± 15
S t r . Lacunosum Moleculare 413 + 1 1 354 ± 22*
CA3 Str. Oriens 272 + 16 231 ± 18
Str. Pyramidale 311 + 3 272 ± 12*
Str. Radiatum/
Lacunosum Mol. 340 + 6 306 ± 18
CA4 Str. Pyramidale 346 + 1 1 312 ± 1 1
2. Dentate Gvrus
Superior Blade:
Molecular Layer (outer) 437 + 14 409 ± 14
Molecular Layer (inner) 393 ± 20 362 ± 13
'Granular Layer 330 ± 16 289 ± 13
Infragranular Layer 334 + 10 309 ± 13
In fer io r  Blade:
Molecular Layer (outer) 433 + 23 374 ± 21
Molecular Layer (inner) 425 ± 17 379 ± 19
Granular Layer 329 + 8 295 ± 17
3. Subicular Complex: 
Subiculum 368 ± 20 301 ± 35
Presubiculum 187 ± 22 158 ± 23
4. Entorhinal Cortex:
Medial Portion, Layers I - I I 237 ± 21 213 ± 16
Layers III-VI 272 ± 19 215 ± 16*
"Lateral Portion, Layers I - I I 270 ± 13 208 ± 16**
Layers III-VI 267 ± 10 238 ± 19
5. Septal Nuclei: 
Medial Septum 103 ± 20 53 ± 9*
Lateral Septum 341 ± 27 277 ± 22
Diagonal Band (V ertical Line) 97 ± 7 84 ± 10
Data are presented as [HJ-AMPA binding, pmol .g ' 1 t i s s u e  in  7 sham or 7 
les ion ed  animals. *P<0.05 **P<0.01 for s t a t i s t i c a l  comparison between 
shams and les ion ed  animals.
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APPENDIX V - TABLE 3
f^l-KAINATE BINDING IN HIPPOCAMPAL AND ASSOCIATED STRUCTURES
FOLLOWING MEDIAL SEPTAL LESIONS
[ 38 ] -KAINATE BINDING
STRUCTURE SHAM (N=6 ) LESION (N=7)
1 . Ammon' s Horn
CA1 Str. Oriens 36 ± 4 37 + 2
Str. Pyramidale 34 ± 4 35 ± 2
Str. Radiatum 40 ± 4 43 ± 1
Str. Lacunosum Moleculare 42 ± 5 49 ± 1
CA2 Str. Oriens 37 ± 4 41 + 1
Str. Pyramidale 61 ± 7 63 + 6
Str. Radiatum 47 ± 4 51 ± 5
Str. Lacunosum Moleculare 38 ± 3 44 ± 2
CA3 Str. Oriens 34 ± 2 35 + 2
Str. Pyramidale 73 ± 5 83 + 4
Str. Radiatum/
Lacunosum Mol. 47 ± 3 49 ± 2
CA4 Str. Pyramidale 100 + 8 114 + 4
Str. Lucidum 187 + 6 187 + 6
2 . Dentate Gvrus 
Superior Blade:
Molecular Layer (outer) 49 + 4 55 + 1
Molecular Layer (inner) 63 ± 5 72 ± 1
Granular Layer 51 ± 4 58 ± 2
Infragranular Layer 65 + 4 72 + 1
In fer ior  Blade:
Molecular Layer (outer) 52 ± 4 58 + 2
Molecular Layer (inner) 70 + 5 79 + 2
Granular Layer 57 + 3 62 + 2
3. Subicular Complex: 
Subiculum 62 + 6 66 + 5
Presubiculum 74 + 6 84 + 6
4. Entorhinal Cortex:
Medial Portion, Layers I - I I 86 ± 4 87 + 7
Layers III-VI 62 + 6 65 + 8
Lateral Portion, Layers I - I I 94 + 8 98 + 9
Layers III-VI 45 + 7 46 + 5
5. Septal Nuclei: 
Medial Septum 39 + 2 37 ± 2
Lateral Septum 53 ± 4 60 ± 4
Diagonal Band (V ertica l Line) 44 ± 4 49 ± 3
Data are presented as [3H]-kainate binding, pmol g 1 t i s s u e  in  6 sham or 
7 lesioned  animals.
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APPENDIX V - TABLE 4
NMDA-DISPLACEABLE \ 1-GLUTAMATE BINDING IN HIPPOCAMPAL AND
ASSOCIATED STRUCTURES FOLLOWING MEDIAL SEPTAL LESIONS
[ 3HI -NMDA DISPLACEABLE
GLUTAMATE BINDING
STRUCTURE SHAM VOIIz LESION (N=6 )
1. Ammon's Horn
CA1 Str. Oriens 56 + 10 66 + 12
Str. Pyramidale 54 + 12 63 + 1 1
Str. Radiatum 67 + 10 78 ± 14
Str. Lacunosum Moleculare 45 + 9 48 + 4
CA2 Str. Oriens 35 + 9 30 ± 4
Str. Pyramidale 32 ± 8 32 ± 9
Str. Radiatum 38 + 8 40 ± 7
Str. Lacunosum Moleculare 41 + 8 35 + 7 .
CA3 Str. Oriens 29 + 7 30 + 6
Str. Pyramidale 22 + 5 17 + 4
Str. Radiatum/
Lacunosum Mol. 31 + 6 32 + 7
CA4 Str. Pyramidale 32 + 8 32 ± 5
2. Dentate Gvrus
Superior Blade:
Molecular Layer (outer) 51 + 9 54 ± 7
Molecular Layer (inner) 53 + 8 56 + 8
Granular Layer 40 + 8 41 + 9
Infragranular Layer 26 ± 8 25 + 6
In fer ior  Blade:
Molecular Layer (outer) 49 + 7 48 + 6
Molecular Layer (inner) 51 + 8 56 + 8
Granular Layer 38 ± 8 39 ± 7
3. Subicular Complex: 
Subiculum 40 + 7 54 + 11
Presubiculum 19 + 3 32 + 6
4. Entorhinal Cortex:
Medial Portion, Layers I - I I 62 + 7 76 + 19
Layers III-VI 57 + 3 70 + 18
Lateral Portion, Layers I - I I 74 + 9 84 + 11
Layers III-VI 53 + 6 69 ± 17
5. Septal Nuclei: 
Medial Septum 13 + 2 (a) 10 + 3
Lateral Septum 22 ± 6 30 + 6
Diagonal Band (V ertica l Line) 13 ± 2 ( b ) 25 + 5
Data are presented as [3H]-L-glutamate binding, pmol g 1 t i s s u e  in  6 sham 
or 6 le s ion ed  animals. (a) n=5 (b) n=4.
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APPENDIX VI
LOCAL CEREBRAL GLUCOSE UTILISATION IN RESPONSE 
TO ACUTE SUBDURAL HAEMATOMA
Glucose utilisation was measured in conscious, lightly restrained rats two hours 
following acute subdural haematoma, acute subdural haematoma with D-CPP-ene 
pre-treatment or sham operation. The data in Tables 2-7 represent mean glucose 
utilisation (pimol 100g_1min_1) ± S.E.M. of 41 anatomically defined regions of the 
brain. Data presented in Table 1 represents physiological parameters in response 
to experimental procedures. Statistical comparison was made using unpaired 
Student’s t-test, two-tailed, with Bonferroni correction. *P<0.05, **P<0.01 for 
statistical comparison between sham operation and acute subdural haematoma; 
+P<0.05, ++P<0.01 for statistical comparison between acute subdural haematoma 
and D-CPP-ene pre-treatment.
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APPENDIX VI -  TABLE 1 
PHYSIOLOGICAL PARAMETERS FOLLOWING ACUTE SUBDURAL HAEMATOMA IN THE RAT
+ D-CPP-ene 
15mg kg- 1 
(n=5)
SHAM
(n=5)
ASDH
(n=5)PHYSIOLOGICAL PARAMETER
Body Weight (g) 440 ± 43 398 ± 22 449 ± 9
Mean A rter ia l Blood Pressure
(mmHg) 114 ± 6 131 ± 16 121 ± 11
A rter ia l Plasma
Glucose (mM) 7.7 ± 0.5 8 . 6  ± 0.7 7.6  ± 0.7
A rter ia l pH 7.43 ± 0.03 7.43 ± 0.01 7.38 ± 0.02
PaCO^ (mmHg) 43 ± 4 41 ± 3 47 ± 2
PaOjL (mmHg) 96 ± 9 109 ± 6 84 ± 10
Rectal Temperature (°C) 36.1 ± 0.3 34.9 ± 0.8 36.0 ± 0.5
Mean a r te r ia l  blood pressure was measured prior to  adm inistrtion of [ C]-2- 
deoxyglucose. A rter ia l plasma glucose values are those measured 1 minute p ost­
in je c t io n  of [ C]-deoxyglucose. Rectal temperature and blood gases were measured 
35 minutes a f te r  deoxyglucose adm inistration.
D-CPP-ene (15mg kg-1) was administered 15 minutes prior to  induction of ASDH.
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APPENDIX VI - TABLE 2
LOCAL CEREBRAL GLUCOSE UTILISATION FOLLOWING ACUTE SUBDURAL HAEMATOMA:
HIPPOCAMPAL AREA
LCGU (jimol. 1 00g_1min )
SHAM ASDH ASDH + I)-CPP--ENE
STRUCTURE IPSI. CONTRA. IPSI. CONTRA. IPSI. CONTRA.
Ammon's Horn:
CA1 Str . Oriens/
Pyramidale 42 ± 2 42 ± 3 88 ± 11* 74 ± 15 54 ± 7 47 ± 2
CA1 Str . Radiatum 43 ± 3 43 ± 3 104 ± 1 1 88 ± 15 61 + 10 49 ± 3
CA1 Str. Lacunosum 
Moleculare 62 ± 4 63 ± 3 116 ±
**
10 111 ± 14* 102 ±
t
14 88 ± 3
CA2 Str. Oriens/ 
Pyramidale 61 ± 3 60 ± 3 111 ±
**
16* 80 ± 12 81 ± 3 71 ± 4
CA2 Str. Radiatum 55 ± 2 59 + 3 121 + 17* 97 ± 16 74 + 7 64 ± 2
CA2/3 Str.
Lacunosum
Molecular 71 + 2 73 + 4 141 + 12 122 ± 17 110 + 16 91 ± 2
CA3 Str. Oriens/  
Pyramidale 57 + 4 56 ± 3 114 ±
**
12 98 ± 13 73 ± 5 + 68 ± 4
CA3 Str. Radiatum 56 ± 4 56 ± 4 119 ±
**
13
*
99 ± 17 67 + 8+ 63 ± 4
Dentate Gvrus:
**
Molecular Layer
(Superior Blade) 53 ± 3 52 + 4 97 + 15* 89 ± 11 *
62 ± 7 58 ± 2
Polymorphic Layer 42 ± 2 41 ± 3 89 ± 11* 75 ± 13 53 ± 6 48 ± 2
Pre Subiculum 70 + 4 73 + 4 69 ± 1 1 62 ± 10 98 + 17 120 ± 9t
Subiculum 60 + 3 64 + 5 84 + 8 72 ± 9 76 + 5 71 ± 4
Data are presented as mean ± S.E.M. of 5 con tro l,  ASDH or ASDH + D-CPP-ene- 
treated  animals. Glucose u t i l i s a t i o n  i s  expressed in  jimol 100g"min” . 
*P<0.05, **P<0.01 for s t a t i s t i c a l  comparison of ASDH with con tro ls .  
tP<0.05 for s t a t i s t i c a l  comparison of ASDH + D-CPP-ene with ASDH.
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APPENDIX VI - TABLE 3
LOCAL CEREBRAL GLUCOSE UTILISATION FOLLOWING ACUTE SUBDURAL HAEMATOMA:
AREAS ASSOCIATED WITH LIMBIC FUNCTION
LCGU iy.mol.100g 1min 1 )
SHAM ASDH ASDH + I)-CPP--ENE
STRUCTURE IPSI. CONTRA. IPSI • CONTRA. IPSI. CONTRA.
Mamillary Body 83 ± 3 84 ± 3 81 ± 8 81 ± 7 88 ± 4 88 ± 6
Thalamus;
Anterodorsal
Nucleus 67 + 5 71 ± 4 57 ± 4 68 ± 2 76 ± 9 85 ± 1 1
Anteroventral
Nucleus 90 + 11 96 ± 3 64 + 10 81 ± 5 108
(a) 
± 12 112
(a) 
± 10
Laterodorsal
Nucleus 71 + 4 70 ± 4 40 + 8* 68 ± 2 65
(a) 
± 12 92
t (a) 
± 9
Habenular Nucleus: 
Medial 59 + 4 72 + 5 74 ± 8 78 ± 8 53
(b) 
± 3 56
(b)  
± 4
Lateral 105 + 7 106 + 7 97 ± 8 101 ± 9 63
(b) 
± 10 62
(b)  
± 10
Amygdala
(B aso latera l Nuc.) 60 ± 6 61 + 6 55 ± 4 57 ± 6 70
(b) 
± 4 74
(b)  
± 6
Hypothalamus 38 ± 4 39 ± 4 39 ± 3 41 ± 4 37 ± 3 36 ± 3
Medial Septum 52 + 4 53 + 4 51 ± 4 57 ± 5 60 ± 6 64 ± 6
Lateral Septum 36 ± 2 36 + 2 64 ± 13 59 ± 1 1 35 ± 3 35 ± 3
Diagonal Band, 
V ertica l Limb 57 ± 3 53 ± 4 55 ± 6 57 ± 5 57 ± 3 58 ± 4
Diagonal Band, 
Horizontal Limb 71 ± 3 74 ± 2 66 ± 8 77 ± 9 72 ± 5 75 ± 4
Nucleus Accumbens 49 + 4 49 + 4 49 ± 4 54 ± 4 56 ± 8 56 ± 8
Cortex:
Post.Cing. cortex  
(Layer IV) 69 + 5 75 + 3 61 ± 6 70 ± 4 90
(b) 
± 8 104
(b)  
± 4
Ant. Cing. Cortex 
(Layer IV) 82 + 6 80 + 5 89 ± 13 74 ± 7 85
t 
± 6 84
t t  
± 7
P a r ie ta l  Cortex 
(Layer IV) 55 ± 8 81 + 5 - ( c ) 71 ± 5 - ( c ) 61 ± 5
P a r ie ta l  Cortex 
( Ischaemic  
Penumbra) ( a ) ’67 + 3 81 ± 4 102 ± 11* 70 ± 8 83 ± 3 69 ± 6
Frontal Cortex 
(Layer IV) 79 ± 8 88 ± 6 82 + 11 82 ± 5 55 ± 4 62 ± 4 t
Entorhinal Cortex 
(Layers I - I I ) 60 + 4 63 + 3 74 ± 12 64 ± 4 80 ± 4 86 ± 5 t
Lat. Olf. Tract. 
(Layers I - I I ) 77 ± 6 81 + 1 11 1 ± 12 96 ± 8 133 ± 8 143 ± 8 t
Data are presented as mean ± S.E.M. of 5 con tro l,  ASDH or ASDH + D-CPP-ene- 
treated  animals. Glucose u t i l i s a t i o n  i s  expressed in ymol.100g min . *P<0.05
for s t a t i s t i c a l  comparison of ASDH with contro ls  +P<0.05, t+P<0.01 for
s t a t i s t i c a l  comparison between ASDH -t- D-CPP-ene and ASDH alone (Student's  
unpaired t - t e s t ,  tw o-ta iled  with Bonferroni c o r r e c t io n ) . (a) n=3 (b) n=4 (c)
in farcted  area below ASDH; minimal deoxyglucose uptake (d) p a r ie ta l  cortex .
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APPENDIX VI - TABLE 4
LOCAL CEREBRAL GLUCOSE UTILISATION FOLLOWING ACUTE SUBDURAL HAEMATOMA:
OTHER AREAS
LCGU (umol.100g 1min )
SHAM ASDH ASDH + D-CPP--ENE
STRUCTURE IPSI. CONTRA. IPSI. CONTRA. IPS! CONTRA.
Auditory & Visual 
R egions:
Auditory Cortex 
Layer IV 99 ± 5 119 ± 6 62 ± 13 84 ± 11 66 ± 6 68 ± 5
Medial
Geniculate Body 92 ± 3 99 ± 1 48 ± 5 
**
73 ± 12 69 ± 7 63 ± 5
Visual Cortex 
Layer IV 75 ± 5 81 ± 4 85 ± 18 **
77 ± 8 59 ± 13 71 ± 6
D orsolateral  
Geniculate Body 72 + 4 73 ± 4 41 ± 5 
**
70 ± 6 61 ± 9 72 ± 7
Superior
C o ll icu lu s
(S u p er f ic ia l) 70 + 5 71 ± 3 72 ± 9 74 ± 7 56 ± 4 54 ± 4
Superior
Col1i c u lu s (Deep) 63 ± 2 68 + 2 .61 ± 3 69 ± 5 56 ± 3 63 ± 6
Extraovramidal 
and Sensorimotor 
Areas:
Caudate Nucleus 73 + 5 80 + 5 52 ± 6 77 ± 6 63 ± 2 72 ± 7
Myelinated Fibre 
T racts :
Corpus Callosum 29 ± 1 28 ± 2 49 ± 10 31 ± 6 35 ± 3 31 ± 2
Lateral Septum 20 ± 2 21 ± 2 27 ± 4 26 ± 1 24 ± 2 25 ± 2
Data are presented as mean ± S.E.M. of 5 contro l, ASDH or ASDH + D-CPP-ene- 
treated  animals. Glucose u t i l i s a t i o n  i s  expressed in ]imol.100g min- .
**P<0.01 for s t a t i s t i c a l  comparison of ASDH with co n tro ls .  (Student's unpaired 
t - t e s t ,  tw o -ta iled  with Bonferroni correctio n ) .
2 4 3
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